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. ا - فلسطين منطقة رام س.ر.بي الحساس كعامل لمراض القلب في
ملخص الدراسة:
 تعتبر الوفيات الناتجة عن أمراض شرايين القلب من أعلى النسب في العالم، ومن المعروف
 أن هذه المراض لها علقة مع ارتفاع نسبة الكولسترول في الدم وبخاصة الكولسترول
  % من المراض المرتبطة06-05المنخفض الكثافة ) الكولسترول السيئ(. إن حوالي 
 بالقلب يساعد فحص نسبة الكولسترول السيئ في الدم في تشخيصها. هذا الفحص المسحي
 للكولسترول المنخفض الكثافة فشل أحيانا في تشخيص الشخاص الذين عندهم عوامل خطرة
 تهيء للصابة بأمراض القلب وخاصة عندما يكون الكولسترول السيئ ضمن المعدل الطبيعي.
 من هنا يحاول الختصاصيون التعرف على عوامل أخرى تسهم في تشخيص هذه الفئة من
 الشخاص . إن ظاهرة تصلب الشرايين بحد ذاته هي أنها مرض التهابي ولهذا  فانه يرافق
 هذا المرض عوامل التهابية تساعد في تشخيصه من أهمها سي، ر، بي آو سي ريا كتف
 بروتين الذي يتم قياسه بالطرق الحساسة والدقيقة جدا ويعتبر من أهم هذه العوامل
 08 حالة) 061المصاحبة لمراض القلب المستقبلية. لقد تم في هذه الدراسة دراسة حوالي 
  حالة ل تعاني من أية أمراض08حالة مرضية مشخصة على أنها تعاني من أمراض القلب و 
 في القلب( من رام ا – فلسطين . إن كل المجموعتين تتعرض لكافة العوامل التي قد تسبب
 في تصلب الشرايين مثل التدخين والضغط والسكري والكولسترول. لقد تم قياس س.ر.بي
 الحساس بواسطة طرق اليزا للمجموعتين ليجاد أي علقة ما بين هذا البروتين وأمراض
 القلب. وفي المقابل تم المقارنة ما بين هذا البروتين والكولسترول السيئ لمعرفة الفضل
 منهما في اكتشاف أمراض القلب المستقبلية. لقد تم إيجاد علقة إحصائية قوية بين وجود
  الحصائي. وقدtset -t  باستعمال عامل 500.0 <Pسي, ر, بي الحساس وأمراض القلب 
 52.4(  لفئات سي,ر,بي الثلث ما بين المرضى وغير المرضى oitar sddo( ROكانت 
x
  ملغم لكل ليتر والكولسترول3( . سي,ر,بي الحساس أكثر من 22.7-43.2( IC% 59
 (4.32-5.2( IC %59 66.7   RO ملغم لكل ديسيليتر كانت 031السيئ اقل من 
بالمقارنة مع المجموعة المرجعية )س.ر.بي قليل مع الكولسترول السيء قليل(.
 إن هذه النتائج تشير إلى أهمية إضافة فحص س.ر.بي إلى فحص الكولسترول السيئ المسحي
 لتشخيص الشخاص المعرضين لمراض القلب المستقبلية حيث ثبت فعاليته أكثر من فحص
 الكولسترول السيئ لوحده فقط. ويمكن إضافته أيضا في المختبر إلى جانب نسبة الكولسترول
 الكلي على الكولسترول الجيد مما يزيد من نسبة الكشف عن حالت المراض القلبية
المستقبلية.
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High sensitive CRP (hs-CRP) as a marker for Coronary 
Heart Disease (CHD) in Ramallah area- Palestine.
Abstract
 Mortality from (CHD) is the highest worldwide. For long time it  has 
been associated with high lipids concentration, mainly LDL-C. About 50-
60% of cases associated with CHD were diagnosed by lipid screening 
profile.  This profile failed to diagnose people who had a high risk for 
CHD in certain cases, and in some cases associated with normal LDL-C. 
Because of this, scientists are trying to identify other risk factors that may 
help  in  diagnosing  people  with  high  risk  for  developing future  CHD. 
Atherosclerosis is considered an inflammatory and atherogenic disease. 
As a result, inflammatory factors are considered as the most important 
factors  in  this  aspect.  C  -  reactive  protein  (CRP)  measured  by  high 
sensitive methods is considered the most predictive factor associated with 
future  coronary  heart  disease.  In  this  case  –control  study,  we  have 
selected 160 subjects (80 cases and 80 controls) from the West  Bank. 
Controls were free of CHD, while cases were diagnosed to have CHD. 
Both  groups  had  the  same  conditional  risk  factors,  such  as  smoking, 
hypertension,  diabetes,  and dislipedemia.  hs-CRP measured  by ELISA 
methods for both groups to find out the association between levels of hs- 
CRP and CHD. In addition a comparison between hs-CRP and LDL-C in 
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predicting future detection rate of CHD were studied. It was found that 
there  was  a  statistically  significant  relationship  between  hs-CRP  and 
CHD,  P  < 0.005 using  independent  t-test.  The  odds  ratio  for  equal 
quartiles of hs-CRP between control  and cases were found to be  4.25 
95% CI (2.34-7.22). hs-CRP greater than 3.0 mg/L and LDL-C less than 
130 mg/dl odds ratio was  7.66 with 95% CI (2.5-23.4)  compared to the 
reference group( Low CRP/ Low LDL-C).  These finding indicated the 
importance of adding hs-CRP to lipid screening profile. In this study it 
was found that  hs-CRP can be considered a good predictor  for  events 
associated with CHD more than LDL-C, and clinically can be added with 
T-cholesterol/HDL-C ratio to predict the risk for CHD.
xiii
Introduction
Coronary heart diseases (CHD) are the most prevalent causes of 
death  in  the  industrialized  nations  worldwide.   Half  of  all  events 
associated  with  CHD were  reported  in  apparently  healthy  individuals. 
Those individuals have normal or low cholesterol levels and have none of 
the traditional risk factors associated with CHD  (1). Therefore, attention 
has  been  focused  on  the  role  of other  factors,  such  as  inflammatory 
markers in patients at risk for atherosclerosis and CHD  (2). The goal to 
search for inflammatory biomarkers was to improve the detection of CHD 
risk among seemingly healthy individuals  (3). Several studies  (1,  6,  9) have 
shown  that  hs-  CRP,  a  protein  found  in  blood  circulation,  can  be 
predictive  of  future  (CHD)  events,  and  a  marker  of  inflammation  in 
detection patients at increased risk for CHD. Several prospective studies (1, 
10, 11, 12, and 21) have demonstrated that hs-CRP is an independent predictor of 
future risk for cardiovascular events among healthy individuals, as well as 
among  patients  with  acute  coronary  syndromes.  hs-CRP  can  add 
prognostic  information  on risk  at  all  levels  of  low-density  lipoprotein 
cholesterol  (LDL-C),  Framingham  Risk  Score,  and  at  all  levels  of 
metabolic syndrome (3, 33). The center for Disease Control and prevention 
(CDC) and the American Heart Association (AHA) recommended that 
hs-CRP  should  be  measured  among  individuals without  known  CHD 
twice and results  used to evaluate the risk for  the purpose of primary 
prevention  and  risk  detection  (2).  Most  (CHD)  events  begin  with 
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atherosclerosis  early  in  life  and  can  progress  in  the  body  silently  for 
decades  without symptoms  (4).  Recent  laboratory and clinical  evidence 
revealed that systemic inflammation plays a major role in the initiation, 
progression, and destabilization of atheromas  (5). Cholesterol and (LDL-
C) were used as screening tools for identifying individuals at increased 
risk of developing future coronary events.  Although this approach has 
been  useful,  it  fails  to  identify  about  one-half  of  the  1.3  million 
individuals who develop myocardial infarction (MI) in the United States 
(US) each year whose cholesterol level is normal or moderately elevated 
(5) . In a recent analysis of about 27939 healthy American females, it was 
found that about 77% of future myocardial infarction (MI), strokes and 
vascular related deaths occurred among women with LDL-C levels less 
than 160 mg/dl, and about 46% of events occurred among women with 
LDL-C less than 130 mg/dl. (6) . This has given rise to extensive study to 
add another  inflammatory  risk factor  mainly  hs-CRP to predict  future 
CHD. High sensitive assays for  determining hs- CRP concentration in 
blood to predict first cardiovascular events were developed. The aim of 
this research is to find out if hs-CRP considered as a marker of CHD in 
Ramallah area -Palestine.
C-Reactive Proteins
C - reactive protein (CRP) is a member of the hepatic pentraxin 
family of proteins, a group so named because they are composed of five 
identical subunits. Each subunit is composed of 206 amino acids with 
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molecular weight of 23027 Daltons arranged around a central pore as 
shown in Figure (1) (7).
Figure (1): CRP pentamere particle. (7)
CRP is an acute phase plasma protein, it was discovered in 1930. 
William Tillet and Thomas Francis define CRP as a substance present in 
the serum of patients with acute inflammation and reacted with the ‘C’ 
polysaccharide  of  pneumoccocus  (7,  9).  CRP is  a  member  of  a  special 
response  type  protein  called  ‘Acute  phase  reactants’.  CRP appears  in 
serum  in  response  to  a  variety  of  inflammatory  stimuli  including 
myocardial inflammation (7). CRP has a relatively stable concentration in 
the  body  and  a  long  half-life  in  the  absence  of  major  infection  or 
inflammation that may influence its concentration. The concentration of 
CRP  in  the  blood  measured  in  milligram  per  liters  (mg/L).  In  a 
comprehensive study hs-CRP mean level was found to be 1.8 mg/L for 
men and 2.0 mg/L for women. Furthermore, hs-CRP levels was found to 
increase  with  age,  approximately  30% of  those  subjects  in  the  study 
showed  hs-CRP  concentrations  greater  than  3.0  mg/L.  (7) .  Blood 
concentration  of  CRP  can  become  elevated  several  folds  during  an 
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infection,  inflammation or  neoplastic diseases.  Following tissue injury, 
CRP levels  begin to  rise  within 4-6  hours,  doubling  every  8-9 hours, 
reaching peak within 24 hours. Conditions that can elevate CRP levels in 
the body include rheumatoid diseases, vasculitides and chronic infections 
such  as  tuberculosis.  Other  conditions  that  fall  in  this  category  are 
allograft  vasculopathy  and  graft  occlusion,  connective  tissue  diseases, 
coronary  artery  diseases,  obesity,  sepsis,  smoking  and  vasculitis  (7,  9). 
Frequent  exercise,  aspirin  and statins  (3-hydroxy-3-methylglutaryl)  are 
shown to exert inhibitory effect on the production of CRP resulting in a 
reduced  concentration  of  this  protein  in  the  blood  (9)  .  During  major 
trauma or infection, inflammatory cells (neutrophils granulocytes etc) and 
red blood cells in response to the inflammation, secrete large amounts of 
cytokines. The most prominent secreted cytokines are the Interleukins 1, 
6 and 8 (IL-1, IL-6 and IL-8) and the tumor necrosis factor-alpha (TNF-
alpha). These cytokines then stimulate the liver to produce large amount 
of C-reactive proteins (CRP) (7, 8, and 9). In CHD, current events suggest that 
atherosclerotic lesions generate CRP, but the liver produces the bulk of 
CRP (7)  . Other proteins secreted by the liver in response to inflammatory 
stimulation includes, serum amyloid A, fibrinogen and mannan-binding 
lectin.  Since  these  proteins  are  released  in  response  to  acute 
inflammation,  they  are  appropriately  referred  to  as  ‘acute  phase 
reactants’.  Of all  acute phase reactants,  CRP has stood out as a novel 
biomarker for predicting the development and progress of several disease 
conditions,  mainly  cardiovascular  events  (9,  10,  and  11).   As  part  of  its 
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inflammatory  response  functions,  CRP  has  been  shown  to  stimulate 
monocyte to release pro-inflammatory cytokines such as interleukin-1b 
(IL-1b), IL-6, and tumor necrosis factor – alpha (TNF). It also mediates 
monocytes chemotactic protein-1(MCP-1) induction in endothelial cells 
and causes expression of intercellular adhesion molecule -1(ICAM-1) and 
vascular cellular adhesion molecule-1(VCAM-1) by endothelial cells (7, 12, 
13). It appears that CRP has direct interaction with LDL-C (9). The binding 
of atherogenic lipid in vitro and opsonization of LDL-C by CRP mediates 
uptake  of  LDL  by  macrophages  (12).  CRP  is  also  a  factor in  the 
development of atherosclerotic plaque. Although CRP was believed to be 
a marker of vascular inflammation, recent research indicates that it plays 
an  active  role in  atherogenesis.  It  is  detectable  in  the  early  stages  of 
plaque  development  and  believed  to  be  involved  throughout the 
atherogenic  process,  facilitating  the  whole  process  starting  with 
recruitment of leukocytes to the arterial wall and eventually rupture of the 
plaque (7, 12) . Calabro et al. have proposed that the smooth muscle cells of 
human coronary arteries may also produce CRP as a local response to 
inflammatory cytokines (8). They further noted that this locally produced 
CRP might participate in the atherogenic process (8). In addition, Khreiss 
et al. have suggested that loss of the pentameric symmetry of CRP can 
result in a modified or monomeric CRP, which may be the major CRP 
promoter of the proinflammatory response in the coronary arteries (13). As 
CRP concentration is traced back to inflammation,  its  measurement  is 
used  to  detect  the  presence  of  active  inflammation.  Latex, 
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immunoturbidimetric or immunoelectrophorectic assays are used for the 
measurement of CRP. The normal serum concentration of CRP measured 
by these procedures is from 3 mg/L to above 200 mg/L (9) . This range is 
not sensitive enough to predict cardiovascular risk in seemingly healthy 
men and women.  Scientists  had developed an improved and modified 
technique to measure hs-CRP. The new hs-CRP assay has the ability to 
detect concentrations of CRP below 0.2 mg/L. The technique relies on the 
use of labeled monoclonal or polyclonal antibodies to CRP in Enzyme 
linked Immunosorbent assay (ELISA) or immunofluorescent assay (7).  
Coronary Heart Diseases 
Coronary  heart  disease  (CHD),  also  known  as  Coronary  artery 
disease (CAD) is the most common cause of heart disease. This condition 
is due to problems with the coronary arteries i.e. arteries supplying blood 
to heart.  These arteries become narrowed and hardened due to the build 
up  of  fat  deposits  and  plaques  on  the  inner  walls  resulting  in 
atherosclerosis  (14).  The  cross  section  of  a  normal  vein  and  artery  are 
shown in Figure (2). Arteries carry oxygenated blood away from the heart 
while  veins  carry  non-oxygenated  blood  back  to  the  heart.  The  blue 
colored veins indicate the transport of blood with relatively low content 
of oxygen and high content of carbon dioxide. The red colored arteries 
indicate the transport of blood with relatively high content of oxygen and 
low content of carbon dioxide.
6
Figure (2): Cross section of a normal vein and artery (15) .
The  common  clinical  manifestations  and  complications  that  correlate 
with CHD are the following: (14)
- Stable Angina.
- Unstable Angina.
- Acute Myocardial Infarction.
- Heart failure.
- Arrhythmia.
- Sudden death.
Angina
 Stable angina:  It is ischemia due to fixed atheromatous stenosis of one 
or  more  coronary  arteries,  and  it  is  known as  angina  pectoris.  Stable 
angina is chest pain or discomfort that occurs when your heart muscle 
does  not  get  enough  oxygen-rich  blood. There  is  a pressure  or  a 
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squeezing pain in the chest and in the shoulders,  arms, neck, jaw, and 
back. This pain tends to get worse with activity and go away when you 
rest. Emotional stress also can trigger the pain. These symptoms occur 
when the vessels that carry blood to the heart become narrowed due to 
atherosclerosis, as shown in the Figure (3) (14, 15). 
Figure (3) Angina.(15)
Unstable  angina:  A  clinical  syndrome  that  is  intermediate  between 
stable angina and myocardial infarction. Chest pain occurs at rest or with 
less  exertion  more  often  than  stable  angina.  It  is  less  responsive  to 
medication. Unstable angina and myocardial infarction known as acute 
coronary syndromes (ACS). While stable angina considered as a chronic 
condition (15).
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Acute Myocardial Infarction: 
Acute myocardial infarction (MI) or heart attack occurs when one of 
the arteries that supply the heart muscle becomes blocked. This happens 
when an area of plaque in a coronary artery breaks apart,  causing a 
blood clot to form. The blood clot cuts off the blood to the part of the 
heart muscle that has fed by that artery. Cells in the heart muscle die 
because they do not receive enough oxygen-rich blood. This can cause 
irreversible lasting damage and necrosis to that part of the heart tissue 
as shown in the figure (4) (15).
Figure (4) Acut  Myocardial Infarction (15) .  
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Cardiovascular Risk Factors
Risk factors are conditions or behaviors that increase the chance of 
getting a certain disease. These factors are different types: (14).
Nonmodifiable Risk Factors:
- Age: The risk increases after age 45 in men, and after age 55 in women.
- Gender: Male sex develops higher risk than female, but by age 60-70 
years old they become equal frequency while after that age women 
became higher in risk in comparison to men.
- Family history of early heart disease. 
Increased risk if first-degree blood relatives have had coronary heart 
disease before the age 55 years for a male or 65 years for a female.
Modifiable Risk Factors: 
 
- Smoking.
- Hypertension.
- Dyslipidemia high total cholesterol, LDL- cholesterol and triglyceride. 
Levels and low level of HDL cholesterol 
- Obesity.
- Physical inactivity.
- Diabetes Mellitus.
- Unhealthy diet.
Novel Risk Factors
- Inflammation: Elevated C - reactive protein (CRP)
- Homocystine.
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CHD  is  diagnosed  by  medical  history,  physical  examination,  and 
diagnostic tests include non- invasive and invasive test, the non-invasive 
tests  include    Electrocardiogram (ECG),  exercise  stress  ECG test  by 
treadmill, pharmacologic stress tests, and stress echocardiography (14). 
Invasive  tests  such  as  cardiac  catheterization  (arteriography)  used  as 
diagnostic test to diagnose CHD (14) 
Atherosclerosis.
Atherosclerosis is a disease in which plaque builds up on the 
insides of the blood arteries that carry oxygen-rich blood to the heart and 
other parts of the body. Plaque is made up of fat, cholesterol, calcium, 
and other substances found in the blood.  These fatty materials deposited 
in the vessel wall, resulting in narrowing, hardening of the artery. 
Severely restricted blood flow in the arteries to the heart muscle leads to 
certain problems such as angina and heart attack. Atherosclerosis shows 
no symptoms until complications occur (15).
Atherosclerosis  is  a  vascular  inflammatory  disease 
characterized by activation of the endothelium followed by 
cellular  infiltration  and  cytokine  production.  This  process 
leads to the formation of foamy macrophages, formation of 
atheromatous plaques, and atherothrombotic disease. (9) .
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Cigarette  smoking,  limited  exercise,  obesity,  and  a  diet  high  in 
carbohydrate or high in cholesterol and saturated fat are manageable 
high-risk  factors  for  atherosclerosis.  Some  people  are  genetically 
susceptible  to formation  of  plaques,  while  others  are not  genetically 
susceptible. Those that are susceptible form fatty streaks in the tunica 
intima at a young age. A fatty streak emerges when the endothelial cells 
subjected to large concentrations of cholesterol and lipoproteins in the 
blood. Prolonged exposure to cholesterol and lipoproteins transforms 
the fatty streaks into a plaque (15). Recent medical advancement suggests 
that  atherosclerosis  and atherogenesis  is  due to  more  than just  lipid 
deposits.  Research studies define the process of atherosclerosis as (a 
progressive  inflammatory  disorder  of  the  arterial  wall  that  is 
characterized  by  focal  lipid  rich  deposits  of  atheroma  that  remain 
clinically  silent  until  they  become  large  enough  to  impair  arterial 
perfusion or disruption of the lesions results in thrombolic occlusion or 
embolisation at the affected vessel  )  (14).  This process is divided into 
four stages as shown in figure 5: (4) 
1: Endothelial dysfunction.
2: Fatty streak formation.
3: Formation of an advanced, complicated lesion of atherosclerosis.
4: Rupture of the fibrous cap or ulceration.
12
                      Figure 5 : different stages of atherosclerosis. Ref (4)
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Several  proinflammatory  mediators  considered  in  atherosclerosis 
process:
1- Prolonged high levels of  LDL particles in blood stream 
infiltrate the arterial intima.
2- Lipoprotein  particles  undergo  oxidation  or  other 
modification give rise to proinflammatory and pro- oxidant derivatives.
3- Cytokines,  such  as  interleukins-1(IL-1),  tumor  necrosis 
factor (TNF), and angiotensin II.
4- Adipose tissue may drive inflammatory responses in the artery 
wall.
5- A failure of counter regulatory mechanism, example HDL 
particles  may  function  as  carriers  for  anti  inflammatory 
and anti-oxidant mediators (7, 14) .
CRP and Atherosclerosis
Recently hs-CRP linked to future development of (CHD) and the baseline 
levels of hs-CRP in the absence of any infection or tissue injury used in 
cardiac  risk  assessment  (7) .  Khreiss  at  al.  provided the  first  evidence 
suggesting  structural  modification  of  pentameric  CRP  to  monomeric 
subunits which is a potent atherogenic in human aortic endothelial cells 
(13) . Figure (6) illustrates the potential role of CRP in atherogenesis that is 
composed of four stages: (7 )
1-  Endothelial  dysfunction: CRP  in  this  stage  inhibits  the 
generation of endothelial nitric oxide synthase (e-NOS), nitric oxide, and 
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prostacyclin.  CRP  also  stimulates  endothelial  cell  apoptosis  and  the 
production of vasoconstrictor endolthelin-1 (ET-1) and IL-6 resulting in 
blunting of endothelial vasoreactivity.
2-  Endothelial  activation: CRP  activates  factor  NFkB  and 
stimulates  production  of  IL-6,  IL-8,  vascular  cell  adhesion  molecule 
(VCAM-1),  Intracellular  adhesion  molecule  (ICAM-1),  and E-selectin. 
The result of this activation is monocyte adhesion and recruitment to the 
endothelium.
3- Plaque formation:   CRP stimulates the expression of monocyte 
chemotactic  protein  (MCP-1)  which  promotes  the  transmigration  of 
monocyte  to  arterial  wall.  CRP  also  promotes  LDL  uptake  by 
macrophages and formation of foam cells and generation of both reactive 
oxygen  species  and  cytokines  that  fuel  plaque  formation.  CRP  may 
promote plaque remolding and maturation by stimulating smooth muscle 
cell  proliferation  and  migration  via  the  angiotensin  type1  receptors 
(AT1R) which regulated by CRP.
4-  Plaque  rupture: CRP  promotes  matrix  metalloproteinase 
(MMP) activity,  which denatures collagen and destabilizes the plaque. 
CRP  inhibits  (NO)  and  prostacyclin  release  and  endothelial  cell 
migration. On the other hand, stimulate the release of tissue factors from 
monocytes and the synthesis of plasminogen activator inhibitor (PAI-1). 
These conditions create a prothrombolic environment and favors plaque 
rupture and vessel thrombosis.
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Figure (6) the potential role of CRP in atherogenisis. Adopted from Ref. (7 p 56)
hs-CRP as an Independent Risk Factor
A number of large prospective epidemiologic studies have indicated that 
hs-CRP is a strong independent predictor of future cardiovascular events. 
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These events include myocardial infarction, ischemic stroke, peripheral 
vascular disease, and sudden cardiac death. In a Women’s Health Study 
(WHS),  it  was  found that  hs-CRP compared  to  LDL-C was the  most 
powerful  predictor  of  future  vascular  events.  Among  27939  healthy 
females  studied  and  followed  over  8  years  period  for  future  vascular 
events and evaluated for a full  lipid panel as well as baseline hs-CRP 
levels, they found that there is a minimal relationship between hs-CRP 
and LDL-C (r=0.08) and thus the inflammatory process was providing 
information on plaque rupture separately from that of lipid evaluation (6) . 
The WHS study established a clinical cut points for hs-CRP as mentioned 
above less than 1.0, 1.0-3.0, and greater than 3.0. These cut points, can 
predict vascular risk across all levels of LDL-C after adjustment for other 
risk factors and across all levels of the Framingham Risk score  (6)  . Paul 
Ridker,  and  others  in  a  prospective  study  among  women  shows  the 
independence of hs-CRP and LDL-C as risk factors for cardiovascular 
disease  (16). In another study that  are more recent quartiles for  hs-CRP 
shown  to  provide  additive  prognostic  information  across  all  levels  of 
LDL-C,  apolipoprotien  B100,  T-Cholesterol/HDL ratio  even  after  full 
adjustment  for  traditional  risk  factors  (17) .  The  association  between 
elevated  hs-CRP  levels  and  future  CHD events  has  generally  been 
consistent among different studies. In a cohort study of 1086 apparently 
healthy middle-aged men, subjects with baseline levels of hs-CRP that 
were in the highest quartile had a twofold increase in risk of ischemic 
stroke or peripheral vascular disease (P=.02),  and a threefold increase in 
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risk of myocardial infarction (P<.001) relative to subjects in the lowest 
quartile.  These  effects  were  independent of  other  cardiovascular  risk 
factors,  including  lipid  levels and  smoking  (18) .  The  Honolulu  Heart 
Program analyzed frozen serum samples to assess the relationship of hs-
CRP to the development  of  myocardial infarction in  clinically  healthy 
men over a follow-up period of 20 years. Overall, hs-CRP levels in this 
study were associated with coronary events that occurred as many as 15 
years later. As early as five years into follow-up, the risk of myocardial 
infarction grew with increasing hs-CRP levels (P=.009). At 10 to 15 years 
into follow-up, the relative odds of myocardial infarction in the highest 
hs-CRP  quartile  were  2.1  times  that of  the  lowest  quartile,  after 
adjustment  for  such risk factors as total  cholesterol,  hypertension,  and 
type 2 diabetes  mellitus (P=.016)  (19) .  Nested case-control analyses of 
121,700 women in the Nurses' Health Study and 51,529 men in the Health 
Professionals.   Follow-up Study  of  239  women  and  265  men  free  of 
cardiovascular  disease  supported  the  results  of  the  Women's  Health 
Study, it  was  found  that  hs-CRP  is  a  predictor  of  CHD  and  it  is 
independent of other  cardiovascular  risk factors  (20)  .  In contrast  to the 
results of these and many other trials, a nested case –control study of 157 
elderly subjects from the Rotterdam Study in 2003 raised concerns about 
whether hs-CRP adds predictive value to traditional risk factors. In this 
study measurements of CRP adds no additional value to traditional risk 
factors  (21) . This concern raised again in 2004 by a cohort study of the 
Reykjavik  trial  that  questioned the  usefulness  of  CRP  over  more 
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established risk markers. In this study, 2459 patients diagnosed with CHD 
after  enrollment matched with 3969 controls that  did not have a CHD 
event. After adjustments for smoking status and other established CHD 
risk  factors,  patients  whose  baseline  hs-CRP  levels  were  in the  top 
quartiles  (cutoff  value=2.0  mg/L)  had an  odds  ratio  for CHD of  1.45 
(95% CI, 1.25-1.68) compared with those in the bottom quartiles (cutoff 
value=0.78 mg/L). The Reykjavik investigators concluded that hs-CRP 
added only little predictive value of established risk factors (22) .
Relationship between hs-CRP and Coronary Heart Diseases
Recent clinical and laboratory studies have shown that atherosclerosis, 
the precursor to most coronary heart diseases, is not simply a disease of 
fat deposit and inflammation plays a crucial role in the progression and 
development of this disease (4). Attention turned towards studying the role 
played by C-reactive protein (CRP) in atherosclerosis and several results 
emphasized  the  relationship  between  hs-CRP  and  (CHD),  and  its 
prognostic  value  in  acute  coronary  syndromes  and  the  ability  to 
effectively predict a future coronary event in seemingly healthy men and 
women. CRP extensively researched over the last  couple of years as a 
surrogate marker of other inflammatory mediators  like IL-6, IL-1, and 
TNF-alpha to understand the inflammatory component of atherosclerosis. 
These barrages of studies have shown that the level of CRP in the blood 
might  be  a  yardstick  to  measure  or  predict  the  possibility  of 
cardiovascular events both in acute coronary syndromes and in seemingly 
healthy individuals (23) . Elevated hs-CRP shown to be a strong predictor 
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of future cardiovascular risk in patients with established CHD, with or 
without a previous CHD. In a study shows the relation between high CRP 
and thromboembolic stroke, it was found that elevated CRP considered as 
important  risk  factor  in  healthy  men  for  those  people.  In  this  study, 
patients in the highest quartile for hs-CRP levels had the highest risk of 
stroke compared to those in the lowest quartiles (24) . Furthermore, Blake 
and  Ridker  had  shown  that elevated  hs-CRP  could  predict  risk  of 
cardiovascular events (including death, acute myocardial infarction, and 
need  for  revascularization procedures)  in  patients  with  acute  coronary 
syndromes (ACS) (12)  . Morrow and his mates were able to demonstrate in 
a study that elevated CRP in patients with unstable angina or non-Q wave 
myocardial  infarction  (NQMI)  is  correlated  with  increased  14-day 
myocardial  infarction  even  in  patients  with  a  negative  rapid  cardiac 
specific troponin T (cTnT)  (25) .  A study by Liuzzo and his colleagues 
showed that in 32  patients with chronic stable angina, 31 patients with 
severe unstable angina, and 29 patients with myocardial infarction (MI) 
hs-CRP level greater than 3mg/L on admission was associated with an 
increased incidence of recurrent angina, myocardial infarction and even 
cardiovascular  death  (26) .  Also,  Bholasing,  de  Winter  and others  in  a 
separate  study  demonstrated  that  hs-CR  concentrations  greater  than 
5mg/L on admission of 150 patients with acute coronary syndrome was 
associated  with an increased  incidence  of  major  cardiac events  within 
6months,  irrespective  of  cardiac  troponin  I  values  (27) .  To  further 
emphasize the relationship between hs-CRP and coronary heart events, A 
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Report from a study carried out by the Multiple Risk Factors Intervention 
Trial (MRFIT) showed that a direct positive association exists between 
hs-CRP  and  coronary  heart  disease  mortality  in  seemingly  healthy 
smoker men followed over a 17-year period (28) . 
hs-CRP as global risk factor
Using traditional risk factors, clinicians can predict approximately 
50% to 60% of future coronary heart event in healthy individuals. The 
addition of hs-CRP to current strategies for global risk assessment, such 
as the Framingham Risk Score (FRS), may therefore have the potential to 
increase  the  accuracy  of  cardiovascular  risk  prediction.  The  most 
surprising fact about the predictive utility of hs-CRP is that the results 
and estimates derived from most  of  the above-mentioned studies were 
independent of other recognized cardiovascular risk factors. For instance, 
result  from  the  Physicians’  Health  Study  (PHS)  demonstrated  a 
significantly higher predictive value associated with hs-CRP compared to 
that attributed to traditional biochemical  coronary heart disease (CHD) 
risk markers such as Total Cholesterol (TC), (HDL-C) and (LDL-C). In a 
study  carried  out  by  Ridker  and  his  colleagues  on  post  menopausal 
women, hs-CRP was shown to predict cardiovascular risk among women 
with  LDL-C  value  of  lesser  than  130mg/L,  a  concentration  that 
considered to be normal for LDL-C (16) .
Besides  lipids,  it  appears  that  some  coronary  heart  disease  risk 
factors affect inflammation response and hence hs-CRP concentrations. 
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One of such outstanding facts is the relationship between obesity and hs-
CRP. Obesity has a direct association with increase concentration of hs-
CRP, Interleukin 6, the primary stimulant of the hepatic synthesis of CRP 
secreted by adipose tissues.  This  logically  explains  the mechanism by 
which weight loss and diet reduces cardiovascular risk – due to reduction 
in  inflammatory  response  (29,  30).  In  a  different  study,  Festa,  and  Ford 
reported  increased  hs-CRP  concentrations  in  diabetic  patients,  which 
considered  as  a  direct  relationship  between  the  insulin  resistance 
syndrome and hs-CRP (31). In addition, Liu et al. and McCaron et al. in 
different experiments were able to demonstrate the effect of high blood 
pressure on hs-CRP. The report of their experimental study showed that 
high blood pressure promotes endothelial cytokines causing inflammatory 
activation in rats (32). Recent evidence suggests that hs-CRP plays a major 
role in the physiologic processes associated with the metabolic syndrome. 
High  levels  of  hs-CRP  shown  to  be  an  independent  predictor of 
cardiovascular risk for all degrees of severity of the metabolic syndrome 
(33) . Albert et al., demonstrated that hs-CRP levels are correlated with the 
calculated 10-year FRS in men, as well as in women not taking hormone 
replacement  therapy  (34) .  Data  from  the  Augsburg cohort  of  the 
Monitoring  Trends  and  Determinants  in  Cardiovascular  Disease 
(MONICA) study also showed that hs-CRP enhances the assessment of 
global coronary risk as measured by the FRS, particularly in persons at 
intermediate risk for CHD  (35). In the Women's Health Study, both very 
low (<0.5 mg/L) and very high (>10 mg/L) levels of hs-CRP were useful 
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for risk prediction across a full range of FRS. Women with hs-CRP levels 
of less than 0.5 mg per liter had the lowest risk of future cardiovascular 
events. Women with hs-CRP levels of greater than 20 mg per liter had a 
risk almost 8 times higher than normal women did. In a reanalysis of the 
WHS  data,  a  linear  response  between  hs-CRP  and  vascular  risk  was 
observed even among those with levels of hs-CRP greater than 20 mg/L. 
Thus, those patients recognized as very high-risk patients (Figure 7) (36).
Figure (7): Relative risk of future cardiovascular events across a full clinical range 
of  hs-CRP  values.  Black  bars  represent  crude  relative  risks  and  gray  bars  risk  
adjusted to FRS. Ref.  (36)
hs-CRP modified  as  global  risk factor  by  calculating the Framingham 
Risk Score based on current scoring system and divide patients into three 
groups with 10-year risks of less than 5 percent, 5-10 percent, and 10-20 
percent. Then hs-CRP data utilized in five gradations (<0.50, 0.5- <1.0, 
23
1.0- <3.0, 3.0- <10, and ≥10.0) to generate an “hs-CRP Modified Global 
CHD Risk” (Figure 8) (37).
Figure (8): Relative risks of future vascular disease using baseline levels of
hs-CRP in addition to calculated 10-year Framingham risk. Ref (37)
Clinical trials have shown that statins reduce patient levels of CRP by 
15% to 28% as early as six weeks after treatment begins independent of 
the  magnitude  of  reduction  in  LDL-C levels.  Although  statin  therapy 
showed to benefit  individuals with elevated hs-CRP levels,  not  known 
whether  aggressive statin  therapy  can  reduce  the  risk  of  a  first 
cardiovascular event in persons with low LDL-C but high hs-CRP (38).
Guidelines for Use of hs-CRP in risk assessment
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In January 2003, guidelines from the Centers for Disease Control 
and  Prevention  (CDC)  and  the  American  Heart  Association (AHA) 
named  hs-CRP  as  the  inflammatory  marker  of  choice  to  assess 
cardiovascular  risk  (2).  The  guidelines  support  the  use  of  hs-CRP in 
primary  prevention  and  set  cutoff  points  according  to  relative risk 
categories: low risk (<1.0 mg/L), moderate risk (1.0-3.0 mg/L), and high 
risk  (>3.0  mg/L)  (2) .  Recently,  Ridker  and Cook suggested  that  even 
though levels of very low < 0.5 mg/L, and very high >10 mg/L of hs-CRP 
uncertain to give positive predictive value for CHD. These values of hs-
CRP would provide clinicians with additional prognostic information on 
cardiovascular risk  (36). The CDC-AHA guidelines state that the optimal 
use of hs-CRP is to help guide the evaluation and therapy for primary 
CHD prevention for patients at intermediate risk  (2,). The guidelines also 
consider  measurements  of  hs-CRP as  a  possible  predictor of recurrent 
events in patients with stable coronary disease or ACS (2)  . The use of hs-
CRP as an adjunct to lipid screening in primary prevention intended to 
improve global risk prediction in patients not clearly identified as being at 
high risk by cholesterol levels alone.  This  adjustment  to the screening 
procedure is especially important for individuals with low LDL-C levels 
(<130 mg/dL)  but  high  hs-CRP  levels  (>3  mg/L).  Preliminary  data 
suggest that patients with low LDL-C and high hs-CRP levels may benefit 
from pharmacologic intervention, preferably with statin therapy  (3)  . The 
addition  of  hs-CRP levels  to  standard  cholesterol  evaluation protocols 
improves the predictive value of lipid parameters for determining future 
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risk of myocardial infarction. Men with high levels of both hs-CRP and 
total  cholesterol  had a  5.3  times  greater  relative  risk  of  a  future 
myocardial  infarction (P<.001)  than  did  men  with  either  high  total 
cholesterol or  high hs-CRP levels  alone  (23).  Furthermore, women with 
high hs-CRP and low LDL-C levels had a higher absolute risk of a future 
CHD event than did women with low hs-CRP and high LDL-C levels, 
despite the fact that high LDL-C is traditionally targeted for aggressive 
intervention in primary prevention  (6). Many studies suggests that CRP 
might  have  implications  for  future  risk  assessment,  especially  in 
intermediate risk group ,  and adding it to Total Cholesterol/HDL ratio 
will independently related to incident coronary events (35) .
Hypothesis and Specific aims
Hypothesis 
We  hypothesize  that  hs-CRP  is  a  marker  of  Coronary  Heart 
Disease (CHD) among Palestinian people in the Ramallah area, Palestine.
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Specific Aims
The specific aims of this Case –control study are:
-  To  evaluate  the  association  between  hs-CRP  and  the 
coronary Heart disease (CHD) in West Bank _Palestine. 
- To compare  hs-CRP and LDL-cholesterol  as  risk factors 
associated with CHD.
- To  establish  a  relative  risk  for  a  CHD  based  on  Total 
Cholesterol/HDL ratio and hs-CRP. 
Materials and Methods
A signed consent was obtained from the patients prior to enrollment in 
this study.
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 Subjects: Subjects enrolled in this study were divided into two groups; 
the  first  group  consisted  of  80  patients  (64  males  and  16  females) 
diagnosed to have CHD by a cardiologist. The second group consisted of 
80 healthy subjects (49 males and 31 females) with no symptoms of CHD 
prior to the study. All subjects are from the West Bank selected from the 
Medical  Relief  Prevention  and  Diagnostic  Center  of  Cardiovascular 
Diseases –Ramallah during the period from September 2005 until Feb. 
2006.  Risk  factors  for  coronary  heart  disease  such  as  smoking, 
hypertension, diabetes, and dyslipidemia were equal in both groups. The 
cardiologist,  who  diagnosed  these  cases,  completed  a  written 
questionnaire  for  all  patients  and  controls  with  comprehensive 
information.   For  each  patient,  the  medical  record  was  reviewed  to 
determine the presence of risk factors for atherosclerotic cardiovascular 
disease.  The Total  Cholesterol,  HDL-cholesterol,  LDL-cholesterol,  and 
Triglycerides  were  assayed  using  standard  manual  methods  for  all 
subjects. hs- CRP was determined using Enzyme Immunoassay (ELISA) 
technique and the results for hs-CRP were calculated in mg/L. The data 
was analyzed to find if there is significant  difference between patients 
and control group.
Sample collection: Samples were collected from fasting subjects in 10-ml 
plain glass tubes (Becton Dickinson Vacutainer Systems).  The samples 
were allowed to clot at room temperature for 30 min. The serum was then 
separated  by  centrifugation.  Each  specimen  was  divided  into  two 
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aliquots, one for lipid profile, and the other was kept at-20 C for hs-CRP 
testing.  Repeated  freezing  and  thawing  was  avoided,  and  hemolysed 
samples were rejected.
Methods
CRP  assay:  CRP  was  assayed  by  a  sandwich  enzyme  immunoassay 
(ELISA) kit (CRP DiaMed EuroGen, Lot No. 98104666 and expiry date 
in  Sep/2007)  Belgium.  The  minimal  detectable  concentration  for  the 
assay  was  determined by the manufacturer  to be less  than 1.0 mg/L. 
Standards  0.0,  1.25,  2.5,5.0,10,25,and  50 mg/L  were  used  to  plot  the 
calibration  curve  to  calculate  the  patients  results.  The  assay  was 
performed according to manufacturer instructions.  
Principle  of  the  test:  CRP  in  the  patient  serum samples  and  diluted 
standards react with polyclonal anti-CRP antibodies, immobilized on the 
solid phase of micro titer plates. Following an incubation period of 30 
min at RT, unbound serum components were removed by a wash step. 
After  removal  of  the  unbound  serum  proteins,  the  antigen-  antibody 
complex in each well was detected with specific peroxidase conjugated 
antibodies. After the removal of the unbound conjugate, the strips were 
incubated with the chromogen solution 3, 3, 5, 5-tetramethyl-benzidine 
(TMB) and hydrogen peroxidase. A blue color developed in proportion to 
the  amount  of  immunocomplex  bound to  the  wells  of  the  strips.  The 
enzyme reaction was stopped by dispensing an acidic solution (H2SO4) 
into  the wells  turning the  solution  from blue  to  yellow.  The standard 
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curve was then plotted. The concentration of CRP in each sample was 
determined by interpolation from the standard curve.
Total Cholesterol: Total Cholesterol was measured by using Randox, UK 
reagents. The cholesterol was determined after enzymatic hydrolysis and 
oxidation. Aliquetes of 10 ul of Standards, controls, and samples were 
added to 1000 ul of cholesterol reagents. Then the tubes were incubated 
for  5 min at  37º c.  The absorbance of the samples and standards was 
determined  against  reagent  blank  using  spectrophotometer  within  60 
minutes  at  546  nm  Hg.  The  results  were  calculated  by  dividing  the 
absorbance  of  the sample  against  the standard  and multiplying by the 
concentration of the standard.
HDL – Cholesterol:  HDL-Cholesterol was measured after precipitating 
LDL,  VLDL,  and  chylomicron  fractions,  by  the  addition  of 
phosphotungstic  acid  in  the  presence  of  magnesium  ions  (Randox). 
Aliquot  of  500 ul  of  serum was  added  to  1000 ul  of  precipitant  and 
allowed to stand for 10 min at room temperature. After centrifugation at 
4000 rpm for 10 minutes, to get a clear supernatant containing the HDL 
cholesterol, HDL –cholesterol was determined using cholesterol reagent 
as mentioned previously of a Total Cholesterol.
LDL –Cholesterol: LDL- cholesterol was measured after precipitation by 
heparin  at  their  isoelectric  point  using  Randox  reagents.  After 
centrifugation, the HDL and VLDL remain in the supernatant and were 
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measured by a spectrophotometer at 415 nm. The LDL-cholesterol was 
then calculated according to the following formula:
LDL –cholesterol = Total cholesterol – Cholesterol in the supernatant.
100 ul of serum was added to 1000 ul precipitation reagent and allowed 
to stand for 10 min at room temperature. The tubes were then centrifuged 
for 15 min at 4000 rpm. The cholesterol concentration of the supernatant 
was determined using cholesterol reagents. 
Triglycerides:  Randox  reagent  was  used  to  assay  triglycerides.  The 
triglycerides  were  determined  after  enzymatic  hydrolysis  with  lipases. 
Serum  specimens  were  collected  after  fasting  12-14  hours.  10  ul  of 
standards,  controls,  and samples were added to 1000 ul of triglyceride 
reagents. Then they were incubated for 5 min at 37O C. The absorbance 
was determined for both standards and samples against reagent blank at 
500 nm. The results were determined by interpolation from the standard 
curve.
Statistical Analysis
31
The statistical analysis was performed using the Statistical Package 
for Social Sciences Software (SPSS for windows version 12).
Means  and  proportions  for  risk  factors  for  cardiovascular  events at 
baseline were calculated for both cases and controls. The means for hs-
CRP,  Total  Cholesterol,  LDL-cholesterol,  HDL-cholesterol,  and 
Triglycerides were compared between the two groups by using 2-sample 
t-test.  The  proportions  were  compared  by  using  the  chi-square  test. 
Analysis of trends was used to test for associations between increasing 
levels of each plasma variable and the risk of cardiovascular events. The 
study subjects were divided into groups according to low, medium, and 
high  levels  of  LDL-cholesterol,  and  hs-CRP.  Logistic  regression  was 
performed to evaluate relative risk or odds ratio of cardiovascular events 
in each of these groups. The odds ratio of different quartiles of hs-CRP, 
and the odds ratio of combination between quartiles of hs-CRP and LDL-
C  were  calculated.  The  likelihood-ratio  test  was  used  to  determine 
whether logistic-regression  models  that  include  LDL-C and  hs-CRP 
provide  a  significantly better  fit  than  did  logistic-regression  models 
limited to LDL-C or hs-CRP alone.  All P values were two-tailed, and a 
value of less than 0.05 was considered to indicate statistical significance. 
All confidence  intervals (CI) were calculated at the 95 percent level.
Results
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 In this case control study we investigated hs-CRP as a marker of CHDin 
patients from Ramallah area- West Bank –Palestine. This was done by 
defining two groups: one control group free of CHD, and the other group 
is the patients group diagnosed to have CHD. Both groups (the controls 
and the patients) were similar in age, and in the presence of other CHD 
risk factors such as smoking, hypertension, diabetes, and dyslipedemia. 
The results of the different variables, lipid profile tests as well as hs-CRP 
for patients and controls are summarized in Tables 1 and 2. The means ± 
SD  for  the  different  variables  in  this  study  of  both  groups  with  the 
significant P value are shown in Table 3. Our results showed that there is 
a significant difference for hs-CRP concentration between controls and 
patients (P<0.001). The mean ± SD for hs-CRP for patients and controls 
was  5.90±3.1 and 2.62 ±1.59 respectively  (Table  3).  LDL- C showed 
significant  difference  (P  =  0.003)  between  the  patients  and  controls 
(Table  3).  There  was  no  significant  difference  for  total  cholesterol 
(P<0.072), HDL-C (P 0.728), and TG (P=0.355) between patients and 
controls. Other factors evaluated such as age, sex, hypertension, diabetes 
reflected a significant difference (P<0.05) between patients and controls. 
There  was  no  significant  difference  for  smoking  (P  =  0.124),  and 
dyslipidimia (P=0.115) between two groups tested. Analysis of hs-CRP 
to  find  out  the  odds  ratio  was  found  to  be  1.88  95%  CI  (1.54-2.3), 
compared to LDL-C odds ratio 0.98 CI 95 % (0.97-0.99). These values 
indicates the increased risk per unit for both hs-CRP and LDL-C.
33
Table (3) - Mean and standard deviation of the different variables for both patients  
and control, and statistical significance (P trend).
Variable Control N=(80) Cases N=(80) P trend
Age, mean ±SD. 51.1±13.6 60.7±11.9 0.000
Sex, % male
        % Female
49(61.3 %) 
31 (38.3%)
64 (80%)
16 (20%)
0.009
Smokers, % 26.3 16.3 0.124
Hypertension,% 16.3 56.3 0.000
Diabetes, % 35 60 0.001
Dyslipedemia, % 86.3 93.8 0.115
Total Cholesterol
Mean ± SD
220±38.3 209.0±36.1 0.072
LDL-C 141.5±25.1 128.2±31.0 0.003
HDL-C 36.4±7.4 36.5±7.0 0.728
TG 143±56 153.8±81.2 0.355
hs-CRP 2.62±1.59 5.90±3.1 0.000
In  this  study,  we  grouped  our  results  for  hs-CRP,  LDL-C  to  three 
quartiles. The Ratio of T-cholesterol/HDL-C was calculated and divided 
into five quartiles as in Table 4. These different quartiles were used to 
find out the odds ratio for both hs-CRP, and LDL-C quartiles. In addition, 
these groups were used to evaluate interaction between hs-CRP and LDL-
C. 
Table (4).Different quartiles of hs-CRP, LDL-C, and T-cholesterol/HDL ratio.
CRP Quartiles Total
 1.00 2.00 3.00  
Cases control 10 43 27 80
 patient 4 13 63 80
Total 14 56 90 160
LDL Quartiles Total
 1.00 2.00 3.00  
Cases control 24 37 19 80
 patient 42 27 11 80
Total 66 64 30 160
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T-Cholesterol/HDL ratio Total
 1.0 2.00 3.00 4.00 5.0  
Cases control 3 4 8 14 51 80
 patient 1 7 17 11 44 80
Total 4 11 25 25 95 160
CRP (1.0) represents <1.0 mg/L, (2.0): 1.0-3.0 mg/L, and (3.0): >3.0 mg/L. For LDL-
cholesterol (1.0) less than 130 mg/dl, (2.0): 130-160 mg/dl, and (3.0) greater than 
160 mg/dl.And for T-chol/HDL ratio (1.0) : <3.4, (2.0): 3.4-4.0, (3.0); 4.1-4.8, (4.0):  
4.8-5.50, and 5.0 >5.5. 
The odds ratio (OR) and the confidant interval (CI) for hs-CRP were 4.25 
95%  CI  (2.34-7.72),  P  < 0.001.  These  finding  for  hs-CRP  before 
adjustment of other risk factors evaluated in the study. hs-CRP odds ratio 
after adjustment with LDL –C was 5.93 and the 95% CI (3.0-11.6),  P< 
0.001. After adjustment with LDL-C and T-cholesterol/HDL ratio it was 
6.5  95%  CI (8.1-13.4), P <0.001. Odds ratio for hs-CRP adjusted with 
other  risk  factors  such  as  age,  smoking,  hypertension,  diabetes,  and 
dyslipedemia,  was  (4.0)  95% CI  (2.0-7.9) as  shown  in  Table  (5).  In 
comparison  to  hs-CRP,   LDL-C odds  ratio  was  0.584  95% CI  (0.35-
0.84), P< 0.006, which is significant ratio but the odds ratio was less than 
one, indicating a decrease in risk. 
Table (5) (OR) Odds Ratio, (CI) confidant Interval and P trend for different quartiles  
of hs-CRP and other variables associated with CHD risk factors before and after  
adjustment. 
Test Odds 
Ratio
CI P trend
hs-CRP 4.25 2.34 -7.72 0.000
hs-CRP * 5.93 3.0-11.6 0.000
hs-CRP ** 6.5 8.1-13.4 0.000
hs-CRP *** 4.0 2.0-7.9 0.000
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LDL-C 0.543 0.35-0.84 0.006
T-
cholesterol/HDL 
ratio
0.90 0.76-1.0 0.202
* LDL-C adjustment.
** LDL-C & T-cholesterol/HDL ratio adjustment.
*** Adjustment with Age, Sex, Diabetes, HTN, Smoking, and Dyslipedemia.
To explore that hs-CRP added to the predictive value of lipid-based 
screening, several additional analyses were performed.  First, we 
computed the OR of LDL -cholesterol quartiles as well as hs-CRP (Table 
6). We found that there was an increase in OR between different quartiles 
of hs-CRP compared to LDL-C quartiles in this study. The odds ratio for 
CRP group ( > 3.0 mg/L) was 5.25 95% CI ( 1.522-18.1), P < 0.009 as 
compared to reference  group CRP (< 1.0mg/L) which was significant. 
The second group for hs-CRP (1.0-3.0 mg/L) the odds ratio was 0.813 
and 95% CI (0.218- 3.0) compared to reference group and it was not 
significant. In our study, all quartiles of LDL-C showed significant P 
values < 0.05, and the odds ratio showed a decrease in risk for these 
different quartiles (Table 6). 
Table (6): Odds Ratio for hs-CRP and LDL-C quartiles of both groups before and 
after adjustment of risk factors.
Test Odds 
Ratio
CI P value
Quartiles of hs-CRP 
CRP<1.0) * 1.0
CRP(1.0-3.0) 0.813 0.218-3.0 0.757
CRP( >3.0) 5.25 1.52-18.1 0.009
CRP (1.0-3.0) after 0.466 0.101-2.15 0.328
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adjustment
CRP( >3.0) after adjustment 3.68 1.06-15.1 0.049
Quartiles of LDL-C
 (LDL<130) * 1.0
(LDL 130-160) 0.381 0.185-0.783 0.009
 (LDL >160) 0.400 0.171-0.933 0.034
LDL (130-160) after 
adjustment
0.291 0.116-0.728 0.008
(LDL >160) after adjustment 0.192 0.062-0.596 0.004
* Reference group. , (CI): confidant Interval.
Low hs-CRP < 1.0 mg/L, high hs-CRP >3.0 mg/L. Low LDL-C < 130 mg/dL, high 
LDL-C > 160 mg/dL.
To test if both hs-CRP and LDL-C interact to increase the risk of disease, 
different combinations of hs-CRP and LDL-C were studied (Table 7). 
The OR was computed for each combination using the low levels of hs-
CRP and LDL-C as the reference. The first quartile (hs-CRP low <1.0 
and LDL-C low < 130 mg/dL) was considered as reference group (OR 
1.0).   The second quartile (hs-CRP high >3.0 mg/L, and LDL-C high > 
160 mg/dL), the OR was (2.0) with CI (1.01-3.9) and P 0.025 before 
adjustment. After adjustment with risk factors the odds ratio was still 
significant 2.3 CI (1.05-5.9) P 0.036. Table 7 and Figure 9. The most 
significant group was the third quartile, (high hs- CRP and low LDL-C). 
Patients with LDL-C levels < 130 mg/dl and high levels of hs-CRP >3.0 
mg/L have higher risk (OR 7.66) CI (2.5-23.4) than patients with low hs-
CRP, and high LDL-C, (OR 5.2) CI (0.61-46.0) Table 7. A correlation 
between hs-CRP and LDL cholesterol for both groups was performed and 
r= 0.174 (P 0.028). This value considered low but there is a significant 
correlation between hs-CRP and LDL-C. The correlation between hs-
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CRP and LDL-C in controls 0.429, p < 0.05. Where the correlation in 
patients 0.385, p < 0.05. 
Table (7) Odds ratio of different combinations of hs-CRP & LDL-C quartiles. 
TEST OR CI P value
Low hs-CRP/Low LDL-C * 1.0
Low hs-CRP/high LDL-C 5.278 0.61-46.1 0.133
high hs-CRP/low LDL-C 7.66 2.5-23.4 0.00
high hs-CRP/high LDL-C 2.0 1.01-3.9 0.025
Low hs-CRP/high LDL-C** 1.69 0.162-17.7 0.659
high hs-CRP/low LDL-C ** 7.52 1.94-29.0 0.003
high hs-CRP/high LDL-C ** 2.3 1.05-5.19 0.036
* Reference group
** after adjustment with age, sex, Diabetes, HNT, smoking, and dyslipid.
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Figure (9) Odds Ratio for combination of different quartiles of hs-CRP & LDL-C
The  likelihood-ratio  tests  were  used  to  compare  the  fit of  predictive 
models that were based on measurement of hs-CRP in combination with 
LDL-C, and the fit of models based on LDL-C measurements alone. The 
likelihood ratio Chi-square statistics was higher for the models based on 
hs-CRP than that based on LDL-C (54.35 vs.15.35, both with 2 df). The 
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addition of CRP to the model based on LDL-C was stronger (chi- square 
= 51.3, 3 df,  and  P <0.001) than the addition of LDL-C to the model 
based on CRP (chi square = 44.6, 3df, and P<0.001). On the other hand, 
addition of CRP to the T-Cholesterol/HDL ratio was stronger (chi square 
41.5, df 3, P<0.001) than addition of the T-cholesterol/HDL ratio to CRP 
(chi square 38.74, df 5, P< 0.001).
Discussion
hs-CRP was found to be a significant predictor for the risk of future 
CHD events (1, 5, 9,and 10) . In addition, measurement of this marker increased 
the predictive value of models  based only on standard lipid screening. 
Among different parameters measured, and evaluated in many studies hs-
CRP was the most significant predictor of the risk for CHD events; when 
measured  with  a  highly  sensitive assay.  This  marker  distinguished 
between persons at high risk and those at low risk, even in the subgroup 
of persons with LDL cholesterol levels below 130 mg /dl (6).
Liuzzo and his colleagues showed that in 31 patients with no evidences of 
myocardial infarction (MI), hs-CRP levels were greater than 3mg/L upon 
admission to hospital. They were associated with an increased incidence 
of recurrent angina, myocardial infarction and even cardiovascular death 
(26). Another study, done by Bholasing, de Winter and others demonstrated 
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that hs-CRP concentrations of greater than 5mg/L upon admission of 150 
patients with acute coronary syndrome was associated with an increased 
incidence of major cardiac events within 6 months (27) .
The  results  of  this  study  showed  that  there  is  a  significant  difference 
between  the  patients  and control  groups.  The  odds  ratio  was  1.88  CI 
(1.54-2.3),  p < 0.001. This means that increased hs-CRP one unit  will 
increase  the  risk  factor  1.88  times.  This  indicates  a  good  association 
between high results of hs-CRP and the CHD in West Bank –Palestine. 
The mean ± SD for hs-CRP for patients and controls was 5.90±3.1, and 
2.62  ±1.59  respectively,  which  was  very  significant.  These  findings 
confirmed that hs-CRP marker is an important independent predictor of 
the risk of CHD events. The current data supported the hypothesis that 
atherosclerosis is, in part, an inflammatory disease (4), and hs- CRP can be 
used as a marker of this disease. To compare hs-CRP and LDL-C as a 
risk factor for CHD, different quartiles for both hs-CRP and LDL-C were 
done for low, moderate, and high risk. In this study, it was found that the 
odds ratio of all different  quartiles of hs-CRP was 4.25, and 95 % CI 
(2.34-7.72). This means that patients group had 4-fold increase in risk for 
CHD than control  group.  After  adjustment  of  hs-CRP with  other  risk 
factors mainly LDL-C, and total Cholesterol / HDL ratio, the odds ratio 
still very high and significant 5.9, and 6.5 respectively as shown in Table 
5.  These  results  was  evident  that  hs-CRP  remained  a  strong  and 
independent factor for CHD even in the presence or absence of other risk 
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factors.  In a prospective study among women, Paul Ridker, and others 
shows  the  independence  of  hs-CRP  and  LDL-C  as  risk  factors  for 
cardiovascular  disease  (16). The  addition  of  hs-CRP  levels  to  standard 
cholesterol evaluation   protocols improves the predictive value of lipid 
parameters for determining future risk of myocardial infarction. Men with 
high levels of both hs-CRP and total cholesterol had a 5.3 times greater 
relative risk of a future myocardial infarction (P<.001) than did men with 
either  high  total  cholesterol or  high  hs-CRP  levels  alone  (23).  In  a 
prospective study of  CRP and the risk of future  cardiovascular  events 
among  healthy  women,  those  in  the  highest  quartiles  had  five  fold 
increase in risk of any vascular events (Relative risk RR 4.8, ),  and a 
seven fold increase in risk of MI or stroke (RR 7.3) (16).  In a cohort study 
of  1086  apparently healthy  middle-aged  men,  subjects  with  baseline 
levels of hs-CRP in the highest quartile had a twofold increase in risk of 
ischemic stroke or peripheral vascular disease (P=.02) and a three fold 
increase in risk of myocardial infarction (P<.001), relative to subjects in 
the  lowest  quartile.  These  results  were  independent of  other 
cardiovascular risk factors including lipid levels and smoking (18) .
In  another  middle  age  group  men,  levels  of  CRP  were  positively 
associated with thromboembolic stroke (TE) through 20 years follow up, 
where the odds ratio of CRP was 3.8-fold excess by 10-15 years of follow 
up  between  the  highest  and  lowest  quartiles  (24) .  Several  additional 
analysis were performed on the different quartiles of hs-CRP and LDL-C 
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separately.  It  was  found  that  the  odds  ratio,  for  hs-CRP was  5.25  CI 
(1.522-18.1), P < 0.009 when (CRP more than 3.0 mg/L) compared to a 
reference group (CRP less than 1.0) which was significant. This means 
that a person falls in this quartile have 5-fold chance to develop CHD 
more than person in the first quartile does. The second quartiles for hs-
CRP (1.0-3.0 mg/L) was considered not significant (Odds ratio 0.813 CI 
0.218- 3.0). This means that high concentration of hs-CRP more than 3.0 
mg/L can be considered predictive for future events of CHD more than 
the second quartile.  On the other hand, all quartiles of LDL-C showed 
significant values  P < 0.05, where odds ratio showed a decrease in risk 
for the different quartiles as shown in Table 6.
In this study we test the interaction between both quartiles of hs-CRP and 
LDL-C. Table 7. Low hs-CRP and Low LDL-C were considered as a 
reference group. It was found that the odds ratio was 7.66, 95% CI (2.5-
23.4) for the quartile of hs-CRP > 3.0 mg/L, and LDL-C < 130 mg/ dl. 
These results support the idea that hs-CRP can predict risk if greater than 
3.0 mg/L even though LDL-C less than 130 mg/dL. But in our study this 
rule does not fit because all the control and patients group on drug 
therapy for LDL-C lowering. Another group significant when hs-CRP > 
3.0 mg/L, and LDL-C > 160 mg/dl. The odds ratio was 2.0, 95% CI 
(1.01-3.9) indicating that subject fall in the highest quartile have two 
times risk for CHD than subjects in the first quartile. These results for 
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this quartile less than the previous one because LDL-C results are not the 
true results, where most of the patients take medication Figure 10.
 These findings indicate that lipid screening needs other risk factors to 
detect events of future CHD. These results for LDL-C considered not 
significant because both controls and patients receive therapy to lower 
LDL cholesterol.  As a result, we need other risk factors independent on 
LDL-C. Our study indicated that hs-CRP was an independent factor for 
detection of CHD, even though there was a minimal correlation between 
hs-CRP and LDL-C (r = 0.174). In a similar study on 27939 healthy 
females, studied and followed over 10 years period for future vascular 
events and evaluated for a full lipid panel as well as baseline hs-CRP 
levels. They found that there is a minimal relationship between hs-CRP 
and LDL-C (r=0.08) and thus the inflammatory process was providing 
information on plaque rupture separately from that of lipid evaluation (16). 
This correlation for the controls 0.429, and for the patients 0.385 when 
analysis done separately for the controls and patients. In addition, in 
likelihood ratio tests of the contribution of each variable, the addition of 
CRP to the model based on LDL-C was stronger (chi- square = 51.3, 3 df, 
and P <0.001) than the addition of LDL-C to the model based on CRP 
(chi square = 44.6, 3df, and P<0.001). On the other hand, addition of 
CRP to the T-Cholesterol/HDL ratio was stronger (chi square 41.5, df 3, 
P<0.001) than addition of the T-cholesterol/HDL ratio to CRP (chi 
square 38.74, df 5, P< 0.001). Our study showed that CRP adds to the 
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predictive value of Total Cholesterol/HDL ratio in determining risk of 
cardiovascular disease. Where, adding hs-CRP to this ratio increases the 
predictive detection value.  hs-CRP and T-Cholesterol/HDL ratio were 
determined and arranged in Figure  (10) as shown below  for both men 
and women. Studies using data from the PHS have demonstrated that hs-
CRP is the most effective predictive marker and in combination with TC/ 
HDL ratio is the best overall predictor of relative risk estimates for future 
coronary events. The relative risk estimates for MI increased significantly 
with each increasing quartiles of baseline hs-CRP combined with TC/ 
HDL, where a relative risk (RR was 4.4) in the highest quartiles 
compared to the lowest quartiles (RR 1.0) (23).
Similar to men, the combination of hs-CRP and the TC/ HDL ratio 
provides the best predictive value for risk of future coronary events in 
women. Women with the highest quartiles levels of combined hs-CRP 
and TC:HDL ratio had a relative risk for future coronary events that were 
also 8.7 times higher compared to the lowest quartiles (39).
As a result,  measuring both hs-CRP and the ratio of Total Cholesterol  to 
HDL cholesterol allowed significantly better prediction of risk than did 
models based solely on this lipid ratio alone. Adding this risk factor to 
detect the risk for healthy people for CHD will help us in the laboratories 
to  increase  the  prediction  risk. Finally,  we  believe  that  these  current 
results have public health implications both in terms of the prediction of 
the risk of cardiovascular events and in terms of the use of statin therapy 
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for primary prevention. As in our findings, which indicate that hs-CRP is 
a potent independent predictor of risk regardless of the LDL cholesterol 
level; data from the Cholesterol and Recurrent Events trial indicated that 
use of  pravastatin  resulted in decreased levels  of hs-CRP in a manner 
largely independent of LDL cholesterol (42). 
Quintile of hs-C Reactive Protein, mg/L
1 2 3 4 5
<0.7 0.7-1.1 1.2-1.9 2.0-3.8 3.9-15.0
Quintile of
Chol./HDL ratio Men Women
1 <3.4 <3.4 1 1.2 1.4 1.7 2.2
2 3.4-4.0 3.4-4.1 1.4 1.7 2.1 2.5 3
3 4.1-4.7 4.2-4.7 2 2.5 2.9 3.5 4.2
4 4.8-5.5 4.8-5.8 2.9 3.5 4.2 5.1 6
5 >5.5 >5.8 4.2 5 6 7.2 8.7
Reference Ranges of Relative Risk values for a 
Future Coronary Event
Low <1.1
Mild 1.1 - 1.7
Moderate 1.8 - 2.9
High 3.0 - 5.1
Highest 5.2 - 8.7
 Figure (10) shows the relative risk for future coronary events among apparently  
healthy men and women associated with different hs-CRP concentrations and TC:  
HDL ratios. (5) 
Methodological considerations:
Several limitations to be considered for this case control study: First, our 
study  comprised  apparently  healthy  persons  without  CHD  as  control 
group and patients with CHD as case group, and the significant difference 
found to be between these  groups.  Therefore,  we recommend doing a 
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large study for the prediction of risk factors in our population to find out 
who  will  be  at  increased  risk  for  cardiovascular  events.  Second, we 
measured  hs-CRP  marker  and  thus could  not  evaluate  the  effects  of 
changes in the levels of this marker over time.  However, studies have 
found  that levels  of  hs-CRP are  stable  over  long  periods,  as  long  as 
measurements are  not  made  within  two  to  three  weeks  of  an  acute 
infection. Moreover, with respect to the current results, levels of hs-CRP 
over 20 mg/L where excluded from our study to avoid any acute cases of 
other diseases. Finally, the patients included in the study take medication 
for lowering LDL-C, as a result  both LDL-C and hs-CRP marker will 
decrease due to this therapy. This decrease may vary depending on the 
test measured where LDL-C may decrease due to therapy more than hs-
CRP.For this reason, the results of hs-CRP considered more predictive. 
For that reason to get the true level of hs-CRP to be considered as a risk 
factor,  a large number of subjects free of CHD with follow up over a 
period  are  recommended.  Another  conditional  factors  included in  this 
study are not significant such as smoking, this because most of the people 
asked if they are smoking or not during the study, not before. As a result, 
the percentage of smokers is very low in this study and this affect the 
results during analysis.
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Conclusions
In conclusion, in this study, the evaluation of hs-CRP proved to be 
a significant predictor of the risks of future CHD events. Thus, the data 
raise  the  possibility  that  the  addition  of hs-CRP  to  standard  lipid 
screening will  generate an improved method for  identifying persons at 
high risk for future cardiovascular events, who would thus be candidates 
for primary-prevention interventions such as the use of statin therapy. 
Testing of CRP with T-cholesterol/HDL ratio is a better criteria to predict 
the risk for future CHD than depending in the LDL-C and the ratio only. 
This factor of inflammation is an independent risk factor, and can be 
tested independent of other factors. 
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High sensitive CRP (hs-CRP) as a marker for coronary heart 
disease in Ramallah area –Palestine.
 Questionnaire
Questionnaire No.
1
2
Name..…………………………………………………………… :
DOB:………………………………..Age: ……..years. Sex:  M or F
Fasting Hours: 1) less than 8 hrs 2) 8-12 hrs 3) more than 12 hrs.
Wieght:                 kg.             Occupation:
Marital status: M/ S/ D / W.
Place of living: 1) city     2) village   3) camp
Type of Diet:  vegetarian   2) Non vegetarian 3) both
Risk factors:
1  (Smoking 1) yes                           2) No
2 (Hypertension:  1) yes                   2) No
3 (Diabetes: 1) yes                            2) No
4 (Dyslipidemia: 1) yes                    2) No
5 (Family history of HTN: 1) yes   2) No DM: 1) yes 2) No 
Dyslipidemia 1) yes 2) No
Family history of CHD: 1) yes       2) No
Date:                                                          Patient Signature:
Table (1) Summary for all cases (80 cases), and results obtained for 
the patients group. 
ID Age sex Smoking HTN Diabetes Dyslipid T.choles LDL HDL TG
hs-
CRP
10
1 56 1 2 2 2 1 221 110 40 416 0.99
10
2 58 1 1 2 2 1 205 132 28 442 7.1
10
3 55 1 2 1 1 1 238 160 31 136 7
10
4 64 1 2 1 2 1 324 174 25 167 7.3
10
5 50 1 2 2 1 1 181 93 37 183 2.99
10
6 75 1 1 1 1 1 232 174 44 166 4.7
10
7 60 1 2 1 1 1 247 141 34 167 6.9
10
8 62 1 1 1 1 1 139 58 39 210 2.88
10
9 71 1 2 1 2 1 188 84 42 311 2.8
11
0 80 2 2 1 1 1 188 87 33 139 4.9
11
1 71 1 2 2 1 1 241 154 37 97 7.7
11
2 65 1 2 2 2 1 202 118 32 183 5.2
11
3 50 1 2 1 1 1 235 126 39 140 8.3
11
4 65 1 2 1 1 1 161 92 39 147 5.6
11
5 44 1 1 2 2 1 221 155 46 98 7.2
11
6 79 1 2 1 2 1 193 142 33 53 2.2
11
7 73 1 2 2 1 1 189 112 47 125 5.3
11
8 69 1 2 1 1 1 222 158 46 91 7.6
11
9 80 2 2 1 1 1 250 89 35 140 9.2
12
0 67 2 2 1 2 1 251 184 34 86 14.2
12
1 43 1 2 2 2 1 192 140 32 101 7
12
2 38 2 2 2 2 2 196 90 27 141 6.8
12
3 66 1 2 1 1 1 193 123 49 105 8
12
4 81 1 2 2 1 1 172 115 35 280 3.5
12
5 51 2 2 2 2 1 196 130 44 110 7.4
12
6 55 1 2 2 2 1 223 141 31 128 5.9
12
7 37 1 2 1 1 1 148 88 35 140 2.65
12
8 72 1 2 1 1 1 220 160 31 136 8
12
9 67 1 1 1 1 1 241 135 28 145 13.5
13
0 59 1 2 1 1 1 161 92 39 147 5
13
1 58 2 2 1 1 1 196 130 44 110 6.6
13
2 65 1 2 1 1 1 241 154 36 97 10.7
13
3 42 1 2 2 1 1 161 92 39 147 6.2
13
4 45 1 1 2 2 1 231 115 35 140 11.6
13
5 57 1 2 2 1 1 239 167 28 125 9
13
6 64 1 2 1 2 2 193 123 49 105 8
13
7 64 1 2 2 1 1 196 130 44 110 16.3
13
8 56 1 2 2 2 1 225 148 41 416 6.6
13
9 58 1 1 2 2 1 207 92 38 442 9.7
14
0 55 1 2 1 1 1 220 162 30 137 5.9
14
1 64 1 2 1 2 1 325 176 37 165 9.7
14
2 50 1 2 2 1 1 182 100 50 185 5.9
14
3 75 1 1 1 1 1 152 76 43 167 2.88
ID Age sex Smoking HTN Diabetes Dyslipid T.choles LDL HDL TG
hs-
CRP
14
4 60 1 2 1 1 1 248 182 32 158 11.8
14
5 62 1 1 1 1 1 240 162 32 208 6.8
14 71 1 2 1 2 1 200 105 35 300 2.2
6
14
7 80 2 2 1 1 1 212 87 30 140 0.89
14
8 71 1 2 2 1 1 241 154 37 97 6.8
14
9 65 1 2 2 2 1 162 93 32 183 4.9
15
0 50 1 2 1 1 1 235 168 29 140 6.5
15
1 65 1 2 1 1 1 161 92 39 147 4.6
15
2 44 1 1 2 2 1 221 155 26 98 7.6
15
3 79 1 2 1 2 1 205 142 33 53 4.3
15
4 73 1 2 2 1 1 239 167 47 125 6.9
15
5 69 1 2 1 1 1 222 158 46 91 3.5
15
6 80 2 2 1 1 1 150 89 35 140 3.5
15
7 67 2 2 1 2 1 151 84 50 86 0.97
15
8 43 1 2 2 2 1 192 140 32 101 6
15
9 36 2 2 2 2 2 165 90 27 141 2.99
16
0 66 1 2 1 1 1 193 123 49 105 4.7
16
1 81 1 2 2 1 1 275 115 35 280 6.6
16
2 51 2 2 2 2 1 196 130 44 110 6.4
16
3 55 1 2 2 2 1 223 141 32 128 6.3
16
4 37 1 2 1 1 1 248 138 35 140 3.2
16
5 72 1 2 1 1 1 190 160 31 136 1.8
16
6 67 1 1 1 1 1 196 135 28 145 6.7
16
7 59 1 2 1 1 1 202 92 39 147 6
16
8 58 2 2 1 1 1 196 130 44 110 5.6
16
9 65 1 2 1 1 1 241 154 24 97 11.9
17
0 42 1 2 2 1 1 161 92 39 147 7.4
17
1 45 1 1 2 2 1 215 159 35 140 6.4
17
2 57 1 2 2 1 1 189 67 47 125 0.99
17
3 64 1 2 1 2 2 193 123 49 105 1.99
17
4 64 1 2 2 1 1 196 130 44 110 1.4
17
5 50 1 1 2 2 1 201 125 49 79 4.8
17
6 78 2 2 1 1 1 231 151 30 286 1.2
17
7 49 1 2 2 2 2 193 145 35 66 2.4
17
8 49 2 2 2 2 1 224 130 36 75 3.6
17
9 65 2 2 1 1 1 298 189 23 141 4.6
18
0 52 2 2 1 2 1 200 140 32 152 4.9
For sex (1) indicates male (2) indicates female. Smoking, HTN, 
Diabetes, and dyslipid (1) means yes, and (2) means NO.
Table (2) Summary for all cases (80 cases), and results obtained for 
the control group.
ID Age sex Smoking HTN Diabetes Dyslipid Chol LDL HDL TG
hs-
CRP
201 42 1 1 2 2 1 292 165 44 157 2.9
202 68 2 2 1 1 1 256 139 44 164 2.3
203 37 1 1 2 2 1 286 171 24 110 3.2
204 54 2 2 2 2 1 217 136 38 117 1.8
205 53 1 2 1 2 1 198 115 36 163 1.1
206 73 2 2 2 2 1 244 141 29 100 2.3
207 62 1 1 2 2 1 155 84 44 111 0.2
208 55 1 2 2 2 1 145 82 63 113 0.3
209 69 2 2 2 1 1 200 128 35 88 1.4
210 81 2 2 2 1 2 262 145 52 157 4.1
211 38 1 2 2 2 1 199 131 43 128 2.2
212 36 1 1 1 2 1 238 146 34 88 1.4
213 41 1 2 2 2 1 210 135 33 254 3.2
214 52 2 1 2 1 1 120 89 49 95 0.1
215 38 1 1 2 2 1 214 139 33 195 1.3
216 67 1 2 2 1 1 245 155 51 162 3.5
217 59 2 2 2 1 1 232 161 34 100 3.1
218 35 1 2 2 2 1 238 165 31 218 5.5
219 68 1 2 2 1 2 183 120 32 81 5.9
220 47 2 2 2 2 1 256 162 28 319 6.2
221 37 1 2 2 2 1 193 141 35 84 3
222 38 2 2 1 2 1 186 128 29 110 1.8
223 64 1 1 2 1 1 255 169 24 152 7.7
224 38 1 1 2 2 1 209 155 35 91 2.4
225 40 1 2 2 2 2 117 77 30 156 1.3
226 50 1 1 2 2 1 211 128 35 79 1.9
227 78 2 2 1 1 1 244 161 30 286 6.2
228 49 1 2 2 2 2 213 145 35 66 4.9
229 49 2 2 2 2 1 224 130 43 75 3.4
230 65 2 2 1 1 1 202 139 48 141 2.1
231 52 2 2 1 2 1 220 140 32 152 3.2
232 42 1 1 2 2 1 292 155 44 157 3.6
233 68 2 2 1 1 1 200 141 44 164 2.3
234 37 1 1 2 2 1 286 169 24 110 3.7
235 54 2 2 2 2 1 247 158 26 117 4.6
236 53 1 2 1 2 1 198 115 36 163 3.8
237 73 2 2 2 2 1 244 141 24 100 6.5
238 62 1 1 2 2 1 222 155 44 111 1.9
239 55 1 2 2 2 1 291 185 33 213 4.3
240 69 2 2 2 1 1 192 190 35 88 2.7
ID Age sex Smoking HTN Diabetes Dyslipid T.choles LDL HDL TG
hs-
CRP
241 81 2 2 2 1 2 162 85 52 157 1.1
242 38 1 2 2 2 1 199 129 43 128 2.1
243 36 1 1 1 2 1 238 166 54 88 1
244 39 1 2 2 2 1 210 135 33 254 1.6
245 52 2 1 2 1 1 200 147 37 95 0.1
246 37 1 1 2 2 1 214 139 39 195 0.1
247 67 1 2 2 1 1 245 155 31 162 2.8
248 59 2 2 2 1 1 202 159 41 100 3
249 35 1 2 2 2 1 238 154 40 218 2.3
250 68 1 2 2 1 2 241 147 30 81 4.2
251 47 2 2 2 2 1 208 106 38 219 2.4
252 36 1 2 2 2 1 193 141 35 84 0.6
253 37 2 2 1 2 1 218 129 33 110 1.8
254 64 1 1 2 1 1 193 112 40 152 2.2
255 38 1 1 2 2 1 209 155 35 91 1.6
256 40 1 2 2 2 2 117 81 30 156 2.1
257 55 1 2 2 2 1 280 175 28 189 2.8
258 55 1 2 2 2 1 200 135 35 213 1.5
259 69 2 2 2 1 1 263 162 24 88 4
260 81 2 2 2 1 2 195 128 32 157 2.5
261 36 1 2 2 2 1 199 134 38 128 0.5
262 36 1 1 1 2 1 238 139 36 112 1.5
263 32 1 2 2 2 1 252 168 33 254 3.1
264 52 2 1 2 1 1 225 157 39 148 0.6
265 36 1 1 2 2 1 246 169 33 195 1.4
266 58 1 2 2 1 1 245 155 42 162 4.8
267 59 2 2 2 1 1 240 138 33 100 1.2
268 35 1 2 2 2 1 240 160 39 220 2.4
269 62 1 2 2 1 2 238 129 29 85 3.6
270 47 2 2 2 2 1 210 116 37 259 4.6
271 35 1 2 2 2 1 195 144 35 84 3.5
272 55 1 2 2 2 1 291 185 33 213 2.5
273 55 2 2 2 1 1 252 190 34 98 2.6
274 62 2 2 2 1 2 162 105 42 157 1.9
275 34 1 2 2 2 1 200 130 43 128 1.4
276 36 1 1 1 2 1 212 164 39 88 2
277 55 1 2 2 2 1 235 142 31 213 3
278 59 2 2 2 1 1 292 177 27 88 4
279 66 2 2 2 1 2 169 125 37 157 1.4
280 35 1 2 2 2 1 201 129 43 128 0.6
For sex (1) indicates male (2) indicates female. Smoking, HTN, 
Diabetes, and dyslipid (1) means yes, and (2) means NO.
Appendix
Novel Inflammatory Markers of Coronary Risk
Theory Versus Practice
Peter Libby, MD; Paul M. Ridker, MD, MPH
For practitioners committed to coronary risk reduction,recent clinical trial data pose a considerable challenge.Specifically, in the Air Force/Texas Coronary Athero-
sclerosis Prevention Study (AFCAPS/TexCAPS), a primary
prevention trial,1 treatment with lovastatin among an appar-
ently healthy group of individuals without traditional coro-
nary risk factors resulted in significant reductions in future
cardiovascular events. Application of the results of that trial
and of the West of Scotland primary prevention trial of
pravastatin2 suggests that tens of millions of Americans
without manifest atherosclerosis could benefit from lipid-
lowering therapy.
See p 1169
Such a blanket approach, however, may be unwise from
medical as well as economic perspectives. Unnecessary
exposure to pharmacological agents, even those as safe as the
statins, will ultimately subject some asymptomatic and low-
risk individuals to unwanted side effects. Furthermore, eco-
nomic constraints dictate that primary prevention strategies
with even modest cost must be limited to those individuals
who are likely to gain the greatest benefit. Even when an
inexpensive preventive therapy such as low-dose aspirin is
proven effective,3 behavioral barriers on the parts of both
physicians and patients must be overcome if long-term
compliance is to be achieved. All of these considerations
highlight the need for better methods to stratify risk of
atherosclerotic events in apparently healthy populations.
New Approaches to Coronary
Risk Assessment
Clinical strategies designed to improve risk prediction have
taken several forms. Imaging techniques including carotid
ultrasound, MRI, and electron beam computed tomography
(EBCT) all hold promise for identifying “vulnerable plaques”
and detecting silent atheroma. However, prospective studies
demonstrating the clinical utility of these approaches are
limited. For example, a recent study4 of coronary calcification
detected by EBCT has shown that this method does not
accurately predict future coronary events, even in high-risk
patients. The cost of these noninvasive imaging modalities
may also prohibit their application for widespread screening
application.
Provocative testing of endothelium-dependent vasodilation
has a firm pathophysiological foundation and may also
furnish information regarding an asymptomatic individual’s
risk for future coronary events. However, as in the case of
imaging modalities, the specificity of this approach is uncer-
tain, and practical barriers preclude its utility for screening in
outpatient clinic settings. Similarly, although the rapid
progress in identifying genetic polymorphisms that correlate
with coronary risk holds great promise, we have much work
to do before we will know how to apply these data in practice.
By contrast, several serum markers have recently come to
the fore as potential solutions to the challenge of detecting
high-risk individuals for primary prevention.5 Indeed, be-
cause of their low cost and simplicity for outpatient use, the
identification of a simple blood test, or a battery of such tests,
has become a major initiative in preventive cardiology. In this
issue of Circulation, Xu and colleagues6 furnish new evi-
dence that antibodies to heat-shock protein 65 (hsp65) are
associated with increased risk of atherosclerotic events in a
free-living population. What can we learn from such studies
about the pathophysiology of atherosclerosis and its compli-
cations? What criteria should we use in deciding how and
when to apply these new techniques to our clinical practice?
Markers of Inflammation and Stress Furnish
Insight Into Pathophysiology
Serum markers of inflammation provide an avenue of insight
into the pathophysiology of atherosclerosis and its complica-
tions. High-sensitivity testing for C-reactive protein (hs-
CRP), a nonspecific marker of low-grade systemic inflamma-
tion, has received much attention, and several studies now
support a strong link between baseline elevations of hs-CRP
and future risk of coronary events.7,8 “Distal” indicators of
inflammation likewise predict coronary risk (Figure 1). Ex-
amples include the soluble forms of leukocyte adhesion
molecules, such as intercellular adhesion molecule-1
(sICAM-1).9,10 These distal markers may reflect the conse-
quences of elevated levels of proinflammatory cytokines. For
example, interleukin-6 (IL-6) probably provokes the aug-
mented expression of the C-reactive protein (CRP) gene in
the liver. Cytokines such as tumor necrosis factor-a (TNF-a)
or IL-1 isoforms can in turn stimulate the expression of IL-6
and of the leukocyte adhesion molecules, such as ICAM-1
(Figure 1).
The source of these cytokines remains unclear. Increased
levels of cytokines might arise from atheroma themselves,
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reflecting their quantity (atherosclerotic burden) or quality
(the degree of inflammatory activity within these lesions).
The cytokines might also derive from nonvascular sources
and reflect inflammatory states such as chronic infections that
may accelerate atherogenesis and its manifestations.11 Both
vascular and extravascular sources of inflammatory cytokines
may prove important to various degrees in different individ-
uals. Regardless of the source of the inflammatory cytokines,
emerging work on serum inflammatory markers supports the
notion of a “pathway” of inflammatory activation related to
acute coronary events (Figure 1). The inflammation (vascular
or extravascular) begets cytokines (local and systemic),
which in turn elicit the expression of acute-phase reactants
such as hs-CRP and fibrinogen and of other effector mole-
cules in the inflammatory response, such as adhesion mole-
cules for leukocytes (Figure 1). Indeed, prospective epidemi-
ological studies have now shown that measurements of serum
inflammatory markers at each level of this pathway are
associated with increased coronary risk (Figure 2).
Where do hsps fit into this schema? Cells that are stressed
by thermal and other injuries augment their synthesis of a
series of molecules known as hsps or chaperonins.12 By
binding to proteins critical to cellular function, these molec-
ular “chaperones” can stabilize them and increase their
resistance to denaturation (for example, by heat). Whatever
their function, the expression of hsps does reflect cellular
trauma, a process that in turn appears to activate vascular
endothelium and smooth muscle cells, as well as regulate
macrophage TNF-a and matrix metalloproteinase expres-
sion.13,14 Furthermore, cytokines and oxidized LDLs can
induce adhesion molecules such as ICAM-1 and hsp60.15 A
body of work from the laboratories of Xu and Wick has
implicated hsp65 as an antigen involved in instigating the
chronic immune response characteristic of human atheroscle-
rosis. Specifically, previous cross-sectional data from this
group have shown a direct relationship between antibodies
against hsp60 and carotid wall atherosclerosis.16 In the
present follow-up study, these antibodies are sustained among
those with the most severe degrees of underlying atheroscle-
rosis and were demonstrated to predict 5-year mortality.6
These new data furnish additional support for the inflamma-
tory hypothesis of atherogenesis and of the acute coronary
syndromes.
Should We Use Novel Inflammatory Markers
of Coronary Risk in the Clinic Today?
Although studies of serum markers of inflammation provide
substantial insight into the pathophysiology of atherothrom-
bosis, the clinical utility of measuring these markers remains
uncertain. In general, we advocate a cautious approach for
several reasons.5 First, for a novel inflammatory marker to
have a clinical role, there must be a widely available
diagnostic test with reproducible assay characteristics appro-
priate for patient-related purposes. Of the major inflammatory
markers, only CRP has an established World Health Organi-
zation standard, and high-sensitivity assays for this parameter
appear to provide reliable results. Second, there must be a
consistent series of prospective studies that indicate that
baseline elevations of a given inflammatory marker predict
future coronary events. In this regard, prospective data
remain limited for the cellular adhesion molecules and for
various hsps. In contrast, a remarkably consistent series of
prospective data is available for both hs-CRP and fibrinogen.
Third, to be of clinical use, markers of inflammation must be
Figure 1. Pathways by which vascular and extravascular
sources of inflammation result in circulating levels of serum
markers that provide a reflection of the underlying inflammatory
response. Inflammation, systemic or local, either in the blood
vessel itself or elsewhere, triggers the production of multipotent
proinflammatory cytokines we denote here as “primary” (eg,
IL-1b or TNF-a). These primary cytokines can directly elicit pro-
duction by endothelial and other cells of adhesion molecules,
procoagulants, and other mediators that may be released in sol-
uble form into circulating blood. Primary cytokines also stimu-
late production of “messenger” cytokine, IL-6, which induces
expression of hepatic genes encoding acute-phase reactants
found in blood, including CRP and serum amyloid-A (SAA).
Thus, these markers in serum can provide a window on the
inflammatory status of the individual, otherwise inaccessible in
the intact subject.
Figure 2. Relative risks of future myocardial infarction for
apparently healthy middle aged men according to baseline
plasma concentrations of fibrinogen, sICAM-1, IL-6, hs-CRP,
and the combination of hs-CRP with the total cholesterol–to–
HDL cholesterol ratio (TC:HDL). Data derive from participants in
the Physicians Health Study.5,7,8,10 For consistency, risks are
computed for men in top vs bottom quartiles for each
parameter.
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shown to add substantially to our ability to predict risk
beyond that achievable by use of traditional risk factors such
as those incorporated into the Framingham risk algorithms or
the European guidelines.17 Although some studies suggest
that inflammatory markers may well improve risk-prediction
models,7,8,18,19 we believe more data are needed before firm
clinical recommendations can be made. Finally, whether
inflammation per se represents a modifiable risk factor is
currently uncertain, although preliminary data suggest that
several common preventive therapies may work in part
through anti-inflammatory targets.
As evidenced by the current study from Xu and colleagues
concerning hsps, we are in a rapidly expanding phase of
knowledge with respect to novel markers of vascular inflam-
mation. Although extraordinarily valuable as research tools,
we must await completion of prospective evaluations of
various panels of these peripheral markers before implement-
ing their use in daily practice. In all likelihood, a combination
of genetic markers (reflecting heredity) and serum markers
(reflecting the net interaction between heredity and the
environment) will ultimately afford a solution to the current
challenges posed in primary prevention.
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Conformational Rearrangement in C-Reactive Protein Is
Required for Proinflammatory Actions on Human
Endothelial Cells
Tarek Khreiss, MSc; Levente József, MSc; Lawrence A. Potempa, PhD; János G. Filep, MD
Background—C-reactive protein (CRP) has been suggested to actively amplify the inflammatory response underlying
coronary heart diseases by directly activating endothelial cells. In this study, we investigated whether loss of the cyclic
pentameric structure of CRP, resulting in formation of modified or monomeric CRP (mCRP), is a prerequisite for
endothelial cell activation.
Methods and Results—We examined the impact of native CRP and mCRP on the production of monocyte chemoattractant
protein-1 (MCP-1) and interleukin-8 (IL-8), key regulators of leukocyte recruitment, and on the expression of
intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular adhesion molecule-1 (VCAM-1) in human
cultured coronary artery endothelial cells (HCAECs). Incubation with mCRP for 4 hours increased MCP-1 and IL-8
secretion and mRNA levels and expression of ICAM-1, E-selectin, and VCAM-1 protein and mRNA. Significant
induction occurred at 1 to 5 g/mL, reached a maximum at 30 g/mL, and did not require the presence of serum. Native
CRP was without detectable effects at 4 hours, whereas it enhanced cytokine release after a 24-hour incubation. An
anti-FcRIII (CD16) but not an anti-FcRII (CD32) antibody produced a 14% to 32% reduction of the mCRP effects
(P0.05). mCRP but not CRP evoked phosphorylation of p38 mitogen-activated protein kinase, and inhibition of this
kinase with SB 203580 reversed the effects of mCRP. Furthermore, culture of HCAECs in the presence of SB203580
markedly decreased mCRP-stimulated E-selectin and ICAM-1–dependent adhesion of neutrophils to HCAECs
(P0.001).
Conclusions—Loss of pentameric symmetry in CRP, resulting in formation of mCRP, promotes a proinflammatory
HCAEC phenotype through a p38 MAPK–dependent mechanism. (Circulation. 2004;109:2016-2022.)
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Acute coronary artery diseases are associated with evi-dence of inflammation both systemically and in the
arterial wall.1,2 Elevated plasma levels of C-reactive protein
(CRP) are predictive of subsequent acute coronary events
among apparently healthy subjects and patients with stable or
unstable angina.3–5 However, the exact role and mechanisms
of action of CRP as a modulator of inflammation have not
been well defined, because both proinflammatory and antiin-
flammatory actions have been reported.6–12 Recent results
suggest that CRP may directly contribute to endothelial
dysfunction by inducing cytokine release and surface expres-
sion of adhesion molecules.13–15 Intriguingly, these actions
were evident only after 12 to 24 hours of incubation, whereas
maximum increases in adhesion molecule expression can be
detected within 4 to 6 hours in response to proinflammatory
cytokines or bacterial lipopolysaccharide (LPS). These obser-
vations raise the possibility that CRP may undergo structural
changes to activate endothelial cells. Indeed, it has been
proposed that distinct isoforms of CRP are formed during
inflammation. Conformationally altered forms of CRP ex-
press several epitopes that are not present on native CRP16
and display properties distinct from those of native CRP.17–19
See p 1914
Native, pentameric CRP dissociates into free subunits within
a few hours after binding to plasma membrane.20 These
subunits expressing several neoepitopes are referred to as
modified or monomeric CRP (mCRP). mCRP antigens were
detected in the wall of human normal blood vessels21 and in
inflamed tissues.22
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In the present study, we investigated whether conforma-
tional rearrangement of native CRP, resulting in formation of
mCRP, may be required for induction of release of
interleukin-8 (IL-8) and monocyte chemoattractant protein-1
(MCP-1), key regulators of leukocyte recruitment, and ex-
pression of adhesion molecules in human coronary artery
endothelial cells (HCAECs). To gain insight into the under-
lying mechanisms, we also examined whether the mCRP
actions on HCAECs are mediated through binding to one of
the IgG receptor subtypes similarly to that reported for
leukocytes18,23,24 and via activation of p38 mitogen-activated
protein kinase (MAPK).
Methods
CRP Isoforms
High-purity (99%) human native CRP (Calbiochem) was stored in
a NaN3-free buffer containing CaCl2 to prevent spontaneous forma-
tion of mCRP from the native pentamer. A recombinant form of
mCRP (rm-CRP) that cannot rearrange into a pentameric structure
was engineered as described previously.18 Native CRP was distin-
guished from mCRP by binding and antigenicity differences using
monoclonal antibodies described for each form of the molecule16,17
and by their secondary structure.18 The endotoxin levels of all
peptide solutions were below the detection limit (0.125 EU/mL,
corresponding to 0.01 ng/mL LPS) of the Limulus assay (Sigma).
HCAEC Stimulation
HCAECs (passage 3, from Clonetics) were cultured in EGM-MV
medium (Clonetics) supplemented with 10% FBS.11 Monolayers of
HCAECs (passages 4 through 6) in 24-well or 96-well microplates
(confluence 97%, 28 000 cells/cm2) were incubated with native
CRP or mCRP. In some experiments, HCAECs were pretreated with
the MAPK kinase inhibitor PD98059 (50 mol/L), the p38 MAPK
inhibitor SB203580 (0.1 to 1 mol/L), the phosphatidylinositol
3-kinase inhibitor wortmannin (100 nmol/L), the anti-FcRIII
(CD16) antibody 3G8, anti-FcRIIa (CD32) antibody FLI8.26, or
the irrelevant antibody MOPC-21 (each at 2.5 g/mL, Pharmingen)
for 30 minutes before addition of mCRP. At the indicated times,
culture supernatants were collected, and the cells were processed as
described below.
MCP-1 and IL-8 Production
The concentrations of MCP-1 and IL-8 in culture supernatants were
determined in duplicate by selective ELISAs (BD Pharmingen).
Intra-assay and interassay coefficients of variation were typically
4% and 6%, respectively. There was no cross-reactivity with
CRP isoforms in the assays.
Cell Adhesion Molecule Expression
After incubation for 4 hours, HCAECs were detached with EDTA
(0.01% in PBS) from the 24-well microplates and then stained for
intercellular adhesion molecule-1 (ICAM-1), E-selectin, or vascular
adhesion molecule-1 (VCAM-1) using fluorescent dye–conjugated
anti–ICAM-1, anti–VCAM-1 (Pharmingen) or anti–E-selectin (Se-
rotec) antibodies as described previously.19 Nonspecific binding was
evaluated by use of appropriately labeled mouse IgG1. Immunofluo-
rescence (10 000 cells for each sample) was analyzed with a
FACScan flow cytometer with CellQuestPro software.
RNase Protection Assay
For multiprobe RNase protection assays, HCAECs were lysed with
50 L of lysis/denaturation solution (Ambion). [32P]-labeled anti-
sense RNA probes were generated using templates for IL-8, MCP-1,
ICAM-1, E-selectin, VCAM-1, L32, and GAPDH (RiboQuant, BD
Pharmingen), and the assays were performed with the Direct Protect
kit (Ambion) as described previously.25
Neutrophil–Endothelial Cell Adhesion Assay
The adhesion assay was performed as described previously.11,19 In
brief, monolayers of HCAECs in 96-well microplates were cultured
with CRP, mCRP, or LPS (1 g/mL, a positive control) for 4 hours
at 37°C and washed extensively, and 2105 human 51Cr-labeled
neutrophils in 100 L were then added. In some experiments, mCRP
was added back together with neutrophils to mCRP-treated
HCAECs. Some experiments were repeated using function-blocking
monoclonal antibodies against E-selectin [ENA-2, 10 g/mL, puri-
fied F(ab)2, Monosan], L-selectin (DREG-56, 20 g/mL), CD18
(L130, 10 g/mL), or the irrelevant antibody MOPC-21 (20 g/mL,
all from BD Biosciences). HCAECs were incubated with neutrophils
for 30 minutes at 37°C on an orbital shaker at 90 rpm. Loosely
adherent or unattached cells were removed by washing, and the
endothelial monolayer and the adherent neutrophils were lysed. The
number of adherent neutrophils in each experiment was calculated
from the radioactivity of a control sample.
Western Blot for p38 MAPK
Protein extracts were prepared by lysing 5104 HCAECs in 100 L
of lysis buffer. Western blot analysis of phosphorylated and total p38
MAPK was performed using the PhosphoPlus p38 MAPK antibody
kit (New England Biolabs).18,19
Statistical Analysis
Results are expressed as meanSEM. Statistical comparisons were
made by ANOVA using ranks (Kruskal-Wallis test) followed by
Dunn’s multiple contrast hypothesis test to identify differences
between various treatments or by the Mann-Whitney U test for
unpaired observations. Values of P0.05 were considered signifi-
cant for all tests.
Results
mCRP Induces p38 MAPK-Dependent Expression
of IL-8 and MCP-1 in HCAECs
Culture of HCAECs with mCRP for 4 hours resulted in
concentration-dependent increases in IL-8 and MCP-1 re-
lease, whereas native CRP was without effect (Figure 1A).
Significant induction was detected even with 1 g/mL, which
peaked at 100 g/mL mCRP. The maximal effects of mCRP
were 50% of those of LPS 1 g/mL (IL-8, 3.90.2 ng/mL;
MCP-1, 11.40.5 ng/mL). Native CRP induced significant
release of IL-8 and MCP-1 at 24-hours; however, it was a
considerable less potent inducer of cytokine production than
mCRP (Figure 1B). The absence of serum did not affect the
responses to mCRP (Figure 1C).
Preincubation of HCAECs with SB203580 concentration-
dependently decreased mCRP-induced IL-8 and MCP-1 re-
lease at 4-hours, whereas neither wortmannin nor PD98059
affected the responses to mCRP (Figure 2A). Furthermore,
mCRP but not native CRP induced phosphorylation of p38
MAPK relative to unstimulated controls. Phosphorylation
was rapid in onset (peak at 30 minutes) and occurred in a
concentration-dependent manner (Figure 2B).
We performed RNase protection assays on RNA extracted
from HCAECs after 4 hours of incubation with mCRP.
Consistent with the observations at protein levels, mCRP
stimulated IL-8 and MCP-1 mRNA levels, which was sup-
pressed by SB203580 but not by PD98059 or wortmannin
(Figure 3). Native CRP did not produce detectable changes
(Figure 3).
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mCRP Induces Expression of Adhesion Molecules
Under our experimental conditions, 2%, 39%, and 1% of
untreated HCAECs expressed E-selectin, ICAM-1, and
VCAM-1, respectively (Figure 4A). Treatment with mCRP
for 4 hours evoked concentration-dependent increases in the
overall expression and in the percentage of HCAECs express-
ing these adhesion molecules, whereas native CRP was
without effect (Figure 4A). As a positive control, LPS
produced on average 10-, 10-, and 5-fold increases in
E-selectin, ICAM-1, and VCAM-1 expression, respectively
(Figure 4A). SB203580 markedly attenuated mCRP-
stimulated expression of these adhesion molecules, whereas
PD98059 or wortmannin was without effect (Figure 4B).
Likewise, mCRP induced increases in E-selectin, ICAM-1,
and VCAM-1 mRNA levels that were markedly attenuated by
SB203580 (Figure 3). After 24 hours of incubation, native
CRP (100 g/mL) increased ICAM-1 and VCAM-1 expres-
sion on HCAECs from 22.91.6 to 52.92.0 relative fluo-
rescence units (RFU) and from 3.20.2 to 7.60.5 RFU,
respectively (n4, P0.05), although it was less potent than
mCRP (ICAM-1, 107.98.9 RFU; VCAM-1, 10.70.5
RFU; n4, P0.05 versus native CRP). Cell viability as-
sessed by propidium iodide staining was 92% in all
experiments.
mCRP Promotes Neutrophil Adhesion to HCAECs
The biological significance of adhesion molecule expression
was confirmed by the significant increase of adhesion of
neutrophils to HCAECs cultured with mCRP (Figure 5A).
Enhanced neutrophil attachment was evident with mCRP at 1
g/mL and reached an apparent maximum at 100 g/mL. By
contrast, native CRP even at 100 g/mL failed to promote
adherence (Figure 5A). The number of adherent neutrophils
to mCRP-activated HCAECs was further enhanced when the
adhesion assay was performed in the presence of mCRP
(Figure 5B), indicating that mCRP activates both neutrophils
and HCAECs.
Because multiple receptors are involved in neutrophil
adhesion to HCAECs under nonstatic conditions11 and mCRP
affects adhesion molecule expression on both neutrophils19
Figure 1. Effects of CRP isoforms on IL-8 and MCP-1 release in
HCAECs. HCAECs were cultured with native CRP or mCRP for
4 hours (A) or 24 hours (B) in presence of 10% FBS. C, Com-
parison of effects of 4 hours of incubation with mCRP in pres-
ence of 10% FBS (with serum) or in serum-free conditions (no
serum). Results are meanSEM for 4 to 8 experiments.
*P0.05, **P0.01 vs vehicle.
Figure 2. Effect of p38 MAPK inhibition on mCRP-stimulated
IL-8 and MCP-1 release. A, HCAECs were preincubated with
PD98059 (an MEK inhibitor), SB203580 (p38 MAPK inhibitor), or
wortmannin (phosphatidylinositol-3 kinase inhibitor) for 20 min-
utes and then were cultured with mCRP (30 g/mL) for 4 hours.
n5 to 6 per group. #P0.05, ##P0.01 vs mCRP alone. B,
Time- and concentration-dependent induction of phosphoryla-
tion of p38 MAPK by mCRP. HCAECs were challenged for 30
minutes with various concentrations of mCRP or CRP or with 30
g/mL mCRP for indicated times. Experiments were repeated 4
times with similar results.
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and endothelial cells (the present study), we assessed the
contribution of L-selectin, 2-integrins, and E-selectin to the
binding interaction by using function-blocking monoclonal
antibodies. mCRP-stimulated neutrophil attachment to
mCRP-activated HCAECs was blocked by antibodies against
CD18 (574%, n6), E-selectin (383%), and L-selectin
(142%) (Figure 5C). The combination of these antibodies
inhibited neutrophil adhesion by 923% (Figure 5C). The
number of adherent neutrophils was reduced from
2.80.2104 cells/well to 1.40.1104 cells/well when
HCAECs were cultured with mCRP (30 g/mL) in the
absence and presence of SB203580 (n6, P0.01). Neither
PD98059 nor wortmannin significantly affected the
neutrophil-HCAEC attachment (data not shown).
Search for mCRP Receptors on HCAECs
Because CRP binds predominantly to the low-affinity IgG
FcRIIa (CD32)23,24 and mCRP utilizes the low-affinity
immune-complex FcRIII (CD16)18 on leukocytes, we used
function-blocking antibodies as competitors to assess the
possible involvement of these receptors in mediating the
actions of mCRP on HCAECs. Preincubation of HCAECs
with the anti-CD16 antibody resulted in 14% to 32% atten-
uation of the responses to mCRP (Figure 6). Neither the
anti-CD32 antibody (Figure 6) nor the irrelevant MOPC-21
antibody (data not shown) affected the responses to mCRP.
Discussion
The present results provide evidence for a novel molecular
mechanism by which CRP may activate endothelial cells.
This bioactivity of CRP is expressed when the pentameric
structure dissociates and undergoes a conformational rear-
rangement, resulting in formation of mCRP.
Formation of mCRP from native CRP involves the disso-
ciation of the CRP pentameric disk. This is accompanied by
a loss of predominantly -sheet secondary structure with an
increase in -helix18 and exposure of intersubunit contact
residues, in particular residues 198 to 206, the predominant
neoepitope expressed on mCRP,16 and expression of distinct
biological activities.17–19 For instance, native CRP inhibits
whereas mCRP promotes adhesion of neutrophils to LPS-ac-
tivated HCAECs.11,19 Furthermore, recent results suggest that
aggregated (ie, structurally modified) CRP rather than native
CRP may promote uptake of low-density lipoproteins by
macrophages.26,27 To avoid the confounding effects of spon-
Figure 3. Effects of mCRP and native CRP on IL-8, MCP-1,
E-selectin, ICAM-1, VCAM-1, L32, and GAPDH mRNA expres-
sion. HCAECs were cultured with CRP (100 g/mL) or mCRP in
presence of PD98059 (PD), SB203580 (SB), or wortmannin (Wo)
for 4 hours. C indicates control (medium only). Effects of LPS (1
g/mL) are shown for comparison. Shown is a representative
multiprobe RNase protection assay of 4 independent
experiments.
Figure 4. Induction of adhesion molecule
expression by mCRP. A, Monolayers of
HCAECs were cultured for 4 hours with
mCRP, native CRP, or LPS (1 g/mL).
Adhesion molecule expression was
assessed by flow cytometry and is
expressed as relative fluorescence inten-
sity (RFU) after subtracting nonspecific
immunostaining. Positive cells represent
percentage of HCAECs that stained pos-
itive for indicated adhesion molecule. B,
HCAECs were preincubated with
PD98059, SB203580, or wortmannin for
20 minutes and then challenged with
mCRP (30 g/mL) for 4 hours. Values
are meanSEM for 4 to 6 independent
experiments. *P0.05, **P0.01 vs con-
trol (cells cultured in medium alone).
#P0.05; ##P0.01 vs mCRP alone.
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taneous formation of mCRP from native CRP during pro-
longed storage in the absence of calcium (our unpublished
observations), we used CRP preparations devoid of mCRP
contamination and engineered mCRP that cannot reassemble
to form a pentamer.
Our study shows that mCRP, unlike native CRP, can
induce cytokine release and expression of adhesion molecules
on HCAECs after a 4-hour incubation period. We also
examined the mechanisms of mCRP signaling in HCAECs,
observing a predominant role for the p38 MAPK pathway.
At low g/mL concentrations, mCRP induced transcription
of IL-8, MCP-1, E-selectin, ICAM-1, and VCAM-1 genes
within 4 hours of its addition to HCAECs. These effects were
comparable in magnitude to those observed with LPS, a
well-known activator of endothelial cells. Consistent with
previous studies,13–15 native CRP did not evoke detectable
changes at 4 hours. The CRP induction became detectable
only after 6 to 12 hours of incubation, reaching maximal
effects at 24 hours,13–15 coinciding with in vitro kinetics of
dissociation into subunits.20 Although CRP clearly enhanced
IL-8 and MCP-1 production at 24 hours of culture, it was a
significantly less potent inducer of cytokine production than
mCRP. These observations suggest that conformational rear-
rangement of CRP is a prerequisite for activation of HCAECs
and that the amounts of mCRP generated from CRP within 4
hours are not sufficient to evoke detectable responses. An-
other important difference between the actions of CRP and
mCRP is that the mCRP effects do not depend on, whereas
the CRP effects are dependent on, an as yet unidentified
serum cofactor(s).13 The mCRP action is based on a tissue
rather than a serum environment, thus minimizing the need
for serum cofactors.
The present study did not address the functional signifi-
cance of mCRP-induced expression of IL-8 and MCP-1.
MCP-1 and IL-8 play important roles in recruitment of
monocytes into the vessel wall,28,29 and IL-8 is a key
regulator of neutrophil trafficking and activation.30 Thus, by
enhancing chemokine production, mCRP may contribute to
the evolution of atherogenesis28 and to the widespread neu-
trophil activation observed in patients with unstable angina.2
The biological significance of adhesion molecule expression
was confirmed by the significant increase of adhesion of
neutrophils to mCRP-activated HCAECs. These observations
extend previous findings that mCRP promoted neutrophil
adhesion to LPS-activated HCAECs through upregulation of
CD11b/CD18 on neutrophils.19 Our results show that mCRP-
induced expression of ICAM-1 and E-selectin also contrib-
utes to neutrophil-HCAEC attachment. Significantly higher
numbers of neutrophils adhered to mCRP-activated HCAECs
when the adhesion assay was performed in the presence than
in the absence of mCRP, indicating that mCRP can promote
Figure 5. mCRP but not native CRP promotes neutrophil adhe-
sion to HCAECs. Confluent HCAEC monolayers were cultured in
medium only (control) or challenged with mCRP, CRP, or LPS
for 4 hours, then radiolabeled neutrophils (PMN) without (A) or
together with (B) mCRP were added and incubated with
HCAECs for 30 minutes at 37°C. C, Inhibition of mCRP-
stimulated neutrophil adhesion by function-blocking anti–E-
selectin, anti-CD18, and anti–L-selectin monoclonal antibodies
(mAb). HCAECs were cultured with mCRP (30 g/mL, 4 hours),
then neutrophils together with mCRP (30 g/mL) were added for
30 minutes in presence of mAbs, as indicated. Irrelevant anti-
body MOPC-21 served as a negative control. Results are
meanSEM of 6 experiments. *P0.05, **P0.01, ***P0.001
vs control (medium only); #P0.05; ##P0.01 vs mCRP without
mAbs (solid column).
Figure 6. Effect of anti-CD16 and anti-CD32 antibody on
HCAEC responses to mCRP. HCAECs were cultured with or
without mCRP (30 g/mL) plus an anti-CD16 antibody (Ab),
anti-CD32 antibody, or irrelevant antibody MOPC-21 (all at 2.5
g/mL). Culture medium was assayed for IL-8 and MCP-1; sur-
face expression of E-selectin and ICAM-1 was assessed by flow
cytometry. n4 for each group. *P0.05.
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adhesion by activating both HCAECs and neutrophils. Leu-
kocyte–endothelial cell interaction involves a complex inter-
play among adhesion molecules.31 Indeed, the anti-CD18,
anti–E-selectin, and anti–L-selectin antibody alone inhibited
57%, 34%, and 14% of neutrophil attachment, respectively,
whereas combination of the 3 antibodies blocked 90% of
adhesion. We also detected enhanced VCAM-1 expression
after 4 hours of culture of HCAECs with mCRP, indicating
that mCRP closely mimics the effect of 24 hours of incuba-
tion with CRP,13,15 although the possible role of VCAM-1 in
neutrophil adhesion was not investigated.
Our results indicate that mCRP activation of HCAECs
involves p38 MAPK. mCRP stimulated rapid phosphoryla-
tion of this kinase, and the specific p38 MAPK inhibitor
SB203580 markedly inhibited HCAEC responses to mCRP,
although the inhibition was incomplete. These results are
consistent with those observed with SB203580 on thrombin-
induced endothelial chemokine production and ICAM-1 ex-
pression,32,33 and suggest involvement of other intracellular
signaling mechanism(s). Unlike in neutrophils,18,19 mCRP
does not appear to activate the MAPK kinase and phospha-
tidylinositol 3-kinase pathways in HCAECs, because there
was no reduction in the presence of PD98059 and
wortmannin.
Little is known at present about the CRP or mCRP
receptor(s) on endothelial cells. Human aortic endothelial
cells may express the receptors FcRII and FcRI,34 which
bind CRP on leukocytes.23,24 In HCAECs, an anti-FcRII
antibody failed to affect the responses to mCRP, whereas an
anti-FcRIII antibody that effectively blocked the apoptosis
delaying action of mCRP in neutrophils19 produced a slight
attenuation of mCRP-induced HCAEC activation. Although
these observations would suggest the involvement of
FcRIII, additional studies are needed to confirm the pres-
ence of this receptor on HCAECs and to identify the major
binding site(s) for mCRP on HCAECs.
Limitations of this study are that the mechanisms regulat-
ing mCRP formation in vivo are still unidentified and that
mCRP levels are difficult to estimate in vivo, because, unlike
CRP, mCRP is expressed on cell membranes rather than in
the plasma.21,22 Because the ratio of membrane-bound mCRP
to mCRP in the culture medium is unknown, it is extremely
complicated to measure the amount of native CRP that
dissociated into free subunits in vitro. If indeed mCRP is a
tissue-associated mediator, at the sites of injury it may come
in contact with the endothelium and leukocytes, amplifying
the proinflammatory response triggered by the initial endo-
thelial injury.
In summary, the present results indicate that loss of
pentameric symmetry in CRP, resulting in formation of
mCRP, is prerequisite for the appearance of proinflammatory
actions on HCAECs. Indeed, mCRP directly facilitates endo-
thelial cell adhesion molecule expression, leukocyte adhe-
sion, and MCP-1 and IL-8 production. Importantly, these
effects are, in part, mediated by activation of the p38 MAPK
pathway. These findings indicate that mCRP rather than
native CRP may contribute to the development of vascular
inflammation and suggest that inhibition of p38 MAPK may
be a target for antiinflammatory strategies in vascular
diseases.
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C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION
IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
 
P
 
AUL
 
 M. R
 
IDKER
 
, M.D., C
 
HARLES
 
 H. H
 
ENNEKENS
 
, M.D., J
 
ULIE
 
 E. B
 
URING
 
, S
 
C
 
.D., 
 
AND
 
 N
 
ADER
 
 R
 
IFAI
 
, P
 
H
 
.D.
 
A
 
BSTRACT
 
Background
 
Since inflammation is believed to have
a role in the pathogenesis of cardiovascular events,
measurement of markers of inflammation has been
proposed as a method to improve the prediction of
the risk of these events.
 
Methods
 
We conducted a prospective, nested case–
control study among 28,263 apparently healthy post-
menopausal women over a mean follow-up period
of three years to assess the risk of cardiovascular
events associated with base-line levels of markers of
inflammation. The markers included high-sensitivity
C-reactive protein (hs-CRP), serum amyloid A, inter-
leukin-6, and soluble intercellular adhesion molecule
type 1 (slCAM-1). We also studied homocysteine and
several lipid and lipoprotein measurements. Cardio-
vascular events were defined as death from coro-
nary heart disease, nonfatal myocardial infarction
or stroke, or the need for coronary-revascularization
procedures.
 
Results
 
Of the 12 markers measured, hs-CRP was
the strongest univariate predictor of the risk of car-
diovascular events; the relative risk of events for wom-
en in the highest as compared with the lowest quar-
tile for this marker was 4.4 (95 percent confidence
interval, 2.2 to 8.9). Other markers significantly asso-
ciated with the risk of cardiovascular events were se-
rum amyloid A (relative risk for the highest as com-
pared with the lowest quartile, 3.0), slCAM-1 (2.6),
interleukin-6 (2.2), homocysteine (2.0), total choles-
terol (2.4), low-density lipoprotein (LDL) cholesterol
(2.4), apolipoprotein B-100 (3.4), high-density lipopro-
tein (HDL) cholesterol (0.3), and the ratio of total cho-
lesterol to HDL cholesterol (3.4). Prediction models that
incorporated markers of inflammation in addition to
lipids were significantly better at predicting risk than
models based on lipid levels alone (P<0.001). The lev-
els of hs-CRP and serum amyloid A were significant
predictors of risk even in the subgroup of women
with LDL cholesterol levels below 130 mg per deciliter
(3.4 mmol per liter), the target for primary preven-
tion established by the National Cholesterol Educa-
tion Program. In multivariate analyses, the only plas-
ma markers that independently predicted risk were
hs-CRP (relative risk for the highest as compared with
the lowest quartile, 1.5; 95 percent confidence inter-
val, 1.1 to 2.1) and the ratio of total cholesterol to HDL
cholesterol (relative risk, 1.4; 95 percent confidence
interval, 1.1 to 1.9).
 
Conclusions
 
The addition of the measurement of
C-reactive protein to screening based on lipid levels
may provide an improved method of identifying wom-
en at risk for cardiovascular events. (N Engl J Med
2000;342:836-43.)
 
©2000, Massachusetts Medical Society.
 
From the Center for Cardiovascular Disease Prevention (P.M.R.) and the
Divisions of Cardiology (P.M.R.) and Preventive Medicine (P.M.R., C.H.H.,
J.E.B.), Brigham and Women’s Hospital and Harvard Medical School, Bos-
ton; and the Department of Pathology, Children’s Hospital Medical Center
and Harvard Medical School, Boston (N.R.). Address reprint requests to
Dr. Ridker at Brigham and Women’s Hospital, 75 Francis St., Boston, MA
02115, or at pridker@rics.bwh.harvard.edu.
 
ALF of all myocardial infarctions occur in
persons in whom plasma lipid levels are
normal.
 
1
 
 In an effort to better identify
patients at high risk for cardiovascular
events, several markers of risk have been proposed for
use in screening, including homocysteine and fibrin-
ogen levels, fibrinolytic capacity, and levels of apolipo-
protein A-I, apolipoprotein B-100, and Lp(a) lipo-
protein. However, the clinical value of many of these
markers has been limited because of inadequate stand-
ardization of assay conditions, inconsistency of pro-
spective data, or lack of evidence of significant im-
provement in the prediction of risk over that afforded
by standard lipid screening alone.
 
2
 
With the recognition that atherosclerosis is an in-
flammatory process,
 
3
 
 several plasma markers of inflam-
mation have also been evaluated as potential tools for
prediction of the risk of coronary events. Among them
are markers of systemic inflammation produced in
the liver, such as high-sensitivity C-reactive protein
(hs-CRP) and serum amyloid A; cytokines such as
interleukin-6; and adhesion molecules such as soluble
intercellular adhesion molecule type 1 (sICAM-1).
 
4-11
 
However, as with other proposed predictors of the
risk of cardiovascular events, the prognostic value of
these markers of inflammation remains uncertain. For
example, a widely held clinical view is that levels of
markers of inflammation vary too greatly over time
to allow accurate prediction of risk. Furthermore, few
prospective studies have measured all these markers
of inflammation in a single group of patients, so the
relative usefulness of each marker cannot be easily
evaluated. In addition, data supporting the hypothe-
sis that markers of inflammation significantly increase
the predictive value of lipid screening are scant and
are limited almost exclusively to data from studies of
hs-CRP in middle-aged men.
 
7,12
 
 Finally, clinical appli-
cation of these findings has been limited, since stand-
ardized, commercial assays for most markers of in-
flammation are only now being developed.
In a previous study, in which we used an experi-
mental assay for hs-CRP, we found higher levels of this
marker among healthy postmenopausal women par-
ticipating in the Women’s Health Study who subse-
H
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quently had cardiovascular events than among those
who did not have such events.
 
13
 
 On the basis of that
finding and in the effort to address the clinical issues
outlined above, we used a commercial assay to meas-
ure hs-CRP in the same cohort and simultaneously
measured plasma levels of serum amyloid A, interleu-
kin-6, sICAM-1, total cholesterol, low-density lipo-
protein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, the ratio of total cholesterol to
HDL cholesterol, apolipoprotein A-I, and apolipopro-
tein B-100. In addition, to allow comparison with oth-
er proposed markers, we measured plasma levels of
Lp(a) lipoprotein and homocysteine. We thus were
able to evaluate directly the relative value of each of
these 12 measurements as an independent predictor
of future cardiovascular events in a large cohort of ap-
parently healthy women. We also sought to determine
whether the measurement of markers of inflamma-
tion in addition to standard screening of lipid levels
might provide a clinically useful method for improving
overall prediction of the risk of cardiovascular events.
 
METHODS
 
Study Participants
 
We designed a prospective, nested case–control study involving
participants in the Women’s Health Study, an ongoing trial of as-
pirin and vitamin E for primary prevention among postmenopaus-
al women with no history of cardiovascular disease or cancer.
 
14
 
Blood samples were collected in tubes containing EDTA at base
line from 28,263 women (71 percent of the Women’s Health Study
participants) and stored in liquid nitrogen until the time of analysis.
For this analysis, case subjects were study participants from whom
a base-line blood sample was obtained who subsequently had a car-
diovascular event (defined as death from coronary heart disease,
nonfatal myocardial infarction or stroke, or a coronary-revascular-
ization procedure) during a mean follow-up period of three years.
Myocardial infarction was classified as confirmed if symptoms met
the criteria of the World Health Organization
 
15
 
 and if the event
was associated with abnormal levels of cardiac enzymes or diag-
nostic electrocardiographic changes. Stroke was classified as con-
firmed if the patient had a new neurologic deficit that lasted more
than 24 hours. Computed tomographic scans or magnetic reso-
nance images were available for the majority of women in whom
stroke occurred. Performance of revascularization procedures was
confirmed by review of hospital records. Death from coronary heart
disease was confirmed by review of the autopsy report, the death
certificate, medical records, or information from family members
regarding the circumstances of death.
For each woman who had a confirmed cardiovascular event dur-
ing follow-up, two control subjects of the same age (within one
year) and smoking status (former smoker, current smoker, or non-
smoker) were selected from among the remaining study partici-
pants from whom a base-line blood sample had been obtained and
who remained free of reported cardiovascular disease during follow-
up. With use of these criteria, 122 case subjects and 244 control
subjects were selected.
 
Procedures
 
Base-line plasma samples from each woman with an event and
each control subject were thawed and assayed for hs-CRP, serum
amyloid A, and Lp(a) lipoprotein with use of latex-enhanced im-
munonephelometric assays on a BN II analyzer (Dade Behring,
Newark, Del.). Apolipoprotein A-I and apolipoprotein B-100 were
simultaneously measured with this device by immunoassay. Total
cholesterol, HDL cholesterol, and directly obtained LDL choles-
terol levels were measured on a Hitachi 911 analyzer (Roche Di-
agnostics, Indianapolis) with reagents from Roche Diagnostics and
Genzyme (Cambridge, Mass.). Plasma levels of sICAM-1 and inter-
leukin-6 were measured by enzyme-linked immunosorbent assay
(R & D Systems, Minneapolis), and the total plasma homocysteine
level was measured with an IMx homocysteine assay (Abbott Lab-
oratories, Abbott Park, Ill.) as previously reported.
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 Samples were
handled in identical and in blinded fashion throughout the study.
Samples were analyzed in triplicate and in random order so as to
reduce systematic bias and interassay variation.
 
Statistical Analysis
 
Means and proportions for risk factors for cardiovascular events
at base line were calculated for women who had cardiovascular
events during follow-up and those who did not. The significance
of differences in means between the two groups was assessed with
Student’s t-test, and the significance of differences in proportions
was tested with use of the chi-square statistic. Analysis of trends was
used to test for associations between increasing levels of each plas-
ma variable and the risk of future cardiovascular events, after the
sample was divided into quartiles according to the distribution of
control values for that marker. Adjusted risk estimates were ob-
tained with use of logistic-regression models that, in addition to
accounting for the variables used for matching (age and smoking
status), adjusted for random assignment to aspirin or vitamin E in
the Women’s Health Study; several risk factors for cardiovascular
events, including a history of hypertension, body-mass index, a his-
tory of diabetes, and a parental history of myocardial infarction
before the age of 60 years; and other measured plasma markers.
We evaluated the combined role of lipid levels and markers of in-
flammation as predictors of the risk of future cardiovascular events
in a series of analyses in which we explored the sensitivity and ro-
bustness of our findings from a clinical perspective. First, we used
the likelihood-ratio test to determine whether logistic-regression
models that included measurements of lipid variables and markers
of inflammation provided a significantly better fit than did logistic-
regression models limited to lipid measurements alone. Second,
to estimate the clinical relevance of these effects, we computed the
area under receiver-operating-characteristic curves for prediction
models based on lipid measurements alone and for models based
on measurements of both lipid levels and markers of inflammation.
Third, we divided the study participants into nine groups accord-
ing to low, medium, and high levels of total cholesterol and low,
medium, and high levels of each marker of inflammation. In these
analyses, logistic regression was used to evaluate simultaneously the
risk of future cardiovascular events in each of the nine groups;
the group of women in the lowest third for total cholesterol and in
the lowest third for the respective marker of inflammation was con-
sidered the reference group. Finally, to address the clinical need for
improved assessment of risk among persons with cholesterol levels
currently considered safe, we performed a subgroup analysis of
study participants with LDL cholesterol levels of less than 130 mg
per deciliter (3.4 mmol per liter), the target level for the primary
prevention of coronary heart disease according to the current guide-
lines of the National Cholesterol Education Program.
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All P values were two-tailed, and values of less than 0.05 were
considered to indicate statistical significance. All confidence inter-
vals were calculated at the 95 percent level.
 
RESULTS
 
The base-line characteristics of the women who
subsequently had cardiovascular events (case subjects)
and those who remained free of reported cardiovas-
cular disease (controls) are shown in Table 1. As ex-
pected, women who had cardiovascular events were
heavier at base line than those who remained free of
cardiovascular disease and were more likely to have
hypertension, diabetes, or a parental history of prema-
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ture myocardial infarction (before the age of 60 years).
The frequency of exercise, the frequency of alcohol
consumption, and rate of use of hormone-replace-
ment therapy were similar in the two groups. Because
of matching, the women who had cardiovascular
events and the control subjects were virtually identi-
cal with respect to mean age and smoking status.
Base-line plasma levels of the inflammation markers
hs-CRP (P<0.001), serum amyloid A (P=0.003),
sICAM-1 (P=0.03), and interleukin-6 (P=0.003)
were higher among the women who subsequently had
cardiovascular events than among those who did not
(Table 2). Similarly, base-line plasma levels of total
cholesterol (P=0.01), LDL cholesterol (P=0.003),
apolipoprotein B-100 (P<0.001), and homocysteine
(P=0.02) and the ratio of total cholesterol to HDL
cholesterol (P<0.001) were significantly higher among
women with subsequent events than those without
such events, whereas levels of HDL cholesterol were
significantly lower among women with subsequent
events (P<0.001). Base-line levels of Lp(a) lipoprotein
were somewhat higher and levels of apolipoprotein
A-I somewhat lower among the women with events
than among control subjects, but these differences
were not significant.
Table 3 shows the relative risks of cardiovascular
events according to the quartile of each marker of
inflammation or lipid measured in plasma. Measure-
ments of hs-CRP, serum amyloid A, sICAM-1, and
interleukin-6 were predictive of the risk of future car-
diovascular events. Of the 12 measures, the level of
hs-CRP was the most powerful predictor of risk in the
univariate analysis (relative risk for women in the high-
est quartile as compared with the lowest quartile, 4.4;
95 percent confidence interval, 2.2 to 8.9; P<0.001).
Of the lipid variables, the ratio of total cholesterol
to HDL cholesterol (relative risk, 3.4; P=0.001) and
the apolipoprotein B-100 level (relative risk, 3.4;
P=0.001) were the most powerful predictors of risk.
Nonsignificant trends were observed for apolipopro-
tein A-I and Lp(a) lipoprotein. As reported previ-
ously,
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 increasing levels of homocysteine were also
associated with increased risk.
Levels of several markers of inflammation were
highly correlated. For example, the correlation coef-
ficient for the relation between hs-CRP and serum
 
*Because of rounding, not all percentages total 100.
†P values were not calculated for variables used in matching of case and
control subjects, since the distribution of these variables was identical in the
two groups.
‡The body-mass index is the weight in kilograms divided by the square
of the height in meters.
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Mean age (yr) 59.3 59.3 —
Mean body-mass index‡ 27.1 26.0 0.04
History of hypertension (%) 55.5 31.3 0.001
History of diabetes (%) 9.8 2.1 0.001
Parental history of myocardial
infarction before 60 yr (%)
21.3 12.7 0.04
Smoking status (%) —
Former smoker 29.5 29.5
Current smoker 27.9 27.9
Nonsmoker 42.6 42.6
Frequency of exercise (%) 0.9
>3 times/wk 6.6 8.2
1–3 times/wk 27.9 27.1
<1 time/wk 21.3 20.1
Rarely or never 44.3 44.5
Frequency of alcohol con-
sumption (%)
0.6
Daily 12.3 8.2
Weekly 27.9 31.2
Monthly 14.8 13.9
Rarely or never 45.1 46.7
Current use of hormone-
replacement therapy (%)
44.3 41.0 0.1
*Plus–minus values are means ±SD. For normally distributed variables,
P values were computed with t-tests; for non-normally distributed variables,
P values were computed with the Wilcoxon rank-sum test for the difference
in medians. LDL denotes low-density lipoprotein, and HDL high-density
lipoprotein. To convert values for cholesterol to millimoles per liter, multi-
ply by 0.02586.
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High-sensitivity C-reactive 
protein (mg/dl)
<0.001
Median 0.42 0.28
Interquartile range 0.21–0.83 0.11–0.55
Serum amyloid A (mg/dl) 0.003
Median 0.63 0.52
Interquartile range 0.45–1.01 0.35–0.78
Soluble intercellular adhesion
molecule type 1 (ng/ml)
349.7±121.3 321.3±107.4 0.03
Interleukin-6 (pg/ml) 0.003
Median 1.65 1.30
Interquartile range 1.14–2.62 1.00–2.03
Total cholesterol (mg/dl) 230.5±41.2 219.2±37.5 0.01
LDL cholesterol (mg/dl) 132.2±34.6 121.5±30.2 0.003
HDL cholesterol (mg/dl) 45.4±14.6 51.1±15.4 <0.001
Apolipoprotein A-I (mg/dl) 163.8±40.3 168.5±36.1 0.3
Apolipoprotein B-100 (mg/dl) 128.5±31.0 115.0±26.7 <0.001
Lp(a) lipoprotein (mg/liter) 0.3
Median 79 74
Interquartile range 34–247 29–203
Ratio of total cholesterol to 
HDL cholesterol
5.5±1.9 4.6±1.4 <0.001
Homocysteine (µmol/liter) 14.1±8.0 12.4±5.8 0.02
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amyloid A was 0.81 (P<0.001). In contrast, corre-
lations between markers of inflammation and lipid
measures were low; less than 10 percent of the vari-
ance in any marker of inflammation was explained by
any of the lipid measures.
To determine the independent predictive value
of each of the 12 measures, we performed a series of
logistic-regression analyses that simultaneously con-
trolled for increasing quartiles of hs-CRP, serum amy-
loid A, sICAM-1, interleukin-6, homocysteine, and
Lp(a) lipoprotein and the ratio of total cholesterol
to HDL cholesterol (because of colinearity with this
ratio, levels of apolipoprotein A-I, apolipoprotein
B-100, and LDL cholesterol were not included in
these analyses). As shown in Table 4, only the level
of hs-CRP and the ratio of total cholesterol to HDL
cholesterol were found to be independent predictors
of risk in models in which women were matched for
smoking status and age or in models that included
further adjustments for body-mass index, hyperten-
sion, diabetes, and parental history of premature cor-
onary artery disease. In similar models that were lim-
ited to markers of inflammation, hs-CRP remained an
independent predictor of the risk of future cardio-
vascular events. In contrast, the beta coefficients asso-
ciated with serum amyloid A, sICAM-1, and inter-
leukin-6 decreased substantially and were no longer
statistically significant in analyses that included con-
trol for the quartile of hs-CRP.
To explore whether any of the markers of inflam-
 
*P values were calculated by logistic-regression analyses. In all models, subjects were matched ac-
cording to age and smoking status, and all models were adjusted for random assignment to aspirin
or vitamin E. CI denotes confidence interval, LDL low-density lipoprotein, and HDL high-density
lipoprotein. To convert values for cholesterol to millimoles per liter, multiply by 0.02586.
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1 2 3 4
High-sensitivity C-reactive 
protein
Median — mg/dl 0.06 0.19 0.38 0.85
Relative risk (95% CI) 1.0 2.1 (1.0–4.5) 2.1 (1.0–4.4) 4.4 (2.2–8.9) <0.001
Serum amyloid A
Median — mg/dl 0.25 0.43 0.62 1.17
Relative risk (95% CI) 1.0 1.8 (0.9–3.6) 1.9 (0.9–3.8) 3.0 (1.5–6.0) 0.002
Soluble intercellular adhesion 
molecule type 1
Median — ng/ml 228.7 273.9 319.1 439.3
Relative risk (95% CI) 1.0 1.5 (0.7–3.1) 2.0 (1.0–4.1) 2.6 (1.3–5.1) 0.004
Interleukin-6
Median — pg/ml 0.82 1.15 1.58 2.70
Relative risk (95% CI) 1.0 1.3 (0.6–2.7) 1.4 (0.7–2.8) 2.2 (1.1–4.3) 0.02
Total cholesterol 
Median — mg/dl 176 206 224 267
Relative risk (95% CI) 1.0 1.2 (0.6–2.3) 1.7 (0.9–3.3) 2.4 (1.3–4.7) 0.003
LDL cholesterol
Median — mg/dl 88.4 108.9 127.4 156.6
Relative risk (95% CI) 1.0 0.9 (0.4–1.9) 1.7 (0.9–3.3) 2.4 (1.3–4.6) 0.001
HDL cholesterol
Median — mg/dl 34.5 44.5 54.9 68.5
Relative risk (95% CI) 1.0 0.5 (0.3–0.8) 0.5 (0.2–0.8) 0.3 (0.2–0.6) 0.001
Apolipoprotein A-I
Median — mg/dl 127 152 176 212
Relative risk (95% CI) 1.0 0.8 (0.4–1.4) 0.4 (0.2–0.8) 0.8 (0.4–1.4) 0.1
Apolipoprotein B-100
Median — mg/dl 86 104 121 149
Relative risk (95% CI) 1.0 1.1 (0.5–2.3) 1.6 (0.8–3.3) 3.4 (1.8–6.8) <0.001
Lp(a) lipoprotein
Median — mg/liter 16 55 107 329
Relative risk (95% CI) 1.0 1.0 (0.5–1.9) 1.1 (0.6–2.1) 1.3 (0.7–2.4) 0.4
Ratio of total cholesterol to 
HDL cholesterol
Median 3.06 4.00 4.80 6.34
Relative risk (95% CI) 1.0 0.8 (0.3–1.5) 1.7 (0.9–3.4) 3.4 (1.8–5.9) <0.001
Homocysteine
Median — µmol/liter 8.2 10.3 12.1 15.7
Relative risk (95% CI) 1.0 1.1 (0.6–2.2) 1.1 (0.5–2.1) 2.0 (1.1–3.8) 0.02
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mation added to the predictive value of lipid-based
screening, several additional analyses were performed.
First, we computed the relative risk of cardiovascular
events in analyses in which study participants were
stratified into nine groups according to total choles-
terol level as well as each marker of inflammation. As
shown in Figure 1, for each marker of inflammation
included in this analysis, the risk of cardiovascular
events was lowest among women with low total cho-
lesterol levels and low levels of the marker in ques-
tion. In contrast, the risk tended to be highest among
women with high total cholesterol levels and high
levels of a marker of inflammation. However, even
among the women with low total cholesterol levels,
the risk of cardiovascular events was significantly high-
er among those with high levels of hs-CRP and serum
amyloid A than among those with low levels of these
markers (Fig. 1). These associations were also evident,
but to a lesser extent, for interleukin-6 and sICAM-1.
In all of the analyses, these additive effects were ro-
bust with respect to the choice of cutoff point and the
choice of the lipid variable analyzed. For example,
the addition of hs-CRP to lipid screening produced a
significant and additive predictive effect when regres-
sion analyses were based on cutoff points for quartiles
(rather than cutoff points for the division of the study
group into thirds) and on analysis of the ratio of to-
tal cholesterol to HDL cholesterol (rather than on
total cholesterol alone).
Second, likelihood-ratio tests were used to com-
pare the fit of predictive models that were based on
measurement of a marker of inflammation in combi-
nation with lipids to the fit of models based on lipid
measurements alone. In these analyses, each of the
markers of inflammation significantly improved the
usefulness of lipid screening in predicting risk. For
example, models including both hs-CRP and total
cholesterol were significantly better in the prediction
of the risk of cardiovascular events than were models
including only total cholesterol (P<0.001). Likewise,
models involving both hs-CRP and the ratio of total
cholesterol to HDL cholesterol allowed significantly
better prediction of risk than did models based solely
on this lipid ratio alone (P<0.001). Similar additive
effects were seen for serum amyloid A, sICAM-1, and
interleukin-6 when these markers were added to mod-
els based on total cholesterol or the ratio of total cho-
lesterol to HDL cholesterol alone (P<0.01 for all
comparisons).
Third, as a measure of clinical usefulness, we com-
puted the area under the receiver-operating-character-
istic curve associated with risk-prediction models based
on lipid screening alone and compared it with those
based on a combination of lipids and markers of in-
flammation. In these analyses, the use of hs-CRP lev-
els in addition to total cholesterol increased the area
under the receiver-operating-characteristic curve from
0.59 to 0.66 (P<0.001) and in addition to the ratio
of total cholesterol to HDL cholesterol increased the
area under the curve from 0.64 to 0.68 (P<0.001).
Similar effects were observed for analyses that included
serum amyloid A, sICAM-1, and interleukin-6: the
addition of these markers to screening based on total
cholesterol increased the area under the curve from
0.59 to 0.63, 0.63, and 0.64, respectively (P<0.003
for all three comparisons). Use of the serum amy-
loid A level in addition to the ratio of total cholesterol
to HDL cholesterol increased the area under the curve
from 0.64 to 0.67 (P=0.007); the use of sICAM-1 in
addition to this ratio led to a smaller change (area un-
der the curve, 0.65; P=0.01), as did the use of inter-
leukin-6 (area under the curve, 0.65; P=0.01).
Finally, to address the clinical observation that many
persons with “safe” lipid levels nonetheless have car-
diovascular events, we performed a subgroup analysis
limited to women whose levels of LDL cholesterol
were less than 130 mg per deciliter, the target level
currently recommended for primary prevention of cor-
onary heart disease by the National Cholesterol Ed-
ucation Program.
 
17
 
 In this analysis, women with in-
creased base-line levels of hs-CRP, serum amyloid A,
interleukin-6, or sICAM-1 were found to be at in-
creased risk for future cardiovascular events. This ef-
fect was strongest for hs-CRP and serum amyloid A.
In this subgroup, the relative risks of cardiovascular
events for women in the lowest to the highest quar-
tiles of hs-CRP were 1.0, 2.4, 2.9, and 4.1 (95 percent
confidence interval for women in the highest as com-
pared with the lowest quartile, 1.7 to 11.3; P=0.002;
P for trend across quartiles, 0.005). After adjustment
 
*In all models, subjects were matched according to age and smoking sta-
tus, and all models were adjusted for random assignment to aspirin or vita-
min E. CI denotes confidence interval, and HDL high-density lipoprotein.
†These models were adjusted for the following additional risk factors:
body-mass index (the weight in kilograms divided by the square of the height
in meters), a history of hypertension, a history of diabetes, and a parental
history of myocardial infarction.
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ADJUSTED FOR OTHER 
PLASMA MARKERS AND 
RISK FACTORS†
RELATIVE RISK
(95% CI) P VALUE
RELATIVE RISK
(95% CI) P VALUE
High-sensitivity C-reac-
tive protein
1.4 (1.1–1.9) 0.02 1.5 (1.1–2.1) 0.02
Serum amyloid A 1.1 (0.8–1.4) 0.5 1.1 (0.8–1.6) 0.4
Soluble intercellular ad-
hesion molecule type 1
1.1 (0.9–1.4) 0.4 1.1 (0.8–1.4) 0.6
Interleukin-6 0.9 (0.7–1.2) 0.6 0.8 (0.6–1.1) 0.2
Homocysteine 1.1 (0.9–1.4) 0.2 1.1 (0.8–1.4) 0.6
Lp(a) lipoprotein 1.1 (0.9–1.3) 0.6 1.0 (0.8–1.2) 0.8
Ratio of total cholesterol 
to HDL cholesterol
1.4 (1.1–1.7) 0.01 1.4 (1.1–1.9) 0.02
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for body-mass index, the presence or absence of hy-
pertension, diabetes, or a parental history of premature
myocardial infarction, and the level of HDL choles-
terol, the increased risk for women in the highest
quartile of hs-CRP at base line remained statistically
significant (relative risk, 3.1; 95 percent confidence in-
terval, 1.1 to 8.3; P=0.03). Thus, even among women
with “safe” levels of LDL cholesterol, the adjusted
relative risk of cardiovascular events increased approx-
imately 39 percent with each increasing quartile for
hs-CRP (95 percent confidence interval, 13 to 89
percent; P=0.03). The mean LDL cholesterol level
in this subgroup analysis was 104 mg per deciliter
(2.7 mmol per liter).
DISCUSSION
In this prospective study of apparently healthy post-
menopausal women, four markers of inflammation
— hs-CRP, serum amyloid A, interleukin-6, and
sICAM-1 — were found to be significant predictors
of the risk of future cardiovascular events. In addition,
measurement of these markers increased the pre-
dictive value of models based only on standard lipid
screening. Of the 12 plasma measures evaluated in this
study, hs-CRP was the most significant predictor of
the risk of cardiovascular events; when measured with
a widely available, standardized commercial assay,18
this marker distinguished between women at high risk
and those at low risk, even in the subgroup of wom-
en with LDL cholesterol levels below 130 mg per dec-
iliter (mean, 104 mg per deciliter), the target consid-
ered safe in the current guidelines of the National
Cholesterol Education Program.17
The results of the current study have several im-
portant implications. First, the findings confirm that
in women, markers of inflammation are important
predictors of the risk of cardiovascular events. Previ-
ous data on this issue have been derived largely from
Figure 1. Relative Risk of Cardiovascular Events among Apparently Healthy Postmenopausal Women According to Base-Line Levels
of Total Cholesterol and Markers of Inflammation.
Each marker of inflammation improved risk-prediction models based on lipid testing alone, an effect that was strongest for hs-CRP
and serum amyloid A.
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studies of middle-aged men.4-11 Thus, from a patho-
physiologic perspective, the current data support the
hypothesis that atherosclerosis is, in part, an inflam-
matory disease.3
Second, because we used a commercially available
assay to measure plasma hs-CRP,18 our results pro-
vide clinically relevant confirmation of previous find-
ings in this cohort, which were obtained with use of
an experimental assay.13 The commercial assay is in-
expensive and can be used with standard hospital and
outpatient laboratory equipment; thus, screening for
this predictor of cardiovascular risk would be practi-
cal in many clinical settings.
Third, we believe the current results have public
health implications both in terms of the prediction of
the risk of cardiovascular events and in terms of the
use of inhibitors of 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase for primary preven-
tion. Although the results of large-scale randomized
trials have indicated that HMG-CoA reductase inhi-
bition is effective even among persons at low-to-mod-
erate risk as defined by standard lipid screening,19,20
the large number of patients who would need to be
treated and the high cost of this approach have lim-
ited the clinical application of those findings. Thus,
our observation that measurement of markers of in-
flammation such as hs-CRP can significantly improve
models for the prediction of cardiovascular risk may
lead to better clinical identification of patients who
might benefit from primary prevention and for whom
the cost-to-benefit ratio for long-term use of statins
would be improved. This issue is particularly intrigu-
ing because recent data from the Cholesterol and Re-
current Events trial indicate that long-term therapy
with pravastatin significantly lowers plasma levels of
hs-CRP21 and that the efficacy of pravastatin in low-
ering the rate of cardiovascular events is greatest in
those with increased levels of hs-CRP.22 As in the cur-
rent findings, which indicate that hs-CRP is a potent
predictor of risk regardless of the LDL cholesterol
level, data from the Cholesterol and Recurrent Events
trial indicate that use of pravastatin resulted in de-
creased levels of hs-CRP in a manner largely independ-
ent of LDL cholesterol.21
Several limitations of these analyses merit consider-
ation. First, our cohort comprised apparently healthy
postmenopausal women, and thus the results may
not apply to younger women, who may also be at
increased risk for cardiovascular events. Second, we
measured each marker of inflammation at study entry
and thus could not evaluate the effects of changes in
the levels of these markers over time. However, follow-
up studies have found that levels of hs-CRP are stable
over long periods, as long as measurements are not
made within two to three weeks of an acute infec-
tion.21,23 Moreover, with respect to the current results,
variation over time in levels of these markers and re-
gression dilution bias would tend, if anything, to lead
to an underestimation of net effects. Finally, although
base-line levels of several markers of inflammation
were greater than normal among women at risk for
future cardiovascular events, the mechanisms under-
lying these elevations remain uncertain. In this study,
we did not find significant associations between car-
diovascular risk and titers of IgG antibodies against
Chlamydia pneumoniae, Helicobacter pylori, herpes sim-
plex virus, or cytomegalovirus or between titers of
these antibodies and plasma levels of hs-CRP.24 On
the other hand, markers of inflammation, including
hs-CRP, interleukin-6, and interleukin-1–receptor
antagonist,25-31 have proved to have predictive value
among persons with unstable angina or acute coro-
nary syndromes. Thus, it is also possible that the in-
flammation that we detected in apparently healthy
women who were at risk for future cardiovascular
events may be an indirect marker of an enhanced cy-
tokine response to a variety of inflammatory stim-
uli that ultimately prove critical at the time of acute
plaque rupture.32
In conclusion, in this prospective evaluation of 12
plasma variables, hs-CRP proved to be the strongest
and most significant predictor of the risk of future
cardiovascular events. As in previous population-based
epidemiologic studies, half of all cardiovascular events
in our cohort occurred among women without overt
hyperlipidemia. Thus, these data raise the possibility
that the addition of hs-CRP to standard lipid screen-
ing will generate an improved method for identifying
persons at high risk for future cardiovascular events,
who would thus be candidates for primary-prevention
interventions such as the use of HMG-CoA reduc-
tase inhibitors.
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CORRECTION
C-Reactive Protein in the Prediction of
Cardiovascular Disease
To the Editor: Ridker et al. provided a stimulating article on inflamma-
tory markers and cardiovascular disease in women (March 23 issue).1
Not surprisingly, the popular press picked up on the article and gave
their findings prominent coverage. It is not clear that Ridker et al.
wanted this to happen. Their findings are cast in terms of relative
risk only, not in terms of traditional predictive value; it is the latter that
is more relevant to the practicing physician.2 That is, we learn that
subjects in the highest quartile for high-sensitivity C-reactive protein
(hs-CRP), relative to those in the lowest quartile, had a 4.4-fold risk of
cardiovascular events. However, the overall risk was just 0.4 percent
(122 events in 28,263 subjects over a period of three years). We sus-
pect that the positive predictive value (the proportion of all subjects
with `` elevated´´ levels of hs-CRP who had cardiac events) in this pop-
ulation was low.
We were unable to calculate the conventional predictive values from
the data supplied in the article. It would be instructive if the au-
thors provided the predictive values so that readers could determine
whether this new test is genuinely ready for `` prime-time´´ screening.
Even though this test performed better than measurements of conven-
tional lipid markers such as low-density lipoprotein (LDL) cholesterol
in this population (at least in terms of relative risk), there are other
relevant data about LDL cholesterol that are lacking for hs-CRP. For
example, we know that lowering LDL cholesterol levels has beneficial
effects,3 we have effective methods to lower LDL cholesterol levels,
and we have data on the cost effectiveness of such strategies.4
Gary L. Horowitz, M.D.
Bruce A. Beckwith, M.D.
Beth Israel Deaconess Medical Center
Boston, MA 02215
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The authors reply:
To the Editor: In our study of inflammatory and lipid markers we used
a matched, nested case–control analysis that allowed direct compar-
ison of the magnitude of risk associated with various cardiovascular
risk factors after age and smoking status were taken into account.
Of the 12 factors evaluated — which included LDL cholesterol, high-
density lipoprotein (HDL) cholesterol, Lp(a) lipoprotein, and homocys-
teine — hs-CRP was the strongest predictor of future cardiovascular
events. Moreover, hs-CRP levels were predictive of the risk of car-
diovascular events among study participants with low levels of LDL
cholesterol; these data underscore the importance of the inflamma-
tory process in atherothrombosis.
Our matched, nested case–control study was designed to maximize
biologic validity. It is not, however, conducive to calculating absolute
risks. We thus concur with Horowitz and Beckwith that generalizing
our results to other populations must be done with caution and that
studies addressing absolute risks are needed. We further concur that
the reduction of lipid levels remains a fundamentally important method
to reduce cardiovascular risk. At the same time, since half of all heart
attacks and strokes occur among apparently healthy men and women
without overt hyperlipidemia, we believe it important for clinicians to
consider emerging biologic data that go beyond the use of cholesterol
screening as the sole method of assessing cardiovascular risk. With
regard to hs-CRP, several large-scale studies in the United States1,2,3
and Europe4,5 have now demonstrated the potential importance of
this inflammatory marker in the detection of cardiovascular risk.
Finally, we wish to correct an error in the last sentence of the Results
section of our abstract. As described in the text and in Table 4 of our
article, our multivariate analysis was performed on a per-quartile ba-
sis. Thus, this sentence should read, `` In multivariate analyses, the
only plasma markers that independently predicted risk were hs-CRP
(increase in relative risk per quartile, 1.5; 95 percent confidence in-
terval, 1.1 to 2.1) and the ratio of total cholesterol to HDL cholesterol
(increase in relative risk per quartile, 1.4; 95 percent confidence inter-
val, 1.1 to 1.9).´´
Paul M. Ridker, M.D.
Julie E. Buring, Sc.D.
Nader Rifai, Ph.D.
Brigham and Women’s Hospital
Boston, MA 02115
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BSTRACT
 
Background
 
Inflammation may be important in
the pathogenesis of atherothrombosis. We studied
whether inflammation increases the risk of a first
thrombotic event and whether treatment with aspi-
rin decreases the risk.
 
Methods
 
We measured plasma C-reactive protein,
a marker for systemic inflammation, in 543 appar-
ently healthy men participating in the Physicians’
Health Study in whom myocardial infarction, stroke,
or venous thrombosis subsequently developed, and
in 543 study participants who did not report vascular
disease during a follow-up period exceeding eight
years. Subjects were randomly assigned to receive as-
pirin or placebo at the beginning of the trial.
 
Results
 
Base-line plasma C-reactive protein con-
centrations were higher among men who went on to
have myocardial infarction (1.51 vs. 1.13 mg per liter,
P
 

 
0.001) or ischemic stroke (1.38 vs. 1.13 mg per liter,
P
 

 
0.02), but not venous thrombosis (1.26 vs. 1.13 mg
per liter, P
 

 
0.34), than among men without vascu-
lar events. The men in the quartile with the highest
C-reactive protein values had three times the risk of
myocardial infarction (relative risk, 2.9; P
 

 
0.001) and
two times the risk of ischemic stroke (relative risk,
1.9; P
 

 
0.02) of the men in the lowest quartile. Risks
were stable over long periods, were not modified by
smoking, and were independent of other lipid-relat-
ed and non–lipid-related risk factors. The use of as-
pirin was associated with significant reductions in the
risk of myocardial infarction (55.7 percent reduction,
P
 

 
0.02) among men in the highest quartile but with
only small, nonsignificant reductions among those in
the lowest quartile (13.9 percent, P
 

 
0.77).
 
Conclusions
 
The base-line plasma concentration
of C-reactive protein predicts the risk of future myo-
cardial infarction and stroke. Moreover, the reduction
associated with the use of aspirin in the risk of a first
myocardial infarction appears to be directly related
to the level of C-reactive protein, raising the pos-
sibility that antiinflammatory agents may have clini-
cal benefits in preventing cardiovascular disease.
(N Engl J Med 1997;336:973-9.)
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HROMBUS formation is the proximate
cause of myocardial infarction, but ath-
erosclerosis, the chief underlying cause, is a
chronic disease that progresses over dec-
ades of life.
 
1
 
 Laboratory and pathological data sup-
port the idea that inflammation has a role in both
the initiation and the progression of atherosclerosis,
and antiinflammatory agents may have a role in the
prevention of cardiovascular disease.
 
2-5
 
 However, there
are few data to indicate whether inflammation increas-
es the risk of first myocardial infarction, stroke, and
venous thrombosis or whether antiinflammatory ther-
apy decreases that risk.
C-reactive protein is an acute-phase reactant that
is a marker for underlying systemic inflammation.
Elevated plasma concentrations of C-reactive protein
have been reported in patients with acute ischemia
 
6
 
or myocardial infarction
 
7,8
 
 and have been found to
predict recurrent ischemia among those hospitalized
with unstable angina.
 
9
 
 C-reactive protein is also as-
sociated with a risk of myocardial infarction among
patients with angina pectoris
 
10
 
 and with a risk of fa-
tal coronary disease among smokers with multiple
risk factors for atherosclerosis.
 
11
 
 However, since con-
centrations of C-reactive protein and other acute-
phase reactants increase after acute ischemia
 
6
 
 and are
directly related to cigarette smoking,
 
11,12
 
 it has been
uncertain whether associations observed in previous
studies of acutely ill patients
 
9
 
 or high-risk popula-
T
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tions
 
10,11
 
 are causal or are due to short-term inflam-
matory changes or to interrelations with other risk
factors, in particular smoking and hyperlipidemia.
To address these issues, we measured base-line
plasma C-reactive protein concentrations in 1086
apparently healthy men participating in the Physi-
cians’ Health Study
 
13,14
 
; myocardial infarction, stroke,
or venous thrombosis subsequently developed in 543.
We hypothesized a priori that levels of C-reactive
protein would predict the risk of myocardial infarc-
tion and stroke but not of venous thrombosis — an
occlusive vascular disease generally not associated
with chronic atherosclerosis. After providing base-
line blood samples, study participants were randomly
assigned to receive aspirin or placebo. Thus, we had
the unique opportunity to evaluate directly whether
aspirin, an agent with both antiplatelet and antiin-
flammatory properties, might modify any relation
between C-reactive protein and the risk of first my-
ocardial infarction.
 
METHODS
 
Study Population and Collection of Plasma Samples
 
The Physicians’ Health Study was a randomized, double-blind,
placebo-controlled two-by-two factorial trial of aspirin and beta
carotene in the primary prevention of cardiovascular disease and
cancer. A total of 22,071 U.S. male physicians 40 to 84 years of
age in 1982, with no history of myocardial infarction, stroke,
transient ischemic attack, or cancer, were assigned to one of four
treatments: 325 mg of aspirin on alternate days (Bufferin, provid-
ed by Bristol-Myers), 50 mg of beta carotene on alternate days
(Lurotin, provided by BASF Corporation), both, or neither. The
aspirin component of the study was terminated early, on January
25, 1988, primarily because of a statistically extreme 44 percent
reduction in the risk of a first infarction in the aspirin group.
 
13
 
The beta carotene component continued until the study’s sched-
uled termination on December 31, 1995.
 
14
 
Before randomization, between August 1982 and December
1984, potential participants were asked to provide base-line blood
samples during a 16-week run-in period during which all subjects
were given aspirin and none received placebo. Blood-collection
kits, including EDTA Vacutainer tubes, were sent to participants
with instructions for taking blood. Participants were asked to have
their blood drawn into the EDTA tubes, centrifuge the tubes, and
return the plasma (accompanied by a cold pack provided to par-
ticipants) by overnight courier. The specimens were then divided
into aliquots and stored at 
 

 
80°C. Of the 22,071 participants in
the Physicians’ Health Study, 14,916 (68 percent) provided base-
line plasma samples. Over the 14 years of the trial, no specimen
inadvertently thawed during storage.
 
Confirmation of End Points and Selection of Controls
 
We requested hospital records (and for fatal events, death cer-
tificates and autopsy reports) for all reported cases of myocardial
infarction, stroke, and venous thrombosis. The records were re-
viewed by a committee of physicians using standardized criteria
to confirm or refute reported events. Reviewers of end points
were unaware of treatment assignments.
Reported myocardial infarction was confirmed if its symptoms
met World Health Organization (WHO) criteria and it was asso-
ciated with either elevated plasma concentrations of enzymes or
characteristic electrocardiographic changes. Silent myocardial in-
farctions were not included, since they could not be dated accu-
rately. Deaths due to coronary disease were confirmed on the basis
of autopsy reports, symptoms, circumstances of death, and a his-
tory of coronary disease. Reported stroke was confirmed on the
basis of medical records showing a neurologic deficit of sudden or
rapid onset that persisted for more than 24 hours or until death.
Strokes were classified as ischemic or hemorrhagic. Computed to-
mographic scans were available for more than 95 percent of the
confirmed strokes. Reported deep venous thrombosis was con-
firmed by the documentation of a positive venography study or a
positive ultrasound study; deep venous thromboses documented
only by impedance plethysmography or Doppler examination with-
out ultrasound were not considered confirmed. Reported pul-
monary embolism was confirmed by a positive angiogram or a
completed ventilation-perfusion scan demonstrating at least two
segmental perfusion defects with normal ventilation.
Each participant who provided an adequate base-line plasma
sample and had a confirmed myocardial infarction, stroke, or venous
thrombosis after randomization was matched with one control.
Controls were participating physicians who provided base-line plas-
ma samples and reported no cardiovascular disease at the time the
patient reported his event. Controls were selected randomly from
among study participants who met the matching criteria of age
(
 

 
1 year), smoking status (smoking currently, smoked in the
past, or never smoked), and length of time since randomization
(in 6-month intervals). Using these methods, we evaluated 543
patients and 543 controls in this prospective, nested, case–control
study.
 
Laboratory Analysis
 
For each patient and control, plasma collected and stored at
base line was thawed and assayed for C-reactive protein by en-
zyme-linked immunosorbent assay (ELISA) based on purified
protein and polyclonal anti–C-reactive protein antibodies (Cal-
biochem).
 
15
 
 Antibodies were used to coat microtiter-plate wells,
and biotinylated C-reactive protein, together with the patient’s
plasma, was diluted 1:700 in assay buffer (phosphate-buffered sa-
line with 0.1 percent Tween 20 and 1 percent bovine serum al-
bumin). The excess was then washed off and the amount of bio-
tinylated protein estimated by the addition of avidin–peroxidase
(Vectastain, Vector Laboratories). Purified C-reactive protein was
used as the standard, with protein concentrations as determined
by the manufacturer. The C-reactive protein assay was standard-
ized according to the WHO First International Reference Stand-
ard and had a sensitivity of 0.08 
 
m
 
g per microliter, with a standard
reference range of between 0.5 and 2.5 mg per liter. Methods
used to measure plasma total and high-density lipoprotein (HDL)
cholesterol, triglyceride, lipoprotein(a), total homocysteine, fi-
brinogen, 
 
D
 
-dimer, and endogenous tissue plasminogen activator
(t-PA) antigen have been described elsewhere.
 
16-20
 
Blood specimens were analyzed in blinded pairs, with the po-
sition of the patient’s specimen varied at random within the pairs
to reduce the possibility of systematic bias and decrease interassay
variability. The mean coefficient of variation for C-reactive pro-
tein across assay runs was 4.2 percent.
 
Statistical Analysis
 
Means or proportions for base-line risk factors were calculated
for patients and controls. The significance of any difference in
means was tested by using Student’s t-test, and the significance
of any differences in proportions was tested by using the chi-
square statistic. Because C-reactive protein values are skewed, me-
dian concentrations were computed and the significance of any
differences in median values between patients and controls was
assessed by using Wilcoxon’s rank-sum test. Geometric mean con-
centrations of C-reactive protein were also computed after log
transformation that resulted in nearly normal distribution. We
used tests for trend to assess any relation of increasing C-reactive
protein values with the risk of future vascular disease after divid-
ing the sample into quartiles defined by the distribution of the
control values. We obtained adjusted estimates by using condi-
tional logistic-regression models that accounted for the matching
variables and controlled for the random treatment assignment,
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body-mass index, diabetes, history of hypertension, and parental
history of coronary artery disease. Similar models were employed
to adjust for measured base-line plasma concentrations of total
and HDL cholesterol, triglyceride, lipoprotein(a), t-PA antigen,
fibrinogen, 
 
D
 
-dimer, and homocysteine. To evaluate whether as-
pirin affected these relations, analyses were repeated for all cases
of myocardial infarction occurring on or before January 25, 1988
— the date when randomized aspirin assignment was terminated.
All P values are two-tailed, and confidence intervals were calcu-
lated at the 95 percent level.
 
RESULTS
 
Table 1 shows the base-line characteristics of the
study participants. As expected, those in whom my-
ocardial infarction subsequently developed were more
likely than those who remained free of vascular dis-
ease to have a history of hypertension or hyperlipi-
demia or a parental history of coronary artery dis-
ease. Similarly, those in whom stroke subsequently
developed were more likely to be hypertensive. Be-
cause of the matching, patients and controls were
similar in age and history of smoking.
Geometric mean and median plasma concentra-
tions of C-reactive protein at base line were signifi-
cantly higher among those in whom any vascular
event subsequently developed than among those
who remained free of vascular disease (P
 

 
0.001).
The difference between patients and controls was
greatest for those in whom myocardial infarction
subsequently developed (1.51 vs. 1.13 mg per liter,
P
 

 
0.001), although differences were also significant
for stroke (P
 

 
0.03), particularly ischemic stroke
(P
 

 
0.02). In contrast, concentrations of C-reactive
protein were not significantly higher among those in
whom venous thrombosis subsequently developed
(P
 

 
0.34) (Table 2).
The relative risk of first myocardial infarction in-
creased significantly with each increasing quartile of
base-line concentrations of C-reactive protein (P for
trend across quartiles, 
 

 
0.001), in such a way that
the men in the highest quartile had a risk of future
myocardial infarction almost three times that among
those in the lowest quartile (relative risk, 2.9; 95
percent confidence interval, 1.8 to 4.6; P
 

 
0.001)
(Table 3). Similarly, men with the highest base-line
C-reactive protein values had twice the risk of future
ischemic stroke (relative risk, 1.9; 95 percent confi-
dence interval, 1.1 to 3.3; P
 

 
0.02). No significant
associations were observed for venous thrombosis.
The findings were similar in analyses limited to non-
fatal events.
To evaluate whether increased base-line C-reactive
protein values were associated with early rather than
late thrombosis, we stratified the analysis of myocar-
dial infarction according to the number of years of
follow-up. The relative risk of future myocardial in-
farction that was associated with the highest quartile
of C-reactive protein (as compared with the lowest
quartile) ranged from 2.4 for events occurring in the
first two years of follow-up to 3.2 for events occur-
ring six or more years into follow-up (Table 4). Sim-
ilarly, the relative risk of future myocardial infarction
that was associated with a one-quartile change in the
C-reactive protein concentration was stable over long
periods (Fig. 1).
Smokers had significantly higher median concen-
trations of C-reactive protein than nonsmokers (2.20
vs. 1.19 mg per liter, P
 

 
0.001). By matching pa-
tients and controls for smoking status, we mini-
mized the potential for confounding by smoking. To
assess for effect modification, however, we repeated
the analyses, limiting the cohort to nonsmokers. As
Table 3 also shows, the relative risk of future myo-
cardial infarction among nonsmokers increased sig-
 
*Plus–minus values are means 
 

 
SD.
†The body-mass index is the weight in kilograms divided by the square of the height in meters. 
 
T
 
ABLE
 
 1.
 
 B
 
ASE
 
-L
 
INE
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 S
 
TUDY
 
 P
 
ARTICIPANTS
 
.
 
C
 
HARACTERISTIC
 
C
 
ARDIOVASCULAR
 
 D
 
ISEASE
 
 
 
DURING
 
 F
 
OLLOW
 
-
 
UP
 
*
 
NONE
 
(
 
N
 

 
543)
 
ANY
 
(
 
N
 

 
543)
 
MYOCARDIAL
INFARCTION
 
(
 
N
 

 
246)
 
STROKE
 
(
 
N
 

 
196)
 
VENOUS
THROMBOSIS
 
(
 
N
 

 
101)
Age (yr) 59
 

 
9.1 59
 

 
9.2 58
 

 
8.6 62
 

 
9.1 57
 

 
9.4
Smoking status (%)
Never smoked
Smoked in the past
Currently a smoker
44
41
15
44
41
15
45
40
15
42
40
18
50
44
6
Diabetes (%) 4 7 5 12 2
Body-mass index† 25
 

 
2.8 26
 

 
3.2 26
 

 
3.3 25
 

 
3.2 26
 

 
2.9
History of high plasma cho-
lesterol (%)
9 13 17 10 7
History of hypertension (%) 16 29 27 35 20
Parental history of coronary artery
disease (%)
10 13 17 11 8
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nificantly with each increasing quartile of C-reac-
tive protein (P for trend, 
 

 
0.001). Similarly, the
long-term effects of the concentration of C-reactive
protein on the risk of myocardial infarction were
virtually identical among nonsmokers (Table 4).
Moreover, the relation between the concentration of
C-reactive protein and myocardial infarction was not
significantly altered in analyses that adjusted for
body-mass index; the presence or absence of diabe-
tes, hypertension, or a family history of premature
coronary artery disease; and the plasma concentra-
tions of total cholesterol, HDL cholesterol, triglyc-
erides, lipoprotein(a), t-PA antigen, 
 
D
 
-dimer, fibrin-
ogen, or homocysteine (Table 5).
Finally, to assess whether the beneficial effect of
aspirin on the risk of myocardial infarction varied ac-
cording to the base-line level of C-reactive protein,
we repeated these analyses for events occurring be-
fore January 25, 1988, the date when randomized
aspirin treatment was terminated.
The risk of future myocardial infarction increased
with each increasing quartile of C-reactive protein
values for men randomly assigned to either aspirin
or placebo, and the rates of myocardial infarction were
lower in the aspirin group for all quartiles of C-reac-
tive protein (Fig. 2). However, the magnitude of the
beneficial effect of aspirin in preventing myocardial
infarction was directly related to base-line levels of
C-reactive protein. Specifically, randomized aspirin
assignment was associated with a large and statis-
tically significant reduction in the risk of myocar-
dial infarction among men with base-line levels of
C-reactive protein in the highest quartile (risk re-
duction, 55.7 percent; P
 

 
0.02). Among those with
base-line levels of C-reactive protein in the lowest
quartile, however, the reduction in risk associated
with aspirin was far smaller and no longer statistical-
ly significant (risk reduction, 13.9 percent; P
 

 
0.77).
These effects were linear across quartiles, so that the
apparent benefit of aspirin diminished in magnitude
with each decreasing quartile of inflammatory risk
(Fig. 2). This finding remained essentially unchanged
after further adjustment for other coronary risk fac-
tors, and the interaction between assignment to the
aspirin group and base-line levels of C-reactive pro-
tein (treated as a log-transformed continuous vari-
able) was statistically significant (P
 

 
0.048).
 
DISCUSSION
 
These prospective data indicate that the base-line
plasma concentration of C-reactive protein in appar-
ently healthy men can predict the risk of first myocar-
dial infarction and ischemic stroke. In addition, the
risk of arterial thrombosis associated with the level of
C-reactive protein was stable over long periods and
was not modified by other factors, including smoking
status, body-mass index, blood pressure, or the plas-
ma concentration of total or HDL cholesterol, tri-
 
T
 
ABLE
 
 2.
 
 B
 
ASE
 
-L
 
INE
 
 P
 
LASMA
 
 C
 
ONCENTRATIONS
 
 
 
OF
 
 C-REACTIVE 
PROTEIN IN STUDY PARTICIPANTS WHO REMAINED 
FREE OF VASCULAR DISEASE DURING FOLLOW-UP (CONTROLS) 
AND IN THOSE IN WHOM MYOCARDIAL INFARCTION, STROKE, 
OR VENOUS THROMBOSIS DEVELOPED (PATIENTS).
CARDIOVASCULAR DISEASE 
DURING FOLLOW-UP PLASMA C-REACTIVE PROTEIN
GEOMETRIC 
MEAN
P 
VALUE MEDIAN
P
VALUE
mg/liter mg/liter
None (n543) 1.10 — 1.13 —
Any vascular event (n543)
Myocardial infarction (n246)
Any stroke (n196)
Ischemic stroke (n154)
Venous thrombosis (n101)
1.37
1.48
1.30
1.36
1.24
0.001
0.001
0.03
0.01
0.22
1.40
1.51
1.36
1.38
1.26
0.001
0.001
0.03
0.02
0.34
*CI denotes confidence interval.
TABLE 3. RELATIVE RISK OF FUTURE MYOCARDIAL INFARCTION, 
STROKE, AND VENOUS THROMBOSIS ACCORDING TO BASE-LINE 
PLASMA CONCENTRATIONS OF C-REACTIVE PROTEIN.
VASCULAR EVENT*
QUARTILE OF C-REACTIVE PROTEIN
CONCENTRATION (mg/liter)
P FOR 
TREND
0.55 0.56–1.14 1.15–2.10 2.11
Myocardial infarction
(total cohort)
Relative risk
95% CI
P value
1.0
—
—
1.7
1.1–2.9
0.03
2.6
1.6–4.3
0.001
2.9
1.8–4.6
0.001
0.001
Myocardial infarction
(nonsmokers)
Relative risk
95% CI
P value
1.0
—
—
1.7
1.0–2.8
0.06
2.5
1.5–4.1
0.001
2.8
1.7–4.7
0.001
0.001
Ischemic stroke
Relative risk
95% CI
P value
1.0
—
—
1.7
0.9–2.9
0.07
1.9
1.1–3.2
0.02
1.9
1.1–3.3
0.02
0.03
Venous thrombosis
Relative risk
95% CI
P value
1.0
—
—
1.1
0.6–2.0
0.78
1.2
0.7–2.3
0.51
1.3
0.7–2.4
0.42
0.38
*CI denotes confidence interval.
TABLE 4. RELATIVE RISK OF FIRST MYOCARDIAL INFARCTION 
ASSOCIATED WITH THE HIGHEST QUARTILE OF BASE-LINE 
PLASMA C-REACTIVE PROTEIN CONCENTRATIONS
AS COMPARED WITH THE LOWEST QUARTILE, ACCORDING TO 
THE YEAR OF STUDY FOLLOW-UP.
GROUP* FOLLOW-UP (YR)
0–2 2– 4 4– 6 6
Total cohort
Relative risk
95% CI
P value
2.4
0.9–6.8
0.09
2.9
1.1–7.6
0.03
2.8
1.1–6.9
0.03
3.2
1.2–8.5
0.02
Nonsmokers
Relative risk
95% CI
P value
2.8
0.9–8.7
0.07
2.9
1.0–8.3
0.05
2.7
1.0–7.0
0.05
2.9
1.1–8.2
0.04
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glyceride, lipoprotein(a), t-PA antigen, D-dimer, fi-
brinogen, or homocysteine. In contrast, the benefits
of aspirin in reducing the risk of a first myocardial in-
farction diminished significantly with decreasing con-
centrations of C-reactive protein — an intriguing
finding, since this substance has antiinflammatory as
well as antiplatelet properties. Finally, there was no
significant association for venous thromboembolism,
suggesting that the relation of inflammation to vas-
cular risk may be limited to the arterial circulation.
Because blood samples were collected at base line,
we can exclude the possibility that acute ischemia af-
fected levels of C-reactive protein. Furthermore, the
statistically significant associations observed were
present among nonsmokers, indicating that the ef-
fect of C-reactive protein on vascular risk is not sim-
ply the result of cigarette smoking.11,12 Thus, our
prospective data relating base-line levels of C-reac-
tive protein to future risks of myocardial infarction
and stroke among apparently healthy men greatly
Figure 1. Relative Risk (and 95 Percent Confidence Intervals) of
a First Myocardial Infarction Associated with Each Increasing
Quartile of Base-Line C-Reactive Protein Values, According to
the Year of Study Follow-up.
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*All models were further adjusted for random assignment of patients to receive aspirin and beta
carotene. CI denotes confidence interval.
TABLE 5. RELATIVE RISK OF FUTURE MYOCARDIAL INFARCTION, ACCORDING TO 
BASE-LINE PLASMA CONCENTRATIONS OF C-REACTIVE PROTEIN, ADJUSTED FOR LIPID 
AND NONLIPID VARIABLES.*
VARIABLES ADJUSTED FOR
QUARTILE OF C-REACTIVE PROTEIN
CONCENTRATION (mg/liter)
P FOR 
TREND
0.55 0.56–1.14 1.15–2.10 2.11
Total and HDL cholesterol 
Adjusted relative risk
95% CI
P value
1.0
—
—
1.8
1.0–3.1
0.05
2.2
1.3–3.7
0.004
2.3
1.4–3.9
0.002
0.002
Triglycerides
Adjusted relative risk
95% CI
P value
1.0
—
—
1.8
1.0–3.2
0.06
2.1
1.2–3.7
0.008
2.8
1.6–4.9
0.001
0.001
Lipoprotein(a) 
Adjusted relative risk
95% CI
P value
1.0
—
—
2.0
1.2–3.4
0.01
2.5
1.5–4.2
0.001
2.5
1.5–4.2
0.001
0.001
t-PA antigen 
Adjusted relative risk
95% CI
P value
1.0
—
—
1.7
0.9–3.4
0.13
1.9
1.0–3.6
0.06
2.9
1.5–5.6
0.002
0.002
Total homocysteine 
Adjusted relative risk
95% CI
P value
1.0
—
—
1.8
1.1–3.1
0.02
2.9
1.7–4.8
0.001
3.6
2.1–5.9
0.001
0.001
D-Dimer 
Adjusted relative risk
95% CI
P value
1.0
—
—
2.2
1.2–4.1
0.007
2.4
1.3–4.2
0.003
2.7
1.5–4.7
0.001
0.001
Fibrinogen 
Adjusted relative risk
95% CI
P value
1.0
—
—
2.2
1.1–4.7
0.04
2.2
1.0–4.4
0.04
2.9
1.4–5.9
0.005
0.01
Body-mass index, diabetes, history 
of hypertension, and family 
history of coronary artery disease
Adjusted relative risk
95% CI
P value
1.0
—
—
1.5
0.9–2.5
0.14
2.4
1.5–4.0
0.001
2.6
1.6–4.4
0.001
0.001
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extend previous observations from studies of acutely
ill patients,9 patients with symptomatic coronary dis-
ease,10 or those at high risk partly because of ciga-
rette smoking.11 Moreover, in these data, the effects
of C-reactive protein were independent of a large
number of lipid-related and non–lipid-related risk
factors.
The mechanism that relates the level of C-reactive
protein to atherothrombosis is unclear. Previous in-
fection with Chlamydia pneumoniae, Helicobacter py-
lori, herpes simplex virus, or cytomegalovirus may be
a source of the chronic inflammation detected by
C-reactive protein.21-27 It is also possible that C-reactive
protein is a surrogate for interleukin-6,28 a cellular cy-
tokine associated with the recruitment of macrophages
and monocytes into atherosclerotic plaques.29 In ad-
dition, C-reactive protein can induce monocytes to
express tissue factor, a membrane glycoprotein im-
portant in initiating coagulation.30 Finally, it had been
hypothesized that bronchial inflammation due to
smoking was responsible for associations seen in pre-
vious studies relating C-reactive protein to vascular
risk.11 In this regard, our observation that the effect
of C-reactive protein is present among nonsmok-
ers makes bronchial inflammation a less likely mech-
anism. Furthermore, the finding that the effects are
stable over long periods suggests that short-term ef-
fects on clotting are unlikely.
Our data regarding the interrelation of C-reactive
protein and aspirin merit careful consideration. In
the Physicians’ Health Study, aspirin reduced the risk
of a first myocardial infarction by 44 percent.13 The
present findings indicate that the effect of aspirin in
preventing a first myocardial infarction was greatest
among the men with the highest base-line C-reac-
tive protein concentrations and that the benefit di-
minished significantly with decreasing concentrations
of this inflammatory marker. Thus, although the an-
tiplatelet effects of aspirin may be modified by un-
derlying inflammation, these data also suggest the
possibility that the benefit of aspirin may have been
due, at least in part, to antiinflammatory effects.31 Al-
ternatively, patients with large inflammatory burdens
may have a distinct vascular mechanism leading to
thrombosis that is affected differently by aspirin ther-
apy. For example, the protective effect of aspirin may
differ in the setting of plaque rupture as compared
with focal endothelial erosion.32,33
The potential limitations of these data also merit
consideration. First, our analyses are based on a sin-
gle base-line determination that may not accurately
reflect inflammatory status over long periods. Fur-
thermore, although coefficients of variation were low,
misclassification due to laboratory error cannot be
ruled out. It is important to note, however, that nei-
ther of these sources of variability can account for
the observed associations, since any random mis-
classification would bias results toward the null hy-
pothesis. Since our study was limited to measures of
C-reactive protein, other prospective studies evaluat-
ing specific cytokines, cellular adhesion molecules, and
chronic infectious agents will be required to further
elucidate the role of inflammation in the initiation
and progression of atherosclerosis.
We draw four main conclusions from these data.
First, among apparently healthy men, the base-line
level of inflammation as assessed by the plasma con-
centration of C-reactive protein predicts the risk of
a first myocardial infarction and ischemic stroke, in-
dependently of other risk factors. Second, the base-
line concentration of C-reactive protein is not asso-
ciated with the risk of venous thrombosis, a vascular
event generally not associated with atherosclerosis.
Third, C-reactive protein is not simply a short-term
marker of risk, as has previously been demonstrated
in patients with unstable angina,9 but is also a long-
term marker of risk, even for events occurring six
or more years later. This observation suggests that
the effects of inflammation are probably mediated
through a chronic process and excludes the possi-
bility that undetected acute illness at base line is re-
sponsible for the observed effects. Finally, the ben-
efits of aspirin appear to be modified by underlying
inflammation — an observation that raises the pos-
sibility of antiinflammatory as well as antiplatelet
effects of this agent. The latter observation also
suggests the possibility that other antiinflammatory
agents may have a role in preventing cardiovascular
Figure 2. Relative Risk of a First Myocardial Infarction Associ-
ated with Base-Line Plasma Concentrations of C-Reactive Pro-
tein, Stratified According to Randomized Assignment to Aspi-
rin or Placebo Therapy.
Analyses are limited to events occurring before the unblinding
of the aspirin component of the Physicians’ Health Study. The
reduction in the risk of myocardial infarction associated with
the use of aspirin was 13.9 percent in the first (lowest) quartile
of C-reactive protein values, 33.4 percent in the second quar-
tile, 46.3 percent in the third quartile, and 55.7 percent in the
fourth (highest) quartile.
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disease. Moreover, these data suggest that inflamma-
tory markers such as C-reactive protein may provide
a method of identifying people for whom aspirin is
likely to be more or less effective — a hypothesis re-
quiring direct testing in randomized trials.
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CORRECTION
Inflammation, Aspirin, and the Risk of Cardiovascular
Disease in Apparently Healthy Men
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Ap-
parently Healthy Men . On page 974, the sentence that begins in line
13 under the heading `` Laboratory Analysis´´ should have read, `` The
C-reactive protein assay was standardized according to the WHO
First International Reference Standard and had a sensitivity of 0.08
µg per milliliter,´´ not `` 0.08 µg per microliter,´´ as printed.
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background
 
Few studies have simultaneously investigated the role of soluble tumor necrosis fac-
tor 
 
a
 
 (TNF-
 
a
 
) receptors types 1 and 2 (sTNF-R1 and sTNF-R2), C-reactive protein, and
interleukin-6 as predictors of cardiovascular events. The value of these inflammatory
markers as independent predictors remains controversial.
 
methods
 
We examined plasma levels of sTNF-R1, sTNF-R2, interleukin-6, and C-reactive pro-
tein as markers of risk for coronary heart disease among women participating in the
Nurses’ Health Study and men participating in the Health Professionals Follow-up
Study in nested case–control analyses. Among participants who provided a blood sam-
ple and who were free of cardiovascular disease at baseline, 239 women and 265 men
had a nonfatal myocardial infarction or fatal coronary heart disease during eight years
and six years of follow-up, respectively. Using risk-set sampling, we selected controls
in a 2:1 ratio with matching for age, smoking status, and date of blood sampling.
 
results
 
After adjustment for matching factors, high levels of interleukin-6 and C-reactive pro-
tein were significantly related to an increased risk of coronary heart disease in both sex-
es, whereas high levels of soluble TNF-
 
a 
 
receptors were significant only among wom-
en. Further adjustment for lipid and nonlipid factors attenuated all associations; only
C-reactive protein levels remained significant. The relative risk among all participants
was 1.79 for those with C-reactive protein levels of at least 3.0 mg per liter, as compared
with those with levels of less than 1.0 mg per liter (95 percent confidence interval, 1.27
to 2.51; P for trend <0.001). Additional adjustment for the presence or absence of dia-
betes and hypertension moderately attenuated the relative risk to 1.68 (95 percent con-
fidence interval, 1.18 to 2.38; P for trend=0.008).
 
conclusions
 
Elevated levels of inflammatory markers, particularly C-reactive protein, indicate an
increased risk of coronary heart disease. Although plasma lipid levels were more
strongly associated with an increased risk than were inflammatory markers, the level
of C-reactive protein remained a significant contributor to the prediction of coronary
heart disease.
abstract
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nflammation plays an essential role
 
in the development of insulin resistance and
type 2 diabetes mellitus, the initiation and pro-
gression of atherosclerotic lesions, and plaque dis-
ruption.
 
1,2
 
 Interleukin-6 and tumor necrosis fac-
tor 
 
a
 
 (TNF-
 
a
 
) are inflammatory cytokines and the
main inducers of the secretion of C-reactive protein
in the liver.
 
3
 
 C-reactive protein is a marker of low-
grade inflammation, and recent studies suggest that
this protein has a role in the pathogenesis of athero-
sclerotic lesions in humans.
 
4
 
 The effects of TNF-
 
a
 
are mediated by two receptors, type 1 and type 2
(TNF-R1 and TNF-R2), which circulate in soluble
forms (sTNF-R1 and sTNF-R2, respectively) and
can be measured with greater sensitivity and reli-
ability than can TNF-
 
a
 
 itself.
 
5
 
 The soluble receptors
may attenuate the bioactivity of TNF-
 
a
 
 but may also
serve as slow-release reservoirs and promote in-
flammation in the absence of free TNF ligand.
 
6
 
Nonetheless, only a few studies have examined
the relationship between levels of sTNF-R1, sTNF-
R2, and interleukin-6 and the risk of coronary heart
disease.
 
7-10
 
 The predictive value of C-reactive pro-
tein for screening and its causal relationship to cor-
onary heart disease remain matters of controver-
sy.
 
11-17
 
 We prospectively examined the association
between inflammatory markers and the risk of cor-
onary heart disease and the role of potential media-
tors among men and women in a nested case–con-
trol analysis.
 
study population
 
The Nurses’ Health Study (NHS) and the Health Pro-
fessionals Follow-up Study (HPFS) are prospective
cohort investigations respectively involving 121,700
female U.S. registered nurses who were 30 to 55
years old at baseline in 1976 and 51,529 U.S. male
health professionals who were 40 to 75 years old
at baseline in 1986. Information about health and
disease is assessed biennially, and information
about diet is obtained every four years by means of
self-administered questionnaires.
 
18,19
 
 From 1989
through 1990, a blood sample was requested from
all participants in the NHS, and 32,826 women pro-
vided one. Similarly, between 1993 and 1995, a
blood sample was provided as requested by 18,225
men in the HPFS. Participants who provided blood
samples were similar to those who did not, albeit the
men who provided samples were somewhat young-
er than those who did not. In the NHS, among wom-
en without cardiovascular disease or cancer before
1990, we identified 249 women who had a nonfatal
myocardial infarction or fatal coronary heart disease
between the date of blood drawing and June 1998.
In the HPFS, we identified 266 men who had a non-
fatal myocardial infarction or fatal coronary heart
disease between the date of blood drawing and the
return of the 2000 questionnaire. Using risk-set
sampling,
 
20
 
 we randomly selected controls in a 2:1
ratio who were matched for age, smoking status,
and date of blood sampling from the subgroup of
participants who were free of cardiovascular dis-
ease at the time coronary disease was diagnosed in
the case patients. Within the NHS cohort, an addi-
tional matching criterion was fasting status at the
time of blood sampling.
 
assessment of coronary heart disease
 
Study physicians who were unaware of the partici-
pant’s exposure status confirmed the diagnosis of
myocardial infarction on the basis of the criteria of
the World Health Organization (symptoms plus ei-
ther diagnostic electrocardiographic changes or
elevated levels of cardiac enzymes). Deaths were
identified from state vital records and the National
Death Index or reported by the participant’s next of
kin or the postal system. Fatal coronary heart dis-
ease was confirmed by an examination of hospital
or autopsy records, by the listing of coronary heart
disease as the cause of death on the death certifi-
cate, if coronary heart disease was the underlying
and most plausible cause, and if evidence of previ-
ous coronary heart disease was available.
 
assessment of other factors
 
Anthropometric, lifestyle, and dietary data were de-
rived from the questionnaire administered in 1990
to women and 1994 to men, with missing infor-
mation substituted from previous questionnaires.
Body-mass index was calculated as the weight in
kilograms divided by the square of the height in
meters. Average nutrient intake was computed with
the use of a semiquantitative food-frequency ques-
tionnaire. Physical activity was expressed in terms of
metabolic equivalent (MET)–hours. The question-
naires and the validity and reproducibility of mea-
surements have been described previously.
 
18,21
 
measurement of biochemical variables
 
Blood samples from women were collected in tubes
treated with liquid sodium heparin, and those from
men were collected in EDTA-treated tubes. The
i
methods
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tubes were then placed on ice packs, stored in Styro-
foam containers, returned to our laboratory by over-
night courier, centrifuged, and divided into aliquots
for storage in liquid-nitrogen freezers (¡130°C or
colder).
The levels of C-reactive protein were determined
by means of a highly sensitive immunoturbidimetric
assay with the use of reagents and calibrators from
Denka Seiken; this assay has a day-to-day variability
of 1 to 2 percent. Levels of sTNF-R1, sTNF-R2, and
interleukin-6 were measured by means of enzyme-
linked immunosorbent assays (R&D Systems),
which have a day-to-day variability of 3.5 to 9.0 per-
cent. Levels of inflammatory markers were largely
unaffected by transport conditions and reproducible
within subjects over time.
 
22,23
 
 Total, high-density
lipoprotein (HDL), and directly obtained low-den-
sity lipoprotein (LDL) cholesterol and triglycerides
were measured according to standard methods with
the use of reagents from Roche Diagnostics and
Genzyme. Study samples were sent to the labora-
tory for analysis in randomly ordered batches, and
the laboratory personnel were unaware of a sam-
ple’s case–control status.
The study protocol was approved by the institu-
tional review board of the Brigham and Women’s
Hospital and the Human Subjects Committee Re-
view Board of Harvard School of Public Health.
 
exclusions
 
After the exclusion of participants with missing data
on biomarker levels, our data sets consisted of 708
women (239 patients and 469 controls) and 794
men (265 patients and 529 controls). The assay for
interleukin-6 required slightly more plasma than we
originally reserved for this assay among women.
Therefore, analyses involving interleukin-6 were re-
stricted to the subgroup of 676 women for whom
interleukin-6 levels were available.
 
statistical analysis
 
We analyzed the two cohorts separately. Inflamma-
tory markers were divided into quintiles, from the
lowest to highest levels, on the basis of the sex-spe-
cific distributions among the controls. With risk-set
sampling, the odds ratio derived from the logistic
regression directly estimates the hazard ratio and,
thus, the relative risk.
 
20
 
 We analyzed the association
between biomarker levels and the risk of coronary
heart disease using both conditional and uncon-
ditional logistic regression, with adjustment for
matching factors. Because both analyses provided
essentially the same results, we present the results
of unconditional logistic regression, which parallel
the results in the subgroup analyses. 
In our multivariable model, we further adjusted
for parental history of coronary heart disease before
the age of 60 years (yes vs. no), alcohol intake (non-
drinker, 0.1 to 4.9 g per day, 5.0 to 14.9 g per day,
15.0 to 29.9 g per day, or at least 30.0 g per day),
body-mass index (less than 20, 20 to 24, 25 to 29,
30 to 34, or 35 or more), physical activity (in quin-
tiles from lowest to highest level), ratio of total to
HDL cholesterol (in quintiles from lowest to high-
est ratio), and use of postmenopausal hormone
therapy (yes vs. no — for women only). Finally, we
also added a history of diabetes (yes vs. no) and hy-
pertension (yes vs. no) at baseline to the model to
assess the effect of these potential mediators. Base-
line was defined as the year blood was drawn. 
Correlation coefficients were calculated with the
use of age-adjusted Spearman partial-correlation
coefficients. To test for linear trend, we used the me-
dian levels of inflammatory markers in the control
categories as a continuous variable. To pool the esti-
mates of relative risk for men and women, we used
the weighted average of estimates according to the
random-effects model of DerSimonian and Laird.
 
24
 
All P values are two-tailed, and P values below
0.05 were considered to indicate statistical signifi-
cance. All analyses were performed with the use of
SAS software, version 8.2 (SAS Institute).
 
baseline characteristics
 
Women in whom coronary heart disease developed
during follow-up had significantly higher baseline
levels of sTNF-R1 and sTNF-R2 than did control
women; however, the levels did not differ signifi-
cantly between men in whom coronary heart dis-
ease developed during follow-up and men in the
control group (Table 1). In the case of both men and
women, patients had significantly higher baseline
levels of interleukin-6 and C-reactive protein than
controls.
The levels of sTNF-R1 and sTNF-R2 showed a
high degree of correlation with each other (Table 2).
The correlation with and between the other inflam-
matory markers was moderate and ranged from
0.27 for sTNF-R1 and C-reactive protein to 0.45 for
interleukin-6 and C-reactive protein. The levels of
inflammatory markers were moderately inversely
associated with HDL cholesterol levels.
results
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* Data on women are from the Nurses’ Health Study and include eight years of follow-up, and data on men are from the 
Health Professionals Follow-up Study and include six years of follow-up. Matching criteria were age, smoking status, and 
date of blood sampling; among women, additional matching criteria included fasting status at the time of blood sam-
pling. Plus–minus values are means ±SD. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To 
convert values for triglycerides to millimoles per liter, multiply by 0.01129. sTNF-R1 and sTNF-R2 denote soluble tumor 
necrosis factor receptor types 1 and 2, CHD coronary heart disease, and MET-hr metabolic equivalent–hours. The body-
mass index is the weight in kilograms divided by the square of the height in meters.
 
†
 
P values for the difference between patients and controls (unadjusted) were determined by Student’s t-test for variables 
expressed as means ±SD, by Wilcoxon’s rank-sum test for variables expressed as medians, and by the chi-square test for 
variables expressed as percentages.
‡ Current aspirin use was defined as every one to four days for women and as two or more times per week for men.
§ The metabolic syndrome is defined by the presence of at least three of the following five abnormalities: a body-mass in-
dex of at least 25, a triglyceride level of at least 150 mg per deciliter (1.7 mmol per liter), an HDL cholesterol level of less 
than 50 mg per deciliter for women or less than 40 mg per deciliter for men, a history of hypertension or a history of diabetes 
or the development of diabetes during follow-up, or a glycosylated hemoglobin level of at least 7 percent at baseline.
 
¶Data on interleukin-6 levels were missing for 32 women.
 
Table 1. Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up 
and Matched Controls.*
Characteristic Women Men
 
Patients
(N=239)
Controls
(N=469) P Value
 
†
 
Patients
(N=265)
Controls
(N=529) P Value
 
†
 
Age (yr) 60.4±6.5 60.2±6.5 — 65.2±8.3 65.1±8.3  —
Current smoker (%) 31.4 31.8 — 12.4 11.5  —
Body-mass index 26.9±5.7 25.3±4.3 <0.001 26.2±3.5 25.7±3.5 0.05
Parental history of CHD before
60 yr of age (%)
21.3 12.4 0.002 15.1 11.0 0.10
Postmenopausal (%) 89.9 87.3 0.31  —  —  —
Postmenopausal hormone 
therapy among postmeno-
pausal women (%)
31.7 41.0 0.03  — —  —
Medications (%)
Aspirin
 
‡
 
15.1 21.3 0.05 39.1 34.9 0.25
Cholesterol-lowering drug 4.2 2.6 0.24 8.8 6.9 0.32
History of hypertension (%) 57.7 28.8 <0.001 42.3 30.6 0.001
History of diabetes (%) 19.7 6.4 <0.001 9.4 4.4 0.005
Metabolic syndrome (%)§ 43.9 18.3 <0.001 40.4 26.1 <0.001
Total fat intake (% of energy) 31.8±5.8 31.7±6.1 0.82 31.0±6.7 30.3±7.0 0.23
Saturated fat intake (% of energy) 10.8±2.5 10.7±2.7 0.84 10.4±2.7 10.1±2.9 0.12
Alcohol consumption (g/day)
Median 0.9 1.8 <0.001 5.5 7.0 0.11
Interquartile range 0.0–3.7 0.0–8.6 0.9–15.4 0.9–18.3
Physical activity (MET-hr/wk)
Median 11.0 11.5 0.26 22.8 27.3 0.06
Interquartile range 3.9–22.7 5.1–23.0 8.5–44.7 11.8–48.9
sTNF-R1 (pg/ml) 1438±585 1267±354 <0.001 1513±502 1506±541 0.86
sTNF-R2 (pg/ml) 2777±987 2489±710 <0.001 2991±869 2945±870 0.48
Interleukin-6 (pg/ml)¶
Median 1.99 1.65 0.001 1.86 1.53 0.01
Interquartile range 1.30–3.05 1.15–2.65 1.10–3.07 0.98–2.88
C-reactive protein (mg/liter)
Median 3.10 2.20 <0.001 1.68 1.08 <0.001
Interquartile range 1.30–7.50 1.00–5.10 0.76–3.15 0.52–2.38
Cholesterol (mg/dl)
Total 235.4±40.1 225.7±38.7 0.002 214.7±39.9 204.7±36.7 <0.001
LDL 142.9±34.1 132.2±36.4 <0.001 135.6±36.4 127.0±31.1 0.001
HDL 51.5±14.7 60.5±17.4 <0.001 42.1±11.3 45.9±12.5 <0.001
Total-to-HDL cholesterol ratio 4.91±1.55 4.02±1.31 <0.001 5.37±1.41 4.74±1.40 <0.001
Triglycerides (mg/dl) 157.6±96.7 126.3±76.3 <0.001 181.8±116.7 153.8±121.1 0.002
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main effects
 
After adjustment for matching factors, women in
the highest quintile of each inflammatory marker,
as compared with women in the lowest quintile, had
a significantly increased risk of coronary heart dis-
ease — by a factor of 1.95 to 2.57 — with signifi-
cant trends across quintiles (Table 3). After addi-
tional adjustment for the presence or absence of a
parental history of coronary heart disease before
the age of 60 years, alcohol intake, level of physical
activity, the ratio of total to HDL cholesterol, body-
mass index, and the use or nonuse of postmeno-
pausal hormone therapy, these associations were
attenuated and no longer significant, except for
C-reactive protein (model 2 in Table 3). Addition-
al adjustment for the presence or absence of diabe-
tes and hypertension, which are potentially in the
causal pathway, further reduced the association for
all inflammatory markers.
Among men, we did not find an association be-
tween the levels of soluble TNF-
 
a 
 
receptors and
the risk of coronary heart disease (Table 3). Men in
the highest quintile of interleukin-6 had a 57 per-
cent increase in the risk of coronary heart disease,
as compared with men in the lowest quintile, after
adjustment for matching factors, although this as-
sociation was not significant and was further atten-
uated after multivariable adjustment. However, we
found a significant association between C-reactive
protein levels and the risk of coronary heart disease.
Multivariable adjustment and adjustment for the
presence or absence of hypertension and diabetes
 
* sTNF-R1 and sTNF-R2 denote soluble tumor necrosis factor receptor types 1 and 2, CRP C-reactive protein, TC total cho-
lesterol, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, and BMI body-mass index.
† Seventeen women were excluded from the analysis of interleukin-6 because they had missing values.
‡ P<0.001.
§ P<0.05.
 
¶P<0.01.
 
Table 2. Age-Adjusted Spearman Partial-Correlation Coefficients between Selected Cardiovascular Risk Factors 
among 469 Control Women and 529 Control Men.*
Sex and 
Risk Factor Risk Factor
 
sTNF-R1 sTNF-R2
Interleu-
kin-6† CRP TC LDL HDL TC:HDL BMI
 
Women
 
sTNF-R1 —
sTNF-R2 0.77‡ —
Interleukin-6 0.31‡ 0.28‡ —
CRP 0.29‡ 0.28‡ 0.44‡ —
TC ¡0.07 ¡0.09§ ¡0.05 0.03 —
LDL 0.02 <0.01 ¡0.03 0.04 0.87‡ —
HDL ¡0.30‡ ¡0.36‡ ¡0.15¶ ¡0.17‡ 0.08 ¡0.22‡ —
TC:HDL 0.22‡ 0.27‡ 0.09 0.15‡ 0.45‡ 0.67‡ ¡0.83‡ —
BMI 0.30‡ 0.27‡ 0.26‡ 0.37‡ 0.12§ 0.18‡ ¡0.33‡ 0.37‡ —
 
Men
 
sTNF-R1 —
sTNF-R2 0.67‡ —
Interleukin-6 0.32‡ 0.28‡ —
CRP 0.27‡ 0.28‡ 0.45‡ —
TC ¡0.16‡ ¡0.13‡ ¡0.17‡ 0.03 —
LDL ¡0.16‡ ¡0.11§ ¡0.16‡ ¡0.003 0.86‡ —
HDL ¡0.25‡ ¡0.21‡ ¡0.20‡ ¡0.24‡ 0.20‡ 0.13¶ —
TC:HDL 0.15‡ 0.12¶ 0.10§ 0.25‡ 0.39‡ 0.39‡ ¡0.80‡ —
BMI 0.16‡ 0.14‡ 0.23‡ 0.40‡ 0.04 0.01 ¡0.28‡ 0.31‡ —
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moderately attenuated this relationship; after ac-
counting for these variables, men in the highest
quintile of C-reactive protein, as compared with
those in the lowest quintile, had a relative risk of cor-
onary heart disease of 2.55 (95 percent confidence
interval, 1.40 to 4.65; P for trend=0.02).
For comparison, in the final multivariable-adjust-
ed model (including the presence or absence of di-
abetes and hypertension and C-reactive protein lev-
els), the relative risk of coronary heart disease for
the highest quintile of the ratio of total to HDL cho-
lesterol, as compared with the lowest quintile, was
4.33 (95 percent confidence interval, 2.11 to 8.90;
P for trend <0.001) in women and 3.29 (95 percent
confidence interval, 1.84 to 5.90; P for trend <0.001)
in men.
 
subgroup analyses
 
Overall, we found no significant interactions be-
tween various low and high cardiovascular risk
groups and the association of biomarkers with the
risk of coronary heart disease, although the associ-
ation of C-reactive protein was generally stronger in
low-risk subgroups. For example, in the multivari-
 
Table 3. Relative Risks of Coronary Heart Disease during Follow-up, According to the Quintile of Plasma Levels of Inflammatory Markers
at Baseline.*
Variable† Quintile of Plasma Level
P for 
Trend‡
 
1 2 3 4 5
 
relative risk (95 percent confidence interval)
 
Women
sTNF-R1
 
Median — pg/ml 880 1083 1221 1379 1744
Quintile value — pg/ml <928 928–1146 1147–1296 1297–1508 ≥1509
Model 1 (matching factors) 1.0 1.21 (0.69 –2.11) 1.20 (0.68 –2.09) 1.56 (0.90 –2.70) 2.57 (1.50 –4.39) <0.001
Model 2 (multivariable) 1.0 1.08 (0.60 –1.97) 0.91 (0.50–1.67) 1.14 (0.63–2.08) 1.50 (0.82–2.74) 0.12
Model 3 (model 2+diabetes
and hypertension)
1.0 1.06 (0.57–1.97) 0.90 (0.48–1.69) 1.02 (0.54–1.90) 1.24 (0.66–2.34) 0.43
 
sTNF-R2
 
Median — pg/ml 1718 2060 2365 2724 3405
Quintile value — pg/ml <1892 1892–2223 2224–2549 2550–3019 ≥3020
Model 1 (matching factors) 1.0 1.72 (0.97–3.04) 1.92 (1.09–3.39) 2.19 (1.24–3.88) 2.51 (1.41–4.45) 0.003
Model 2 (multivariable) 1.0 1.39 (0.75–2.56) 1.48 (0.80–2.74) 1.41 (0.76–2.60) 1.36 (0.72–2.58) 0.59
Model 3 (model 2+diabetes
and hypertension)
1.0 1.40 (0.74–2.65) 1.38 (0.73–2.62) 1.30 (0.69–2.46) 1.20 (0.62–2.33) 0.96
 
Interleukin-6§
 
Median — pg/ml 0.82 1.23 1.65 2.37 4.15
Quintile value — pg/ml <1.08 1.08–1.44 1.45–1.91 1.92–2.91 ≥2.92
Model 1 (matching factors) 1.0 1.42 (0.81–2.51) 1.15 (0.65–2.05) 1.98 (1.16–3.40) 1.92 (1.11–3.31) 0.01
Model 2 (multivariable) 1.0 1.16 (0.63–2.13) 0.96 (0.51–1.79) 1.32 (0.72–2.40) 1.33 (0.73–2.43) 0.30
Model 3 (model 2+diabetes 
and hypertension)
1.0 1.08 (0.58–2.03) 0.81 (0.42–1.55) 1.01 (0.54–1.89) 1.05 (0.56–1.97) 0.79
 
C-reactive protein
 
Median — mg/liter 0.50 1.18 2.20 4.02 9.14
Quintile value — mg/liter <0.80 0.80–1.70 1.71–2.91 2.92–5.96 ≥5.97
Model 1 (matching factors) 1.0 1.28 (0.74–2.23) 1.03 (0.59–1.81) 1.54 (0.91–2.63) 2.18 (1.30–3.64) <0.001
Model 2 (multivariable) 1.0 1.17 (0.64–2.14) 0.81 (0.43–1.52) 1.17 (0.64–2.14) 1.86 (1.00–3.46) 0.008
Model 3 (model 2+diabetes 
and hypertension)
1.0 1.23 (0.66–2.32) 0.89 (0.46–1.72) 1.22 (0.65–2.30) 1.61 (0.84–3.07) 0.08
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able-adjusted model (excluding the presence or ab-
sence of hypertension and diabetes), the relative risk
in the highest as compared with the lowest quintile
of C-reactive protein was 2.53 among women with
a body-mass index of less than 25 (95 percent con-
fidence interval, 1.04 to 6.18; P for trend=0.02) and
6.25 among men with a body-mass index of less
than 25 (95 percent confidence interval, 2.28 to 17.1;
P for trend=0.005). Similarly, among participants
with LDL cholesterol levels of less than 130 mg per
 
* The group of women included 239 patients and 469 controls with eight years of follow-up. The group of men included 265 patients and 529 
controls with six years of follow-up. sTNF denotes soluble tumor necrosis factor receptor. Quintiles and median values of plasma inflamma-
tory markers are based on values in controls. For each relative risk, quintile 1 served as the reference group.
† Model 1 was adjusted for matching factors (age, smoking status, and the month of blood sampling). Among women, data were also adjusted 
for fasting status at the time of blood sampling. Model 2 was adjusted for matching factors, presence or absence of a parental history of cor-
onary heart disease before the age of 60 years, alcohol intake, level of physical activity, ratio of total cholesterol to HDL cholesterol, and body-
mass index. Among women, the multivariable model was also adjusted for the use or nonuse of postmenopausal hormone therapy.
‡ P values for trend are based on the median levels of inflammatory markers in quintiles of the controls.
§ A total of 32 women were excluded from the analyses for interleukin-6 owing to missing values for interleukin; 224 patients and 452 controls 
 
were analyzed.
 
Table 3. (Continued.)
Variable† Quintile of Plasma Level
P for 
Trend‡
 
1 2 3 4 5
 
relative risk (95 percent confidence interval)
 
Men
sTNF-R1
 
Median — pg/ml 1005 1205 1391 1627 2124
Quintile value — pg/ml <1111 1111–1301 1302–1510 1511–1793 ≥1794
Model 1 (matching factors) 1.0 1.01 (0.63–1.63) 1.13 (0.70–1.82) 0.96 (0.58–1.57) 1.06 (0.64–1.77) 0.90
Model 2 (multivariable) 1.0 0.95 (0.57–1.58) 1.00 (0.60–1.65) 0.84 (0.49–1.42) 0.85 (0.49–1.46) 0.48
Model 3 (model 2+diabetes
and hypertension)
1.0 0.94 (0.56–1.56) 0.99 (0.60–1.65) 0.82 (0.48–1.40) 0.78 (0.45–1.36) 0.32
 
sTNF-R2
 
Median — pg/ml 1969 2421 2812 3209 4090
Quintile value — pg/ml <2242 2242–2614 2615–2966 2967–3564 ≥3565
Model 1 (matching factors) 1.0 0.80 (0.49–1.31) 0.90 (0.55–1.47) 1.12 (0.69–1.82) 1.12 (0.68–1.86) 0.33
Model 2 (multivariable) 1.0 0.68 (0.40–1.15) 0.81 (0.48–1.36) 0.94 (0.56–1.57) 0.91 (0.54–1.56) 0.78
Model 3 (model 2+diabetes
and hypertension)
1.0 0.72 (0.42–1.21) 0.81 (0.48–1.37) 0.98 (0.59–1.65) 0.92 (0.53–1.58) 0.80
 
Interleukin-6
 
Median — pg/ml 0.69 1.09 1.53 2.43 5.73
Quintile value — pg/ml <0.88 0.88–1.29 1.30–1.89 1.90–3.15 ≥3.16
Model 1 (matching factors) 1.0 1.09 (0.66–1.81) 1.19 (0.72–1.98) 1.52 (0.93–2.48) 1.57 (0.95–2.57) 0.06
Model 2 (multivariable) 1.0 0.94 (0.55–1.60) 0.99 (0.59–1.69) 1.25 (0.74–2.10) 1.31 (0.78–2.21) 0.17
Model 3 (model 2+diabetes
and hypertension)
1.0 0.97 (0.57–1.65) 0.98 (0.58–1.68) 1.24 (0.73–2.09) 1.31 (0.77–2.22) 0.19
 
C-reactive protein
 
Median — mg/liter 0.27 0.60 1.08 2.05 5.24
Quintile value — mg/liter <0.44 0.44–0.80 0.81–1.49 1.50–2.78 ≥2.79
Model 1 (matching factors) 1.0 1.81 (1.04–3.17) 2.00 (1.15–3.50) 2.74 (1.59–4.71) 3.29 (1.91–5.65) <0.001
Model 2 (multivariable) 1.0 1.75 (0.97–3.14) 1.83 (1.02–3.30) 2.27 (1.26–4.09) 2.73 (1.51–4.96) 0.007
Model 3 (model 2+diabetes
and hypertension)
1.0 1.75 (0.97–3.16) 1.74 (0.96–3.15) 2.14 (1.18–3.88) 2.55 (1.40–4.65) 0.02
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deciliter (3.4 mmol per liter), the corresponding rel-
ative risks were 3.54 (95 percent confidence inter-
val, 1.19 to 10.5; P for trend=0.01) for women and
2.52 (95 percent confidence interval, 1.09 to 5.83;
P for trend= 0.04) for men. Among participants
without hypertension, the corresponding relative
risks were 1.87 (95 percent confidence interval,
0.77 to 4.56; P for trend=0.02) for women and 3.01
(95 percent confidence interval, 1.41 to 6.44; P for
trend=0.02) for men.
 
clinical cutoff points for c-reactive 
protein
 
We further categorized the study participants, on
the basis of recently proposed cutoff points for
C-reactive protein, as having low levels (less than
1.0 mg per liter), moderate levels (1.0 to 2.9 mg per
liter), and high levels (at least 3.0 mg per liter).
 
25
 
In these analyses, participants with high levels of
C-reactive protein, as compared with those with low
levels, had a relative risk of coronary heart disease
of approximately 1.8 after adjustment for covari-
ates (including body-mass index and lipid levels)
(Table 4). When we pooled the risk estimates for
men and women, the final multivariable-adjusted
relative risk (including adjustment for the presence
or absence of diabetes and hypertension) was 1.68
in the group with high levels of C-reactive protein,
as compared with the group with low levels (95 per-
cent confidence interval, 1.18 to 2.38; P for trend=
0.008) (Table 4). This is similar to the pooled esti-
mate (relative risk, 1.48; 95 percent confidence
interval, 1.08 to 2.04; P for trend=0.03) after we
controlled for covariates from the Framingham risk
score,
 
26
 
 including age, presence or absence of hy-
pertension and diabetes, ratio of total to HDL cho-
lesterol, and smoking status.
We found a gradient of risk of coronary heart
disease within each increasing category of C-reac-
tive protein and ratio of total to HDL cholesterol
(Fig. 1). This finding supports the hypothesis that
the levels of C-reactive protein may predict risk be-
yond the information afforded by lipid levels. How-
ever, despite the independent associations, the gra-
dient of risk associated with lipid levels was greater
than that for C-reactive protein levels.
 
additional analyses
 
When we stratified our analysis according to the
time to an event in two-year intervals, the relative
risk of coronary heart disease associated with
C-reactive protein levels remained relatively stable
over time (data not shown). When we repeated our
main analyses after excluding participants with
C-reactive protein levels of at least 10.0 mg per liter,
we found essentially the same results. C-reactive
protein levels may be affected by hormone therapy.
 
10
 
However, results were similar when we used quin-
tiles of C-reactive protein based on levels in women
in the control group who reported never using hor-
mones.
In these two nested case–control studies, we found
that high plasma levels of C-reactive protein were
associated with an increased risk of coronary heart
disease among women and men without previous
cardiovascular disease. Elevated plasma levels of
sTNF-R1 and sTNF-R2 were related to an increased
risk among women, but not men. We found only a
moderate suggestion of increased risk associated
with elevated levels of interleukin-6. For all mark-
ers, associations were substantially attenuated and
— with the exception of C-reactive protein — no
longer significant after adjustment for cardiovas-
cular risk factors, particularly body-mass index and
the presence or absence of diabetes and hyperten-
sion. These findings are consistent with a role of
these inflammatory markers in the elevated risk of
cardiovascular events that is associated with type 2
diabetes and hypertension.
TNF-
 
a
 
 and interleukin-6 are the main inducers
of hepatic production of acute-phase proteins, in-
cluding C-reactive protein.
 
3
 
 These inflammatory
markers are associated with biologic and environ-
mental risk factors for cardiovascular events, includ-
ing components of the metabolic syndrome (obe-
sity, insulin resistance, diabetes, hypertension, and
low HDL cholesterol levels), and lifestyle factors,
such as smoking, abstinence from alcohol, and
physical inactivity.
 
27-29
 
Compelling evidence suggests that inflamma-
tion causally contributes to several precursors of car-
diovascular disease. TNF-
 
a
 
 and interleukin-6 can
cause insulin resistance in animal models, and plas-
ma levels of C-reactive protein and interleukin-6
have been shown to predict type 2 diabetes in hu-
mans.
 
30,31
 
 The increased cytokine synthesis in obe-
sity may promote insulin resistance and impaired
glucose uptake, type 2 diabetes, and ultimately, cor-
onary heart disease.
 
30
 
 In line with these hypothe-
ses, we found that plasma levels of interleukin-6
and C-reactive protein, in particular, were related to
discussion
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the risk of coronary heart disease and that the risks
were attenuated after adjustment for the presence
or absence of diabetes and hypertension.
TNF-
 
a
 
 has a limited half-life and is difficult to
measure in large-scale epidemiologic studies.
 
5,6
 
 In
a nested case–control study, Ridker et al. reported a
multivariable-adjusted relative risk of recurrent cor-
onary events of 2.5 (95 percent confidence interval,
1.3 to 5.1) among men whose TNF-
 
a
 
 levels exceed-
ed the 95th percentile, as compared with men with
lower levels.
 
32
 
 Cesari et al. reported a relative risk of
of coronary events of 1.79 (95 percent confidence
interval, 1.18 to 2.71) among elderly participants
without cardiovascular disease who had the high-
est of three levels of TNF-
 
a
 
, as compared with
those who had the lowest levels.
 
8
 
 The value of as-
 
* Data on women are from the Nurses’ Health Study and include eight years of follow-up, and data on men are from the 
Health Professionals Follow-up Study and include six years of follow-up. The subjects with the lowest level of C-reactive 
protein (CRP) served as the reference group. TC:HDL denotes the ratio of total cholesterol to high-density lipoprotein 
cholesterol.
† Model 1 was adjusted for matching factors (age, smoking status, and month of blood sampling); data for women were 
also adjusted for fasting status at the time of blood sampling. Model 2 was adjusted for matching factors, as well as the 
presence or absence of a parental history of coronary heart disease before the age of 60 years, alcohol intake, level of 
physical activity, and use or nonuse of hormone therapy among postmenopausal women. Model 5 was adjusted for ev-
erything listed in model 4 as well as the presence or absence of diabetes and hypertension.
 
‡ P values for trend are based on median levels in the three C-reactive protein groups in the controls.
 
Table 4. Relative Risks of Coronary Heart Disease during Follow-up According to the Baseline Level of C-Reactive
Protein.* 
Variable† CRP <1.0 mg/liter CRP 1.0–2.9 mg/liter CRP ≥3.0 mg/liter P for Trend‡
 
relative risk (95 percent confidence interval)
 
Women
 
No. of patients 41 73 125
No. of controls 114 170 185
Model 1 (matching factors) 1.0 1.22 (0.77–1.93) 1.93 (1.25–2.99) <0.001
Model 2 (multivariable) 1.0 1.21 (0.75–1.96) 1.94 (1.21–3.10) 0.002
Model 3 (model 2+body-mass
index)
1.0 1.16 (0.71–1.90) 1.71 (1.04–2.80) 0.02
Model 4 (model 3+TC:HDL) 1.0 1.09 (0.66–1.82) 1.64 (0.98–2.75) 0.02
Model 5 (model 4+diabetes and hy-
pertension)
1.0 1.17 (0.69–2.00) 1.53 (0.89–2.62) 0.09
 
Men
 
No. of patients  86 108 71
No. of controls 254 175 100
Model 1 (matching factors) 1.0 1.90 (1.34–2.71) 2.20 (1.46–3.32) <0.001
Model 2 (multivariable) 1.0 1.88 (1.31–2.69) 2.17 (1.43–3.31) 0.002
Model 3 (model 2+body-mass
index)
1.0 1.85 (1.28 –2.68) 2.08 (1.34–3.23) 0.006
Model 4 (model 3+TC:HDL) 1.0 1.71 (1.17–2.49) 1.91 (1.22–3.00) 0.02
Model 5 (model 4+diabetes and hy-
pertension)
1.0 1.60 (1.09–2.34)  1.79 (1.14–2.83) 0.03
 
Men and Women
 
Model 1 (matching factors) 1.0 1.61 (1.22–2.14) 2.07 (1.54–2.79) <0.001
Model 2 (multivariable) 1.0 1.61 (1.20–2.14)  2.06 (1.51–2.82) <0.001
Model 3 (model 2+body-mass
index)
1.0 1.57 (1.17–2.11) 1.90 (1.37–2.65) <0.001
Model 4 (model 3+TC:HDL) 1.0 1.46 (1.08–1.98)  1.79 (1.27–2.51) <0.001
Model 5 (model 4+diabetes and hy-
pertension)
1.0 1.44 (1.05–1.96)  1.68 (1.18–2.38) 0.008
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sessing circulating levels of TNF-
 
a
 
 is unknown,
since such levels can be very low and unstable. The
levels of soluble TNF-
 
a
 
 receptors may be more sta-
ble and may better reflect longer-term average cir-
culating levels of TNF-
 
a
 
, although data on the role
of soluble TNF-
 
a
 
 receptors in coronary heart dis-
ease are scarce.
 
7,33
 
 It is unclear why we found a dif-
ference in risk between men and women associat-
ed with elevated levels of soluble TNF-
 
a
 
 receptors;
however, others also have found differences be-
tween women and men with respect to lipids
 
34
 
 and
in the overall prediction of risk.
 
35
 
 Similarly, mech-
anisms of insulin sensitivity, rather than inflamma-
tion, may contribute more to the risk of coronary
heart disease in women than men.
Findings of an association between interleukin-
6 levels and the risk of coronary heart disease have
been inconsistent.
 
8,10,36
 
 In our study, this associa-
tion was substantially reduced and no longer sig-
nificant after multivariable adjustment.
C-reactive protein is the most extensively stud-
ied inflammatory marker in prospective settings.
In an early meta-analysis of 11 prospective studies,
the relative risk of coronary heart disease in subjects
with the highest of three C-reactive protein levels, as
compared with those with the lowest levels, was 2.0
(95 percent confidence interval, 1.6 to 2.5) among
population-based studies.
 
37
 
 Eleven other prospec-
tive studies have since been published. In an updat-
ed meta-analysis, Danesh et al. reported an overall
odds ratio of 1.58 (95 percent confidence interval,
1.48 to 1.68) among subjects with the highest of
three levels of C-reactive protein, as compared with
subjects with the lowest level.
 
16
 
 This risk estimate
is similar to that in our comparisons of C-reactive
protein levels of at least 3.0 mg per liter with those
of less than 1.0 mg per liter. However, the degree of
adjustment for traditional cardiovascular risk fac-
tors differed markedly among the studies included
in the meta-analysis.
An important question is whether knowing the
level of C-reactive protein adds materially to risk
prediction. In the Women’s Health Study, Ridker
et al. reported that the level of C-reactive protein was
a stronger predictor than the LDL cholesterol level
and that it added to the information provided by the
Framingham risk score.
 
12,38
 
 Comparing C-reactive
protein levels of at least 3.0 mg per liter with those
of less than 1.0 mg per liter, they reported a relative
risk of 1.5 (95 percent confidence interval, 1.2 to
1.9) after adjustment for the Framingham risk score
and the presence or absence of diabetes.
 
38
 
 
In the Atherosclerosis Risk in Communities
Study, Ballantyne et al. reported a relative risk of
coronary heart disease of 1.72 (95 percent confi-
dence interval, 1.24 to 2.39) among subjects with a
C-reactive protein level of at least 3.0 mg per liter,
as compared with subjects with a level of less than
1.0 mg per liter (adjusted for components of the Fra-
mingham risk score, including the presence or ab-
 
Figure 1. Multivariable-Adjusted Relative Risk of Coronary Heart Disease 
among Women (Panel A) and Men (Panel B), According to the Baseline 
Level of C-Reactive Protein (CRP) and the Quintile of the Ratio of Total 
to HDL Cholesterol. 
 
Data on women are from the Nurses’ Health Study and include eight years 
of follow-up, and data on men are from the Health Professionals Follow-up 
Study and include six years of follow-up. The model was adjusted for age, 
smoking status, date of blood sampling, presence or absence of a parental 
history of coronary heart disease before the age of 60 years, alcohol intake, 
level of physical activity, and body-mass index. Among women, the multivari-
able model was also adjusted for fasting status at the time of blood sampling 
and the use or nonuse of postmenopausal hormone therapy. In each panel, 
the subjects in quintile 1 who had a CRP level of less than 1.0 mg per liter 
served as the reference group.
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sence of diabetes).14 In the Monitoring Trends and
Determinants in Cardiovascular Disease (MONICA)
study, comparing C-reactive protein levels of at
least 3.0 mg per liter with those of less than 1.0 mg
per liter, Koenig et al. reported a hazard ratio of
2.21 (95 percent confidence interval, 1.49 to 3.27),
adjusted for the Framingham risk score.13 In con-
trast, in the Rotterdam Study, measuring the level of
C-reactive protein did not improve the prediction
of coronary events beyond that afforded by the Fra-
mingham risk score, with an odds ratio of 1.2 (95
percent confidence interval, 0.6 to 2.2) among par-
ticipants in the highest quartile of C-reactive protein,
as compared with those in the lowest quartile.39
In our analysis, the pooled relative risk among
men and women classified according to clinical cut-
off points for the levels of C-reactive protein was
1.48 (95 percent confidence interval, 1.08 to 2.04;
P for trend=0.03) after we accounted for covariates
in the Framingham risk score, including the pres-
ence or absence of diabetes. Our results are similar
to those of Ridker et al.38 and Ballantyne et al.,14 as
well as those of the recent meta-analysis by Danesh
et al.,16 a fact that suggests that after adjustment
for the Framingham risk score, the relative risk as-
sociated with a clinical cutoff point of at least 3.0
mg per liter, as compared with a cutoff of less than
1.0 mg per liter, is probably moderately less than
previously suggested in the guidelines for the clin-
ical assessment of inflammatory markers issued by
the American Heart Association and the Centers for
Disease Control and Prevention (relative risk, 1.5 vs.
approximately 2.0).25 Nevertheless, our findings
support the theory that the level of C-reactive pro-
tein provides an additional measure of the risk of
coronary heart disease beyond that afforded by the
Framingham risk score.
Our study has some limitations. As with any
observational study design, there is the possibility
of unmeasured confounding. However, we con-
trolled for most known cardiovascular risk factors.
Though we obtained only a single blood sample at
baseline, previous studies have shown the levels of
biomarkers to be relatively stable over time.22,23
Since the ranges of anthropometric variables in our
cohorts were quite broad, the biologic relationships
found should be widely generalizable. Though we
excluded men and women with missing data on
blood levels, generalizability should be minimally
affected because the participants were similar to
those who did not provide blood samples.
Although the Framingham risk score is a tool for
estimating the 10-year risk of coronary heart disease
among healthy subjects,26 it does not include other
well-established risk factors, such as body-mass in-
dex, alcohol intake, level of physical activity, or the
presence or absence of a parental history of coro-
nary heart disease.40 Therefore, to examine the role
of inflammatory markers in coronary heart disease,
we used an etiologic approach in our main analyses,
to take into account the pathophysiology of coro-
nary heart disease and include the major cardiovas-
cular risk factors, beyond those included in the Fra-
mingham risk score, for comparison.
Our questionnaires did not include questions on
the use of hydroxymethylglutarylcoenzyme A reduc-
tase inhibitors (statins) because these drugs were
not widely used at time of blood sampling. Howev-
er, the reported use of cholesterol-lowering drugs
was generally low in both cohorts.
In conclusion, our findings suggest that high
levels of C-reactive protein are associated with an in-
creased risk of coronary heart disease among men
and women and that the level of C-reactive protein
is a significant marker of the risk of coronary heart
disease, even after careful multivariable adjustment.
Though all other associations were attenuated after
multivariable adjustment, high levels of sTNF-R1
and sTNF-R2 may be also associated with an in-
creased risk and deserve further exploration in other
populations. From a clinical standpoint, although
the ratio of total to HDL cholesterol was more
strongly associated with the risk of coronary heart
disease than were the levels of inflammatory mark-
ers, the level of C-reactive protein was still a signif-
icant contributor to the prediction of coronary heart
disease.
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background
 
C-reactive protein is an inflammatory marker believed to be of value in the prediction of
coronary events. We report data from a large study of C-reactive protein and other circu-
lating inflammatory markers, as well as updated meta-analyses, to evaluate their rele-
vance to the prediction of coronary heart disease.
 
methods
 
Measurements were made in samples obtained at base line from up to 2459 patients
who had a nonfatal myocardial infarction or died of coronary heart disease during the
study and from up to 3969 controls without a coronary heart disease event in the Reyk-
javik prospective study of 18,569 participants. Measurements were made in paired
samples obtained an average of 12 years apart from 379 of these participants in order to
quantify within-person fluctuations in inflammatory marker levels.
 
results
 
The long-term stability of C-reactive protein values (within-person correlation coeffi-
cient, 0.59; 95 percent confidence interval, 0.52 to 0.66) was similar to that of both
blood pressure and total serum cholesterol. After adjustment for base-line values for
established risk factors, the odds ratio for coronary heart disease was 1.45 (95 percent
confidence interval, 1.25 to 1.68) in a comparison of participants in the top third of the
group with respect to base-line C-reactive protein values with those in the bottom third,
and similar overall findings were observed in an updated meta-analysis involving a total
of 7068 patients with coronary heart disease. By comparison, the odds ratios in the
Reykjavik Study for coronary heart disease were somewhat weaker for the erythrocyte
sedimentation rate (1.30; 95 percent confidence interval, 1.13 to 1.51) and the von Wil-
lebrand factor concentration (1.11; 95 percent confidence interval, 0.97 to 1.27) but
generally stronger for established risk factors, such as an increased total cholesterol
concentration (2.35; 95 percent confidence interval, 2.03 to 2.74) and cigarette smok-
ing (1.87; 95 percent confidence interval, 1.62 to 2.16).
 
conclusions
 
C-reactive protein is a relatively moderate predictor of coronary heart disease. Recom-
mendations regarding its use in predicting the likelihood of coronary heart disease may
need to be reviewed.
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ince atherosclerosis may, in part, be
 
an inflammatory disease,
 
1
 
 circulating factors
related to inflammation may be predictors of
cardiovascular disease in general populations.
 
2
 
 A re-
cent statement from the Centers for Disease Control
and Prevention and the American Heart Association
concluded that it is reasonable to measure C-reac-
tive protein, a sensitive circulating marker of inflam-
mation, as an adjunct to the measurement of es-
tablished risk factors in order to assess the risk of
coronary heart disease.
 
3
 
 The report acknowledged,
however, that the epidemiologic data to support this
view were not entirely consistent and recommend-
ed that larger prospective studies be conducted to
improve the reliability of the evidence.
We measured C-reactive protein concentrations
in approximately 2400 patients with coronary heart
disease diagnosed since their enrollment in the co-
hort and approximately 4000 controls nested within
the Reykjavik Study, a prospective cohort study of
about 19,000 middle-aged men and women with-
out a history of myocardial infarction. The number
of cases of coronary heart disease in this cohort was
about four times as great as in the largest previous
study
 
4
 
 and should reduce the scope for random er-
ror in our estimates. We also assessed the effect of
within-person variation in the concentrations of in-
flammatory markers
 
5
 
 in serial blood samples ob-
tained over a period of several years in several hun-
dred participants. To compare the predictive value
of the C-reactive protein concentration with that of
some other inflammatory markers studied in coro-
nary heart disease, we also analyzed the erythrocyte
sedimentation rate and circulating concentrations
of von Willebrand factor, each of which can also
fluctuate considerably in acute-phase inflammatory
responses.
 
6,7
 
 To help put the new data in context,
we updated meta-analyses of previous relevant
studies of each of these inflammatory markers.
 
patients and controls
 
The Reykjavik Study, initiated in 1967 as a prospec-
tive study of cardiovascular disease, has been de-
scribed in detail previously.
 
8
 
 All men born between
1907 and 1934 and all women born between 1908
and 1935 who were residents of Reykjavik, Iceland,
and its adjacent communities on December 1, 1966,
were identified in the national population register
and then invited to participate in the study during
five stages of recruitment between 1967 and 1991.
A total of 8888 men and 9681 women without a his-
tory of myocardial infarction were enrolled, reflect-
ing a response rate of 72 percent.
 
9
 
Nurses administered questionnaires, made phy-
sical measurements, performed spirometry and
electrocardiography, and collected venous blood
samples after an overnight fast for the measurement
of the erythrocyte sedimentation rate and to prepare
aliquots of serum, which were stored at ¡20°C for
subsequent analysis. All participants have subse-
quently been monitored with respect to death from
any cause and the occurrence of major cardiovas-
cular conditions, with a total loss to follow-up of
only about 0.6 percent of participants.
 
9
 
 
A total of 2459 men and women with available
serum samples had major coronary events between
the beginning of follow-up and December 31, 1995,
for a mean (±SD) duration of follow-up of 17.5±8.7
years, as compared with 20.6±8.2 years among con-
trols. Among the men, 1073 deaths from coronary
heart disease and 701 nonfatal myocardial infarc-
tions were recorded (564 confirmed and 137 possi-
ble myocardial infarctions), and among the women,
385 died of coronary heart disease and 300 had a
nonfatal myocardial infarction (237 confirmed and
63 possible myocardial infarctions). Deaths from
coronary heart disease were ascertained from cen-
tral registers on the basis of a death certificate listing
an 
 
International Classification of Diseases
 
 code of 410
through 414, and the diagnosis of nonfatal myo-
cardial infarction was based on the criteria of the
Monitoring Trends and Determinants in Cardiovas-
cular Disease study. 
We selected 3969 control subjects from among
the participants who had survived to the end of the
study period without having a myocardial infarction.
The controls were frequency-matched to the pa-
tients with respect to the calendar year of recruit-
ment, sex, and age (in five-year increments).
 
10
 
The National Bioethics Committee and the
Data Protection Authority of Iceland approved the
study protocol. All participants provided informed
consent.
 
laboratory methods
 
Laboratory measurements were made without
knowledge of the participants’ disease status, and
thus samples from patients and controls were ran-
domly distributed among assay plates. Concentra-
tions of C-reactive protein were measured by latex-
enhanced immunoturbidimetry, with a lower limit
of detection of 0.02 mg per liter (Roche Diagnos-
tics).
 
11
 
 The variation in C-reactive protein values
within runs was less than 1 percent, and the be-
s
methods
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tween-day variability was 1 percent at a concentra-
tion of 14 mg per liter and 3.7 percent at a concen-
tration of 3.8 mg per liter. The concentration of
von Willebrand factor was determined by means
of a sensitive enzyme immunoassay. We also deter-
mined the concentration of von Willebrand factor in
paired plasma and serum samples from 56 healthy
persons from another study and found close agree-
ment between plasma and serum values (correla-
tion coefficient, 0.94).
 
7
 
 The Wintrobe method was
used to measure the erythrocyte sedimentation
rate in fresh blood samples obtained at the time of
base-line venesection.
 
6
 
 Other biochemical and he-
matologic measurements involved the use of stan-
dard assays, as previously described.
 
8
 
 Measure-
ments were made in pairs of samples obtained from
379 participants a mean of about 12 years apart.
Data on erythrocyte sedimentation rate from the
Reykjavik Study have been reported previously.
 
12
 
statistical analysis
 
Comparisons between patients and controls were
made by means of unmatched stratified logistic re-
gression fitted according to the unconditional max-
imum likelihood (Stata software, version 7). To
maximize the ability to compare our results with
those of previous reports, primary analyses of values
of C-reactive protein, erythrocyte sedimentation
rate, and von Willebrand factor were prespecified
to compare extreme thirds of patients and controls
with respect to the distribution of values in the con-
trols. Subsidiary analyses involved other cutoff val-
ues. Odds ratios were sequentially adjusted for the
following variables: age, sex, calendar year of en-
rollment, smoking status, systolic blood pressure,
total cholesterol level, triglyceride level, body-mass
index (the weight in kilograms divided by the
square of the height in meters), forced expiratory
volume in one second, presence or absence of dia-
betes, socioeconomic status, and the concentra-
tions of other markers of inflammation. 
To estimate the discriminative value of predic-
tive models, we calculated the areas under the re-
ceiver-operating-characteristic curve, in order to de-
termine whether the sequential addition of data on
inflammatory markers increased the predictive value
of major established coronary risk factors, as de-
scribed previously.
 
13
 
 We performed meta-analyses
of studies published before January 2003 that in-
cluded essentially general populations (i.e., cohorts
not selected on the basis of preexisting disease)
with more than a year of follow-up, using search,
abstraction, and data-synthesis methods that have
been described previously and using nonfatal myo-
cardial infarction or death from coronary heart dis-
ease as end points.
 
6,7,14
 
 We combined the results
of the studies by using inverse variance-weighted
averages of logarithmic odds ratios. Heterogeneity
was assessed by means of standard 
 
x
 
2
 
 tests. Odds
ratios are given with 95 percent confidence inter-
vals, and two-sided P values are reported. Since pre-
vious studies have reported on the predictive values
of single base-line measurements of inflammatory
markers with respect to coronary heart disease,
odds ratios have not been corrected for regression
dilution in the present study, so as to allow direct
comparisons with previous work.
 
5
 
The mean age at the time of the coronary heart dis-
ease event was 70.2±9.7 years. There were signifi-
cant differences between patients and controls with
respect to established coronary risk factors, such as
smoking status, body-mass index, blood pressure,
and serum lipid concentrations (Table 1).
 
base-line associations and long-term 
stability of inflammatory markers
 
The partial correlation coefficients (adjusted for
age, sex, calendar year of recruitment, and smoking
status) for C-reactive protein, on the one hand, and
the erythrocyte sedimentation rate and von Wille-
brand factor, on the other, were 0.38 and 0.18, re-
spectively (P<0.001 for each comparison), and the
partial correlation coefficient for the erythrocyte
sedimentation rate and the von Willebrand factor
concentration was 0.17 (P<0.001). A higher C-re-
active protein concentration was significantly as-
sociated with cigarette smoking (P<0.001), an in-
creased body-mass index (P<0.001), a low forced
expiratory volume in one second (P<0.001), and an
increased triglyceride concentration (P<0.001)
(data not shown). Higher values for the erythrocyte
sedimentation rate were significantly associated
with older age (P<0.001), female sex (P<0.001), a
low hemoglobin value (P<0.001), a low hematocrit
(P<0.001), an elevated serum uric acid concentra-
tion (P<0.001), a low forced expiratory volume in
one second (P<0.001), and smoking (P<0.001). A
higher von Willebrand factor concentration was
significantly associated with older age (P<0.001)
and smoking (P<0.001).
Among 379 participants who provided paired
blood samples, the within-person correlation coef-
ficients for C-reactive protein, erythrocyte sedimen-
results
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tation rate, and von Willebrand factor were 0.59
(95 percent confidence interval, 0.52 to 0.66), 0.67
(95 percent confidence interval, 0.61 to 0.73), and
0.57 (95 percent confidence interval, 0.50 to 0.64),
respectively. These values were similar with respect
to long-term consistency to the values for systolic
blood pressure (correlation coefficient, 0.66; 95
percent confidence interval, 0.60 to 0.72), diastolic
blood pressure (correlation coefficient, 0.53; 95 per-
cent confidence interval, 0.46 to 0.60), and total
serum cholesterol (correlation coefficient, 0.60; 95
percent confidence interval, 0.54 to 0.66).
 
* Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height 
in meters.
† Information on occupation was available for 1742 patients and 2888 controls.
‡ Information on education was available for 1292 patients and 2157 controls.
§ Information on home ownership was available for 2323 patients and 3754 controls.
¶ Information on the type of residence was available for 2258 patients and 3646 controls. Other categories included
“duplex” and “villa.”
¿ To convert values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert values for triglycerides to mil-
ligrams per deciliter, divide by 0.01129. To convert values for glucose to milligrams per deciliter, divide by 0.05551. To 
convert values for creatinine to milligrams per deciliter, divide by 88.4. To convert values for uric acid to milligrams per 
deciliter, divide by 59.48. To convert values for hemoglobin to grams per deciliter, divide by 0.6206.
** Values were log-transformed for analysis and presented as geometric means ±SD.
†† Information on C-reactive protein, erythrocyte sedimentation rate, and von Willebrand factor was available for 2406, 
 
2440, and 2445 patients, respectively, and 3891, 3942, and 3948 controls, respectively.
 
Table 1. Base-Line Characteristics of the Patients with Coronary Heart Disease and Controls.*
Characteristic Patients (N=2459) Controls (N=3969) P Value
 
Age — yr 55.8±9.3 55.7±9.1 —
Male sex — no. (%) 1774 (72) 2743 (69) —
Current smoker (including cigarettes, cigars, pipes) — no. (%) 1417 (58) 1941 (49) <0.001
Current cigarette smoker — no. (%) 962 (39) 1266 (32) <0.001
History of diabetes — no. (%) 83 (3) 63 (2) <0.001
Nonmanual occupation — no. (%)† 703 (40) 1227 (42) 0.15
Education beyond high school — no. (%)‡ 354 (27) 645 (30) 0.12
Home owner — no. (%)§ 1962 (84) 3201 (85) 0.39
Lives in apartment block — no. (%)¶ 1186 (53) 1833 (50) 0.09
Height — m 1.71±0.087 1.72±0.087 0.07
Weight — kg 76±14 75±14 <0.001
Body-mass index 26±3.9 25±3.7 <0.001
Systolic blood pressure — mm Hg 146±22 141±20 <0.001
Diastolic blood pressure — mm Hg 89±11 87±11 <0.001
Forced expiratory volume in 1 sec — liters 2.8±0.85 2.9±0.86 0.002
Protein or glucose in urine — no. (%) 112 (5) 102 (3) <0.001
Blood value¿
Total serum cholesterol — mmol/liter 6.82±1.18 6.40±1.14 <0.001
Serum triglycerides — mmol/liter** 1.19±0.79 1.03±0.62 <0.001
Fasting glucose — mmol/liter 4.6±1.1 4.5±0.8 <0.001
Serum creatinine — µmol/liter 77±14 75±13 <0.001
Serum uric acid — µmol/liter 312±73 300±66 <0.001
Hemoglobin — mmol/liter 9.2±0.80 9.1±0.81 <0.001
Hematocrit — % 44.8±3.6 44.2±3.5 <0.001
Inflammatory marker††
C-reactive protein — mg/liter** 1.75±5.3 1.28±5.2 <0.001
Erythrocyte sedimentation rate — mm/hr** 7.4±10.6 6.3±9.7 <0.001
von Willebrand factor — IU/dl** 107.4±48.1 103.2±46.2 <0.001
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inflammatory markers and incident 
coronary heart disease
 
The odds ratio for coronary heart disease was 1.92
(95 percent confidence interval, 1.68 to 2.18; 
 
x
 
2
 
=
105, with 1 df ) among patients with values in the
top third (cutoff value, 2.0 mg per liter), as com-
pared with the bottom third (cutoff value, 0.78 mg
per liter), of base-line C-reactive protein concentra-
tions in the control group. The odds ratio fell to 1.45
(95 percent confidence interval, 1.25 to 1.68; 
 
x
 
2
 
=
28, with 1 df ) after adjustment for smoking status,
other established coronary risk factors, and indica-
tors of socioeconomic status (Table 2). Compari-
sons between the top and bottom thirds of patients
and controls with respect to the other markers gave
the following adjusted odds ratios for coronary heart
disease: for erythrocyte sedimentation rate (cutoff
value of 10 mm in first hour of measurement for
the top third and 4 mm in first hour for the bottom
third), 1.30 (95 percent confidence interval, 1.13 to
1.51; 
 
x
 
2
 
=13, with 1 df ), and for von Willebrand
factor (cutoff value of 124 IU per deciliter for the
top third and 88 IU per deciliter for the bottom
third), 1.11 (95 percent confidence interval, 0.97 to
1.27; 
 
x
 
2
 
=26, with 1 df ) (Table 2 and Fig. 1). The
calculated areas under receiver-operating-charac-
teristic curves indicate that information on the
C-reactive protein concentration (and the other in-
flammatory markers that were assessed) provided
comparatively little additional predictive value over
that provided by assessment of major established
risk factors (Fig. 1).
These findings were not materially changed in
analyses restricted to the 2083 patients without evi-
dence of coronary heart disease at base line (Table 2),
to the 2206 patients with C-reactive protein values
who had a confirmed myocardial infarction or died
of coronary heart disease, or to the participants with-
out evidence of acute-phase reactions at the base-
line examination (i.e., this analysis excluded 132 pa-
tients and 152 controls with a C-reactive protein
concentration of more than 10 mg per liter
 
15
 
 or an
erythrocyte sedimentation rate of more than 30 mm
during the first hour). The findings were also unaf-
fected by changes in the cutoff values (e.g., analyses
of quarters or fifths, or according to increases of
1 SD) (Table 2).
Associations between the C-reactive protein con-
centration and the risk of coronary heart disease did
not vary significantly according to established risk
factors, such as smoking or increased blood lipid
concentrations, blood pressure, or body-mass index
(data not shown). An exploratory analysis suggested
the possibility of more extreme odds ratios among
the 1049 patients who died of coronary heart dis-
ease or had a nonfatal myocardial infarction within
10 years after enrollment (odds ratio, 1.84; 95 per-
cent confidence interval, 1.49 to 2.28), as compared
with the 1357 patients who had such an event after
the first decade (odds ratio, 1.26; 95 percent confi-
dence interval, 1.05 to 1.51). Such a trend, however,
was not observed in the updated meta-analysis, de-
scribed below, which was based on published data
from 22 studies
 
2,4,13,14,16-33
 
 (Fig. 2). Therefore, it re-
quires further examination involving larger num-
bers of participants with individual data. Such
analysis is also required for a reliable characteriza-
tion of the shape of the association between C-reac-
tive protein and coronary heart disease.
 
updated meta-analysis
 
Twenty-two prospective studies of C-reactive pro-
tein (including the present study) have involved a
total of 7068 patients, with a weighted mean age at
entry of 57 years and a weighted mean follow-up of
12 years
 
2,4,13,14,16-33
 
 (Table 3). All studies used
high-sensitivity assays, and all but two
 
19,32
 
 report-
 
Figure 1. Odds Ratios for Coronary Heart Disease among 2459 Patients 
with Coronary Heart Disease and 3969 Controls.
 
Comparisons are between patients and controls with values in the top third 
and those in the bottom third of the distribution of values for controls, except 
for comparisons involving smoking status. Squares denote odds ratios, and 
horizontal lines represent 95 percent confidence intervals. The information 
plotted in this figure is based on odds ratios listed in the next-to-last column 
of Table 2. Logistic-regression analysis was used to calculate the areas under 
the receiver-operating-characteristic (ROC) curve after adjustment for age, 
sex, and period, with data on major established risk factors and inflammatory 
markers added to the model in the order of the strength of each variable’s as-
sociation with coronary heart disease.
Risk Factor
Area under the ROC
Curve (95% CI)
1 2 4
Odds Ratio for Coronary Heart Disease
Total cholesterol
Current cigarette smoking
(vs. nonsmoking)
Systolic blood pressure
C-reactive protein
Erythrocyte sedimentation
rate
von Willebrand factor
0.61 (0.59–0.62)
0.63 (0.61–0.64)
0.64 (0.63–0.65)
0.65 (0.64–0.67)
0.65 (0.64–0.67)
0.66 (0.64–0.67)
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Figure 2. Twenty-Two Prospective Studies of the Association of C-Reactive Protein Concentrations with the Risk of Coro-
nary Heart Disease (CHD) in Essentially General Populations, Grouped According to Several Study Characteristics.
 
One of the 11 studies published before 2000 was updated in 2002
 
13,16
 
; hence, data on 85 cases from this study contrib-
uted to two subtotals, but we did not double-count these cases in estimating the overall odds ratio. Two studies
 
17,18
 
 pub-
lished in 1999 (comprising a total of 98 cases) were not included in a previous meta-analysis of studies published before 
March 2000
 
14
 
; they have been included in the 11 studies published between 2000 and 2002. Although three studies pub-
lished after 2000,
 
17-19
 
 involving a total of 245 cases of coronary heart disease, reported results for deaths from cardiovas-
cular causes rather than specifically from coronary heart disease, the majority of these deaths were likely to have been 
due to coronary heart disease. It was not possible to separate results for 77 cases of coronary revascularization from re-
sults for nonfatal myocardial infarction and death from coronary heart disease in another study.
 
20
 
 The odds ratios used 
were those reported in studies that had adjusted for age, sex, smoking status, and other established risk factors for cor-
onary heart disease (such as blood lipid levels, blood pressure, body-mass index, and diabetes status). The “Other” cat-
egory in “Sample” includes participants selected according to various criteria (e.g., the absence of a history of coronary 
disease in randomized trials). The Reykjavik Study provided separate estimates for men (732 cases with C-reactive pro-
tein values) and women (674 cases with C-reactive protein values). Information on the storage temperature used for 
samples was unavailable for two studies involving a total of 316 cases.
 
26,31 
 
Odds ratios involve comparisons of patients 
in the top third versus those in the bottom third of C-reactive protein concentrations. The horizontal lines represent 99 
percent confidence intervals.
1 2 4
Odds Ratio for Coronary Heart Disease
Variable
No. of Cases
of CHD
Reykjavik (current) Study
Between 2000 and 2002: 11 studies4,13,17-20,24,26-29
Before 2000: 11 studies2,14,16,21,22,25,30-33
Study size
≥500 Patients: 4 studies4,14,20
<500 Patients: 18 studies2,13,17-19,21,22,24-33
Location
Western Europe: 11 studies14,18-21,24,25,28,30,32
North America: 11 studies2,4,13,17,22,26,27,29,31,33
Study sample
Population or general practitioners’ register:
11 studies4,14,17-19,24,25,28-30
Other: 11 studies2,13,20-22,26,27,31-33
Sex
Male: 12 studies2,14,20-22,24,25,28-30,32
Female: 3 studies13,27
Not reported separately: 8 studies4,17-19,26,31,33
Mean duration of follow-up
<10 yr: 14 studies4,13,17,18,20,21,25-27,29-31,33
≥10 yr: 8 studies2,14,19,22,24,28,32
Plasma or serum storage temperature
¡20°C: 7 studies14,19,24,28,30,32
<¡20°C: 13 studies2,4,13,17,18,20-22,25,27,29,33
Date of publication 
2406
2794
1953
4272
1325
1471
4174
2894
3847
2905
4107
2961
4520
2548
4477
2591
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ed adjustment for at least smoking status and some
other established risk factors for coronary heart
disease. There was evidence of heterogeneity be-
tween these studies (
 
x
 
2
 
=46, with 21 df; P=0.001),
but with the exception of the date of publication
(
 
x
 
2
 
=15, with 2 df; P<0.001), characteristics such
as sample size (
 
x
 
2
 
=4.0, with 1 df; P=0.04), loca-
tion (
 
x
 
2
 
=0.3, with 1 df; P=0.58), sampling meth-
od (
 
x
 
2
 
=5.2, with 1 df; P=0.02), sex of participants
(
 
x
 
2
 
=3.4, with 2 df; P=0.18), mean duration of fol-
low-up (
 
x
 
2
 
=1.6, with 1 df; P=0.20), and sample
storage temperature (
 
x
 
2
 
=0.1, with 1 df; P=0.77) did
not account for much of the overall heterogeneity
(Fig. 2). 
The tendency toward more extreme findings in
studies published before 2000 is consistent with
the preferential publication of positive results in
earlier studies. Restriction of analyses to the four
studies involving more than 500 patients,
 
4,14,20
 
comprising 4107 cases of coronary heart disease,
should limit any such bias, and yielded a combined
odds ratio of 1.49 (95 percent confidence interval,
1.37 to 1.62; 
 
x
 
2
 
=10.6, with 3 df; P=0.01). This val-
ue is somewhat smaller than the overall odds ratio
of 1.58 (95 percent confidence interval, 1.48 to
1.68) derived from combining all 22 studies.
A previous meta-analysis
 
6
 
 of prospective studies
of the effect of the erythrocyte sedimentation rate
(based on 1703 cases of coronary heart disease) re-
ported an odds ratio for coronary heart disease of
about 1.3 (95 percent confidence interval, 1.2 to
1.5), and this estimate is reinforced by the odds ratio
of 1.33 (95 percent confidence interval, 1.22 to 1.44)
that we calculated in our updated meta-analysis
(which involved an additional 2683 cases from a
further two studies
 
34
 
). The present updated meta-
analysis of prospective studies of von Willebrand
factor (which adds 2445 cases of coronary heart
disease to the previous total of 1524 cases) yielded
an odds ratio of 1.23 (95 percent confidence inter-
val, 1.14 to 1.33), which is probably weaker than the
previous estimate of about 1.5 (95 percent confi-
dence interval, 1.1 to 2.0).
 
7
 
We found that the decade-to-decade consistency of
values for C-reactive protein, the erythrocyte sedi-
mentation rate, and von Willebrand factor is similar
to that of values for blood pressure and total serum
cholesterol concentration, suggesting that these
inflammatory markers are sufficiently stable for
discussion
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potential use in the long-term prediction of coro-
nary heart disease. Our findings — reinforced by an
updated meta-analysis — indicate, however, that
the odds ratio for coronary heart disease in people
with elevated C-reactive protein values is lower than
that reported recently. Whereas a previous meta-
analysis14 of studies published before 2000 (based
on 1953 cases of coronary heart disease) reported
an odds ratio for coronary heart disease of about
2.0 (95 percent confidence interval, 1.6 to 2.5), our
updated meta-analysis, which adds 5115 cases of
coronary heart disease from a further 12 studies,
yielded an odds ratio of about 1.5 in a comparison
of people with base-line values in the top third with
those with base-line values in the bottom third for
the population. Moreover, in comparison with major
established risk factors (such as an increased total
serum cholesterol concentration and cigarette
smoking), the C-reactive protein concentration was
a relatively moderate predictor of the risk of coro-
nary heart disease and added only marginally to the
predictive value of established risk factors for coro-
nary heart disease. These findings suggest that re-
cent recommendations regarding the use of mea-
surements of C-reactive protein in the prediction of
coronary heart disease may need to be reviewed.3
The potential limitations of our study merit care-
ful consideration. The validity of our measurements
is demonstrated by the reasonably high decade-to-
decade consistency of C-reactive protein values re-
corded in paired samples from 379 participants (a
level of stability that was at least as high as those re-
corded in previous studies with sampling intervals
of just one to five years35-38). Further validation is
suggested by the finding of the expected base-line
associations of C-reactive protein with other in-
flammatory markers and with established coro-
nary risk factors.
The mean values and the distributions of several
established coronary risk factors (and the strength
of their associations with the risk of coronary heart
disease) in our study were generally similar to those
reported in other western European populations.8
Therefore, although the relative homogeneity of the
Reykjavik population should have minimized cer-
tain residual biases (such as that due to differences
in socioeconomic status), the present findings
should have wider relevance. Only total serum cho-
lesterol concentrations were measured in the pres-
ent study (rather than those of its subfractions,
which have opposing effects on the risk of coronary
heart disease), thereby underestimating the predic-
tive ability of lipid concentrations (and potentially
overestimating the adjusted predictive value of the
C-reactive protein concentration). 
No information was recorded on the use of aspi-
rin and statins, which, like hormone-replacement
treatment, may alter C-reactive protein values. How-
ever, fewer than 5 percent of the women in this
study reported the use of such hormonal treatment
during recruitment, and the use of aspirin and of
statins was similarly uncommon in the general
middle-aged population of Reykjavik between 1967
and 1991. We did not address the separate issues of
the predictive value of inflammatory markers with
respect to the risk of cardiac complications among
patients recently hospitalized for acute coronary
syndromes39 or the long-term risk of coronary heart
disease in patients with a history of cardiovascular
disease.14
As suggested by the statement of the Centers for
Disease Control and Prevention and the American
Heart Association,3 further clarification of the pre-
dictive value of C-reactive protein in coronary heart
disease in general populations will require the pool-
ing of studies on the basis of data for individual
participants from each of the available prospective
studies. Such a strategy will permit more complete
adjustment for other risk factors and for within-
person fluctuations of C-reactive protein levels,
more precise quantification of the associations in
particular subgroups (such as age-, sex-, and dura-
tion-specific associations as well as assessments of
combinations of inflammatory markers), more reli-
able characterization of the shape of any dose–re-
sponse relation, and more detailed investigation of
potential sources of heterogeneity.
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C-Reactive Protein Adds to the Predictive Value of Total
and HDL Cholesterol in Determining Risk of First
Myocardial Infarction
Paul M. Ridker, MD; Robert J. Glynn, ScD; Charles H. Hennekens, MD
Background—C-reactive protein (CRP) is a sensitive marker of inflammation, and elevated levels have been associated
with future risk of myocardial infarction (MI). However, whether measurement of CRP adds to the predictive value of
total cholesterol (TC) and HDL cholesterol (HDL-C) in determining risk is uncertain.
Methods and Results—Among 14 916 apparently healthy men participating in the Physicians’ Health Study, baseline
levels of CRP, TC, and HDL-C were measured among 245 study subjects who subsequently developed a first MI (cases)
and among 372 subjects who remained free of cardiovascular disease during an average follow-up period of 9 years
(controls). In univariate analyses, high baseline levels of CRP, TC, and TC:HDL-C ratio were each associated with
significantly increased risks of future MI (all P values ,0.001). In multivariate analyses, models incorporating CRP and
lipid parameters provided a significantly better method to predict risk than did models using lipids alone (all likelihood
ratio test P values ,0.003). For example, relative risks of future MI among those with high levels of both CRP and TC
(RR55.0, P50.0001) were greater than the product of the individual risks associated with isolated elevations of either
CRP (RR51.5) or TC (RR52.3). In stratified analyses, baseline CRP level was predictive of risk for those with low as
well as high levels of TC and the TC:HDL-C ratio. These findings were virtually identical in analyses limited to
nonsmokers and after control for other cardiovascular risk factors.
Conclusions—In prospective data from a large cohort of apparently healthy men, baseline CRP level added to the
predictive value of lipid parameters in determining risk of first MI. (Circulation. 1998;97:2007-2011.)
Key Words: myocardial infarction n epidemiology n C-reactive protein n risk factors n cholesterol
C-reactive protein is a sensitive marker of systemicinflammation, and prospective data from a population of
apparently healthy men indicate that baseline levels predict
risk of first MI.1 Specifically, among men free of prior
cardiovascular disease participating in the Physicians’ Health
Study, we recently reported that those with baseline levels of
CRP in the highest quartile had a threefold increase in risk of
developing future MI compared with those with levels in the
lowest quartile (relative risk, 2.9; P,0.001).1 In this popula-
tion, risk estimates were stable over long periods of time,
were significant among the subgroup of nonsmokers, and
were independent of a number of other risk factors for
cardiovascular disease. As such, these data demonstrate that
CRP is a marker of cardiovascular risk not only among those
with stable and unstable angina,2–4 the elderly,5 and selected
high-risk patients6 but also among individuals with no current
evidence of cardiovascular disease.1
See p 2000
From a clinical perspective, the question has been raised as
to whether CRP adds to the ability to predict atherothrom-
botic risk with more confidence than currently achievable
with standard lipid screening. We therefore reexamined data
from the Physicians’ Health Study to determine whether
measuring CRP added to the predictive value of TC and
HDL-C in determining subsequent risk of first MI. In addi-
tion, we sought to determine whether the risks of future MI
associated with CRP were present among those with low-risk
as well as high-risk profiles as assessed by baseline lipid
status.
Methods
In the US Physicians’ Health Study,7 14 916 men initially free of
reported cardiovascular disease, cancer, or other chronic illness
provided a baseline plasma sample before randomization and were
prospectively followed up for the first occurrence of MI. Details of
the Physicians’ Health Study, a randomized, double-blind, placebo-
controlled trial of aspirin and b-carotene in the primary prevention of
cardiovascular disease and cancer, have been described elsewhere, as
have the methods used to collect, store, and process baseline blood
specimens.1,7 Morbidity follow-up was .99% complete and mortal-
ity follow-up was 100% over the '9 years of follow-up in the
present analysis. Reported MI that occurred during the study fol-
low-up period was confirmed if medical record review demonstrated
symptoms consistent with MI and the presence of either diagnostic
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ECG changes or cardiac enzymes. Silent MIs were not included
because they could not be accurately dated. Deaths due to MI were
confirmed when autopsy reports, symptoms, circumstances of death,
and a history of coronary disease were consistent with this diagnosis.
In our original description of CRP in the Physicians’ Health Study,
we reported data from 246 initially healthy study participants who
subsequently developed a first MI (cases) and from a group of 543
age- and smoking-matched study participants who remained free of
cardiovascular disease during study follow-up (controls).1 For each
of these case and control subjects, blood collected at enrollment was
thawed and assayed for CRP by methods described elsewhere.1 In
addition, baseline blood samples of 245 cases (99%) and 372
controls (69%) were successfully analyzed for TC and HDL-C.8
These 617 initially healthy participants in the Physicians’ Health
Study form the basis for this report.
Means or proportions for baseline clinical characteristics and
measured risk factors were computed for the case and control groups
and compared by Student’s t test or the x2 statistic. Univariate
logistic regression analyses were used to determine whether baseline
levels of CRP, TC, and the TC:HDL-C ratio were predictive of future
risk of MI. In these analyses, baseline levels were divided into
quartiles based on the distribution of the control values.
On an a priori basis, we evaluated the combined role of hyper-
cholesterolemia and elevations of CRP in predicting risk of MI in
three stages, which allowed us to explore from a clinical perspective
the sensitivity and robustness of any findings to the choice of
alternative cut points. Thus, we first used the likelihood ratio test to
determine whether logistic regression models that included lipid
parameters and CRP provided a significantly better fit than did
logistic regression models limited to lipid parameters alone. In these
analyses, lipid parameters and log-normalized CRP levels were both
treated as continuous variables.
Second, logistic regression analyses were performed in which the
referent group was those individuals with both TC and CRP levels
below the 75th percentile cut point for each of these parameters
(TC2, CRP2). In this analysis, relative risks of developing a first
MI were computed for individuals with hypercholesterolemia alone
(TC1, CRP2), for individuals with elevations of CRP alone (TC2,
CRP1), and for individuals with both hypercholesterolemia and
elevations of CRP (TC1, CRP1).
Third, we divided case and control subjects into nine groups
according to tertile of TC and CRP level. In this analysis, logistic
regression was used to simultaneously evaluate the risks of first MI
in each of these groups, with those with the lowest tertile of both TC
and CRP used as the referent group. Similar analyses were per-
formed after case and control subjects were divided into nine groups
according to tertile of the TC:HDL-C ratio.
Finally, to evaluate whether increasing levels of CRP were a
predictor of risk for first MI among those with low as well as high
lipid parameters, we performed stratified analyses in which tests for
trends across increasing quartiles of CRP were computed separately
for those with levels of TC and the TC:HDL-C ratio above or below
the approximate median value for the study group.
All analyses were repeated for the subgroup of nonsmokers, and
additional multivariate analyses were used to control for the presence
or absence of other cardiovascular risk factors. P values are two-
tailed, and 95% CIs were computed.
Results
Table 1 presents the baseline clinical characteristics of the
subjects evaluated. Because study participants in our original
report were matched on smoking and age, these variables
were similar among those who subsequently developed a first
MI (cases) and among those who remained free of reported
cardiovascular disease over the follow-up period (controls).
As expected, case subjects had less favorable lipid profiles
than did control subjects.
Correlations between log-normalized CRP and TC
(r50.15) and between log-normalized CRP and HDL-C
(r520.15) were small in magnitude. Thus, ,3% of the
variance in CRP levels in these data was explained by the
lipid parameters.
In univariate analyses, baseline levels of CRP, TC, and the
TC:HDL-C ratio were each associated with increased risk of
future MI (all P values ,0.001). As shown in Table 2, the
relative risk of future MI increased 38% with each increasing
quartile of CRP (95% CI, 19% to 61%; P,0.001), 62% for
each increasing quartile of TC (95% CI, 39% to 90%;
P,0.001), and 59% for each increasing quartile of the
TC:HDL-C ratio (95% CI, 37% to 86%; P,0.001). The 95%
CIs for these risk estimates overlap and are consistent with
prior reports from the entire cohort.1,4
To evaluate whether CRP added to the predictive value of
lipids on risk of first MI, likelihood ratio tests were used to
compare the fit of prediction models using CRP and lipids to
the fit of models using lipids alone. In these analyses, the
assessment of both parameters provided a significantly im-
proved ability to predict risk. For example, models including
both CRP and TC provided a significant improvement in
prediction (P50.003) compared with models including only
TABLE 1. Baseline Characteristics of Study Participants Who
Subsequently Developed First MI (Cases) and Those Who
Remained Free of Reported Vascular Disease During the
Average 8-Year Follow-up Period (Controls)
Cases
(N5245)
Controls
(N5372) P
Age, y6SD 58.268.6 59.468.9 z z z
Smoking status, %
Never 44.3 41.8 z z z
Past 40.6 39.9
Current 15.2 18.3
Diabetes, % 5.3 3.2 0.2
Body mass index, kg/m2 25.6 24.9 0.01
Systolic blood pressure, mm Hg 128.5 127.3 0.3
Diastolic blood pressure, mm Hg 80.1 79.0 0.08
TC level, mg/dL 229.4 210.9 0.001
HDL-C level, mg/dL 46.4 49.3 0.008
TC;HDL-C ratio 5.3 4.5 0.001
TABLE 2. Relative Risks of First MI Associated With Each
Quartile Increase of CRP, TC, and TC;HDL-C Ratio
Parameter RR 95% CI P
CRP 1.38 1.19–1.61 0.0001
TC 1.62 1.39–1.90 0.0001
TC;HDL-C 1.59 1.37–1.86 0.0001
Selected Abbreviations and Acronyms
CRP 5 C-reactive protein
HDL-C 5 HDL cholesterol
MI 5 myocardial infarction
TC 5 total cholesterol
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TC, whereas models involving CRP significantly improved
prediction compared with models based solely on the
TC:HDL-C ratio (P50.002) or on TC and HDL-C entered as
separate variables (P50.002). These relationships were not
significantly altered in models limited to nonsmokers or that
further controlled for the effects of other cardiovascular risk
factors.
Table 3 presents the relative risks of first MI in analyses in
which study subjects were categorized as being above or
below the 75th percentile cut point for TC and CRP. As
shown, compared with those with levels of TC and CRP less
than the 75th percentile cut point for each parameter (TC2,
CRP2), those with elevations of TC alone (TC1, CRP2)
had a 2.3-fold increase in risk, whereas those with elevations
of CRP alone (TC2, CRP1) had a 1.5-fold increase in risk.
In contrast, the risk of first MI associated with elevations of
both TC and CRP (TC1, CRP1) was increased 5-fold
(RR55.0; 95% CI, 2.5 to 9.8; P50.0001). As shown in Table
3 and in Fig 1, these effects were not significantly altered in
analyses controlling for other risk factors.
Fig 2 illustrates the relative risks of first MI in analyses in
which study participants were stratified into nine groups
according to tertile of TC as well as tertile of CRP. As shown,
risks of future MI increased with each of these parameters
such that those in the highest tertile of both TC and CRP had
a relative risk of first MI 5.3 times that of individuals in the
lowest tertile of both parameters (95% CI, 2.4 to 11.7;
P50.0001). Similarly, Fig 3 illustrates the relative risks of
first MI in analyses in which study participants were stratified
into nine groups according to tertile of the TC:HDL-C ratio as
well as tertile of CRP.
Figure 1. Adjusted relative risks of first MI according to base-
line levels of TC above (TC1) or below (TC2) 75th percentile of
control group (234 mg/dL) and baseline CRP levels above
(CRP1) or below (CRP2) 75th percentile of control group
(2.11 mg/L).
Figure 3. Relative risks of first MI among apparently healthy
men associated with high (.5.01), middle (3.78 to 5.01), and
low (,3.78) tertiles of the TC:HDL-C ratio and high (.1.69
mg/L), middle (0.72 to 1.69 mg/L), and low (,0.72 mg/L) tertiles
of CRP.
Figure 2. Relative risks of first MI among apparently healthy
men associated with high (.223 mg/dL), middle (191 to 223
mg/dL), and low (,191 mg/dL) tertiles of TC and high (.1.69
mg/L), middle (0.72 to 1.69 mg/L), and low (,0.72 mg/L) tertiles
of CRP.
TABLE 3. Relative Risks of First MI According to the Presence (TC1) or
Absence (TC2) of TC Levels in Excess of the 75th Percentile of the Control
Distribution (234 mg/dL) and/or the Presence (CRP1) or Absence (CRP2) of CRP
Levels in Excess of the 75th Percentile of the Control Distribution (2.11 mg/L)
CRP2, TC2 CRP1, TC2 CRP2, TC1 CRP1, TC1
Crude relative risk 1.0 1.5 2.3 5.0
95% CI z z z 0.9–2.4 1.5–3.7 2.5–9.8
P z z z 0.1 0.0003 0.0001
Adjusted relative risk* 1.0 1.4 2.1 5.2
95% CI z z z 0.8–2.3 1.3–3.4 2.5–10.5
P z z z 0.02 0.002 0.0001
*Adjusted for family history of coronary artery disease, history of hypertension, body mass index,
diabetes, age, and smoking status.
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Table 4 presents the relative risks of first MI according to
baseline levels of CRP in analyses in which the study
population was stratified according to baseline lipid profile.
As shown, statistically significant associations were found
between baseline level of CRP and risk of first MI for study
participants with low as well as high levels of TC and the
TC:HDL-C ratio. Similar relationships were found in analy-
ses limited to nonsmokers.
Discussion
In these prospective data deriving from a large cohort of
apparently healthy men, baseline CRP level added to the
predictive value of TC and HDL-C in determining risk of first
MI. Indeed, interactive models evaluating elevations of CRP
and lipids raise the possibility that the joint effects of both
risk factors may be slightly greater than the product of the
individual effects of each risk factor considered separately.
Moreover, baseline level of CRP is a predictor of risk of first
MI for men at low as well as high risk as determined by their
lipid profiles. These relationships were minimally altered in
analyses either limited to nonsmokers or adjusted for other
risk factors, including hypertension, body mass, diabetes, and
family history of coronary disease. Finally, these results were
TABLE 4. Relative Risks of First MI According to Baseline Levels of CRP,
Stratified by Baseline Lipid and Lipoprotein Levels
Quartile of CRP (range, mg/L)
P for Trend
1
(#0.55)
2
(0.56–1.14)
3
(1.15–2.10)
4
($2.11)
TC #210
All subjects
RR 1.0 1.5 1.6 2.5 .03
95% CI z z z 0.6–3.5 0.7–3.6 1.1–5.6
P z z z 0.4 0.3 0.03
Nonsmokers
RR 1.0 1.4 1.2 2.1 .1
95% CI z z z 0.6–3.3 0.5–3.0 0.9–5.0
P z z z 0.5 0.6 0.09
TC .210
All subjects
RR 1.0 2.4 3.1 3.1 .001
95% CI z z z 1.2–4.9 1.6–5.9 1.6–6.0
P z z z 0.01 0.001 0.001
Nonsmokers
RR 1.0 2.2 3.1 3.6 .001
95% CI z z z 1.1–4.7 1.5–6.2 1.7–7.6
P z z z 0.03 0.002 0.001
TC;HDL-C #4.0
All subjects
RR 1.0 2.0 2.2 3.0 .03
95% CI z z z 0.7–5.4 0.8–5.7 1.1–7.9
P z z z 0.2 0.1 0.03
Nonsmokers
RR 1.0 2.0 1.7 2.7 .08
95% CI z z z 0.7–5.6 0.6–4.5 1.0–7.5
P z z z 0.2 0.4 0.05
TC;HDL-C .4.0
All subjects
RR 1.0 1.6 2.2 2.3 .008
95% CI z z z 0.8–3.1 1.2–4.2 1.2–4.2
P z z z 0.2 0.01 0.01
Nonsmokers
RR 1.0 1.5 2.2 2.6 .004
95% CI z z z 0.8–3.0 1.1–4.2 1.3–5.1
P z z z 0.2 0.02 0.007
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robust to the choice of several cut points for both CRP and
lipid parameters.
The present data describing at least additive relationships
between CRP and lipids in terms of risk prediction extend
prior findings relating CRP to cardiovascular disease.1–6
Specifically, elevated levels of CRP are associated with
increased risks of MI or sudden death among those with
stable and unstable angina pectoris,2–4 as well as coronary
heart disease in the elderly5 and coronary mortality among
high-risk patients.6 However, because CRP levels increase in
response to acute ischemia and are chronically elevated
among smokers,9 it had been uncertain whether the inflam-
mation detected by CRP in these studies is causal or due to
the effects of other factors, such as ischemia or cigarette
consumption. Moreover, these prior studies did not evaluate
whether the effects of CRP were present among those with
high- as well as low-risk lipid profiles or whether the risks
associated with CRP were additive to those determined by
standard lipid analysis.
All the apparently healthy men in the Physicians’ Health
Study were free of any history of cardiovascular disease when
blood samples were obtained. Thus, the potential for con-
founding by the presence of symptomatic ischemia in these
data is unlikely. Moreover, the risks of future MI associated
with CRP in the Physicians’ Health Study were present for
nonsmokers, providing evidence against the possibility that
observed effects are simply the result of cigarette
consumption.9
The fact that lipid parameters and CRP levels were
measured only once at baseline in our study is a potential
limitation, because random fluctuation in these parameters
over time would tend to increase the variance in our data.
However, if random, such variation would most likely bias
our findings toward a null result and lead to an underestima-
tion of true predictive values. Conversely, because assays for
CRP as well as all lipid parameters were performed on the
same baseline plasma sample, these data are compatible with
the potential utility of simultaneous assessment of inflamma-
tory markers and lipid parameters as a method of risk
detection.
It is currently estimated that up to half of all MIs in the
United States occur among individuals with moderate to low
risk as determined by assessment of TC and HDL-C levels.10
The present data raise the possibility that assessment of CRP
may provide a method of determining risk of future MI
among apparently low-risk individuals, including nonsmok-
ers. Because relatively simple interventions such as exercise,
weight loss, and diet restriction can lead to substantial
reductions in risk of first MI,10 assessment of CRP might have
clinical utility if improved risk stratification leads to im-
proved compliance with lifestyle modification. Confirmation
of these data in other prospective cohorts is thus of critical
importance, as are studies in women, for whom data are
lacking on the predictive value of inflammatory markers.
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C-Reactive Protein and the Future Risk of Thromboembolic
Stroke in Healthy Men
J. David Curb, MD; Robert D. Abbott, PhD; Beatriz L. Rodriguez, MD, PhD;
Pamela Sakkinen, MD, MPH; Jordan S. Popper, MD; Katsuhiko Yano, MD; Russell P. Tracy, PhD
Background—Evidence suggests that C-reactive protein (CRP) is related to thromboembolic (TE) stroke. Whether
associations are altered in the presence of other risk factors is unclear. The purpose of this study was to additionally
assess the relation between CRP and TE stroke.
Methods and Results—On the basis of 20 years of follow-up after CRP measurement, 259 cases of TE stroke were
identified and compared with 1348 controls. Subjects were aged 48 to 70 years when CRP was measured. Levels of CRP
were positively associated with TE stroke throughout the 20 years of follow-up. Although associations were modest
within 5 years of CRP measurement, the odds of stroke in the top versus bottom CRP quartile increased over time to
a 3.8-fold excess by 10 to 15 years into follow-up (P0.001). For men without hypertension or diabetes, the overall
corresponding odds were 1.6 to 1.7 (P0.05). In men 55 years of age, the odds increased to a 3-fold excess
(P0.006), and in nonsmokers, there was a 5.8-fold excess (P0.001). Associations in past and current smokers, in men
55 years of age, and in those with hypertension or diabetes were not significant.
Conclusions—Findings suggest that elevated CRP in middle adulthood and in men with healthier risk factor profiles may
be important as a risk factor for TE stroke. Use of CRP levels as a clinical screen to identify an increased risk of
cardiovascular disease in otherwise healthy men warrants consideration. (Circulation. 2003;107:2016-2020.)
Key Words: stroke  inflammation  epidemiology
C-reactive protein (CRP) is an acute-phase protein thoughtto be a measure of inflammatory processes in cardiovas-
cular disease.1–12 Although evidence suggests that CRP is
associated with stroke,7–10 it is uncertain whether the associ-
ation has similar meaning in different age groups and in those
at high and low risk of cardiovascular disease. The purpose of
this study was to examine the relation between levels of CRP
and the development of thromboembolic (TE) stroke over a
20-year period in largely middle-aged and healthy Japanese-
American men in the Honolulu Heart Program. The associa-
tion of CRP levels to early versus late disease will also be
assessed, as will its relation with disease that may be poorly
explained by age, hypertension, diabetes, and other cardio-
vascular risk factors. Effects will also be assessed in the
absence of intervening coronary heart disease.
Methods
Baseline Examination
From 1965 to 1968, the Honolulu Heart Program began following
8006 men of Japanese ancestry through a series of physical exami-
nations and comprehensive follow-up for cardiovascular dis-
ease.13–15 At the time of study enrollment, subjects were aged 45 to
68 years. Procedures were in accordance with institutional guidelines
and approved by an institutional review committee. Informed con-
sent was obtained from the study participants.
Because the inventory of frozen sera from the time of study
enrollment was largely depleted, measurement of CRP for this report
is based on samples that were available at examinations given from
1967 to 1970. Other risk factors included diabetes, hypertension,
total cholesterol, body mass index, and the use of cigarettes. Data on
alcohol intake and physical activity were taken from examinations
that were given at the time of study enrollment (1965 to 1968). Atrial
fibrillation was not included among the risk factors, because it was
rarely observed in this age group of Japanese-American men.
Statistical adjustment for atrial fibrillation also failed to alter the
findings in the present report.
Among the collected risk factors, diabetes was diagnosed on the
basis of a medical history or the use of insulin or oral hypoglycemic
therapy. Hypertension was defined as systolic or diastolic blood
pressures 160 and 95 mm Hg, respectively, or when high blood
pressure was being medically treated. Measurement of physical
activity was based on the physical activity index, a commonly used
index for quantifying overall metabolic output during a typical
24-hour period.16,17
TE Stroke Cases and Controls
Assessment of the effects of CRP on the risk of future stroke is based
on a nested case-control design. There were 7498 men (95% of the
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surviving cohort) who were available for follow-up at the time of
CRP measurement. Among this group, cases of TE stroke and
controls were selected from 5686 subjects in whom serum samples
were available. Sera from 1812 participants were not obtained
because of depletion from random selection for special substudies or,
in a few instances, for use in small studies of rare diseases. After
excluding cases of stroke and coronary heart disease that were
identified in 20 years of follow-up, 1348 controls were randomly
selected from the remaining 4145 men.
During the 20-year course of follow-up, information on cardio-
vascular events was obtained through a comprehensive system of
surveillance of hospital discharges, death certificates, autopsy rec-
ords, and repeat examinations. For this report, subjects were fol-
lowed up for the first occurrence of a TE stroke (without distinction
between an atherothrombotic infarction and embolic event), on the
basis of medical records showing a neurological deficit of sudden or
rapid onset that persisted for longer than 24 hours or resulted in
death. A review of all suspected stroke outcomes by the Honolulu
Heart Program Morbidity and Mortality Review Committee con-
firmed all diagnoses. There were 259 cases of stroke that were
identified in the course of follow-up. All were selected without a
history of coronary heart disease.
CRP Determination
Serum specimens collected at the time of CRP measurement were
stored at 20°C until 1980, at which time they were transferred to
70°C. Although specimens in the present study had previously
been thawed and refrozen, measurement of CRP is known to be
relatively stable under such conditions.18 For each participant,
determination of a CRP level was based on an enzyme-linked
immunosorbent assay, a colorimetric competitive immunoassay that
uses purified protein and polyclonal anti-CRP antibodies. The
interassay coefficient of variation was 5%.
Statistical Analysis
Estimated age-adjusted risk factor comparisons between the cases
and controls were derived from analysis of covariance methods after
log-transforming the CRP values.18,19 Similar comparisons were
made across CRP quartiles. Estimated age-adjusted percents of men
with a TE stroke were also derived across CRP quartiles and within
separate 5-year periods of follow-up after the baseline examina-
tion.19,20 Such percents were not intended to represent the incidence
of TE stroke but rather to show how the cases of TE stroke were
distributed across the observed CRP quartiles. Beyond the first 5
years of follow-up, cases of TE stroke and deaths among the controls
that preceded a follow-up period were deleted from the correspond-
ing calculations. Cases of TE stroke that came after a 5-year
follow-up period were treated as controls.
To assess the relation between levels of CRP and the odds of a TE
stroke, statistical analysis relied on proportional hazards regression
models.21 Use of the proportional hazards regression model, which
provides estimates of the relative odds of disease that are similar to
those from logistic regression,22 also allows for the modeling of the
time to an event among the cases of TE stroke and the time to death
among the controls who failed to survive the 20-year period of
follow-up. To provide a test for trend, CRP was also modeled as a
continuous variable. All reported P values were based on 2-sided
tests of significance.
Results
At the time of CRP measurement, the average ages of the
cases and controls were 58.1 years (range, 49 to 69) and 55.8
years (range, 48 to 70), respectively (P0.001). Among the
cases, the average age when a TE stroke occurred was 69
years (range, 51 to 87), and the average time to an event was
10.5 years (range, 2 months to 20 years).
Baseline characteristics of the study participants according to
case-control status are described in Table 1. As expected, at the
time of CRP measurement, risk factor profiles were significantly
less favorable in cases than in controls. Frequency of hyperten-
sion and diabetes were more than doubled in the TE stroke cases
(P0.001). Cases had higher levels of total cholesterol
(P0.01) and body mass index (P0.001) as well. Cases were
more likely to be current cigarette smokers (P0.001) and less
likely to have stopped smoking than controls (P0.05). Cases
also consumed more alcohol and were less physically active than
controls, although differences were not statistically significant.
Risk factor differences across quartiles of CRP are addition-
ally described in Table 2. Here, frequency of hypertension was
more than doubled in the top versus bottom quartile of CRP
(19.4 versus 8.4%, P0.001). Although not statistically signif-
icant, the percent of men with diabetes also seemed positively
related to CRP concentrations. Differences in total cholesterol
across quartile strata were modest. Smoking, however, increased
with rising CRP levels (P0.001), with a jump in the use of
cigarettes between the third and top CRP quartiles. Although less
clear, the percent of men who were past smokers tended to
decline with increasing CRP levels (P0.05). Although body
mass index increased consistently with increasing CRP levels,
amounts of physical activity declined (P0.001). There was no
clear association between the intake of alcohol and levels of
CRP.
Table 3 provides the age-adjusted percent of men with a TE
stroke within each quartile of CRP and within separate 5-year
periods of follow-up after CRP measurement. Although associ-
ations were modest within 5 years of CRP measurement, the
relationship increased over time up to 10 to 15 years into
TABLE 1. Distribution of CRP, Mean Age, and Age-Adjusted
Mean Risk Factor Levels for Controls and Cases of
Thromboembolic Stroke
Risk Factor Controls (n1348)* Cases (n259)
CRP, mg/L
Geometric mean† 0.60 0.78‡
Arithmetic mean† 1.16 1.43
25th percentile 0.32 0.44
Median 0.54 0.73
75th percentile 1.00 1.39
Range 0.1 to 79.20 0.1 to 34.19
Age, y 55.85.4§ 58.15.7‡
Hypertension, % 10.6 27.0‡
Diabetes, % 13.3 27.0‡
Total cholesterol, mmol/L 5.60.9 (21535) 5.81.0 (22240)¶
Body mass index, kg/m2 23.53.0 24.33.3‡
Past cigarette smoker, % 27.8 21.3#
Current cigarette smoker, % 37.6 54.4‡
Alcohol intake, oz/mo 13.222.5 15.226.6
Physical activity index 33.04.5 32.74.6
*Sample size.
†Age-adjusted.
‡Significantly different from controls (P0.001).
§MeanSD.
Corresponding units in mg/dL.
¶Significantly different from controls (P0.01).
#Significantly different from controls (P0.05).
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follow-up. During this time, 8.3% of the men in the top CRP
quartile had a stroke compared with 2.3% in the bottom quartile
(P0.001). Although changes in the relation between CRP and
the risk of TE stroke seemed to occur with time, differences
were not statistically significant.
The estimated relative odds of a TE stroke for men in the top
versus bottom quartile of CRP, after age and risk factor adjustment,
is additionally described for each 5-year period of follow-up in
Table 4. Relative odds of a TE stroke are also provided within risk
factor strata across the entire 20-year period.
After age and risk factor adjustment, the estimated relative
odds of a TE stroke in men in the top versus bottom quartile of
CRP were no longer statistically significant within the 5- to 10-
and 15- to 20-year periods of follow-up. For the 10- to 15-year
period, however, the odds of a TE stroke rose significantly with
increasing CRP level when CRP was modeled as a continuous
risk factor (P0.010). There was also a 2.6-fold excess in the
odds of a TE stroke in the top versus bottom quartile of CRP
during this period of follow-up (P0.05).
Although sample sizes were reduced within risk factor strata,
the estimated odds of a TE stroke continued to increase signif-
icantly with rising CRP levels for middle-aged men (55 years,
P0.018), in men without hypertension or diabetes (P0.019
and P0.006, respectively), and in those who were never
smokers of cigarettes (P0.001). For men without hypertension
or diabetes, there was a 1.6- to 1.7-fold excess (P0.05) in the
odds of a TE stroke in the top versus bottom CRP quartile. In
middle-aged men, the corresponding odds increased to a 3-fold
excess (P0.006), and in nonsmokers, there was a 5.8-fold
excess (P0.001). Effects were also independent of total cho-
lesterol, body mass index, alcohol intake, physical activity index,
and the other risk factors in Table 4. Although associations were
weaker in men with hypertension or diabetes, differences in
associations from those when either condition was absent were
not statistically significant. In contrast, the effect of CRP on the
risk of TE stroke was significantly stronger in never smokers
compared with past smokers (P0.005) and current smokers
(P0.010).
TABLE 2. Mean Age and Age-Adjusted Risk Factor Levels by Quartile of CRP
Quartile* of CRP (Range, mg/L)
Risk Factor 1st (0.10 to 0.32)† 2nd (0.33 to 0.54) 3rd (0.55 to 1.00) 4th (1.01 to 79.2)
Sample size 386 384 412 425
Age, y‡ 55.85.2§ 55.95.4 56.15.6 56.85.8
Hypertension, %‡ 8.4 12.1 12.9 19.4
Diabetes, % 13.1 15.5 15.1 18.5
Total cholesterol, mmol/L 5.50.9 (21436) 5.60.9 (21734) 5.61.0 (21837) 5.60.9 (21736)
Body mass index, kg/m2¶ 22.72.7 23.42.9 24.13.1 24.33.3
Past cigarette smoker, %¶ 28.9 28.2 28.4 21.7
Current cigarette smoker, %‡ 32.3 36.2 37.6 54.1
Alcohol intake, oz/mo 12.522.7 11.418.9 15.326.0 14.624.1
Physical activity index# 33.44.6 33.24.7 32.94.6 32.34.1
*Quartiles are based on the distribution of CRP among the controls.
†Range in C-reactive protein.
‡Significant increase with increasing CRP (P0.001).
§MeanSD.
Corresponding units in mg/dL.
¶Significant decline with increasing CRP (P0.05).
#Significant decline with increasing CRP (P0.001).
TABLE 3. Age-Adjusted Percent of Men Who Suffered a Thromboembolic Stroke
by Quartile of CRP and by Period of Follow-Up After Blood Draw
Quartile* of CRP
Follow-Up Period 1st 2nd 3rd 4th
0 to 5 y 3.8 (14 of 386)† 4.3 (16 of 384) 4.1 (17 of 412) 4.0 (18 of 425)
5 to 10 y‡ 2.0 (7 of 367) 1.7 (6 of 360) 4.4 (17 of 390) 4.8 (20 of 397)§
10 to 15 y 2.3 (8 of 356) 2.6 (9 of 346) 6.2 (22 of 359)§ 8.3 (31 of 361)¶
15 to 20 y‡ 3.7 (12 of 333) 5.8 (19 of 322) 6.1 (19 of 314) 7.9 (24 of 301)§
Overall 10.9 (41 of 386) 13.2 (50 of 384) 18.2 (75 of 412)# 21.1 (93 of 425)¶
*Quartiles are based on the distribution of CRP among the controls.
†Cases of thromboembolic stroke/sample size.
‡Significant increase with increasing CRP (P0.05).
§Significantly different from the 1st quartile (P0.05).
Significant increase with increasing CRP (P0.001).
¶Significantly different from the 1st quartile (P0.001).
#Significantly different from the 1st quartile (P0.01).
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Discussion
Although the longitudinal data in this report provide addi-
tional evidence for an association between CRP and the
incidence of TE stroke, specific strengths of the present study
are worth noting. To date, the Honolulu Heart Program offers
the longest and most complete follow-up of the association
between CRP and stroke.7–10 Follow-up also includes a
well-defined acute event without intervening coronary heart
disease. Although others have also reported on an association
between CRP and cardiovascular disease, documentation of
an association with stroke has been equivocal. Earlier reports
have combined stroke with other forms of cardiovascular
disease as a single event. Recent findings from the Framing-
ham Study are also based on the combination of stroke with
poorly defined transient ischemic attacks as a pooled event in
an elderly sample that comprised half of surviving cohort
members.9 Although the Physician’s Health Study also
showed an increase in the risk of ischemic stroke with
increasing levels of CRP, possible differences in the impor-
tance of the association between age groups, smoking strata,
and groups at high and low risk of cardiovascular disease
were not addressed.7 Although an association between CRP
and the risk of stroke was observed in the Third National
Health and Nutrition Examination Survey, stroke cases were
self-reported, and the timing of events was not recorded.10
Levels of CRP were also undetectable in 71% of the study
participants.
Findings of a stronger relation between CRP levels and the
risk of stroke in low- versus high-risk groups in the Honolulu
Heart Program are also consistent with other reports. As with
stroke, similar effects of CRP on myocardial infarction were also
observed in the Honolulu Heart Program.23 Here, adverse effects
were stronger in middle-aged men, in men without hypertension
or diabetes, and in those who were nonsmokers. Although small
sample sizes could have weakened the capacity to detect effects
in higher-risk individuals, others have described strong relations
between CRP and cardiovascular disease in nonsmoking women
and in women without hypertension or diabetes as well.8
Findings from the Framingham Study also describe stronger
associations in women than in men for the combined events of
ischemic stroke and transient ischemic attack.9
The weaker association in older or less healthy men could
have several explanations. Although inflammation may still be
important, in the presence of other risk factors, a high risk of
stroke could mask any residual (and perhaps weaker) effects of
inflammation. Even in the absence of important cardiovascular
conditions, stroke can still occur.24 In such cases, effects of
isolated processes, such as inflammation, may be more apparent
in disease progression.
Regardless of susceptibility, mechanistic derangements by
which CRP is associated with the long-term incidence of
atherosclerotic disease are not clear. Inflammatory mediators
and products have been associated with cellular proliferation,
lipid accumulation, and thrombosis. Markers of low-level in-
flammation, such as CRP, may reflect activity in any of these
systems.25,26 Levels of CRP may also be directly related to
processes of pathophysiology through complement activation
TABLE 4. Estimated Age-Adjusted and Risk Factor–Adjusted Relative Odds of
Thromboembolic Stroke for Men in the Top vs Bottom Quartiles of CRP
Age-Adjusted Risk Factor–Adjusted*
Risk Strata Relative Odds Test for Trend (P) Relative Odds Test for Trend (P)
Follow-up period, y
0 to 5 1.1 (0.5 to 2.2)† 0.573 0.8 (0.4 to 1.7) 0.861
5 to 10 2.5 (1.1 to 5.9) 0.021 1.9 (0.8 to 4.6) 0.124
10 to 15 3.8 (1.7 to 8.3) 0.001 2.6 (1.1 to 5.8) 0.010
15 to 20 2.5 (1.2 to 5.1) 0.010 1.8 (0.9 to 3.8) 0.144
Overall 2.3 (1.6 to 3.3) 0.001 1.6 (1.1 to 2.4) 0.008
Age, y
48 to 55 3.8 (1.8 to 8.0) 0.001 3.0 (1.4 to 6.4) 0.018
56 to 70 1.8 (1.2 to 2.9) 0.001 1.3 (0.8 to 2.0) 0.076
Hypertension
Absent 2.1 (1.4 to 3.3) 0.001 1.6 (1.0 to 2.6) 0.019
Present 1.3 (0.6 to 2.7) 0.128 1.3 (0.6 to 2.7) 0.221
Diabetes
Absent 2.5 (1.6 to 3.9) 0.001 1.7 (1.0 to 2.7) 0.006
Present 1.5 (0.8 to 3.0) 0.258 1.4 (0.7 to 2.8) 0.580
Smoking status
Never 6.1 (2.5 to 14.8) 0.001 5.8 (2.3 to 14.4) 0.001
Past 1.2 (0.5 to 2.6) 0.508 0.8 (0.3 to 1.8) 0.520
Current 1.6 (1.0 to 2.6) 0.052 1.3 (0.8 to 2.2) 0.152
*Adjusted for total cholesterol, body mass index, alcohol intake, physical activity index, and the
other risk factors in this table.
†95% confidence interval.
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and tissue factor expression. Although reports are conflicting, it
is possible that CRP reflects reactions to infectious agents that
have been associated with atherosclerotic diseases.27 Observa-
tions in the Honolulu Heart Program that show a greater
frequency of smoking cessation in men in the bottom quartile of
CRP (where the risk of stroke is low) versus the top quartile
additionally suggest that inflammation may be reversible. Smok-
ing cessation in individuals with an elevated CRP may also be an
effective strategy for improving CRP levels and reducing the
adverse effects of inflammation.
Among the strengths of the present study, there are also
limitations. For example, the Honolulu Heart Program is entirely
composed of men of Japanese ancestry. Extensions to other
groups could be important. Findings in Framingham and the
Women’s Health Study suggest that associations in men are
likely to apply to women.8,9 In general, the relative risk of stroke
that is associated with most risk factors in Honolulu is similar to
the relative risk observed in other population-based samples.28,29
Levels of CRP also fall within the range of values reported
elsewhere. In some instances, average values are higher,9,10
whereas in others they are lower.3,5,7,8 Overall increases in the
risk of stroke and transient ischemic attacks in Framingham men
and in men in the Physician’s Health Study in the top versus
bottom quartiles of CRP are also similar to those found in
Hawaii.7,9
Although elevated levels of CRP seem to be related to an
increased risk of TE stroke in middle-aged men and in those free
of important cardiovascular risk factors, it remains to be deter-
mined if the measurement of CRP in cigarette smokers or in
those with hypertension or diabetes can provide additional
prognostic information. Whether CRP levels can be used as a
clinical screen to identify an increased risk of cardiovascular
disease in otherwise healthy adults also warrants additional
consideration.
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Elevated C-Reactive Protein Levels
in Overweight and Obese Adults
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ADIPOSE TISSUE PREVIOUSLY WASconsidered a passive storagedepot for fat but is nowknown to play an active role
in metabolism.1,2 Among the recently
discovered compounds expressed in
human adipose tissue is the proinflam-
matory cytokine interleukin 6 (IL-6).3,4
Moreover, IL-6 produced in the adi-
pose tissue of healthy humans is re-
leased into the circulation.4,5 Adipose
tissue is estimated to produce about
25% of the systemic IL-6 in vivo.4 Be-
cause of the inflammatory properties of
IL-6, including the stimulation of acute-
phase protein production in the liver,6,7
the release of IL-6 from adipose tissue
may induce low-grade systemic inflam-
mation in persons with excess body fat.
A sensitive marker for systemic in-
flammationis theacute-phaseC-reactive
protein(CRP).Inameta-analysisof7pro-
spectivestudies,elevatedserumCRPcon-
centration was shown to predict future
riskofcoronaryheartdisease.8 C-reactive
proteinlevelswellbelowtheconventional
clinicalupper limitofnormalof1mg/dL
have been associated with a 2- to 3-fold
increase in riskofmyocardial infarction,
ischemic stroke, peripheral arterial dis-
ease, and coronary heart disease mortal-
ity in healthy men and women.9-13
This study testedwhetheroverweight
andobesityareassociatedwithlow-grade
systemic inflammation as measured by
serum CRP concentration.
METHODS
Survey Design and Data Sources
The study included 16 616 adult par-
ticipants of the Third National Health
and Nutrition Examination Survey
(NHANES III), 1988-1994. NHANES III
was conducted by the National Center
for Health Statistics of the Centers for
Disease Control and Prevention.14 The
survey had a complex, stratified, mul-
tistage probability-cluster design for se-
lecting a sample of approximately
40 000 persons representative of the
noninstitutionalized civilian US popu-
lation. Children younger than 5 years,
persons aged 60 years or older, Mexi-
can American persons, and non-
Hispanic blacks were sampled at higher
rates than others. Eighty-one percent
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Context Human adipose tissue expresses and releases the proinflammatory cyto-
kine interleukin 6, potentially inducing low-grade systemic inflammation in persons
with excess body fat.
Objective To test whether overweight and obesity are associated with low-grade
systemic inflammation as measured by serum C-reactive protein (CRP) level.
Design and Setting The Third National Health and Nutrition Examination Survey,
representative of the US population from 1988 to 1994.
Participants A total of 16 616 men and nonpregnant women aged 17 years or older.
Main Outcome Measures Elevated CRP level of 0.22 mg/dL or more and a more
stringent clinically raised CRP level of more than 1.00 mg/dL.
Results Elevated CRP levels and clinically raised CRP levels were present in 27.6% and
6.7% of the population, respectively. Both overweight (body mass index [BMI], 25-29.9
kg/m2) and obese (BMI, $30 kg/m2) persons were more likely to have elevated CRP
levels than their normal-weight counterparts (BMI, ,25 kg/m2). After adjustment for
potential confounders, including smoking and health status, the odds ratio (OR) for el-
evated CRP was 2.13 (95% confidence interval [CI], 1.56-2.91) for obese men and 6.21
(95% CI, 4.94-7.81) for obese women. In addition, BMI was associated with clinically
raised CRP levels in women, with an OR of 4.76 (95% CI, 3.42-6.61) for obese wom-
en. Waist-to-hip ratio was positively associated with both elevated and clinically raised
CRP levels, independent of BMI. Restricting the analyses to young adults (aged 17-39
years) and excluding smokers, persons with inflammatory disease, cardiovascular dis-
ease, or diabetes mellitus and estrogen users did not change the main findings.
Conclusion Higher BMI is associated with higher CRP concentrations, even among
young adults aged 17 to 39 years. These findings suggest a state of low-grade sys-
temic inflammation in overweight and obese persons.
JAMA. 1999;282:2131-2135 www.jama.com
For editorial comment see p 2169.
©1999 American Medical Association. All rights reserved. JAMA, December 8, 1999—Vol 282, No. 22 2131
 on January 26, 2008 www.jama.comDownloaded from 
of all eligible adults consented to an ini-
tial interview in their household. Of the
20 050 persons aged 17 years or older
who were interviewed, 18 162 were
subsequently examined in a mobile ex-
amination center or in their homes. Per-
sons with missing data on height, body
weight, or serum CRP level (n = 1239)
and pregnant women (n = 307, vali-
dated by urine pregnancy test) were ex-
cluded, leaving 16 616 persons (7938
men and 8678 women) available for the
statistical analyses.
Body weight and height were
measured using standardized proce-
dures.15 Body mass index (BMI) was cal-
culated as weight in kilograms divided
by the square of height in meters and
used as an indicator of body fat.16,17 The
1998 clinical guidelines18 were used to
define overweight (BMI, 25-29.9 kg/m2)
and obesity (BMI $30 kg/m2).
Waist circumference was measured
at the level of the high point of the iliac
crest and the circumference at the level
of maximum extension of the but-
tocks.15 The waist-to-hip ratio, calcu-
lated as waist circumference divided by
hip circumference, was used as an in-
dicator of abdominal visceral fat.19
Serum specimens for the measure-
ment of CRP were stored at −70°C and
analyzed within 2 months after phle-
botomy. C-reactive protein was ana-
lyzed using a modification of the Beh-
ring Latex-Enhanced CRP assay on the
Behring Nephelometer Analyzer Sys-
tem (Behring Diagnostics, Westwood,
Mass) (M.H.W., Phyllis R. Daum, MT
[ASCP], G.M.M., unpublished data,
1999). Both within- and between-assay
quality control procedures were used and
the coefficient of variation of the method
was 3.2% to 16.1% through the period
of data collection. The assay could de-
tect a minimal CRP concentration of 0.22
mg/dL, and values below this level were
classified as undetectable. The assay was
designed primarily to detect inflamma-
tion and was included as part of the
NHANES III cohort to help detect in-
flammation as a confounding variable for
interpretation of nutrition markers. Be-
cause most individuals had values less
than the minimum detectable concen-
tration, CRP is treated as a categorical
rather than a continuous variable.
Race was defined by self-report as non-
Hispanic white, non-Hispanic black, or
Mexican American. People outside these
categories were classified as other. Smok-
ing status was based on self-report and
categorized as never, former, or current
smoking. All persons with a serum co-
tinine concentration of more than 57
nmol/L (10 ng/mL)20 as measured by
high-performance liquid chromatogra-
phy and atmospheric-pressure chemi-
cal ionization tandem mass spectros-
copy21 were categorized as current
smokers, irrespective of self-report. In-
flammatory disease prevalence was de-
termined through self-report of physi-
cian-diagnosed conditions (chronic
bronchitis, asthma, emphysema, and
rheumatoid arthritis) and self-report of
“having a cold” in the past few days. A
serum tube dilution latex fixation test for
rheumatoid factor was assessed in per-
sons aged 60 years or older.22 All per-
sons with a positive test result ($1:40
titer) were categorized as having rheu-
matoid arthritis or a related inflam-
matory disorder, irrespective of self-
report. Cardiovascular disease included
self-reported physician-diagnosed myo-
cardial infarction and stroke and an-
gina as assessed by the Rose Angina
Questionnaire.23 Diabetes mellitus was
defined as self-reported physician-
diagnosed diabetes mellitus with insu-
lin use or, in the case of undiagnosed dia-
betes mellitus, a fasting plasma glucose
level of at least 6.99 mmol/L (126
mg/dL).24,25 Estrogen use was based on
self-report, categorized as contracep-
tive medications (oral or implant) or es-
trogen replacement therapy.
Statistical Analyses
The study population was divided into
2 categories based on CRP concentra-
tion, undetectable (,0.22 mg/dL) and
elevated ($0.22 mg/dL). The popula-
tion was also divided into 2 categories
based on the conventional clinical cut
point for inflammation, a CRP concen-
tration of more than 1.00 mg/dL. Two
outcome variables were defined: el-
evated CRP level ($0.22 mg/dL), which
was compared with undetectable CRP,
and clinically raised CRP level (.1.00
mg/dL), which was compared with CRP
level of no more than 1.00 mg/dL. Within
each sex, the relationship between BMI
and CRP concentration category was ex-
amined by multiple logistic regression
analysis. We calculated odds ratios (ORs)
and 95% confidence intervals (CIs) for
BMI as a categorical variable according
to the clinical guidelines, with normal
weight (BMI ,25 kg/m2) as the refer-
ence category, and for BMI as a continu-
ous variable, expressed per 5-kg/m2
(about 1 SD) increment. Moreover, ORs
per SD increment of waist-to-hip ratio
(0.1 units) were calculated. Adjust-
mentsweremade forpotential confound-
ers, including age, race, smoking
status, estrogen use, inflammatory dis-
ease, and other diseases associated with
low-grade inflammation, including car-
diovascular disease8,26,27 and diabetes
mellitus.28 To assess potential effect
modification by age, smoking status, dis-
ease status, or estrogen use, the analy-
ses were repeated, restricted to young
(aged 17-39 years), healthy non–
estrogen-using nonsmokers. Odds ra-
tios do not approximate risk ratios when
the prevalence of the outcome variable
in the study population is greater than
10%.29 The calculated OR for elevated
CRP concentration therefore should not
be interpreted as a risk ratio. Analyses
were performed using SAS (SAS Insti-
tute Inc, Cary, NC) and SUDAAN (Re-
search Triangle Institute, Research Tri-
angle Park, NC) and incorporated
sampling weights to account for over-
sampling and nonresponse to the house-
hold interview and examination.30 Vari-
ance estimates were calculated with
SUDAAN, incorporating the complex
sampling design of NHANES III.30
RESULTS
ElevatedCRPlevels($0.22mg/dL)were
present in 21.8% of men and 33.1% of
women, and clinically raised CRP lev-
els (.1.00mg/dL) in4.4%and8.9%, re-
spectively. Other characteristics of the
study population are shown inTABLE 1.
With increasing BMI, the preva-
lence of elevated CRP level increased
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in both men and women (FIGURE).
However, with increasing BMI the
prevalence of clinically raised CRP level
increased among women only; the
prevalence was 4.0% (95% CI, 3.3%-
4.8%) in normal-weight women, 7.7%
(95% CI, 6.4%-9.4%) in overweight
women, and 20.2% (95% CI, 18.1%-
22.5%) in obese women.
Obese men were 2.13 times more
likelyandobesewomen6.21timesmore
likely to have elevated CRP levels com-
pared with their normal-weight coun-
terparts (TABLE 2). Per 1-SD increase in
BMI, men were 1.38 and women were
2.04 times more likely to have elevated
CRPlevels.Amongwomen,BMIwasalso
associatedwithclinicallyraisedCRPlev-
els.Obesewomenwere4.76 timesmore
likely to have clinically raised CRP lev-
elscomparedwithnormal-weightwom-
en. Per 1-SD increment in BMI, wom-
en were 1.69 times more likely to have
clinically raised CRP levels.
The waist-to-hip ratio was indepen-
dently associated with both elevated and
clinically raised CRP levels in men and
women. Per 1-SD increase in waist-to-
hip ratio, men were 1.41 and women
were 1.21 times more likely to have el-
evated CRP levels (Table 2). The OR for
clinically raised CRP levels per 1-SD in-
crease in waist-to-hip ratio was 1.36 in
men and 1.28 in women.
The association between BMI and
CRP was also investigated after stratifi-
cation by age group (young = 17-39
years; middle-aged = 40-59 years;
old = $60 years). Among women, the
association between BMI and CRP cat-
egories was influenced by age group.
Older obese women were less likely to
have elevated or clinically raised CRP
levels than young obese women. A simi-
lar effect modification by age group in
women was observed using BMI as a cat-
egorical variable. No effect modifica-
tion by age group was observed in men.
To avoid any potential effect modi-
fication by age, inflammatory disease,
cardiovascular disease, diabetes melli-
tus, current smoking, or estrogen use,
the analyses were repeated restricted to
healthy, nonsmoking, non–estrogen-
using persons aged 17 to 39 years. The
positive association between BMI cat-
egory and elevated CRP level re-
mained statistically significant after ad-
justment for age, race, smoking status
(never and former smoking only), and
waist-to-hip ratio (TABLE 3). In this re-
stricted analysis, BMI also remained
positively associated with clinically
raised CRP levels among women.
COMMENT
Previous studies in middle-aged and el-
derly persons have reported a positive
association between BMI and CRP con-
centration.12,26,27 However, in these age
groups, the association may have been
confounded by disease. Rheumatoid ar-
thritis, diabetes mellitus, and cardio-
vascular disease are prevalent diseases
Figure. Prevalence of Elevated
($0.22 mg/dL) Serum C-Reactive Protein
Concentration by BMI Category in Men
and Women Aged 17 Years or Older
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Normal weight was considered a body mass index
(BMI) of less than 25 kg/m2; overweight, 25 to 29.9
kg/m2; and obese, 30 kg/m2 or more. The preva-
lence of clinically raised (.1.00 mg/dL) serum C-
reactive protein concentration is indicated in black.
Table 1. Characteristics of Study Population*
Men Women
Sample size, No. 7938 8678
Age, y
17-39 50.4 45.6
40-59 30.6 30.4
$60 19.0 24.0
Race
Non-Hispanic white 76.7 76.1
Non-Hispanic black 9.9 11.3
Mexican American 5.7 4.6
Other 7.7 8.0
Body mass index, kg/m2
,25 (normal) 41.9 50.1
25.0-29.9 (overweight) 38.8 25.6
$30 (obese) 19.3 24.3
C-reactive protein level, mg/dL
#0.21 (undetectable) 78.2 66.9
0.22-1.00 (elevated) 17.4 24.2
.1.00 (clinically raised) 4.4 8.9
Smoking status
Never 37.5 54.9
Former 27.9 18.9
Current 34.6 26.2
Disease
Inflammatory disease† 23.6 29.6
Cardiovascular disease‡ 7.4 7.3
Diabetes mellitus 6.1 5.8
Estrogen use
None . . . 80.3
Contraceptive . . . 11.0
Hormone replacement . . . 8.7
Waist-to-hip ratio, mean (SE) 0.95 (0.00) 0.86 (0.00)
*All data are expressed as percentages unless noted. Ellipses indicate data not applicable.
†Includes current cold, asthma, emphysema, chronic bronchitis, and rheumatoid arthritis.
‡Includes angina, myocardial infarction, and stroke.
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in older persons and are associated with
both obesity31-33 and increased CRP con-
centrations.8,26-28,34 We carefully con-
trolled for inflammatory disease and
other factors known to influence CRP
concentrations. A higher prevalence of
low-grade systemic inflammation was
observed in overweight and obese per-
sons compared with normal-weight per-
sons. Most importantly, our study ex-
tends these findings to young adults
aged 17 to 39 years, in whom the preva-
lence of any confounding subclinical
disease is generally very low. Of inter-
est is our observation that the distri-
bution of body fat is associated with
CRP concentration independent of BMI.
A high waist-to-hip ratio, indicative of
a large amount of abdominal visceral
fat, was associated with low-grade sys-
temic inflammation in men and women.
Ourresults, togetherwiththeevidence
of previous studies, have important im-
plications for the health risks of over-
weight andobese individuals, including
those at young ages. Based on NHANES
III data, we estimated that 53.9% of US
adults aged 17 years or older are over-
weight or obese. Overweight, obesity,
anda largewaist-to-hip ratioposeacon-
siderable health risk, including cardio-
vascularhealth.33,35-37Low-gradesystemic
inflammationhasbeenshowntoincrease
the risk for cardiovascular disease.9-13
Someof the increasedrisk forcardiovas-
cular disease in overweight and obese
persons may be explained by our obser-
vationthatincreasedCRPconcentrations
are more prevalent in these persons.
C-reactive protein concentrations well
below the conventional clinical upper
limit of normal of 1 mg/dL have been as-
sociated with a 2- to 3-fold increase in
risk of myocardial infarction, ischemic
stroke, and peripheral arterial disease in
healthy men and women.9-13 In addi-
tion, elevated CRP levels are predictive
of cardiac complications in patients with
unstable angina or myocardial infarc-
tion38,39 and CRP induces the produc-
tion of tissue factor, a potent procoagu-
lant, in monocytes.40 Moreover, elevated
CRP concentrations are associated with
increased coronary heart disease mor-
tality and total mortality.9,41
Approximately 25% of circulating IL-6
is estimated to be released by human sub-
cutaneous adipose tissue in vivo,2 and
IL-6 stimulates the production of acute-
phase proteins in the liver.6,7 This might
explain the observed associations be-
tween BMI and CRP. In vitro, human ab-
dominal visceral adipose tissue releases
more IL-6 compared with subcutane-
ous adipose tissue,5 possibly explaining
our observation that a higher waist-to-
hip ratio, after adjustment for BMI and
several confounders, was indepen-
dentlyassociatedwithelevatedCRPlevel.
Body mass index is an important
clinical indicator of overweight and obe-
sity,18 but its use as an indicator of body
fatness has limitations. At a similar BMI,
women have more body fat than men.42
This difference was reflected in our data,
showing a higher prevalence of el-
evated and clinically raised CRP levels
in women compared with men in over-
weight and obese persons (Figure). The
higher prevalence of elevated and clini-
cally raised CRP levels among obese
women compared with obese men
could also be due to by the fact that
women were more likely to be ex-
tremely obese: a BMI of 35 to 40 kg/m2
was prevalent among 3.4% of men and
6.4% of women, and a BMI of 40 kg/m2
or more was present among 1.7% of
men and 3.6% of women. Both phe-
nomena might also explain why BMI
was associated with clinically raised
CRP levels in women but not men.
Persons with a normal body weight
(BMI ,25 kg/m2) were used as the ref-
erence group. However, this group in-
cluded a small percentage (1.3% of men
and 3.8% of women) of underweight
persons (BMI ,18.5 kg/m2) who might
be more likely to be in poor health, with
associated higher CRP concentra-
tions. However, when the analyses were
Table 2. Adjusted Odds Ratios (95% Confidence Intervals) for Elevated and Clinically Raised
Serum C-Reactive Protein (CRP) Concentrations in 16 616 Men and Women*
Elevated CRP Level
($0.22 mg/dL)†
Clinically Raised CRP Level
(.1.00 mg/dL)‡
Men Women Men Women
Body mass index, kg/m2
,25 (normal weight) 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
25-29.9 (overweight) 1.41 (1.09-1.81) 2.23 (1.86-2.67) 0.90 (0.54-1.51) 1.65 (1.19-2.28)
$30 (obese) 2.13 (1.56-2.91) 6.21 (4.94-7.81) 0.84 (0.49-1.41) 4.76 (3.42-6.61)
Per SD increment 1.38 (1.22-1.55) 2.04 (1.89-2.20) 1.08 (0.88-1.33) 1.69 (1.49-1.92)
Waist-to-hip ratio
per SD increment
1.41 (1.17-1.69) 1.21 (1.07-1.37) 1.36 (1.01-1.84) 1.28 (1.07-1.54)
*Data are adjusted for race, age, smoking status, inflammatory disease, cardiovascular disease, diabetes mellitus, es-
trogen use (women only), and each other.
†Compared with a CRP level of less than 0.22 mg/dL.
‡Compared with a CRP level of no more than 1.00 mg/dL.
Table 3. Adjusted Odds Ratios (95% Confidence Interval) for Elevated and Clinically Raised
Serum C-Reactive Protein (CRP) Concentrations in 3303 Young (Aged 17-39 Years),
Nonsmoking, Non–Estrogen-Using Men and Women Without Inflammatory Disease,
Cardiovascular Disease, or Diabetes Mellitus*
Elevated CRP Level
($0.22 mg/dL)†
Clinically Raised CRP Level
(.1.00 mg/dL)‡
Men Women Men Women
Body mass index, kg/m2
,25 (normal weight) 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
25-29.9 (overweight) 1.35 (0.59-3.11) 2.87 (1.47-5.58) 0.11 (0.01-1.03) 1.42 (0.36-5.64)
$30 (obese) 2.85 (1.33-6.10) 12.90 (5.61-29.65) 0.64 (0.09-4.68) 8.56 (2.09-34.95)
Per SD increment 1.61 (1.20-2.16) 2.46 (1.83-3.32) 1.17 (0.58-2.37) 2.26 (1.49-3.41)
Waist-to-hip ratio
per SD increment
1.59 (1.06-2.38) 1.76 (1.13-2.72) 2.26 (0.89-5.74) 1.43 (0.75-2.71)
*Data are adjusted for race, age, smoking status (never and former smoking), and each other.
†Compared with a CRP level of less than 0.22 mg/dL.
‡Compared with a CRP level of less than 1.00 mg/dL.
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repeated after exclusion of under-
weight people in the reference group,
similar results were obtained.
Because the lower detection limit of
the CRP assay was 0.22 mg/dL, serum
CRP level was used as a categorical vari-
able. It is unlikely that the use of a more
sensitive assay would have changed the
conclusions of the study. The associa-
tion between obesity and CRP concen-
tration was observed regardless of the
CRP cut point that was used ($0.22 or
.1.00mg/dL).Second,althoughthecut
pointof1.0mg/dLhasbeenusedinclini-
cal studies, more recent epidemiologi-
cal studieshave shownan increasedrisk
for cardiovascular disease at CRP levels
of 0.2 mg/dL and higher.9-13
We used a single CRP measurement
that may not accurately reflect long-
term inflammation status. The biologi-
cal variability of CRP is substantial, with
reported values ranging from 10.6% to
63.0%.43-46 However, because random
misclassification due to biological vari-
ability will lead to underestimation of
true associations, this limitation is un-
likely to explain our findings.
Measurements of the serum concen-
tration of IL-6 were not available in the
present study. Although the results sup-
port the hypothesis that IL-6 pro-
duced by the adipocytes increase CRP
concentration, direct assessment of IL-6
concentration is needed in future stud-
ies to further test this hypothesis.
In conclusion, the results of this
large-scale cross-sectional study show
that higher BMI is associated with
higher CRP concentrations that could
not be explained by inflammatory dis-
ease or other factors or diseases known
to increase CRP concentrations. Be-
cause these associations also were ob-
served among young adults aged 17 to
39 years, subclinical disease is un-
likely to explain our findings. These
data suggest that a state of low-grade
systemic inflammation is present in
overweight and obese persons.
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Rosuvastatin in the Primary Prevention of Cardiovascular Disease
Among Patients With Low Levels of Low-Density Lipoprotein
Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Rationale and Design of the JUPITER Trial*
Paul M Ridker, MD, MPH; on behalf of the JUPITER Study Group
Completed randomized trials of statin therapy demonstratethat 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-
CoA) reductase inhibitors reduce the risk of myocardial
infarction, stroke, and other cardiovascular events among
individuals with established coronary disease and overt hy-
perlipidemia.1–6 In aggregate, use of statin therapy in these
trials has been associated with an approximate 30% reduction
in cardiovascular event rates. Largely on the basis of these
cholesterol reduction trials, current treatment algorithms from
the National Cholesterol Education Program (NCEP) Adult
Treatment Panel III endorse the use of statins in secondary
prevention and encourage increased use of statins in primary
prevention among those with hyperlipidemia and diabetes.7
Unfortunately, despite evidence provided by the Air Force/
Texas Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS2) and the West of Scotland Coronary Prevention
Study (WOSCOPS3), use of statins for the primary prevention
of cardiovascular disease has not been widely adopted in a
cost-effective manner. From a clinical perspective, there are
several reasons for this slow adoption.
First, almost half of all cardiovascular events occur among
apparently healthy men and women who have normal or even
low levels of LDL cholesterol (LDL-C). Thus, better screen-
ing methods are needed in primary prevention to detect
high-risk individuals for whom the number needed to treat
(NNT) is small enough to make prophylactic statin therapy
cost effective. Second, there has been controversy within the
completed clinical trials suggesting that the benefits of statins
may extend beyond LDL-C reduction alone. In both the Heart
Protection Study of stable high-risk patients6 and the MIR-
ACL (Myocardial Ischemia Reduction with Aggressive Cho-
lesterol Lowering) study of patients with acute coronary
syndromes,8 the risk reduction associated with statin therapy
was almost identical among those with low as well those with
as high levels of LDL-C. Further, statin therapy reduces the
risk of stroke, yet LDL-C is not an important risk factor for
this disease.9,10
The Role of High-Sensitivity C-Reactive
Protein (hsCRP) in Cardiovascular Disease
In an effort to improve vascular risk detection, many physi-
cians screen for hsCRP, an inflammatory biomarker associ-
ated with a markedly increased risk of myocardial infarction,
stroke, peripheral arterial disease, and sudden cardiac death,
even among apparently healthy individuals with low levels of
LDL-C.11 To date, more than a dozen large-scale studies
demonstrate in aggregate that hsCRP levels are a strong,
independent predictor of future vascular events12–20 and that
hsCRP adds prognostic information on risk at all levels of
LDL-C, at all levels of the Framingham Risk Score, and at all
levels of the metabolic syndrome15,21–23 (Figure 1). Moreover,
hsCRP predicts risk of recurrent coronary events and has
important prognostic value in acute coronary ischemia and
after coronary interventions.24–30
As our understanding that atherothrombosis is fundamen-
tally an inflammatory disease has developed,31 so too has
evidence regarding CRP as a direct participant both in the
early initiation of atherosclerotic lesions and in the conver-
sion of stable to unstable plaques. In particular, evidence has
recently accumulated that shows CRP to be a direct partici-
pant in the atherothrombotic process capable of augmenting
the innate inflammatory response, triggering expression of
adhesion molecules and monocyte chemoattractant protein-1,
attenuating expression of endothelial NO synthase, inducing
plasminogen activator inhibitor-1, and having a direct effect
on arterial thrombosis32–37 (Figure 2).
On the basis of these data, an expert panel assembled by
the Centers for Disease Control and Prevention and the
American Heart Association provided the first guidelines for
use of inflammatory biomarkers in clinical practice in Janu-
ary 2003.38 This report confirmed the importance of hsCRP in
clinical risk detection and recommended use of hsCRP as part
of global risk prediction, particularly among those deemed at
“intermediate risk” by standard risk factors. One of the most
important groups likely to benefit from hsCRP evaluation is
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composed of those with normal or low levels of LDL-C. As
shown in Figure 3 in data from the large-scale Women’s
Health Study, apparently healthy individuals with low levels
of LDL-C but high levels of hsCRP are at higher absolute risk
of future vascular events than are those with high levels of
LDL-C but low levels of hsCRP.15 Such patients, however,
are not currently considered for statin therapy, as they have
LDL-C levels 130 mg/dL, the current treatment target in
primary prevention. Nonetheless, both experimental and clin-
ical studies indicate that statins may have direct anti-
inflammatory effects, and it is now established that statins
lower hsCRP levels on a population basis.39–41 Thus, it has
been hypothesized that hsCRP screening might provide a
method to improve the targeting of statin therapy, particularly
among those with low to normal levels of LDL-C.42
hsCRP, Statin Therapy, and the Prevention of
Cardiovascular Events
To address this issue, a hypothesis-generating study was
recently completed in which hsCRP levels were measured at
baseline among 5742 participants enrolled in AFCAPS/
TexCAPS, a randomized, double-blind, placebo-controlled
trial of lovastatin in the primary prevention of cardiovascular
events conducted among American men and women with
average cholesterol levels and below-average HDL choles-
terol levels.43 In that trial, lovastatin allocation was associated
with a 37% reduction in the primary clinical end point of fatal
or nonfatal myocardial infarction, hospitalization for unstable
angina, or sudden cardiac death. However, after measuring
baseline hsCRP as well as lipid levels in the AFCAPS/
TexCAPS population, several critical observations regarding
the efficacy of statin therapy in primary prevention were
observed.43
First, coronary event rates increased with entry hsCRP
levels such that the relative risks from lowest to highest
quartiles of baseline hsCRP among those allocated to placebo
were 1.0, 1.2, 1.3, and 1.7 (P0.01), an effect that was
independent of traditional risk factors included in the Fra-
mingham Risk Score.
Second, compared with placebo, allocation to lovastatin in
AFCAPS/TexCAPS resulted in a statistically significant re-
duction in median hsCRP levels at the end of the first year of
treatment (95% CI of the median, 17.4 to 12.5%,
P0.001); data were consistent with those of other statins.39–41
As also demonstrated in the Pravastatin INflammation CRP
Evaluation (PRINCE),41 this reduction in hsCRP was not
related to the effect of statin therapy on lipid levels.
Figure 1. hsCRP adds prognostic infor-
mation on vascular risk at all levels of
LDL-C (right) and at all levels of the Fra-
mingham Risk Score (left). Data are
derived from Ridker et al.11,15,21
Figure 2. Mechanisms relating
C-reactive protein (CRP) to development
and progression of the atherothrombotic
process. eNOS indicates endothelial NO
synthase; ET-1, endothelin-1; MCP-1,
monocyte chemoattractant protein-1;
and PAI-1, plasminogen activator
inhibitor-1.
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Third, and most importantly, there were major differences
in the observed efficacy of lovastatin when AFCAPS/Tex-
CAPS participants were stratified into 4 groups on the basis
of median LDL-C and median hsCRP levels43 (Table). As
expected, lovastatin was highly effective in preventing first
vascular events among participants with elevated levels of
LDL-C. However, lovastatin was also highly effective in
reducing coronary events among those with low LDL-C
levels but who had elevated levels of hsCRP, data that
suggest that statin therapy may well have efficacy in the
presence of systemic inflammation even in the absence of
hyperlipidemia. In fact, the low LDL-C/high hsCRP sub-
group in AFCAPS/TexCAPS had a risk of future vascular
events just as high as that observed in the subgroups with
overt hyperlipidemia. In marked contrast, event rates were
low among AFCAPS/TexCAPS participants with low LDL-C
and low hsCRP, a subgroup in which there was no evidence
that lovastatin reduced the risk of future cardiovascular
events. These hypothesis-generating data in primary preven-
tion parallel the data in secondary prevention from the
Cholesterol and Recurrent Events (CARE) trial that previ-
ously suggested that the benefit of statin therapy was greater
among those with elevated hsCRP levels.24
Since publication of the AFCAPS/TexCAPS43 and
CARE24 trial data for hsCRP, several clinical registries have
corroborated the observation that individuals with elevated
hsCRP levels benefit preferentially from the use of statins
both among those with angiographically severe coronary
disease44,45 and in the setting of percutaneous coronary
interventions and stent placement.46,47 Moreover, a number of
studies have suggested direct anti-inflammatory mechanisms
for statin therapy that appear largely independent of LDL
reduction.48–51 One recent study has shown a dose-response
relationship between statin therapy and hsCRP reduction that
was augmented by the addition of ezetimibe.52
For some physicians, these data have been interpreted as
evidence that hsCRP screening should be broadly applied and
that those with elevated levels of hsCRP should be placed on
statin therapy for the primary prevention of cardiovascular
events. It is critical to recognize, however, that observations
regarding hsCRP in both the AFCAPS/TexCAPS and CARE
trials were made on a post hoc basis and that the total number
of events within the low LDL-C/high hsCRP strata in each of
those studies was small. Thus, a large-scale, prospective,
placebo-controlled trial of statin therapy among individuals
without overt hyperlipidemia but with evidence of systemic
inflammation is needed to directly test this hypothesis.
The JUPITER Trial
Study Objectives
The primary objective of the JUPITER trial is to determine
whether long-term treatment with rosuvastatin (20 mg orally
per day) will reduce the rate of first major cardiovascular
events, defined as the combined end point of cardiovascular
death, stroke, myocardial infarction, hospitalization for un-
stable angina, or arterial revascularization among individuals
with LDL-C levels 130 mg/dL (3.36 mmol/L) who are at
high vascular risk because of an enhanced inflammatory
response as indicated by hsCRP levels 2 mg/L. Secondary
objectives of JUPITER are to evaluate the safety of long-term
treatment with rosuvastatin in terms of total mortality, non-
cardiovascular mortality, and adverse events and to determine
whether rosuvastatin reduces the incidence of type 2 diabetes.
This latter objective reflects the fact that hsCRP levels also
predict the onset of diabetes53 and that inflammation appears
to be a critical link between diabetes and atherothrombosis.54
Finally, on the basis of observational evidence regarding
statins, osteoporosis, and hypercoagulability, the JUPITER
trial will also determine whether rosuvastatin reduces the
incidence of bone fractures and venous thromboembolic
events.55,56
Figure 3. Cardiovascular event–free survival according to base-
line levels of LDL-C and hsCRP. Note that those with elevated
levels of hsCRP but low LDL-C (the target population for the
JUPITER trial) appear at higher vascular risk than those with
high LDL-C but low hsCRP. Data are derived from Ridker et al.15
Crude Event Rates, Relative Risks (RR), and the No. Needed to Treat (NNT) Associated With
Lovastatin Allocation Among AFCAPS/TexCAPS Participants, According to Baseline Levels of
LDL Cholesterol and hsCRP
Study Group
Lovastatin Placebo
RR 95% CI NNT*N Rate* N Rate*
Low LDLC/low hsCRP 19/726 0.025 17/722 0.022 1.08 0.56–2.08   
Low LDLC/high hsCRP 22/718 0.029 37/710 0.051 0.58 0.34–0.98 48
High LDLC/low hsCRP 15/709 0.020 37/711 0.050 0.38 0.21–0.70 33
High LDLC/high hsCRP 29/741 0.038 40/705 0.055 0.68 0.42–1.10 58
*Event rates and NNT calculated on the basis of 5 patient-years at risk. Data are derived from Ridker et al.43
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Study Population
The JUPITER trial will enroll up to 15 000 men age 55 years
and older and women age 65 years and older, who, on initial
screening, are found to have hsCRP 2 mg/L, LDL-C 130
mg/dL, and triglycerides 500 mg/dL (5.65 mmol/L), and
who have no history of myocardial infarction, stroke, arterial
revascularization, or coronary risk equivalent as defined by
current NCEP guidelines. Additional exclusion criteria are as
follows: current use of statins or other lipid-lowering thera-
pies, including fibrates, niacin, and bile-acid sequestrants;
known hypersensitivity to statin therapy; current use of
postmenopausal oral hormone therapy; current use of immu-
nosuppressants; active liver disease or elevated liver enzymes
(alanine aminotransferase [ALT] 2 times upper limit of
normal [ULN]); creatine kinase [CK] 3 times ULN; diabetes
mellitus (fasting serum glucose 126 mg/dL [7.0 mmol/L],
or use of insulin or oral hypoglycemic agent); uncontrolled
hypertension (systolic or diastolic blood pressure 190 or
100 mm Hg, respectively); history of cancer, except nonma-
lignant skin cancer, within the past 5 years; uncontrolled
hypothyroidism (thyroid-stimulating hormone 1.5 above
ULN); chronic inflammatory conditions such as severe ar-
thritis, lupus, or inflammatory bowel disease; history of
alcohol or drug abuse within the past year; and serious
medical or psychological conditions that may compromise
successful study participation.
Study Design
The overall design of the JUPITER trial is shown in Figure 4.
At the initial screening visit, informed consent will be sought,
a preliminary assessment of subject eligibility will occur, and
a fasting blood sample will be obtained for analysis of hsCRP
and lipid levels. At a second screening visit, a physical
examination and medical history focusing on cardiovascular
risk factors will be conducted, and fasting blood and urine
samples will be collected for further lipid analysis, hemato-
logic indices, creatinine, thyroid-stimulating hormone, ALT,
CK, glucose, and hemoglobin A1c. For participants who
provide additional consent, plasma and buffy coat samples
will be stored for future genomic and proteomic analyses
relating to lipid metabolism, inflammatory function, and
statin therapy. Eligible subjects will then be enrolled in a
4-week prerandomization run-in period designed to ensure a
group of study participants capable of long-term protocol
compliance.
Following the run-in period, participants will be randomly
assigned to either oral rosuvastatin (20 mg/d; supplied as
CRESTOR by AstraZeneca [Wilmington, Del]) or placebo
for a period of 3 to 4 years, the estimated time needed to
accrue the 520 cardiovascular end points on which the study
is powered. The dose of rosuvastatin selected should result in
50% reductions in LDL cholesterol57 as well as a substan-
tial reduction in hsCRP.
All study participants will visit the clinic sites for evalua-
tion at 3 and 6 months after randomization and thereafter at
6-month intervals for the duration of follow-up. At these
visits, staff will dispense study medication; assess compliance
with pill taking, the use of concomitant medications, and the
development of major illnesses, study end points, or adverse
effects; and collect fasting blood and urine samples to
evaluate changes in lipid and inflammatory parameters and to
monitor safety. Study medication will be discontinued among
subjects who develop myopathy (CK 10 times ULN and
muscle aches or weakness) or a persistent elevation in ALT
(3 times ULN on 2 consecutive tests). Subjects whose
blinded LDL-C levels rise to 130 mg/dL during the study
will be counseled to adopt lifestyle changes recommended by
the NCEP. If, after 3 months, LDL-C levels remain elevated
and the calculated Framingham Risk Score exceeds 10%
despite lifestyle changes, investigators will be encouraged to
consider lipid-lowering therapy with bile-acid sequestrants or
cholesterol-absorption inhibitors for those subjects. However,
if the responsible study physician believes statin therapy is
indicated, the study medication will be discontinued and
open-label statin therapy will be initiated. All subjects in
whom study medication is discontinued will be followed for
the duration of the trial and included in data analyses.
Data Analysis, Power, and Trial Organization
The primary end point under study is the first occurrence of
a major cardiovascular event defined as cardiovascular death,
stroke, myocardial infarction, hospitalization for unstable
angina, or arterial revascularization. Secondary end points are
total mortality, noncardiovascular mortality, diabetes melli-
tus, venous thromboembolic events, bone fractures, and
discontinuation of the study medication because of adverse
Figure 4. Overall design of the JUPITER
trial. CABG indicates coronary artery
bypass graft; CAD, coronary artery dis-
ease; CVD, cardiovascular disease;
HbA1c, hemoglobin A1c; LFTs, liver func-
tion tests; MI, myocardial infarction; and
PTCA, percutaneous transluminal coro-
nary angioplasty.
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effects. All primary analyses will be on an intention-to-treat
basis. Event rates for the rosuvastatin and placebo groups will
be compared using the proportional-hazards regression model
to adjust for variable length of follow-up.
Power estimates are based on the assumption of a mean
follow-up of 3.5 years, a placebo event rate of 1.5 per 100
patient-years at risk, and a net attrition rate of 5% per year.
Given a sample size of 15 000, the power of the trial to detect
a 25% reduction in risk of major vascular events associated
with rosuvastatin exceeds 90%.
The JUPITER trial was designed as an investigator-
initiated protocol from the Center for Cardiovascular Disease
Prevention at the Brigham and Women’s Hospital, Harvard
Medical School, Boston, Mass.42 Members of the JUPITER
Steering Committee are listed in Appendix A.
A fully independent 5-member Data and Safety Monitoring
Board has been established and will review unblinded safety
data at least twice yearly. Frequency of interim efficacy
analyses and rules for early trial termination have been
prespecified and approved by all members of this board
(listed in Appendix B).
What Will the JUPITER Trial Teach Us?
The JUPITER trial has been carefully designed to address a
critical unanswered question regarding inflammation, statins,
and atherothrombosis, as follows: Will statin therapy prevent
first-ever cardiovascular events among those with LDL-C130
mg/dL, but who are nonetheless at increased vascular risk
because of elevated levels of hsCRP? This issue is of exceptional
clinical importance, as half of all vascular events occur among
those with normal or even low levels of LDL-C. Within the
United States alone, as many as 25 to 30 million adults fall into
this potentially high-risk category. Thus, a strong positive
finding from JUPITER will dramatically affect public health and
prevention and would provide a clear rationale for much broader
use of statin therapy for the primary prevention of cardiovascular
events than currently endorsed. On the other hand, a negative
finding would also be of great importance, as it would direct the
use of scarce prevention resources to other nonstatin methods for
coronary risk reduction.
By using rosuvastatin, JUPITER will also be addressing
whether aggressive LDL-C reduction57 has efficacy in pri-
mary prevention among those with relatively low LDL-C
levels. However, because JUPITER is evaluating an agent
that dramatically lowers LDL-C as well as hsCRP, the
JUPITER trial will not directly answer whether CRP reduc-
tion alone leads to reduced vascular risk. This hypothesis will
require testing of agents with targeted vascular anti-
inflammatory effects that lack proven beneficial effects such
as LDL-C reduction.
Initial site recruitment for the JUPITER trial within the
United States and Canada began in mid-2003. Further infor-
mation on the JUPITER trial can be obtained at www.
JUPITERstudy.com or by calling (888) 660-8254.
Appendix A: JUPITER Steering Committee
(United States and Canada)
Paul M Ridker, Harvard Medical School (Study Chairman)
Antonio Gotto, Weill Medical College of Cornell University
Jacques Genest, McGill University
Peter Libby, Harvard Medical School
James Willerson, University of Texas
James Blasetto, Astra-Zeneca (nonvoting)
Appendix B: JUPITER Independent Data and
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Rory Collins, Oxford University (Chair)
Gervasio Lamas, Miami Heart Institute
Douglas Vaughan, Vanderbilt University
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C-Reactive Protein in Healthy Subjects: Associations With
Obesity, Insulin Resistance, and Endothelial Dysfunction
A Potential Role for Cytokines Originating From Adipose Tissue?
John S. Yudkin, C.D.A. Stehouwer, J.J. Emeis, S.W. Coppack
Abstract—C-reactive protein, a hepatic acute phase protein largely regulated by circulating levels of interleukin-6, predicts
coronary heart disease incidence in healthy subjects. We have shown that subcutaneous adipose tissue secretes
interleukin-6 in vivo. In this study we have sought associations of levels of C-reactive protein and interleukin-6 with
measures of obesity and of chronic infection as their putative determinants. We have also related levels of C-reactive
protein and interleukin-6 to markers of the insulin resistance syndrome and of endothelial dysfunction. We performed
a cross-sectional study in 107 nondiabetic subjects: (1) Levels of C-reactive protein, and concentrations of the
proinflammatory cytokines interleukin-6 and tumor necrosis factor-a, were related to all measures of obesity, but titers
of antibodies to Helicobacter pylori were only weakly and those of Chlamydia pneumoniae and cytomegalovirus were
not significantly correlated with levels of these molecules. Levels of C-reactive protein were significantly related to
those of interleukin-6 (r50.37, P,0.0005) and tumor necrosis factor-a (r50.46, P,0.0001). (2) Concentrations of
C-reactive protein were related to insulin resistance as calculated from the homoeostasis model assessment model, blood
pressure, HDL, and triglyceride, and to markers of endothelial dysfunction (plasma levels of von Willebrand factor,
tissue plasminogen activator, and cellular fibronectin). A mean standard deviation score of levels of acute phase markers
correlated closely with a similar score of insulin resistance syndrome variables (r50.59, P,0.00005), this relationship
being weakened only marginally by removing measures of obesity from the insulin resistance score (r50.53,
P,0.00005). These data suggest that adipose tissue is an important determinant of a low level, chronic inflammatory
state as reflected by levels of interleukin-6, tumor necrosis factor-a, and C-reactive protein, and that infection with
H pylori, C pneumoniae, and cytomegalovirus is not. Moreover, our data support the concept that such a low-level,
chronic inflammatory state may induce insulin resistance and endothelial dysfunction and thus link the latter phenomena
with obesity and cardiovascular disease. (Arterioscler Thromb Vasc Biol. 1999;19:972-978.)
Key Words: C-reactive protein n insulin resistance n obesity n endothelial dysfunction n interleukin-6
Inflammatory processes have important roles in the etiologyof coronary heart disease (CHD),1,2 but the mechanisms
underlying this relationship are poorly understood. Several
studies have shown that elevated plasma levels of fibrinogen,
C-reactive protein (CRP), and interleukin-6 (IL-6) are asso-
ciated with the risk of CHD and the severity of atherosclero-
sis.3–6 Whether these molecules play a causative role, or
simply act as markers of the acute phase reaction, is debat-
able. Elevated IL-6 levels have been reported in patients with
unstable angina where inflammatory processes may facilitate
the transition from the clinically stable to unstable atheroscle-
rotic plaques.6 However, it has also been shown that CRP
levels are associated with CHD in healthy subjects, both in a
cross-sectional study in general practice,7 and longitudinally
in the US Physicians Health Study,8 the MONICA-Augsburg
Cohort Study,9 and the MRFIT Study,10 where CRP levels
predicted cardiovascular events or CHD mortality during a
follow-up of between 2 and 17 years. These observations
imply that atheroma progression, as well as plaque rupture,
may be predicted by raised CRP levels. It has nevertheless
remained an issue of debate as to whether the relationship
between CRP and cardiovascular disease reflects inflamma-
tion in the vascular wall, perhaps because of chronic infec-
tions such as Chlamydia pneumonia,11 or inflammation orig-
inating in a more remote site, with secondary effects on the
vascular wall through cytokines and other mediators.
The synthesis of CRP by the liver is largely regulated by
IL-6.12 Although the activated leukocyte is widely assumed to
be the major source of circulating IL-6, with additional
contributions from fibroblasts and endothelial cells,12 novel
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observations from our laboratory have proposed a previously
unsuspected source for this cytokine. Using the technique of
arteriovenous difference measures across a subcutaneous
adipose tissue bed and radio-xenon measures of adipose
tissue blood flow, we have demonstrated IL-6 production by
human subcutaneous adipose tissue in vivo.13 The production
of IL-6, as well as systemic concentrations, increase with
adiposity, and we have estimated that '30% of total circu-
lating concentrations of IL-6 originate from adipose tissue in
healthy subjects.13 Both IL-6 and tumor necrosis factor-a
(TNF-a) are expressed in adipose tissue14,15 and in vitro
release of TNF-a by adipocytes has been reported.16 Among
the known effects of these cytokines are inhibition of insulin
signaling17 and induction of both hypertriglyceridemia18 and
endothelial activation.19
These observations have led us to explore the links of
levels of acute phase markers and concentrations of proin-
flammatory cytokines with two of their proposed determi-
nants, ie, obesity and chronic infection with 3 organisms
proposed to be related to risk of CHD.11,20–22 We have also
explored relationships of acute phase markers with features of
the insulin resistance syndrome23 and of markers of endothe-
lial dysfunction, ie, with the proposed consequences of a
chronic low-level inflammatory state.17,19 We hypothesized
that: (1) If adipose tissue were responsible for production of
proinflammatory cytokines, then circulating concentrations of
C-reactive protein and of proinflammatory cytokines would
be related to measures of obesity; (2) If IL-6 were responsible
for the metabolic and vascular consequences of obesity, then
measures of IL-6 and of CRP would relate to insulin
resistance syndrome and endothelial markers, independently
of measures of adiposity.
We have explored these relationships in a population of
107 healthy subjects in whom a large number of measures
had been assessed, recognizing that this size of study, and its
cross-sectional design, must, by its nature be hypothesis
generating. We have explored associations both between
individual measures of obesity, insulin resistance syndrome,
endothelial and acute phase activation, as well as between
predefined groups of these variables.
Methods
Subjects
We studied 107 white nondiabetic subjects as a follow-up investi-
gation of cardiovascular risk factors.24–28 In summary, we originally
investigated subjects aged 40 to 75 randomly selected from the
age-sex register of a north London general practice, and 36 (SD5)
months later restudied 125 of those with normal glucose tolerance. In
107 of the recall subjects, sufficient serum and plasma was available
to study a range of other variables, these being similar to the total
population in age, gender ratio, and levels of the risk factors under
investigation. The details of the study methods for anthropometry,
blood pressure, daytime and overnight albumin excretion rate,
cardiovascular disease history, and Minnesota code classification of
electrocardiograms have been described previously.26–28
Methods
Fasting blood from these 107 subjects was collected, spun at 2000g
for 15 minutes, and used for assay of total and HDL cholesterol,
triglycerides, insulin, proinsulin, des 32,32 proinsulin, plasminogen
activator inhibitor-1 (PAI-1) activity, and fibrinogen as previously
described,24–27 and for additional measures of endothelial and acute
phase markers and other related variables. Tumor necrosis factor-a
(TNF-a) and interleukin-6 (IL-6) were measured by ELISA (R&D
Systems). Thrombomodulin, von Willebrand factor, cellular fi-
bronectin,29 tissue plasminogen activator (tPA) antigen, PAI-1 anti-
gen, and C-reactive protein (CRP) were measured at the Gaubius
Laboratory, TNO-PG, Leiden, Netherlands. Thrombomodulin was
assayed using an ELISA kit (Stago)30; von Willebrand factor antigen
was measured by an ELISA essentially as described31 using poly-
clonal antibodies from DAKO; and cellular fibronectin was mea-
sured with a sandwich ELISA using a monoclonal antibody IST-9
(Harlan Sera Labs) against the ED-A domain for capture, and a
peroxidase-conjugated polyclonal fibronectin antibody (DAKO) for
detection. Tissue plasminogen activator and PAI-1 antigens were
measured by ELISA (Organon Teknika), which recognizes both free
forms of the factors and complexes of tPA with PAI-1. C-reactive
protein was measured using a highly sensitive ELISA procedure,32
with a range of 0.25 to 10.25 mg/mL and an interassay coefficient of
variation (CV) of 8%. Antibody titers to Helicobacter pylori were
measured using an enzyme immunoassay (Helico-G, Porton Cam-
bridge). C pneumoniae IgG antibody titers were determined by
ELISA according to a published method.33 Cytomegalovirus (CMV)
IgG titers were determined using a standard microtiter complement
fixation assay, using in-house CMV antigen prepared from the
AD169 strain of CMV. These assays were performed in the Depart-
ments of Microbiology and Virology, UCL Hospitals, London.
Insulin sensitivity was calculated using the homeostasis model
assessment (HOMA) model,34 a mathematical estimate of insulin
sensitivity based on fasting glucose and insulin concentrations.
Statistical Methods
Linear correlation was used to look at relationships between vari-
ables, with logarithmic transformation of skewed variables. Compar-
ison of groups was performed using unpaired Student’s t test.
Multiple regression analysis was used to explore the independence of
observed relationships between clusters of variables, with forced
entry of age, gender, smoking, and prevalent CHD, followed by the
standard deviation scores (see below) for the putative independent
variables. Data are presented as mean6SD or as median (interquar-
tile range) for skewed variables. Significance levels are shown for all
comparisons and relationships where P,0.05 although, because of
the number of tests being performed, a more rigorous criterion of
significance should be applied. Nevertheless, because the purpose is
to explore relationships of acute phase markers with obesity, insulin
resistance syndrome, and endothelial activation, another approach
has also been used.
To explore the association between predefined clusters of vari-
ables, we created mean standard deviation scores for insulin resis-
tance variables, endothelial markers, and acute phase markers for
each subject. This approach was taken to reduce the influences of
biological variability of each measure,35 which would make the usual
multivariate approach less suitable, as well as to reduce the number
of associations explored. We also preferred this approach to a formal
factor analysis, as we were interested in possible etiological relation-
ships between three predefined, and ostensibly distinct, groups of
variables. For each subject, each variable was expressed as standard
deviations of difference from the population mean, if necessary after
logarithmic transformation, a value that ranged from '22.5 to 2.5.
The mean scores were calculated as the mean of these standard
deviation scores as follows: (1) Insulin resistance score5{systolic
blood pressure1diastolic blood pressure1triglyceride1[HDL cho-
lesterol3(21)]1[insulin sensitivity3(21)]1body mass index
1waist-to-hip ratio1subscapular-to-triceps ratio}/8. (2) Endothelial
marker score5(thrombomodulin1cellular fibronectin1von Wille-
brand factor1mean albumin excretion rate)/4. (3) Acute phase
marker score5(fibrinogen1C-reactive protein1IL-61TNF-a)/4.
For some of the analyses, including those shown in Table 2, the
obesity variables were omitted from the insulin resistance score as
follows: {systolic blood pressure1diastolic blood pressure1triglyc-
eride1[HDL cholesterol3(21)]1[insulin sensitivity3(21)]}/5.
For some analyses we also derived an obesity score as a mean
standard deviation score: (body mass index1waist-to-hip
ratio1subscapular-to-triceps ratio)/3.
Where results were missing, for insulin (n52), albumin excretion
rate (n51), thrombomodulin (n510), or fibrinogen (n54), the mean
standard deviation scores were calculated for the smaller denomina-
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tor, but the relationships observed were almost identical if all data
from these subjects were omitted. Data for PAI-1 antigen were not
used as a component of the insulin resistance score because this
molecule is also an acute phase protein. Furthermore, tPA antigen
was excluded from the endothelial score because tPA circulates
partly bound to PAI-1, the complex being measured by the assay we
used.
Results
The characteristics of these middle-aged white subjects with
normal glucose tolerance are shown in Table 1. The low
levels of CRP are similar to those found in other healthy
populations.7,8
To explore the possible determinants of the acute phase
markers and of the levels of proinflammatory cytokines, we
explored their relationships with titers of IgG antibodies to 3
organisms which have been proposed as playing a potential
role in atherogenesis.11,20–22 Concentrations of C-reactive
protein correlated weakly with titers of H pylori, C pneu-
moniae, and cytomegalovirus antibodies (Table 2). However,
the only significant correlation seen between titers of such
antibodies and concentrations of cytokines was that of IL-6
with H pylori.
Both IL-6 and TNF-a are expressed in adipose tissue,14,15
and we have recently described the release of the former, but
not the latter, from a subcutaneous adipose tissue bed in
vivo.13 Concentrations of IL-6, TNF-a, and C-reactive pro-
tein were strongly related to measures of total, and particu-
larly central, obesity (Table 2).
Concentrations of CRP correlated both with those of IL-6
(r50.37, P,0.0005) and of TNF-a (r50.46, P,0.0001). In
Table 3 the relationships of concentrations of IL-6, TNF-a,
and C-reactive protein with the components of the insulin
resistance syndrome and with endothelial markers are shown.
Univariate correlations are given as these were little affected
by adjustment for age and gender. Concentrations of TNF-a
were related to all insulin resistance variables, including
proinsulin-like molecules, tPA, and PAI-1. Concentrations of
IL-6 were also related to several of the insulin resistance
syndrome and endothelial markers, including albumin excre-
tion rate, although the relationships for C-reactive protein
were generally stronger. Although there is a weak relation-
ship between concentrations of low-density LDL cholesterol
and those of CRP, no such relationships are seen with TNF-a
or IL-6.
The population was dichotomized into those with high and
those with low concentrations of CRP, based on the median
TABLE 1. Characteristics of Study Subjects
Number (M/F) 107 (59/48)
Age (y) 59.0610.9
Body mass index (kg/m2) 25.964.5
Waist-to-hip ratio 0.8660.08
Subscapular-to-triceps ratio 1.3160.59
Systolic blood pressure (mm Hg) 124.8618.4
Diastolic blood pressure (mm Hg) 80.4611.0
Triglyceride (mmol/L) 1.3 (1.0, 1.7)
HDL cholesterol (mmol/L) 1.3860.37
LDL cholesterol (mmol/L) 3.6261.05
Fasting plasma glucose (mmol/L) 4.860.5
2-h plasma glucose (mmol/L) 4.961.1
PAI-1 activity (AU/mL) 8.1 (4.2, 15.9)
PAI-1 antigen (ng/mL) 95.6658.9
tPA (ng/mL) 21.069.4
von Willebrand factor (%) 109.7640.9
Thrombomodulin (ng/mL) 33.7 (10.9, 121.3)
Cellular fibronectin (%) 108 (71, 159)
Mean albumin excretion rate (mg/min) 10.2 (7.0, 20.6)
Fibrinogen (mg/mL) 289.2675.9
CRP (mg/mL) 1.35 (0.57, 2.18)
TNF-a (pg/mL) 3.65 (2.98, 4.53)
IL-6 (pg/mL) 2.19 (1.18, 4.40)
Variables are presented as mean6SD, or as median (interquartile range) for
skewed variables.
TABLE 2. Relationships of Concentrations of Proinflammatory
Cytokines and C-reactive Protein With Antibody Titers
and Obesity
TNF-a§ IL-6§ CRP§
H pylori titer (n580) 0.18 0.28* 0.24*
C pneumoniae titer (n570) 0.21 0.15 0.25*
CMV titer (n580) 0.21 0.17 0.23*
Body mass index 0.33‡ 0.19* 0.41‡
Waist-to-hip ratio 0.51‡ 0.41‡ 0.32†
Subscapular-to-triceps ratio 0.37‡ 0.26† 0.21*
CRP 0.46‡ 0.37‡ –
Values are shown as Pearson correlation coefficients.
*P,0.05.
†P,0.01.
‡P,0.001.
§Data logarithmically transformed.
TABLE 3. Relationship of Concentrations of Proinflammatory
Cytokines and of C-Reactive Protein With Components of
Insulin Resistance Cluster and Endothelial Markers
TNF-a§ IL-6§ CRP§
Insulin sensitivity§ 20.35‡ 20.09 20.22*
Triglyceride§ 0.37‡ 0.03 0.27†
HDL cholesterol 0.27† 20.26† 20.21*
LDL cholesterol 0.08 0.04 0.25*
Systolic blood pressure 0.33‡ 0.31† 0.34‡
Intact proinsulin§ 0.33‡ 0.16 0.16
Des 31,32 proinsulin§ 0.28† 0.11 0.08
PAI-1 antigen 0.35‡ 0.18 0.19*
tPA antigen 0.40‡ 0.32† 0.40‡
von Willebrand factor 0.38‡ 0.11 0.31‡
Thrombomodulin§ 0.32† 20.05 0.13
Cellular fibronectin§ 0.36‡ 0.13 0.28†
Mean albumin excretion rate§ 0.25* 0.20* 0.07
Values are shown as Pearson correlation coefficients.
*P,0.05.
†P,0.01.
‡P,0.001.
§Data logarithmically transformed.
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value of 1.35 mg/mL (Table 4). Subjects with high concen-
trations of CRP were more obese than those with lower
levels, and had higher levels of blood pressure, triglyceride,
von Willebrand factor, cellular fibronectin, PAI-1, tPA, and
of the proinflammatory cytokines TNF-a and IL-6, but did
not differ in titers of antibodies to Helicobacter, Chlamydia,
or cytomegalovirus.
To overcome the problems of biological variability of the
different measures, and to explore these inter-relationships
further while controlling for potential confounds, we used
summary scores for the insulin resistance syndrome variables,
for endothelial dysfunction, and for acute phase markers by
calculating a mean of a standard deviation score for each
group of variables (see Methods). The relationships of these
are shown in Figure 1. Whereas the insulin resistance syn-
drome and endothelial scores correlate with a coefficient of
0.32 (P50.0008), there is a strong relationship between the
insulin resistance syndrome and acute phase scores (r50.59,
P,0.00005). The third of these correlations, between endo-
thelial and acute phase scores, is also significant (r50.43,
P,0.00005). A sum obesity score correlated with measures
of both endothelial (r50.33, P50.001) and acute phase
(r50.54, P,0.0005) scores. Nevertheless, if the 3 measures
of obesity are removed from the insulin resistance syndrome
score, the relationship with the acute phase score was only
slightly weakened (r50.53, P,0.00005). Moreover, the
strength of the relationship was not substantially affected by
omitting any particular variable from either score. In multiple
regression models, controlling for age, gender, smoking, and
prevalent CHD, if the acute phase and endothelial scores were
included in the same model, the former remained signifi-
cantly associated with insulin resistance syndrome score
(partial r50.61, P,0.00005), but not the latter (partial
r520.02, P50.82). We have also approached the analysis of
clustering of the variables using factor analysis, with gener-
ally similar results. The insulin resistance variables associate
as two clusters, one comprising altered lipid concentrations
with central obesity, and the other blood pressure with body
mass index. Although both clusters correlate with acute phase
markers, it is the second that relates more closely to endo-
thelial dysfunction (data not shown).
Discussion
There has been much interest in the prognostic significance of
raised levels of C-reactive protein in patients with angina,36
with the proposal that it points to release of IL-6 by activated
macrophages in an unstable plaque.37 More recently, how-
ever, the observations that raised concentrations of CRP in
TABLE 4. Characteristics of Subjects With Low (<1.35 mg/mL) and High (>1.35 mg/mL) of
C-Reactive Protein
Low CRP High CRP P
Number (M/F) 53 (27/26) 54 (32/22) 0.38
Age (y) 55.9611.0 62.169.9 0.003
Smokers (non/ex/current) 37/3/13 26/6/22 0.17
Body mass index (kg/m2) 24.364.0 27.564.5 ,0.001
Waist-to-hip ratio 0.8460.08 0.8960.07 0.001
Subscapular-to-triceps ratio 1.1560.51 1.4760.62 0.004
H pylori titer 1/,10 (1/,10, 1/48) 1/24 (1,10, 1/70) 0.57
C pneumoniae titer 1/100 (1,100, 1/400) 1/200 (1/,100, 1/200) 0.55
Cytomegalovirus titre 1/20 (1/,5, 1/80) 1/40 (1/10, 1/80) 0.11
Insulin (pmol/L) 21.4 (14.4, 42.9) 32.8 (19.1, 46.0) 0.032
Insulin sensitivity (HOMA) (%) 107.6 (55.9, 165.6) 73.8 (51.0, 127.6) 0.027
Systolic blood pressure (mm Hg) 118.7615.7 130.8618.9 0.001
Diastolic blood pressure (mm Hg) 77.7611.0 83.0610.3 0.011
Triglyceride (mmol/L) 1.2 (0.9, 1.6) 1.35 (1.18, 1.93) 0.036
HDL cholesterol (mmol/L) 1.4460.39 1.3360.35 0.14
Fasting plasma glucose (mmol/L) 4.860.4 4.860.5 0.40
PAI-1 activity (AU/mL) 6.5 (3.6, 12.2) 10.7 (4.8, 17.2) 0.051
PAI-1 antigen (ng/mL) 83.4655.1 107.6660.5 0.033
tPA (ng/mL) 17.168.6 24.968.6 ,0.001
von Willebrand factor (%) 101.5637.8 117.8642.6 0.038
Thrombomodulin (ng/mL) 33.2 (27.7, 39.6) 34.8 (28.1, 41.1) 0.35
Cellular fibronectin (%) 84.0 (62.0, 138.5) 130.0 (83.3, 178.5) 0.001
Mean albumin excretion rate (mg/min) 10.8 (7.3, 19.4) 9.6 (6.8, 21.6) 0.34
Fibrinogen (mg/mL) 275.2668.7 301.8680.4 0.22
TNF-a (pg/mL) 3.18 (2.63, 3.69) 4.12 (3.58, 5.06) ,0.001
IL-6 (pg/mL) 1.35 (0.89, 3.11) 3.22 (1.79, 5.39) ,0.001
Variables are presented as mean6SD, or as median (interquartile range) for skewed variables.
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healthy subjects predicted the incidence of CHD over a
period of years8–10 have suggested a role for inflammation in
the initiation of atherosclerosis as well as in the precipitation
of an acute event. The synthesis of CRP is predominantly
under the control of IL-6,12 which in turn has been assumed
to originate largely from activated leukocytes, either in the
vessel wall itself or at a remote site of infection.2,11 We found
that concentrations of C-reactive protein were related to titers
of IgG antibodies, evidence of previous infection, for each of
the 3 organisms we investigated. However, the correlations
between these antibody titers and concentrations of fibrino-
gen, TNF-a, and IL-6 were weaker and generally insignifi-
cant. In this study, Chlamydia antibodies were measured
using an ELISA method, and it is possible that antibody titers
by an immunofluorescence assay would have been more
closely related to markers of inflammation.11,38
We have found close relationships between circulating
CRP and cytokine concentrations and each of the anthropo-
metric measures of obesity, compatible with an adipose tissue
origin for TNF-a and IL-6. Mendall et al have previously
shown associations of circulating concentrations of CRP,7
and of TNF-a,39 but not of IL-6,39 with BMI, and the
relationship of CRP levels with obesity were also noted in the
MRFIT cohort,10 and, among nonsmokers, in the Cardiovas-
cular Health Study.40 By contrast, we found no significant
influence of smoking status on the relationships between
acute phase markers and obesity. Both cytokines are ex-
pressed in, and released by, adipose tissue.13–16 We have
recently reported significant in vivo release of IL-6, but not
TNF-a, by a subcutaneous adipose tissue depot.13 However,
the relationships of circulating concentrations of TNF-a with
obesity suggests that adipose tissue, perhaps in other sites,
may contribute to circulating levels. Alternatively, the ex-
pression of one of the TNF-a soluble receptors by adipose
tissue41 raises the possibility that the circulating cytokine is in
the form of a complex, the relationships with measures of
obesity representing secretion of the soluble receptor. Even if
free, it is likely that the presence of this cytokine in the
circulation represents spillover from the interstitial compart-
ment in adipose tissue, and perhaps from adipocytes within
muscle.
We report a relationship between circulating concentra-
tions both of CRP and of two proinflammatory cytokines with
a number of features of the insulin resistance syndrome,23
reflecting our previous report of a relationship between
fibrinogen concentrations and measures of insulin resis-
tance.25 Although relationships of CRP levels with triglycer-
ides, HDL, glucose, and diabetes have been noted previous-
ly,7,40 no such relationship appears to have been reported with
insulin concentrations or measures of insulin resistance. It is
clearly not possible, in a cross-sectional study, to attribute
causality to one of a set of correlated variables, but we have
explored some hypotheses in this setting. The relationship
between elevated concentrations of CRP and of the proin-
flammatory cytokines with the insulin resistance syndrome
could represent associations produced by a confounding
variable, such as adiposity. However, the relationships be-
tween a derived insulin resistance syndrome standard devia-
tion score and one for the acute phase variables was only
slightly weakened by removing all obesity measures from the
former score. We also excluded PAI-1 from the calculation of
an insulin resistance score, both because the measure of
antigen may represent inactive PAI-1 (complexed to tPA or
released from platelets), and also because PAI-1 is recognized
to respond to acute phase stimuli.
Our observations could suggest that the cytokines, arising
in part from adipose tissue, might themselves be partly
responsible for the metabolic, hemodynamic, and hemostatic
abnormalities that cluster with insulin resistance. Although
not itself an inducer of acute phase proteins, TNF-a induces
production of IL-6,42 which is itself the major determinant of
the acute phase response.12 Among the known metabolic
effects of TNF-a are inhibition of the action of lipoprotein
lipase43 and stimulation of lipolysis,18 these actions being
shared with IL-6.44,45 Furthermore, TNF-a impairs the func-
tion of the insulin signaling pathway by effects on phosphor-
ylation of both the insulin receptor and its substrate,
IRS-1.17,46
In addition to their associations with insulin resistance
syndrome variables, elevated levels of CRP and of cytokines
were associated with a series of indicators of endothelial
dysfunction. Tracy et al have previously reported associations
of levels of CRP with a variety of measures of procoagulant
activity and fibrinolysis,40 and have suggested that these
represent consequences either of inflammation in underlying
atherothrombotic disease or of inflammatory cells activated
by products of ongoing coagulation processes. TNF-a is
known to influence endothelial cell function,19,47 and a recent
study suggests that IL-6 may also induce endothelial expres-
sion of chemokines and adhesion molecules in the presence
of IL-6 soluble receptor, which is released in inflammatory
states.48 If endothelial dysfunction, perhaps as a consequence
of elevated concentrations of cytokines, resulted in impair-
(a) The relationship between a derived score of insulin resis-
tance variables and a score for measures of endothelial dys-
function. (b) The relationship between a derived score of insulin
resistance variables and a score for acute phase markers and
proinflammatory cytokines. For the derivation of these scores,
see Methods.
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ment of vasodilatation of resistance vessels,49 it could be
postulated that the cluster of variables that have been attrib-
uted to insulin resistance (dyslipidemia, hypertension, and
impaired fibrinolysis), as well as insulin resistance itself,
might all result as consequences of a common antecedent.
The strong relationship between concentrations of C-reactive
protein and insulin resistance variables (Table 3), compared
with those seen for IL-6, may simply reflect the longer
half-life of C-reactive protein providing a more stable marker
of acute phase mediators. Levels of C-reactive protein are
predominantly modulated by hepatic effects of IL-6,12 which
suggests a more important role for this cytokine in the cluster
than suggested by the correlations shown in Table 3. If
circulating TNF-a represents spillover from adipose tissue
and muscle, where the local concentrations would be more
likely to approximate to those required to exert metabolic
effects in vitro,50,51 this might imply autocrine or paracrine,
and not endocrine, metabolic effects of TNF-a. Adipose
tissue release of IL-6, also induced by TNF-a,42 may then be
responsible for systemic effects on endothelium48 and
lipids.44,45
In conclusion, we have shown, in healthy subjects, rela-
tionships between levels of CRP and measures of obesity,
consistent with our finding of adipose tissue release of IL-6 in
vivo13 and implicating adipose tissue as a major source for
circulating IL-6. We have also found associations between
levels of acute phase proteins and of proinflammatory cyto-
kines not only with blood pressure and dyslipidemia, but both
with a measure of insulin resistance and with markers of
endothelial dysfunction. Furthermore, the association of acute
phase markers with insulin resistance variables is indepen-
dent of anthropometric measures of obesity. We are suggest-
ing a more general role for both IL-6 and TNF-a in
atherogenesis and thrombosis, influencing as they do, the risk
factors which have been termed the insulin resistance syn-
drome, endothelial function and expression of prothrombotic
factors and adhesion molecules, and acute phase proteins,
which in turn may increase cardiovascular risk. Our paradigm
provides a novel explanation for the association of insulin
resistance and cardiovascular risk, as well as a putative
mechanism for the deleterious effects of obesity, and in
particular central adiposity,52 in heart disease risk. Of neces-
sity, however, this study has merely developed a hypothesis
about the common antecedence of adipose tissue-generated
proinflammatory cytokines in insulin resistance and endothe-
lial dysfunction, which will require further testing in both
epidemiological and clinical investigative studies.
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Chronic Subclinical Inflammation as Part of the
Insulin Resistance Syndrome
The Insulin Resistance Atherosclerosis Study (IRAS)
Andreas Festa, MD; Ralph D’Agostino, Jr, PhD; George Howard, DrPH; Leena Mykka¨nen, MD, PhD;
Russell P. Tracy, PhD; Steven M. Haffner, MD
Background—Inflammation has been suggested as a risk factor for the development of atherosclerosis. Recently, some
components of the insulin resistance syndrome (IRS) have been related to inflammatory markers. We hypothesized that
insulin insensitivity, as directly measured, may be associated with inflammation in nondiabetic subjects.
Methods and Results—We studied the relation of C-reactive protein (CRP), fibrinogen, and white cell count to components
of IRS in the nondiabetic population of the Insulin Resistance Atherosclerosis Study (IRAS) (n51008; age, 40 to 69
years; 33% with impaired glucose tolerance), a multicenter, population-based study. None of the subjects had clinical
coronary artery disease. Insulin sensitivity (SI) was measured by a frequently sampled intravenous glucose tolerance test,
and CRP was measured by a highly sensitive competitive immunoassay. All 3 inflammatory markers were correlated
with several components of the IRS. Strong associations were found between CRP and measures of body fat (body mass
index, waist circumference), SI, and fasting insulin and proinsulin (all correlation coefficients .0.3, P,0.0001). The
associations were consistent among the 3 ethnic groups of the IRAS. There was a linear increase in CRP levels with an
increase in the number of metabolic disorders. Body mass index, systolic blood pressure, and SI were related to CRP
levels in a multivariate linear regression model.
Conclusions—We suggest that chronic subclinical inflammation is part of IRS. CRP, a predictor of cardiovascular events
in previous reports, was independently related to SI. These findings suggest potential benefits of anti-inflammatory or
insulin-sensitizing treatment strategies in healthy individuals with features of IRS. (Circulation. 2000;102:42-47.)
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Arelationship between C-reactive protein (CRP), a sensi-tive marker of inflammation, and the development of
atherosclerotic disease has been observed in experimental1–4
and epidemiological studies.5–8 It is still unknown, however,
whether elevated CRP levels merely reflect an epi-
phenomenon accompanying established atherosclerotic dis-
ease or whether the protein itself is involved in the initiation
and/or progression of atherosclerosis.
Previous reports suggest a positive association between
components of the insulin resistance syndrome (IRS) and
markers of the acute-phase response, including CRP6,8–12 and
fibrinogen.13 CRP levels were associated with body mass
index (BMI),6,8–10,12 serum lipids,6,8–10,12 and fasting glu-
cose.9 Elevated levels of inflammatory markers (including
CRP) were also found in type 2 diabetic patients with features
of IRS.11
The nature of the association of CRP with IRS, however, is
poorly understood. We hypothesized that insulin insensitivity
and/or hyperinsulinemia may be associated with circulating
CRP levels. Such an association would potentially provide
insights into the role of CRP in atherosclerotic disease and
further clarify the association of hyperinsulinemia with car-
diovascular disease.14
We studied the relation of inflammatory markers (CRP,
fibrinogen, white cell count) and components of IRS, includ-
ing insulin sensitivity, as directly measured by a frequently
sampled intravenous glucose tolerance test. Furthermore, we
sought to investigate whether CRP levels were independently
related to insulin (or its precursors), insulin sensitivity, or
both. The analyses were restricted to nondiabetic subjects
without clinical coronary artery disease to avoid possible
confounding by preexisting cardiovascular disease. It has
been shown previously that patients with type 2 diabetes
present with higher levels of inflammatory markers8,11 and a
high prevalence of atherosclerosis, including clinically unde-
tected disease.15
Received August 30, 1999; revision received January 21, 2000; accepted February 2, 2000.
From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.);
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC (R.D’A., G.H.); and Laboratory for Clinical
Biochemistry Research, Department of Pathology, University of Vermont College of Medicine, Burlington (R.P.T.).
Correspondence to Andreas Festa, MD, University of Texas Health Science Center at San Antonio, Mail Code 7873, 7703 Floyd Curl Dr, San Antonio,
TX 78228-3900. E-mail festa@magnet.at
© 2000 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org
42
Methods
Study Subjects
The Insulin Resistance Atherosclerosis Study (IRAS) is a multi-
center, population-based epidemiological study exploring relation-
ships between insulin resistance, cardiovascular risk factors, and
cardiovascular disease across different ethnic groups and various
states of glucose tolerance. A full description of the design and
methods of the IRAS has been published.16 The IRAS protocol was
approved by local institutional review committees, and all subjects
gave informed consent.
A total of 1088 nondiabetic individuals participated in the IRAS.
Subjects with a current acute illness (including clinically significant
infectious disease) were excluded from IRAS examination. Subjects
with clinically overt coronary artery disease, defined as past myo-
cardial infarction, PTCA or CABG, or ECG evidence of ischemic
heart disease, were excluded from the present analyses. This report
includes data on 1008 nondiabetic subjects in whom CRP and
fibrinogen levels were measured. Cigarette smoking was dichoto-
mized into “never” and “ever” (including past and current) by use of
a standard questionnaire. BMI (weight/height2 [kg/m2]) was used as
an estimate of overall adiposity. Waist circumference (estimate of
visceral fat) was measured at the natural indentation between the
10th rib and the iliac crest (minimum waist).
A standard 75-g oral glucose tolerance test was performed.
Glucose tolerance status was based on World Health Organization
criteria.17
Laboratory Measurements
Plasma glucose was measured with the glucose oxidase technique on
an automated autoanalyzer (Yellow Springs Equipment Co). Insulin
was measured with the dextran-charcoal radioimmunoassay.18 This
insulin assay cross-reacts with proinsulin. Fasting serum intact
proinsulin and 32–33 split proinsulin were determined at the Depart-
ment of Clinical Biochemistry at Addenbrook’s Hospital, Cam-
bridge, UK (Professor C.N. Hales), by means of highly specific
2-site monoclonal antibody–based immunoradiometric assays.19
Insulin sensitivity was assessed by a frequently sampled intrave-
nous glucose tolerance test20 with minimal model analysis.21 Two
modifications of the original protocol were used: (1) an injection of
regular insulin, rather than tolbutamide, to ensure adequate plasma
insulin levels for the accurate computation of insulin sensitivity
across a broad range of glucose tolerance22 and (2) the reduced
sampling protocol23 because of the large number of subjects. Insulin
sensitivity, expressed as the insulin sensitivity index (SI), was
calculated by mathematical modeling methods (MINMOD, version
3.0, 1994).
Plasma lipoprotein measurements were obtained from fasting
single fresh plasma samples through Lipid Research Clinic methods
at the central IRAS laboratory at Medlantic Research Institute,
Washington, DC (Professor B.V. Howard).
CRP was measured by in-house ultrasensitive competitive immu-
noassay (antibodies and antigens from Calbiochem) with an interas-
say coefficient of variation of 8.9%.24 Fibrinogen was measured in
citrated plasma with a modified clot-rate assay by use of the
Diagnostica STAGO ST4 instrument, as described previously.25
Complete blood cell counts were performed with standard
techniques.
Statistical Analysis
Statistical analyses were performed with the SAS statistical software
system. Descriptive statistics (mean6SE) and number/percent are
shown on Table 1. CRP levels differed by sex and ethnicity in the
present population, and age and smoking were determinants of CRP
levels in previous reports; therefore, multivariate models (partial
Spearman correlations, multiple linear regression analysis) were
tailored to account for these possible confounders. Partial Spearman
correlations (adjusting for age, sex, ethnicity, clinic, and smoking
status) for inflammatory markers with components of the IRS were
estimated for the overall population (Table 2) and stratified by
ethnicity and glucose tolerance status (normal [NGT] versus im-
paired [IGT] glucose tolerance). In these models, we also tested for
interactions between the independent variables of interest (BMI,
fasting glucose, insulin, proinsulin, split proinsulin, and SI) and
ethnicity and glucose tolerance status, respectively. The distribution
of CRP levels was highly skewed. Logarithmically transformed
values of CRP (log CRP) were used because the distribution of the
residuals from the fitted models became normally distributed after
log transformation. Thus, mean values of log CRP (adjusted for age,
sex, ethnicity, clinic, and smoking status) in relation to the number of
metabolic disorders were calculated by ANCOVA (Figure 1). Fur-
TABLE 1. Descriptive Data in Nondiabetic Subjects Without
Clinical Coronary Artery Disease: The IRAS
n 1008
Male sex, % 43
Impaired glucose tolerance, % 33
Age, y 54.760.3
BMI, kg/m2 28.460.2
Waist circumference, cm 90.460.4
Systolic BP, mm Hg 119.660.5
Diastolic BP, mm Hg 77.160.3
Triglyceride, mmol/L 1.5160.03
Total cholesterol, mmol/L 5.4860.03
LDL cholesterol, mmol/L 3.6660.03
HDL cholesterol, mmol/L 1.2360.01
Fasting glucose, mmol/L 5.4760.02
Fasting insulin, pmol/L 94.162.7
Proinsulin, pmol/L 6.060.2
Split proinsulin, pmol/L 8.360.3
SI31024, min21 z mU21 z mL21 2.1960.07
CRP, mg/L 3.5360.18
CRP .10 mg/L, n (%) 70 (6.9)
White cell count, 3103/mm3 5.8160.07
Fibrinogen, mg/dL 276.461.8
BP indicates blood pressure. Data are mean6SE.
TABLE 2. Partial Spearman Correlation Analysis of
Inflammation Markers With Variables of IRS Adjusted for Age,
Sex, Clinic, Ethnicity, and Smoking Status
CRP WBC Fibrinogen
BMI 0.40‡ 0.17‡ 0.22‡
Waist 0.43‡ 0.18‡ 0.27‡
Diastolic BP 0.17‡ 0.01 0.11†
Systolic BP 0.20‡ 0.08* 0.11†
Triglyceride 0.23‡ 0.15‡ 0.03
Cholesterol (total) 0.10† 20.01 0.01
HDL cholesterol 20.11† 20.12† 20.15‡
LDL cholesterol 0.09* 20.01 0.05
Fasting glucose 0.18‡ 0.13‡ 0.07*
Fasting insulin 0.33‡ 0.24‡ 0.18‡
Proinsulin (intact) 0.30‡ 0.17‡ 0.20‡
Proinsulin (split) 0.32‡ 0.21‡ 0.20‡
SI 20.37‡ 20.24‡ 20.18‡
WBC indicates white cell count; BP, blood pressure.
*P,0.05, †P,0.005, ‡P,0.0001.
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thermore, we calculated (unadjusted) mean values of log CRP by
tertile for SI, BMI, and triglycerides and for hypertension (Figure 2).
Stepwise linear regression models were fit for log CRP as a
dependent variable, including all variables of interest at the same
time as independent variables to demonstrate the relative contribu-
tion of each of these variables to the outcome variable. After age,
sex, ethnicity, clinic, and smoking status were forced into the model,
the following independent variables were considered for the model:
BMI, diastolic and systolic blood pressures, fasting glucose, SI,
fasting insulin, and proinsulin (intact). Only variables that had a
P#0.05 were considered in the final fitted model (Table 3). A value
of P,0.05 (2-sided) was considered statistically significant.
Results
Table 1 shows descriptive data. All 3 inflammatory markers
were correlated with several components of IRS (Table 2).
The associations were generally stronger for CRP than for
white cell count and fibrinogen. Strong associations (corre-
lation coefficients .0.3) were found between CRP and
measures of body fat (BMI, waist circumference), SI, fasting
insulin, and proinsulin. There was a linear increase in CRP
levels with an increase in the number of metabolic disorders
(dyslipidemia, upper body adiposity, insulin resistance, hy-
pertension; Figure 1). The respective mean log of CRP levels
Figure 1. Mean levels of log CRP (SE represented by bars)
adjusted for age, sex, ethnicity, clinic, and smoking status
according to number of metabolic disorders (0 to 4), including
(1) dyslipidemia (high triglyceride .2.27 mmol/L [200 mg/dL]
and/or low HDL: men #0.91 mmol/L [35 mg/dL] and women
#1.16 mmol/L [45 mg/dL]), (2) upper body adiposity ($75th per-
centile for waist circumferences: men5103.0 cm and wom-
en599.3 cm), (3) insulin resistance (,25th percentile for SI:
,0.8831024 min21 z mU21 z mL21 or in 47 subjects without fre-
quently sampled intravenous glucose tolerance test, $75th per-
centile for fasting insulin: 114 pmol/L), and (4) hypertension (sys-
tolic blood pressure of $140 mm Hg and/or diastolic blood
pressure of $90 mm Hg or current use of antihypertensive med-
ication). All comparisons, P50.0001, except for 2 versus 4
(P,0.005) and 3 versus 4 (P5NS).
Figure 2. A through D, Distributions and mean values of log CRP stratified by tertiles for SI (A), BMI (B), and triglycerides (C). Mean
values by tertiles are depicted by vertical solid lines (first tertile), dashed lines (second tertile), and dotted lines (third tertile). A, First ter-
tile represents subjects with high insulin resistance (low SI). D, Solid vertical line depicts mean value of log CRP in hypertensive sub-
jects; dashed line, mean value in nonhypertensive subjects.
TABLE 3. Stepwise Multiple Linear Regression Analysis With
Log of CRP as the Dependent Variable
Independent
Variable B SE(B) P
Partial
R 2, %
BMI 0.06 0.006 0.0001 14.2
SI 20.11 0.02 0.0001 3.1
SBP 0.008 0.002 0.0001 1.2
After forcing age, sex, clinic, ethnicity, and smoking status into the model,
BMI, diastolic and systolic blood pressures (SBP), fasting glucose, fasting
insulin, SI, and proinsulin (intact) were analyzed as independent variables. Only
variables that had a P #0.05 were considered in the final fitted model. R 2 for
the model526.0%.
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(6SE) were 0.07560.06, 0.51160.06, 0.84560.07,
1.3460.10, and 1.3960.17 in the presence of 0, 1, 2, 3, or 4
metabolic disorders. The percentage of subjects presenting
with 0, 1, 2, 3, and 4 disorders was 30.3%, 32.7%, 22.7%,
10.4%, and 4.0%, respectively. When mean values of log
CRP were analyzed by tertiles of SI, BMI, and triglycerides
and by hypertension (Figure 2), higher levels of log CRP
were found in the lower tertiles of SI (indicating a relation of
higher CRP levels with higher insulin resistance), in the
higher tertiles of BMI, in the highest tertile of triglycerides,
and in hypertensive subjects. Furthermore, the distribution
curves of log CRP values showed a shift to the right for
hypertensive subjects and for increasing tertiles of BMI and
triglycerides or a shift to the left for increasing tertiles of SI.
The associations as shown in the overall population (Table
2) were also consistent among the 3 ethnic groups. Correla-
tion coefficients for CRP in non-Hispanic whites (n5399),
blacks (n5267), and Hispanics (n5342) were 0.43, 0.43, and
0.38 (BMI); 0.43, 0.46, and 0.39 (waist); 0.35, 0.29, and 0.36
(fasting insulin); 0.30, 0.31, and 0.29 (intact proinsulin); 0.38,
0.28, and 0.29 (split proinsulin); and 20.41, 20.33, and
20.38 (SI), respectively (all P,0.0001). The correlation
coefficient of CRP with fasting glucose was 0.16 (P,0.005)
in non-Hispanic whites, 0.12 (P5NS) in blacks, and 0.25
(P,0.0001) in Hispanics. The association of fasting insulin
with CRP and fibrinogen was less pronounced in blacks
compared with non-Hispanic whites and Hispanics (P,0.005
and P,0.05 for interaction terms), respectively, although the
associations were clearly in the same direction and, for CRP,
highly significant in all 3 ethnic groups. All other interaction
terms were not statistically significant.
The associations were also consistently seen in subjects
with NGT and IGT. Correlation coefficients for CRP in
subjects with NGT and IGT were 0.34 and 0.41 (BMI), 0.37
and 0.40 (waist), 0.32 and 0.23 (fasting insulin), 0.23 and
0.29 (intact proinsulin), 0.25 and 0.31 (split proinsulin), and
20.35 and 20.26 (SI), respectively (all P,0.0001). The
correlation of CRP with fasting glucose was weak in NGT
(r50.11, P,0.05) and not significant in IGT (r50.09). The
association of fasting insulin with CRP was stronger in
subjects with NGT than with IGT (P,0.0001 for interaction
term). All other interaction terms were not statistically
significant.
Multivariate linear regression analyses showed that BMI,
systolic blood pressure, and SI (inversely) were independently
associated with log CRP levels in the overall population
(Table 3).
Discussion
In the present study, we have shown that in healthy, nondi-
abetic subjects, CRP, a sensitive marker of inflammation that
has previously been associated with cardiovascular dis-
ease,5–8 was independently related to insulin sensitivity.
Chronic subclinical inflammation emerged as part of IRS.
The findings were consistent across the 3 ethnic groups of the
IRAS (non-Hispanic whites, blacks, and Hispanics) and in
subjects with NGT and IGT.
Previously, in various populations, CRP levels were asso-
ciated with BMI,6,8–10,12 triglyceride level,6,8–10,12 HDL cho-
lesterol level (inversely),9,10,12 total cholesterol level,9 and
blood pressure.8,12 Mendall et al9 found an association be-
tween CRP levels and fasting glucose, confirmed by Tracy et
al10 in the elderly but only in a nonsmoking subset. However,
information about the association of serum levels of inflam-
matory markers with insulinemia and insulin sensitivity,
hallmarks of the IRS, is scarce. Recently, we have reported
from the IRAS associations of fibrinogen and plasminogen
activator-1 with several components of IRS, including insu-
lin, proinsulin, and SI.26 In 3 other studies, fibrinogen levels
were independently associated with fasting insulin levels in
nondiabetic subjects.13,27,28 In 107 nondiabetic subjects, CRP
levels were related to insulin resistance, as calculated with the
homeostasis model assessment model.12 The present study
clearly corroborates and extends these results, indicating that
chronic, subclinical inflammation is part of IRS. We have
shown that various components of IRS were correlated to
inflammatory markers (Table 2 and Figure 2) and that an
increasing number of components of IRS (dyslipidemia,
abdominal obesity, low SI, and hypertension) paralleled
increasing levels of CRP (Figure 1). The results were consis-
tent across a variety of ethnic groups that differ in insulin
sensitivity,29 indicating that the relations found in our study
apply to populations with high and low SI.
There are several possible explanations for these findings,
which are not necessarily exclusive. First, it is possible that
chronic inflammation may represent a triggering factor in the
origin of IRS, and eventually type 2 diabetes, as previously
discussed by Pickup and Crook.30 According to this hypoth-
esis, stimuli such as overnutrition would result in cytokine
hypersecretion and eventually lead to insulin resistance and
diabetes in genetically or metabolically predisposed individ-
uals. Cytokines, mainly interleukin (IL)-1, IL-6, and tumor
necrosis factor (TNF)-a, exert major stimulatory effects on
hepatic synthesis of acute-phase proteins.31
Second, clustering of cardiovascular risk factors as typi-
cally encountered in subjects with the IRS may yield cardio-
vascular disease (yet undetected), and elevated CRP levels
thus would be the result of preexisting atherosclerosis.32
Previous cross-sectional analyses show an association be-
tween CRP levels and atherosclerotic disease.6,9 CRP was
also elevated in elderly women with subclinical atheroscle-
rosis in the Cardiovascular Health Study7; however, in a
larger cohort from the same population, no significant asso-
ciation of CRP with carotid intimal-medial thickness was
found.10 Atherosclerosis starts very early in life, and insulin
resistance potentially accelerates this process.33 Therefore, it
is highly likely that in our “healthy” middle-aged population,
atherosclerosis prevails, particularly in those with features of
IRS. However, the degree and extent of atherosclerosis
operative in increasing CRP levels is unknown; therefore,
even relatively sensitive methods of assessing preclinical
atherosclerosis (such as carotid ultrasound) may lack accu-
racy in this respect.
Third, decreased insulin sensitivity may lead to enhanced
CRP expression by counteracting the physiological effect of
insulin on hepatic acute-phase protein synthesis.34 Clamp
studies in normal subjects showed that insulin exerts selective
effects on hepatic protein synthesis, with an increase in
Festa et al Inflammation and Insulin Resistance 45
albumin synthesis and a decrease in fibrinogen synthesis,35
the inverse of the picture typically seen during the acute-
phase response.36 Resistance to this effect would then lead to
increased synthesis of acute-phase proteins, such as fibrino-
gen and CRP.
Finally, the effect could be indirect via body fat; we
observed a strong and independent association of CRP levels
with measures of body fat and triglycerides. This is in
accordance with results of previous cross-sectional analy-
ses.6,8–10,12 In a previous interventional study, the synthesis of
proinflammatory cytokines by peripheral monocytes (TNF-a,
IL-1) was suppressed by dietary fish oil supplementation,37
suggesting an effect of dietary fat on cytokine production.38
Another (speculative at this time) mechanism would be a
generally enhanced adipose tissue–derived cytokine expres-
sion (TNF-a, IL-6). Accordingly, weight loss was associated
with a decrease in CRP in the Women’s Healthy Lifestyle
Project (E. Meilahn, personal communication, 1996), also
supporting an association of body fat and chronic
inflammation.
We found a strong and independent association of eleva-
tions in inflammatory markers, namely CRP, with decreased
SI. The association of low SI (indicating high insulin resis-
tance) with elevated CRP levels found in the present study
could potentially explain the association of hyperinsulinemia
(another indicator of insulin resistance) with cardiovascular
disease.14 Several experimental studies suggest a direct role
of CRP in the initiation and/or progression of atherosclerotic
lesions. CRP has been shown to (1) be a potent stimulator of
tissue factor production by macrophages4; (2) activate the
complement system in vivo39; (3) accumulate in early athero-
sclerotic lesions in human aorta2 and coronary arteries3;
(4) bind to lipoproteins, such as LDL and VLDL, thus
inducing their aggregation1; and (5) be expressed by mono-
cytes.40 In epidemiological studies, CRP levels in the upper
normal range have consistently been predictive of cardiovas-
cular disease in various populations.5–8 Moreover, sensitive
assays and the biological properties of CRP (such as its stable
half-life41) make this protein a clinically useful marker of
chronic subclinical inflammation.
The results of the present study are potentially clinically
important. As previously shown, treatment of several com-
ponents of IRS (adiposity, dyslipidemia, hypertension) may
have beneficial effects in terms of preventing type 2 diabe-
tes42 and cardiovascular disease.43,44 Therefore, if subclinical
inflammation is indeed another facet of the IRS, anti-
inflammatory treatment may also be beneficial. Accordingly,
it has been suggested that the effects of aspirin may, at least
partly, be mediated through its anti-inflammatory rather than
its antiplatelet properties.5 Furthermore, treatment aiming at
improving insulin resistance, whether nonpharmacological,
such as exercise and weight reduction, or pharmacological,
such as metformin and thiazolidinediones, may lower CRP
levels and thus provide additional therapeutic benefits beyond
mere glucose lowering. Alternatively, if elevated CRP levels
were merely a marker of prevalent or developing atheroscle-
rosis, these treatment strategies would then be clinically
fruitless. Prospective studies are clearly needed to address
these issues.
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C-Reactive Protein Modulates Risk Prediction Based on the
Framingham Score
Implications for Future Risk Assessment: Results From a Large Cohort
Study in Southern Germany
Wolfgang Koenig, MD; Hannelore Löwel, MD; Jens Baumert, MS; Christa Meisinger, MD, MPH
Background—The Framingham Coronary Heart Disease (CHD) prediction score is recommended for global risk
assessment in subjects prone to CHD. Recently, C-reactive protein (CRP) has emerged as an independent predictor of
CHD. We sought to assess the potential of CRP measurements to enhance risk prediction based on the Framingham Risk
Score (FRS) in a large cohort of middle-aged men from the general population.
Methods and Results—We measured CRP and traditional cardiovascular risk factors at baseline in 3435 white men of
German nationality, 45 to 74 years of age. All men were drawn from 3 random samples of the general population in the
Augsburg area located in Southern Germany in 1984 to 1985, 1989 to 1990, and 1994 to 1995 (response rate, 80%), and
the FRS was calculated in all of them. Outcome was defined as nonfatal and fatal coronary events, including sudden
cardiac death. During an average follow-up of 6.6 years, a total of 191 coronary events occurred. Cox regression showed
a significant contribution of CRP to coronary event risk prediction independent of the FRS (P0.0002). In stratified
analysis for 5 categories of FRS, CRP significantly added prognostic information to the FRS in subjects in 2
intermediate risk categories (P0.03 and P0.02).
Conclusions—Our results suggest that CRP enhances global coronary risk as assessed by the FRS, especially in
intermediate risk groups. This might have implications for future risk assessment. (Circulation. 2004;109:1349-1353.)
Key Words: inflammation  risk factors  coronary disease  epidemiology  prevention
The Framingham Risk Score (FRS) is widely recom-mended to assess global risk for coronary heart disease
(CHD) events.1 However, classic risk factors do not account
for all incident coronary events, and there may be a substan-
tial number of subjects with normal lipoprotein concentra-
tions who have the disease.2 This has led to the search for
additional diagnostic tools,3 and in more than 15 large
prospective studies, C-reactive protein (CRP), through the
use of new high-sensitivity (hs) assays, has emerged as a
strong and consistent predictor of an incident cardiovascular
event in initially healthy subjects.4 A recent prospective study
in women has suggested that CRP may even better predict
future cardiovascular events than LDL cholesterol2 and that it
may add to the prediction of the estimated 10-year risk
according to the FRS.
We sought to investigate the potential of CRP measure-
ments to modify risk prediction based on the FRS in a large
CHD-event free cohort of middle-aged white men of German
nationality sampled from the general population.
Methods
Study Design, Population, and Follow-Up
The population-based MONICA (MONItoring of trends and deter-
minants in CArdiovascular disease) Augsburg studies (Southern
Germany) conducted between 1984 and 1998 were used as the
database.5
Three independent cross-sectional surveys covering the city of
Augsburg and two adjacent counties were conducted in 1984 to 1985
(S1), 1989 to 1990 (S2), and 1994 to 1995 (S3) to estimate the
prevalence of cardiovascular risk factors among men and women.
Altogether, 13,428 white subjects of German nationality (6725 men,
6703 women; response rate, 77%), 25 to 74 years of age, randomly
drawn from the general population, participated in at least one of the
three studies. In a follow-up study, vital status was assessed for all
persons of the three surveys in 1998. During the observation period,
772 participants (531 men, 241 women) had died, and vital status
could not be assessed for 56 persons (31 men, 25 women) who had
moved to an unknown location.
The outcome variable was a combination of incident fatal or
nonfatal acute myocardial infarction (MI) and sudden cardiac death.
They were identified through the MONICA/KORA (KOoperative
Gesundheitsforschung in der Region Augsburg) coronary event
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register of the 25- to 74-year-old study population and censored at
the 75th year of age.6 According to the MONICA manual,5 the
diagnosis of a major nonfatal MI event was based on symptoms,
cardiac enzymes, and typical ECG changes. Deaths from cardiovas-
cular causes were validated by autopsy reports, death certificates,
chart review, and information from the last treating physician.
The present analysis was restricted to men 45 to 74 years of age
(response rate, 80%) at the baseline examination (n3667). Of
those, 990 (27%) subjects were from survey S1, 1324 (36%) from
S2, and 1353 (37%) from S3. A total of 48 subjects had missing
values on CRP or other variables. Participants with prevalent MI
(n184) were excluded. Thus, 3435 subjects were available for the
present analysis.
Survey Methods
All participants completed a standardized questionnaire, including
medical history, lifestyle, and drug history. Blood pressure, body
height (meters) and body weight (kilograms), body mass index
(BMI, kg/m2), smoking behavior, and alcohol consumption (g/d)
were determined as described elsewhere.7 The number of education
years was calculated on the basis of the highest level of formal
education completed.
Laboratory Procedures
A nonfasting venous blood sample was collected from all partici-
pants in a supine resting position. Samples for measurement of CRP
were stored at 70°C until analysis. Serum CRP concentrations
were measured with the use of an hs-immunoradiometric assay
(range, 0.05 to 10 mg/L), as previously described.8 The coefficient of
variation (CV) for repeated measurements was 12% over all ranges.
Total serum cholesterol (TC) and HDL cholesterol (HDL-C) were
measured in multiple batches by routine enzymatic methods. Corre-
sponding CVs were between 1% and 3% for TC and between 3% and
4% for HDL-C.
Statistical Analysis
Means or proportions (adjusted for age and survey) for baseline
demographic and clinical characteristics were computed by AN-
COVA for men with and without incident coronary events. Cox
proportional hazards analysis was used to assess the independent risk
for the incidence of a first fatal or nonfatal acute coronary event
separately in quartiles of TC/HDL-C and in quartiles of CRP.
Relative risks for both variables were adjusted for age and survey
(S1, S2, or S3) and were further adjusted for BMI (according to
Bray, 7), current smoking (yes/no), hypertension (blood pressure less
than versus140/90 mm Hg), education years (less than versus12
years), alcohol consumption (0, 0.1 to 39.9, versus 40 g/d),
physical activity (inactive versus active, that is, 1 hour in at least
1 season), and history of diabetes (yes versus no) in all other models.
Results are presented as hazard ratios (HR), together with their 95%
confidence intervals. Probability values are based on the Wald
statistic.
Finally, using Cox proportional hazards analysis, we assessed
whether CRP contributed information on risk beyond that conveyed
by the 10-year risk calculated with the FRS according to the formula
of Wilson et al9 and beyond the risk associated with the ratio of
TC/HDL-C. In these analyses, CRP concentrations were categorized
according to recently proposed cut-points (1.0 mg/L; 1.0 to 3.0
mg/L; 3.0 mg/L).10 Moreover, to estimate the effects of the
additional value of CRP on the prediction of coronary events in
TABLE 1. Age- and Survey-Adjusted Means and Prevalences (%) for Men With
and Without Incident Coronary Event: MONICA/KORA Augsburg Cohort Study,
1984 to 1998
Men With Event
(n191)
Men Without Event
(n3244) P
Age,* y 59.2 56.2 0.0001
TC/HDL-C ratio (antilog) 5.44 4.85 0.0001
CRP, mg/L (antilog) 2.56 1.64 0.0001
Cholesterol
In mg/dL 257.4 244.4 0.0001
In mmol/L 6.65 6.32 0.0001
HDL-C
In mg/dL 48.4 51.8 0.0034
In mmol/L 1.25 1.33 0.0034
Systolic blood pressure, mm Hg 142.6 138.5 0.0029
Diastolic blood pressure, mm Hg 83.8 83.3 0.5768
BMI, kg/m2 28.0 27.7 0.2083
Normal weight (BMI 25.0 kg/m2), % 18.3 20.8 0.4136
Overweight (BMI 25 to 29.9 kg/m2), % 53.3 57.4 0.2783
Obesity (BMI 30.0 kg/m2), % 28.2 21.7 0.0431
Alcohol intake, %
0 g/d 18.1 15.4 0.3288
1 to 39.9 g/d 41.8 48.0 0.1016
40 g/d 39.6 35.9 0.3264
History of diabetes (yes), % 12.0 5.4 0.0004
Education (12 y), % 76.6 73.5 0.36
Physical activity (1 h/wk), % 14.0 18.0 0.1580
Current smoker, % 44.2 26.4 0.0001
*Only survey-adjusted.
1350 Circulation March 23, 2004
different FRS categories, separate Cox proportional hazards
analyses stratified for FRS categories (3 or 5, respectively) were
performed. For each of the 3, respective 5 FRS categories, a Cox
proportional hazards model was calculated with the inclusion of
CRP (3 categoreis) as exposition variable and FRS (continuous)
and survey as confounding covariates. The percentages of a first
incident coronary event within 10 years estimated by these Cox
models were compared according to percentages estimated by
Cox models with FRS categories (3 or 5, respectively) adjusted
only for survey.
To assess the goodness of fit of the different prediction models, we
calculated Akaike’s Information Criterion (AIC) regarding an AIC
difference between two models of 10 as essentially different.11,12
Although ROC analysis can be only a rough estimate for the
predictive value of a Cox proportional hazards model in our study
design with censored data, we performed such analysis for reasons of
comparison with other studies. We estimated the area under the
curve (AUC) as a measure for the predictive ability of a Cox
proportional hazards model. Different AUCs were tested by a
nonparametric approach of DeLong et al.13 The “change-in-
estimate” method (CIE) was used to evaluate the impact of the
addition of CRP on the HRs of the FRS with a 10% criterion.14
Significance tests are 2 tailed, and probability values 0.05 were
considered statistically significant. All analyses were performed with
the use of the Statistical Analysis System (Version 8.2 for Unix, SAS
Institute Inc).
TABLE 2. Risk of a First Coronary Event Estimated by Cox Proportional Hazards Model
Without and With CRP for the Ratio of TC/HDL-C (A) and the Framingham Risk Score With
Three Categories (B) and Five Categories (C)
Model Without CRP Model With CRP
Factor Events/n HR (95% CI) P HR (95% CI) P
A
TC/HDL-C ratio 0.0001 0.0023
4.3 46/1100 Reference Reference
4.3 to 5.6 55/1152 1.25 (0.85–1.86) 1.18 (0.80–1.74)
5.6 90/1183 2.06 (1.45–2.95) 1.80 (1.26–2.57)
CRP, mg/L    0.0001
1 37/1178    Reference
1 to 3 64/1262    1.73 (1.15–2.60)
3 90/995    2.91 (1.98–4.29)
AIC 2853 2824 AIC: 29
AUC 0.704 0.725 0.1029
B
FRS 1, % 0.0001 0.0001
6 18/809 Reference Reference
6 to 19 117/2090 2.81 (1.71–4.62) 2.39 (1.45–3.94)
20 56/536 6.19 (3.64–10.54) 4.85 (2.82–8.33)
CRP, mg/L    0.0001
1 37/1178    Reference
1 to 3 64/1262    1.54 (1.02–2.32)
3 90/995    2.47 (1.67–3.65)
AIC 2816 2797 AIC: 19
AUC 0.713 0.740 0.0077
C
FRS 2, % 0.0001 0.0001
6 18/809 Reference Reference
6 to 10 32/914 1.63 (0.91–2.90) 1.46 (0.82–2.61)
11 to 14 35/650 2.70 (1.53–4.77) 2.35 (1.32–4.16)
15 to 19 50/526 5.61 (3.27–9.62) 4.50 (2.59–7.80)
20 56/536 6.21 (3.65–10.57) 5.01 (2.91–8.62)
CRP, mg/L    0.0002
1 37/1178    Reference
1 to 3 64/1262    1.44 (0.95–2.17)
3 90/995    2.21 (1.49–3.27)
AIC 2789 2776 AIC: 13
AUC 0.735 0.750 0.0163
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Results
Baseline Characteristics
During an average follow-up of 6.6 years, a total of 191
coronary events occurred. Men with an incident event were
significantly older; had a higher TC/HDL-C ratio, higher
systolic blood pressures, and elevated CRP concentrations;
were more frequently smokers; and had a higher prevalence
of obesity and diabetes (Table 1).
Relative Risks Associated With CRP and the Ratio
of TC/HDL-C
In multivariable analyses, the relative risks associated with
increasing quartiles as compared with the bottom quartiles
were 1.21, 1.43, and 2.03 for CRP (P0.0079) and 1.72,
1.76, and 2.62 for the ratio of TC/HDL-C (P0.0006).
Additive Effect of CRP to the Risk Associated
With the Ratio of TC/HDL-C and the FRS
We performed Cox proportional hazards analyses to assess
the influence of CRP measurements on the risk of a first
coronary event, independent of the TC/HDL-C ratio and the
calculated FRS. For this purpose, TC/HDL-C was catego-
rized into tertiles and the FRS was divided into low (6%),
intermediate (6% to 19%), and high (20%) risk over 10
years (FRS 1), according to Greenland et al,15 and into 5 risk
categories 6%, 6% to 10%, 11% to 14%, 15% to 19%, and
20% (FRS 2) (Table 2). For each of these factors, two Cox
regression models were calculated: The first model included
only the factor under concern as covariate (model without
CRP) and the second model additionally included CRP as
covariate (model with CRP). As shown in Table 2, CRP
significantly contributed to the prediction of incident coro-
nary events through the use of the TC/HDL-C ratio, FRS 1,
and FRS 2 (probability values 0.001). As suggested by
AIC, with differences10 between models without CRP and
those including CRP, the fit of each model containing CRP
was superior to that of the TC/HDL-C ratio and FRS alone.
The AUC as a rough estimate (in our study design) for the
predictive value of the different Cox models revealed a
statistically significant increase from 0.735 (model with FRS
2) to 0.750 (model with FRS 2 and CRP) (P0.0163). The
inclusion of CRP was associated with a remarkable decrease
in the HR of the FRS. The HR of the highest FRS 2 category
(risk 20%/10 years) compared with the lowest FRS 2
category (risk 6%/10 years) decreased from 6.2 to 5.0,
indicating a CIE of 19.4%. All CIEs are greater than the 10%
criterion, indicating a strong impact of CRP on the HRs of
FRS 2. Similar results were observed for the FRS 1 model.
Moreover, we compared the proportions of incident coro-
nary events within 10 years estimated by the Cox model for
the five categories of FRS 2 alone (Figure, left panel) and for
different CRP categories in each category of FRS 2, adjusted
for survey and FRS (Figure, right panel). Probability values
of the stratified analyses are given in the Figure (right panel,
above each FRS category). Cox regression revealed a con-
siderable modification in coronary event incidence based on
CRP concentrations and, more importantly, in categories of
FRS 2 associated with a 10% to 20% risk per 10 years,
elevated concentrations of CRP were consistently and statis-
tically significantly associated with a further increased risk
(P0.03 and P0.02). In contrast, in men with a risk 6%
and 6% to 10% per 10 years, CRP had no statistically
significant additional effect on the prediction of a first
coronary event. Regarding the different AUCs, a remarkable
increase was found for the intermediate FRS categories of
11% to 14% and 15% to 19% (increase in the AUC from
0.725 to 0.776 and from 0.695 to 0.751).
Discussion
In this prospective population-based study, increased CRP
concentrations and an elevated TC/HDL-C ratio were both
independently related to incident coronary events. However,
even if the strongest lipid/lipoprotein variable was chosen for
risk assessment, our data clearly show that the measurement
Occurrence of a first coronary event
within 10 years, estimated by Cox pro-
portional hazards models in percentages.
Left, Percentage estimated by a model
with FRS (5 categories) adjusted for sur-
vey. Right, Percentage estimated for
each of 5 FRS categories by a model
with CRP (3 categories) adjusted for FRS
(continuous) and survey. Probability val-
ues indicate significance status of CRP
in the Cox model. MONICA/KORA-
Augsburg Cohort Study, 1984 to 1998.
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of CRP contributes significantly to the prediction of a first
coronary event and adds clinically relevant information to the
TC/HDL-C ratio. Finally, and most importantly, these pro-
spective data from a large European cohort of middle-aged
men clearly suggest that CRP modulates the risk conveyed by
the FRS as the HRs from the top to the bottom category
decreased remarkably after inclusion of CRP in the various
models. This was observed in particular in those with an FRS
between 10% and 20% over a period of 10 years. These men
may benefit from additional noninvasive tests such as deter-
mination of CRP by a hs assay.
Such conclusions are in agreement with recent findings by
Albert et al.16 They found significant correlations between
CRP concentrations and the FRS but only minimal correla-
tions with its individual components. However, our data are
in contrast to a report from the Rotterdam Study,17 which
found no additional value of CRP in elderly people. Such
discrepancy may be explained by differences in age, the
additional inclusion of left ventricular hypertrophy, another
important risk marker, and the fact that CRP concentrations in
incident cases were considerably lower than in our study
despite the older average age in the Rotterdam population.
In summary, our data confirm and extend results from the
Women’s Health Study2 in a large sample of men from the
general population. If these findings can be replicated in other
populations, this may represent a strong argument for the
inclusion of CRP as an additional variable to further improve
risk prediction in asymptomatic subjects at intermediate risk
of CHD. This would be in line with recent American Heart
Association/Centers for Disease Control guidelines.10
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background
 
Recent trials have demonstrated better outcomes with intensive than with moderate
statin treatment. Intensive treatment produced greater reductions in both low-density
lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship
between these two biomarkers and disease progression.
 
methods
 
We performed intravascular ultrasonography in 502 patients with angiographically doc-
umented coronary disease. Patients were randomly assigned to receive moderate treat-
ment (40 mg of pravastatin orally per day) or intensive treatment (80 mg of atorvastatin
orally per day). Ultrasonography was repeated after 18 months to measure the pro-
gression of atherosclerosis. Lipoprotein and CRP levels were measured at baseline and
follow-up.
 
results
 
In the group as a whole, the mean LDL cholesterol level was reduced from 150.2 mg per
deciliter (3.88 mmol per liter) at baseline to 94.5 mg per deciliter (2.44 mmol per liter) at
18 months (P<0.001), and the geometric mean CRP level decreased from 2.9 to 2.3 mg
per liter (P<0.001). The correlation between the reduction in LDL cholesterol levels and
that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005),
but not in either treatment group alone. In univariate analyses, the percent change in the
levels of LDL cholesterol, CRP, apolipoprotein B-100, and non–high-density lipoprotein
cholesterol were related to the rate of progression of atherosclerosis. After adjustment
for the reduction in these lipid levels, the decrease in CRP levels was independently and
significantly correlated with the rate of progression. Patients with reductions in both
LDL cholesterol and CRP that were greater than the median had significantly slower rates
of progression than patients with reductions in both biomarkers that were less than the
median (P=0.001).
 
conclusions
 
For patients with coronary artery disease, the reduced rate of progression of athero-
sclerosis associated with intensive statin treatment, as compared with moderate statin
treatment, is significantly related to greater reductions in the levels of both atherogenic
lipoproteins and CRP.
abstract
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wo recent trials demonstrated
 
that intensive lipid-lowering therapy with
statins improved clinical outcomes
 
1
 
 and
reduced the progression of atherosclerosis.
 
2
 
 Many
authorities attributed the greater benefits of inten-
sive statin therapy, as compared with moderate
statin therapy, to greater reductions in the levels of
atherogenic lipoproteins, particularly low-density
lipoprotein (LDL) cholesterol.
 
3
 
 However, statins
have a wide range of biologic effects in addition to
lipid lowering, including reductions in the levels of
C-reactive protein (CRP), a phenomenon common-
ly termed a “pleiotropic effect.”
 
4-6
 
 In both recent
comparisons, at the conclusion of the trials, CRP
levels were 30 to 40 percent lower after intensive
statin therapy than after moderate treatment.
 
4
 
 This
finding raises a provocative scientific question: Do
reductions in CRP represent an independent factor
influencing the benefits of more intensive statin
therapy?
Large observational studies have established a
strong relationship between CRP levels and the
morbidity and mortality associated with coronary
disease.
 
7-9
 
 However, the precise mechanism under-
lying the association between CRP levels and ad-
verse outcomes remains incompletely described.
Theoretically, by decreasing the levels of atherogen-
ic lipoproteins, statins could decrease systemic in-
flammation, thereby reducing CRP levels. An alter-
native hypothesis proposes that statins have direct
antiinflammatory effects, independent of their lip-
id-lowering capabilities. In this model, CRP plays a
more direct role in the pathogenesis of atheroscle-
rosis, and a statin-mediated reduction in inflamma-
tion contributes directly to reduced disease activity.
Because statins decrease the levels of both LDL cho-
lesterol and CRP, it is difficult to determine whether
CRP is an indirect biomarker reflecting the benefits
of statins or a direct participant in atherogenesis.
Intravascular ultrasonography is a useful tech-
nique for assessing the effect of therapies on the
vascular wall, providing a precise and continuous
measure of the progression of atherosclerosis. In
the Reversal of Atherosclerosis with Aggressive Lip-
id Lowering (REVERSAL) trial, intensive therapy
with 80 mg of atorvastatin per day slowed the pro-
t
 
Table 1. Laboratory Values at Baseline and Follow-up and Change in Values from Baseline.*
Characteristic
Both Groups 
(N=502)
Pravastatin Group
(N=249)
Atorvastatin Group
(N=253) P Value†
Baseline
 
Total cholesterol (mg/dl) 232.2±34.2 232.6±34.1 231.8±34.2 0.80
LDL cholesterol (mg/dl) 150.2±26.9 150.2±25.9 150.2±27.9 0.99
HDL cholesterol (mg/dl) 42.6±10.7 42.9±11.4 42.3±9.9 0.51
Non-HDL cholesterol (mg/dl) 189.6±32.5 189.7±32.3 189.5±32.7 0.96
Triglycerides (mg/dl) 197.4±100.6 197.7±105.6 197.2±95.7 0.96
Apo B-100 (mg/dl) 152.7±23.4 153.0±22.4 152.4±24.3 0.79
CRP (mg/liter)‡ 0.46
Geometric mean 2.9 3.0 2.8
Interquartile range 1.4 to 6.1 1.4 to 6.1 1.3 to 6.3
 
18-Mo follow-up
 
Total cholesterol (mg/dl) 169.2±40.0 187.5±32.2 151.3±38.9 <0.001
LDL cholesterol (mg/dl) 94.5±32.2 110.4±25.8  78.9±30.2  <0.001
HDL cholesterol (mg/dl) 43.8±11.3 44.6±11.3  43.1±11.3 0.15
Non-HDL cholesterol (mg/dl) 125.4±39.6 142.9±32.2 108.1±38.6 <0.001
Triglycerides (mg/dl) 157.0±93.8 165.8±92.1 148.4±94.9 0.04
Apo B-100 (mg/dl) 104.8±29.1 118.1±24.0  91.8±27.9 <0.001
CRP (mg/liter)‡ <0.001
Geometric mean 2.3 2.9 1.8
Interquartile range 0.9 to 5.4 1.3 to 6.2 0.8 to 4.3
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gression of atherosclerosis more than did moder-
ate treatment with 40 mg of pravastatin per day.
 
2
 
We applied statistical methods to examine the rela-
tionship between the reductions in LDL cholesterol
and CRP levels and the rate of disease progression
measured by intravascular ultrasonography.
 
study design
 
The institutional review board of each participat-
ing center approved the protocol, and all patients
provided written informed consent. Intravascular
ultrasonography was performed in a single vessel
in patients who had a clinical indication for coro-
nary angiography and had stenosis of at least 20
percent on angiography. Eligible patients had to
have an LDL cholesterol level of 125 to 210 mg per
deciliter (3.23 to 5.43 mmol per liter) after a statin-
free washout period of 4 to 10 weeks. Patients were
randomly assigned to receive either 40 mg of prav-
astatin or 80 mg of atorvastatin orally daily. The pa-
tients and all study personnel were unaware of the
treatment assignments or the results of laboratory
measurements.
 
intravascular ultrasonography
 
Investigators performed intravascular ultrasonogra-
phy in the longest and least angulated target vessel
that met the inclusion criteria. After the adminis-
methods
 
* Plus–minus values are means ±SD. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To con-
vert values for triglycerides to millimoles per liter, multiply by 0.01129.
† P values were calculated by means of the two-sample t-test.
‡ CRP levels were not available for six patients at baseline or follow-up (one in the pravastatin group and five in the atorva-
 
statin group).
 
Table 1. (Continued.)
Characteristic
Both Groups 
(N=502)
Pravastatin Group
(N=249)
Atorvastatin Group
(N=253) P Value†
Change from baseline
 
Total cholesterol <0.001
Mean (mg/dl) ¡63±44 ¡45±37 ¡81±43
Percent ¡26.3 ¡18.4 ¡34.1
LDL cholesterol  <0.001
Mean (mg/dl) ¡56±37 ¡40±29 ¡71±37
Percent ¡35.8 ¡25.2 ¡46.3
HDL cholesterol  0.11
Mean (mg/dl) 1.2±7.9 1.6±7.7 0.8±8.0
Percent 4.2 5.6 2.9
Non-HDL cholesterol <0.001
Mean (mg/dl) ¡64±43 ¡47±35 ¡81±43
Percent ¡33.0 ¡23.6 ¡42.2
Triglycerides 0.002
Mean (mg/dl) ¡40±96 ¡32±94 ¡49±98
Percent ¡13.5 ¡6.8 ¡20.0
Apo B-100 <0.001
Mean (mg/dl) ¡48±30 ¡35±25 ¡61±30
Percent ¡30.6 ¡22.0 ¡39.1
CRP‡ <0.001
Geometric mean (mg/liter) ¡0.2 0.2 ¡0.7
Interquartile range (mg/liter) ¡1.9 to 0.8 ¡1.5 to 1.6 ¡2.8 to 0.1
Percent ¡22.4 –5.2 ¡36.4
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tration of intracoronary nitroglycerin, the transduc-
er was positioned in the distal vessel and withdrawn
at a rate of 0.5 mm per second (the “pullback”) with
the use of a motor drive. A core laboratory evaluat-
ed the image quality of each ultrasonogram, and
only patients whose ultrasonograms met prespeci-
fied image-quality requirements were eligible for
randomization. After an 18-month treatment peri-
od, patients again underwent intravascular ultraso-
nography under identical conditions. This method
of intravascular ultrasonography has been described
previously in detail.
 
2,10,11
 
core laboratory measurements
 
Personnel who were unaware of the patients’ clin-
ical characteristics and treatment assignments
used manual planimetry to measure, on a computer
screen, a series of cross-sections of ultrasonograph-
ic images selected exactly 1.0 mm apart along the
long axis of the vessel. Measurements were per-
formed in accordance with the standards of the
American College of Cardiology and the European
Society of Cardiology.
 
12
 
 For each cross-section ana-
lyzed, the operator measured the area of the exter-
nal elastic membrane and the lumen. The accuracy
and reproducibility of this method have been report-
ed previously.
 
2,13
 
calculation of end points
 
The average area of atheroma per cross-section was
calculated as follows:
 
S
 
(EEM
 
CSA
 
– LUMEN
 
CSA
 
),
n
where EEM
 
CSA
 
 is the cross-sectional area of the
external elastic membrane, LUMEN
 
CSA
 
 is the cross-
sectional area of the lumen, and n is the number of
cross-sections in the pullback. To compensate for
pullbacks of differing lengths, the total atheroma
volume for each patient was calculated as the av-
erage area of atheroma multiplied by the median
number of cross-sections in the pullbacks for all
patients in the study. The efficacy variable “change
in normalized total atheroma volume” (TAV) was
calculated as TAV
 
18
 
 months
 
¡TAV
 
baseline
 
. The percent
atheroma volume (PAV) was calculated with the use
of the following formula:
 
S
 
(EEM
 
CSA
 
– LUMEN
 
CSA
 
)
¬100.
 
 
S
 
EEM
 
CSA
 
The efficacy variable “change in PAV” was calculat-
ed as PAV
 
18 
 
months
 
–PAV
 
baseline
 
.
 
laboratory tests
 
A central laboratory performed all biochemical de-
terminations (Medical Research Laboratory, High-
land Heights, Ky.).
 
statistical analysis
 
For continuous variables with a normal distribution,
means 
 
±
 
SD are reported. For CRP levels, the geo-
metric means and interquartile ranges are report-
ed. Because the ultrasonographic end points were
not normally distributed, we applied an analysis-of-
covariance model to rank-transformed data to deter-
mine P values. Correlations between variables are
described with the use of Spearman rank-correla-
tion coefficients, and multivariate regression analy-
ses based on rank-transformed data were used to
obtain partial correlation coefficients adjusted for
the effects of covariates.
 
14
 
 The ultrasonographic
variable served as the dependent variable; the inde-
pendent variables consisted of the change in CRP
coupled with the change in non–high-density lipo-
protein (non-HDL) cholesterol, LDL cholesterol, or
apolipoprotein B-100 (apo B-100). For a further de-
scription of bivariate relationships with ultrasono-
graphic end points, we used the locally weighted
scatterplot smoothing (LOWESS) technique.
 
15
 
 This
technique is designed to produce a smooth fit to
the data and reduces the influence of extreme out-
liers. Analyses were performed with the use of SAS
software, version 6.12.
 
patient population
 
Between June 1999 and September 2001, 502 pa-
tients were enrolled at 34 U.S. centers and under-
went intravascular ultrasonography at both base-
line and 18 months of follow-up that could be
evaluated (249 in the pravastatin group and 253 in
the atorvastatin group). The average age was 56
years, 72 percent were men, 89 percent were white
(race was recorded by the study coordinators on the
case-report form), 26 percent were current smok-
ers, 69 percent had a history of hypertension, and
19 percent had a history of diabetes.
 
2
 
laboratory findings and results 
of intravascular ultrasonography 
 
Table 1 summarizes laboratory values at baseline
and at the completion of the study (18 months) for
the entire population and each treatment group. For
 
results
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all 502 patients, the mean baseline LDL cholester-
ol level was 150.2 mg per deciliter (3.88 mmol per
liter), the non-HDL cholesterol level was 189.6 mg
per deciliter (4.90 mmol per liter), and the geomet-
ric mean CRP level was 2.9 mg per liter. After 18
months of treatment, the mean LDL cholesterol lev-
el was 94.5 mg per deciliter (2.44 mmol per liter),
the non-HDL cholesterol level was 125.4 mg per
deciliter (3.24 mmol per liter), and the geometric
mean CRP level was 2.3 mg per liter. There were
greater reductions in LDL cholesterol, non-HDL
cholesterol, and CRP levels in the atorvastatin group
than in the pravastatin group (P<0.001 for each
comparison).
 
2
 
Table 2 summarizes measures of disease burden
as determined by intravascular ultrasonography at
baseline and the completion of the study for the en-
tire population and the two treatment groups. Both
measures of the progression of atherosclerosis —
total atheroma volume and percent atheroma vol-
ume — reflected a slower rate of progression in the
group that received intensive treatment with ator-
vastatin than in the group that received moderate
treatment with pravastatin.
 
correlation between reductions 
in lipoprotein and crp
 
There was a weak but significant correlation be-
tween the percent reductions in LDL cholesterol and
in CRP levels only for the study group as a whole
(r=0.13, P=0.005) — not for the pravastatin group
alone (r=¡0.008, P=0.90) or the atorvastatin group
alone (r=0.09, P=0.17). Changes in other athero-
genic lipoproteins, such as apo B-100 and non-HDL
cholesterol, had similarly weak correlations with the
reduction in CRP levels in the regression analysis.
 
effect of changes in crp and lipids 
on progression
 
Table 3 summarizes the correlations between the
changes in the levels of atherogenic lipoproteins,
CRP, and HDL cholesterol and the rate of progres-
 
* Values in parentheses are interquartile ranges.
† P values were calculated with the use of the Wilcoxon rank-sum test.
‡ Values were adjusted for pullbacks of different lengths by multiplying the average area of atheroma volume for each patient by the median 
 
number of cross-sections in the pullbacks for all patients in the study.
 
Table 2. Baseline and Follow-up Values for Intravascular Ultrasonographic End Points and Change in Values from Baseline.*
Atheroma Volume Both Groups (N=502) Pravastatin Group (N=249) Atorvastatin Group (N=253) P Value†
 
Mean ±SD Median Mean ±SD Median Mean ±SD Median
 
Baseline
 
Total (mm
 
3
 
) 189.4±115.3 165.9
(113.8 to 238.9)
194.5±114.8 168.6
(117.4 to 246.2)
184.4±115.7 161.9
(111.0 to 228.2)
0.20
Normalized
 
 
 
total (mm
 
3
 
)‡ 184.1±83.1 174.5
(122.1 to 232.3)
189.1±86.5 187.2
(122.1 to 239.1)
179.1±79.4 166.6
(122.4 to 226.6)
0.26
Percent 38.9±11.0 38.9
(32.2 to 46.2)
39.5±10.8 40.0
(32.5 to 46.3)
38.4±11.3 38.2
(31.7 to 45.8)
0.18
 
18-Mo follow-up
 
Total (mm
 
3
 
) 191.7±110.7 169.9
(113.3 to 244.0)
199.6±112.3 180.0
(125.5 to 255.3)
183.9±108.8 160.9
(107.4 to 240.3)
0.04
Normalized
 
 
 
total (mm
 
3
 
)‡ 186.5±81.5 175.7
(124.5 to 239.2)
194.2±86.0 179.7
(128.9 to 248.2)
178.9±76.2 170.5
(119.8 to 222.2)
0.08
Percent 40.2±10.5 39.9
(33.8 to 47.1)
41.4±10.0 41.8
(35.0 to 47.7)
39.0±10.8 38.7
(31.6 to 45.7)
<0.001
 
Change from baseline
 
Total (mm
 
3
 
) 2.3±31.7 1.4
(¡14.4 to 19.5)
5.1±31.4 4.4
(¡13.3 to 21.9)
¡0.4±31.8 ¡0.9
(¡14.5 to 13.8)
0.04
Normalized
 
 
 
total (mm
 
3
 
)‡ 2.4±29.4 1.5
(¡15.3 to 20.1)
5.1±27.6 4.1
(¡13.2 to 23.5)
¡0.2±31.0 ¡0.9
(¡17.9 to 15.3)
0.03
Percent 1.3±5.1 0.9
(¡1.9 to 4.4)
1.9±4.9 1.6
(¡1.6 to 4.7)
0.6±5.1 0.2
(¡2.5 to 3.9)
0.002
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sion of atherosclerosis for both end points assessed
by means of intravascular ultrasonography. Univar-
iate analysis revealed significant correlations be-
tween ultrasonographic measures of disease pro-
gression and laboratory measures of atherogenic
lipoproteins, including LDL cholesterol, apo B-100,
and non-HDL cholesterol. The percent change in
the LDL cholesterol level had the closest correlation
with progression, with a correlation coefficient of
0.12 for total atheroma volume (P=0.005) and of
0.14 for percent atheroma volume (P=0.002).
The correlations between the reduction in CRP
levels and the rates of progression on intravascular
ultrasonography were also significant and similar
in strength to the relationships observed for the
atherogenic lipoproteins. Univariate analysis yield-
ed a correlation coefficient of 0.11 for both total and
percent atheroma volume (P=0.02 and P=0.01, re-
spectively). Most correlations between the rates of
progression on ultrasonography and the percent
change in non-HDL cholesterol, LDL cholesterol,
and CRP levels remained significant on multivariate
analysis but were weaker than those obtained by
univariate analyses (Table 3).
As shown in Figure 1, greater reductions in LDL
cholesterol levels were associated with slower rates
of progression on intravascular ultrasonography.
Figure 2 shows this same relationship for the re-
duction in CRP levels. Patients with the largest re-
ductions in CRP levels had regression of atheroma,
as evidenced by progression rates of less than zero.
Table 4 shows the rates of progression of ath-
erosclerosis on ultrasonography for subgroups de-
fined according to whether the reductions in LDL
cholesterol or CRP levels were greater than or less
than the median decreases. For both efficacy mea-
sures, the highest rates of progression were in the
subgroup in which decreases in both LDL choles-
terol and CRP levels were less than the median. Sig-
nificantly lower progression rates were observed in
the subgroup with decreases in both LDL cholester-
ol and CRP levels that were greater than the median
(P=0.001 for both efficacy measures).
Epidemiologic evidence has established a strong
relationship between elevated levels of atherogenic
lipoproteins, particularly LDL cholesterol, and the
risk of death and complications from cardiovascu-
lar causes. Placebo-controlled trials of statins have
demonstrated that pharmacologic therapies that re-
duce LDL cholesterol levels also proportionally de-
crease cardiovascular risk.
 
16-19
 
 Accordingly, the
clinical benefits of statin therapy have largely been
attributed to reductions in the levels of atherogenic
lipoproteins. However, observational studies have
also established a strong relationship between the
levels of CRP, the most stable and reliable labora-
tory measure of systemic inflammation, and adverse
discussion
 
* Values are Spearman rank-correlation coefficients.
 
Table 3. Relationships between Changes in Laboratory Measures 
and Intravascular Ultrasonographic End Points.
Laboratory Measure
Percent Atheroma
Volume
Total Atheroma 
Volume
 
Correlation
Coefficient*
P
Value
Correlation
Coefficient*
P
Value
 
Univariate analysis
 
LDL cholesterol
Change 0.10 0.03 0.09 0.04
Percent change 0.14 0.002 0.12 0.005
HDL cholesterol
Change ¡0.04 0.40 ¡0.01 0.84
Percent change ¡0.04 0.42 ¡0.01 0.78
Triglycerides
Change 0.05 0.23 0.06 0.19
Percent change 0.08 0.08 0.08 0.09
Non-HDL cholesterol
Change 0.09 0.05 0.07 0.10
Percent change 0.13 0.004 0.10 0.02
apo B-100
Change 0.09 0.05 0.08 0.06
Percent change 0.13 0.004 0.12 0.008
CRP
Change 0.11 0.01 0.11 0.02
Percent change 0.11 0.01 0.11 0.02
 
Multivariate analysis (adjusted for changes 
in CRP and non-HDL cholesterol)
 
Percent change in non-HDL 
cholesterol
0.11 0.01 0.08 0.06
Percent change in CRP 0.09 0.04 0.09 0.05
 
Multivariate analysis (adjusted for changes 
in CRP and LDL cholesterol)
 
Percent change in LDL 
cholesterol
0.12 0.008 0.11 0.02
Percent change in CRP 0.09 0.04 0.08 0.06
 
Multivariate analysis (adjusted for changes 
in CRP and apo B-100)
 
Percent change in apo B-100 0.11 0.01 0.10 0.03
Percent change in CRP 0.09 0.05 0.08 0.07
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cardiovascular outcomes. Statins have a variety of
pleiotropic properties, including their ability to in-
duce dose-dependent decreases in the levels of CRP
and other inflammatory biomarkers.
 
5,6
 
 Since stat-
ins reduce the levels of both LDL cholesterol and
CRP, it is difficult to determine the relative contribu-
tion of the reduction in each of these biomarkers to
the observed clinical benefits.
We sought to close this gap in knowledge by an-
alyzing the correlation among lipid levels, CRP lev-
els, and the rate of progression of atherosclerosis,
using intravascular ultrasonography to measure dis-
ease progression in patients who were being treat-
ed with statins.
 
2
 
 Intravascular ultrasonography is
a useful technique for assessing the effect of thera-
pies on the vascular wall, providing a precise and
continuous measure of disease progression.
 
20
 
 In
the REVERSAL trial, intensive therapy with 80 mg
of atorvastatin per day slowed the rate of progres-
sion of atherosclerosis more than did moderate
treatment with 40 mg of pravastatin per day. Be-
cause we studied two different intensities of statin
therapy, we evaluated a broad range of reductions
in LDL cholesterol and CRP, permitting a post hoc
analysis of the relationship between these two bio-
markers and the rate of progression of atheroscle-
rosis across a clinically important range of values.
Correlation analysis revealed that reductions
in the levels of atherogenic lipoproteins were not
closely correlated with reductions in CRP levels.
There was a weak but significant correlation be-
tween the reduction in LDL cholesterol levels and
the reduction in CRP levels for the overall group of
502 patients (r=0.13, P=0.005), but not in either
treatment group alone. These data demonstrate that
statin-mediated reductions in CRP are largely unre-
lated to the decrease in LDL cholesterol levels. These
findings confirm the work of other investigators
and strongly suggest that the statin-mediated re-
duction in CRP is unlikely to be a secondary conse-
quence of a reduction in LDL cholesterol but, rather,
is potentially mediated by independent pathways.
 
21
 
Analysis of the relationship among lipopro-
tein levels, CRP levels, and the rate of progression
of atherosclerosis yielded particularly informative
results. Reductions in both LDL cholesterol and
CRP levels were significantly correlated to the rate
of progression. In univariate analyses, both ultra-
sonographic measures of progression — the change
in the normalized total atheroma volume and the
change in percent atheroma volume — correlated
significantly with the reduction in the levels of ath-
erogenic lipoproteins, including LDL cholesterol,
non-HDL cholesterol, and apo B-100. The clos-
est correlation was between the LDL cholesterol
level and the percent atheroma volume (r=0.14,
P=0.002). However, similar correlations were ob-
served for the relationship between the reduction
in CRP levels and the rate of progression on intra-
vascular ultrasonography (r=0.11, P=0.01). Substi-
tuting non-HDL cholesterol for LDL cholesterol,
to account for the broad range of atherogenic lipo-
proteins, did not increase the correlation. Since the
levels of both CRP and LDL cholesterol showed rel-
atively weak correlations with the ultrasonographic
end points (r values of 0.11 to 0.14), this analysis
 
Figure 1. Locally Weighted Smoothed Scatterplots Showing the Relationship 
between the Change in LDL Cholesterol Levels and the Rate of Progression 
of Atherosclerosis in the Entire Group of 502 Patients.
 
In each plot, the solid line represents the point estimates and the upper 
and lower lines the 95 percent confidence intervals. To convert values for LDL 
cholesterol to millimoles per liter, multiply by 0.02586.
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demonstrates that biomarkers can account for only
a small fraction of the observed progression rate.
To determine whether the reduction in CRP lev-
els represented an independent factor influencing
the progression of atherosclerosis, we adjusted the
CRP correlations for the effects of atherogenic lipo-
proteins. In this multivariate analysis, CRP remained
significant in most analyses, regardless of which
measure of atherogenic lipoproteins was used —
LDL cholesterol, apo B-100, or non-HDL cholester-
ol. Patients with reductions in the levels of both LDL
cholesterol and CRP that were greater than the me-
dian reduction had significantly lower progression
rates than patients in whom the reductions were
less than the median decrease (P=0.001). These data
provide evidence that the reduction in CRP levels
plays an independent role in the beneficial effects
of statins on the progression of coronary athero-
sclerosis.
Since measures of progression reflected by intra-
vascular ultrasonography are not normally distrib-
uted, we used LOWESS methods to illustrate the
relationships between the reductions in LDL cho-
lesterol and CRP levels and the rates of progres-
sion determined by ultrasonography (Fig. 1 and 2).
These plots demonstrated a continuous relationship
between the magnitude of reduction in either LDL
cholesterol or CRP levels and the rates of progres-
sion of atherosclerosis for both measures of effi-
cacy. Atherosclerosis regressed in patients with the
greatest reduction in CRP levels, but not in those
with the greatest reduction in LDL cholesterol lev-
els. Although the data are not provided in this arti-
cle, LOWESS plots showed slower rates of progres-
sion in the intensively treated atorvastatin subgroup
across a broad range of reductions in lipids and CRP.
The slower rate of progression in the atorvastatin
group for any magnitude of reduction in LDL cho-
lesterol levels can be partially explained by the ad-
ditional effects of treatment on the reduction in CRP
levels, just as the differences in the CRP plots can
be partially explained by the additional reduction
in LDL cholesterol levels effected by atorvastatin
therapy. Thus, the effects of the reductions in both
LDL cholesterol and CRP levels must be considered
to explain the observed differences in progression
between atorvastatin and pravastatin treatment.
Our findings have important implications for
understanding the pathogenesis of the progression
of atherosclerosis and the mechanism of benefit
of statin therapy. The Pravastatin or Atorvastatin
and Infection Therapy (PROVE IT) trial demon-
strated improved outcomes
 
1
 
 and the REVERSAL tri-
al demonstrated reduced rates of progression of
atherosclerosis
 
2
 
 after intensive, as compared with
moderate, statin therapy. Although a single trial had
previously shown that the effects of statins are evi-
dent within 16 weeks,
 
22
 
 the rapidity of the diver-
gence in results between the treatment groups in
both trials was unexpected.
 
4
 
 In most earlier place-
bo-controlled trials, differences between statins
and placebo were not evident for the first two years
after randomization.
 
16-18
 
 However, in both the
REVERSAL and PROVE IT trials, CRP levels were
30 to 40 percent lower at the conclusion of the trial
in the intensively treated patients than in the group
that received moderate treatment, which may ex-
 
Figure 2. Locally Weighted Smoothed Scatterplots Showing the Relationship 
between the Changes in CRP Levels and the Rate of Progression of Athero-
sclerosis in the Entire Group of 502 Patients.
 
In each plot, the solid line represents the point estimates and the upper 
and lower lines the 95 percent confidence intervals.
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plain the magnitude and unexpectedly rapid diver-
gence of outcomes reported by Ridker et al. else-
where in this issue of the 
 
Journal
 
.
 
23
 
Our findings are consistent with a variety of ex-
perimental observations that suggest a direct role
for CRP in the pathogenesis of atherosclerosis.
CRP renders oxidized LDL more susceptible to
uptake by macrophages, induces the expression
of vascular-cell adhesion molecules, stimulates the
production of tissue factor, and impairs the produc-
tion of nitric oxide.
 
24-27
 
 Children with elevated CRP
levels have increased carotid intimal medial thick-
ness and reduced vasodilatation mediated by bra-
chial-artery flow.
 
28
 
 A recent study suggested that
the presence of above-average levels of CRP attenu-
ates the benefits of intensive statin therapy with re-
spect to the carotid intimal media thickness.
 
29
 
Evidence of a dual mechanism of benefit for
statins — lipid lowering and a reduction in inflam-
mation — has important implications for current
and future treatment of atherosclerosis. Current
guidelines emphasize the use of lipid-lowering ther-
apies to reach target levels of LDL cholesterol, non-
HDL cholesterol, or both. However, individual agents
differ in their ability to reduce the levels of inflam-
matory biomarkers. Accordingly, our study raises
the provocative question of whether the effects of
statins on CRP, as well as LDL cholesterol, should
be considered in decisions regarding therapy.
Our study has important limitations. It is a hy-
pothesis-generating post hoc analysis examining
the effect of a single inflammatory marker on dis-
ease progression, not morbidity or mortality. None-
theless, our findings suggest that the level of CRP
may ultimately represent an important therapeutic
target. We do not believe that these data are suffi-
cient to recommend routine serial measurement of
CRP in order to modulate statin therapy, but further
study is warranted. An ongoing clinical trial is as-
sessing the use of CRP levels to guide therapy in pa-
tients who do not have elevated LDL cholesterol
levels.
 
30
 
 Since approaches to the reduction of LDL
cholesterol levels that do not involve statins have
uncertain antiinflammatory effects, the ability of
such therapies to improve the outcome requires
testing in clinical trials.
 
31
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* CRP levels were not available for six patients at baseline or follow-up. The subgroups were formed on the basis of the median percent change 
in LDL cholesterol of ¡37.1 percent and the median percent change in CRP of ¡21.4 percent.
† Values in parentheses are interquartile ranges. Confidence intervals (CIs) are for the medians.
‡ P=0.001 for the comparison with the subgroup in which the reduction in the levels of both LDL cholesterol and CRP was less than the median 
 
reduction (by Wilcoxon’s rank-sum test).
 
Table 4. Rates of Progression According to the Change in LDL Cholesterol and CRP Levels.*
Subgroup
No. of
Patients Percent Atheroma Volume† Total Atheroma Volume (mm
 
3
 
)†
 
Median 95% CI Mean ±SD Median 95% CI Mean ±SD
Reduction in LDL cholesterol and 
CRP both greater than median
141 0.24 (¡2.8 to 3.5)‡ ¡0.77 to 0.54 0.33±5.3 ¡1.98 (¡23.0 to 10.8)‡ ¡6.26 to 3.67 ¡2.41±31.6
Reduction in LDL cholesterol 
greater than median, reduc-
tion in CRP less than median
106 0.81 (¡2.0 to 4.8) ¡0.32 to 1.81 1.62±4.7 2.06 (¡12.8 to 21.5) ¡3.26 to 6.41 4.04±28.7
Reduction in LDL cholesterol less 
than median, reduction in 
CRP greater than median
108 1.21 (¡2.0 to 4.0) ¡0.31 to 2.08 0.91±4.9 ¡1.04 (¡18.6 to 22.5) ¡6.78 to 8.74 1.42±29.2
Reduction in LDL cholesterol and 
CRP both less than median
141 1.82 (¡1.5 to 5.1) 1.0 to 2.84 2.25±5.0 8.21 (¡11.8 to 27.5) 0.40 to 13.05 7.49±27.5
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C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION
IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
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BSTRACT
 
Background
 
Since inflammation is believed to have
a role in the pathogenesis of cardiovascular events,
measurement of markers of inflammation has been
proposed as a method to improve the prediction of
the risk of these events.
 
Methods
 
We conducted a prospective, nested case–
control study among 28,263 apparently healthy post-
menopausal women over a mean follow-up period
of three years to assess the risk of cardiovascular
events associated with base-line levels of markers of
inflammation. The markers included high-sensitivity
C-reactive protein (hs-CRP), serum amyloid A, inter-
leukin-6, and soluble intercellular adhesion molecule
type 1 (slCAM-1). We also studied homocysteine and
several lipid and lipoprotein measurements. Cardio-
vascular events were defined as death from coro-
nary heart disease, nonfatal myocardial infarction
or stroke, or the need for coronary-revascularization
procedures.
 
Results
 
Of the 12 markers measured, hs-CRP was
the strongest univariate predictor of the risk of car-
diovascular events; the relative risk of events for wom-
en in the highest as compared with the lowest quar-
tile for this marker was 4.4 (95 percent confidence
interval, 2.2 to 8.9). Other markers significantly asso-
ciated with the risk of cardiovascular events were se-
rum amyloid A (relative risk for the highest as com-
pared with the lowest quartile, 3.0), slCAM-1 (2.6),
interleukin-6 (2.2), homocysteine (2.0), total choles-
terol (2.4), low-density lipoprotein (LDL) cholesterol
(2.4), apolipoprotein B-100 (3.4), high-density lipopro-
tein (HDL) cholesterol (0.3), and the ratio of total cho-
lesterol to HDL cholesterol (3.4). Prediction models that
incorporated markers of inflammation in addition to
lipids were significantly better at predicting risk than
models based on lipid levels alone (P<0.001). The lev-
els of hs-CRP and serum amyloid A were significant
predictors of risk even in the subgroup of women
with LDL cholesterol levels below 130 mg per deciliter
(3.4 mmol per liter), the target for primary preven-
tion established by the National Cholesterol Educa-
tion Program. In multivariate analyses, the only plas-
ma markers that independently predicted risk were
hs-CRP (relative risk for the highest as compared with
the lowest quartile, 1.5; 95 percent confidence inter-
val, 1.1 to 2.1) and the ratio of total cholesterol to HDL
cholesterol (relative risk, 1.4; 95 percent confidence
interval, 1.1 to 1.9).
 
Conclusions
 
The addition of the measurement of
C-reactive protein to screening based on lipid levels
may provide an improved method of identifying wom-
en at risk for cardiovascular events. (N Engl J Med
2000;342:836-43.)
 
©2000, Massachusetts Medical Society.
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ALF of all myocardial infarctions occur in
persons in whom plasma lipid levels are
normal.
 
1
 
 In an effort to better identify
patients at high risk for cardiovascular
events, several markers of risk have been proposed for
use in screening, including homocysteine and fibrin-
ogen levels, fibrinolytic capacity, and levels of apolipo-
protein A-I, apolipoprotein B-100, and Lp(a) lipo-
protein. However, the clinical value of many of these
markers has been limited because of inadequate stand-
ardization of assay conditions, inconsistency of pro-
spective data, or lack of evidence of significant im-
provement in the prediction of risk over that afforded
by standard lipid screening alone.
 
2
 
With the recognition that atherosclerosis is an in-
flammatory process,
 
3
 
 several plasma markers of inflam-
mation have also been evaluated as potential tools for
prediction of the risk of coronary events. Among them
are markers of systemic inflammation produced in
the liver, such as high-sensitivity C-reactive protein
(hs-CRP) and serum amyloid A; cytokines such as
interleukin-6; and adhesion molecules such as soluble
intercellular adhesion molecule type 1 (sICAM-1).
 
4-11
 
However, as with other proposed predictors of the
risk of cardiovascular events, the prognostic value of
these markers of inflammation remains uncertain. For
example, a widely held clinical view is that levels of
markers of inflammation vary too greatly over time
to allow accurate prediction of risk. Furthermore, few
prospective studies have measured all these markers
of inflammation in a single group of patients, so the
relative usefulness of each marker cannot be easily
evaluated. In addition, data supporting the hypothe-
sis that markers of inflammation significantly increase
the predictive value of lipid screening are scant and
are limited almost exclusively to data from studies of
hs-CRP in middle-aged men.
 
7,12
 
 Finally, clinical appli-
cation of these findings has been limited, since stand-
ardized, commercial assays for most markers of in-
flammation are only now being developed.
In a previous study, in which we used an experi-
mental assay for hs-CRP, we found higher levels of this
marker among healthy postmenopausal women par-
ticipating in the Women’s Health Study who subse-
H
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quently had cardiovascular events than among those
who did not have such events.
 
13
 
 On the basis of that
finding and in the effort to address the clinical issues
outlined above, we used a commercial assay to meas-
ure hs-CRP in the same cohort and simultaneously
measured plasma levels of serum amyloid A, interleu-
kin-6, sICAM-1, total cholesterol, low-density lipo-
protein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, the ratio of total cholesterol to
HDL cholesterol, apolipoprotein A-I, and apolipopro-
tein B-100. In addition, to allow comparison with oth-
er proposed markers, we measured plasma levels of
Lp(a) lipoprotein and homocysteine. We thus were
able to evaluate directly the relative value of each of
these 12 measurements as an independent predictor
of future cardiovascular events in a large cohort of ap-
parently healthy women. We also sought to determine
whether the measurement of markers of inflamma-
tion in addition to standard screening of lipid levels
might provide a clinically useful method for improving
overall prediction of the risk of cardiovascular events.
 
METHODS
 
Study Participants
 
We designed a prospective, nested case–control study involving
participants in the Women’s Health Study, an ongoing trial of as-
pirin and vitamin E for primary prevention among postmenopaus-
al women with no history of cardiovascular disease or cancer.
 
14
 
Blood samples were collected in tubes containing EDTA at base
line from 28,263 women (71 percent of the Women’s Health Study
participants) and stored in liquid nitrogen until the time of analysis.
For this analysis, case subjects were study participants from whom
a base-line blood sample was obtained who subsequently had a car-
diovascular event (defined as death from coronary heart disease,
nonfatal myocardial infarction or stroke, or a coronary-revascular-
ization procedure) during a mean follow-up period of three years.
Myocardial infarction was classified as confirmed if symptoms met
the criteria of the World Health Organization
 
15
 
 and if the event
was associated with abnormal levels of cardiac enzymes or diag-
nostic electrocardiographic changes. Stroke was classified as con-
firmed if the patient had a new neurologic deficit that lasted more
than 24 hours. Computed tomographic scans or magnetic reso-
nance images were available for the majority of women in whom
stroke occurred. Performance of revascularization procedures was
confirmed by review of hospital records. Death from coronary heart
disease was confirmed by review of the autopsy report, the death
certificate, medical records, or information from family members
regarding the circumstances of death.
For each woman who had a confirmed cardiovascular event dur-
ing follow-up, two control subjects of the same age (within one
year) and smoking status (former smoker, current smoker, or non-
smoker) were selected from among the remaining study partici-
pants from whom a base-line blood sample had been obtained and
who remained free of reported cardiovascular disease during follow-
up. With use of these criteria, 122 case subjects and 244 control
subjects were selected.
 
Procedures
 
Base-line plasma samples from each woman with an event and
each control subject were thawed and assayed for hs-CRP, serum
amyloid A, and Lp(a) lipoprotein with use of latex-enhanced im-
munonephelometric assays on a BN II analyzer (Dade Behring,
Newark, Del.). Apolipoprotein A-I and apolipoprotein B-100 were
simultaneously measured with this device by immunoassay. Total
cholesterol, HDL cholesterol, and directly obtained LDL choles-
terol levels were measured on a Hitachi 911 analyzer (Roche Di-
agnostics, Indianapolis) with reagents from Roche Diagnostics and
Genzyme (Cambridge, Mass.). Plasma levels of sICAM-1 and inter-
leukin-6 were measured by enzyme-linked immunosorbent assay
(R & D Systems, Minneapolis), and the total plasma homocysteine
level was measured with an IMx homocysteine assay (Abbott Lab-
oratories, Abbott Park, Ill.) as previously reported.
 
16
 
 Samples were
handled in identical and in blinded fashion throughout the study.
Samples were analyzed in triplicate and in random order so as to
reduce systematic bias and interassay variation.
 
Statistical Analysis
 
Means and proportions for risk factors for cardiovascular events
at base line were calculated for women who had cardiovascular
events during follow-up and those who did not. The significance
of differences in means between the two groups was assessed with
Student’s t-test, and the significance of differences in proportions
was tested with use of the chi-square statistic. Analysis of trends was
used to test for associations between increasing levels of each plas-
ma variable and the risk of future cardiovascular events, after the
sample was divided into quartiles according to the distribution of
control values for that marker. Adjusted risk estimates were ob-
tained with use of logistic-regression models that, in addition to
accounting for the variables used for matching (age and smoking
status), adjusted for random assignment to aspirin or vitamin E in
the Women’s Health Study; several risk factors for cardiovascular
events, including a history of hypertension, body-mass index, a his-
tory of diabetes, and a parental history of myocardial infarction
before the age of 60 years; and other measured plasma markers.
We evaluated the combined role of lipid levels and markers of in-
flammation as predictors of the risk of future cardiovascular events
in a series of analyses in which we explored the sensitivity and ro-
bustness of our findings from a clinical perspective. First, we used
the likelihood-ratio test to determine whether logistic-regression
models that included measurements of lipid variables and markers
of inflammation provided a significantly better fit than did logistic-
regression models limited to lipid measurements alone. Second,
to estimate the clinical relevance of these effects, we computed the
area under receiver-operating-characteristic curves for prediction
models based on lipid measurements alone and for models based
on measurements of both lipid levels and markers of inflammation.
Third, we divided the study participants into nine groups accord-
ing to low, medium, and high levels of total cholesterol and low,
medium, and high levels of each marker of inflammation. In these
analyses, logistic regression was used to evaluate simultaneously the
risk of future cardiovascular events in each of the nine groups;
the group of women in the lowest third for total cholesterol and in
the lowest third for the respective marker of inflammation was con-
sidered the reference group. Finally, to address the clinical need for
improved assessment of risk among persons with cholesterol levels
currently considered safe, we performed a subgroup analysis of
study participants with LDL cholesterol levels of less than 130 mg
per deciliter (3.4 mmol per liter), the target level for the primary
prevention of coronary heart disease according to the current guide-
lines of the National Cholesterol Education Program.
 
17
 
All P values were two-tailed, and values of less than 0.05 were
considered to indicate statistical significance. All confidence inter-
vals were calculated at the 95 percent level.
 
RESULTS
 
The base-line characteristics of the women who
subsequently had cardiovascular events (case subjects)
and those who remained free of reported cardiovas-
cular disease (controls) are shown in Table 1. As ex-
pected, women who had cardiovascular events were
heavier at base line than those who remained free of
cardiovascular disease and were more likely to have
hypertension, diabetes, or a parental history of prema-
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ture myocardial infarction (before the age of 60 years).
The frequency of exercise, the frequency of alcohol
consumption, and rate of use of hormone-replace-
ment therapy were similar in the two groups. Because
of matching, the women who had cardiovascular
events and the control subjects were virtually identi-
cal with respect to mean age and smoking status.
Base-line plasma levels of the inflammation markers
hs-CRP (P<0.001), serum amyloid A (P=0.003),
sICAM-1 (P=0.03), and interleukin-6 (P=0.003)
were higher among the women who subsequently had
cardiovascular events than among those who did not
(Table 2). Similarly, base-line plasma levels of total
cholesterol (P=0.01), LDL cholesterol (P=0.003),
apolipoprotein B-100 (P<0.001), and homocysteine
(P=0.02) and the ratio of total cholesterol to HDL
cholesterol (P<0.001) were significantly higher among
women with subsequent events than those without
such events, whereas levels of HDL cholesterol were
significantly lower among women with subsequent
events (P<0.001). Base-line levels of Lp(a) lipoprotein
were somewhat higher and levels of apolipoprotein
A-I somewhat lower among the women with events
than among control subjects, but these differences
were not significant.
Table 3 shows the relative risks of cardiovascular
events according to the quartile of each marker of
inflammation or lipid measured in plasma. Measure-
ments of hs-CRP, serum amyloid A, sICAM-1, and
interleukin-6 were predictive of the risk of future car-
diovascular events. Of the 12 measures, the level of
hs-CRP was the most powerful predictor of risk in the
univariate analysis (relative risk for women in the high-
est quartile as compared with the lowest quartile, 4.4;
95 percent confidence interval, 2.2 to 8.9; P<0.001).
Of the lipid variables, the ratio of total cholesterol
to HDL cholesterol (relative risk, 3.4; P=0.001) and
the apolipoprotein B-100 level (relative risk, 3.4;
P=0.001) were the most powerful predictors of risk.
Nonsignificant trends were observed for apolipopro-
tein A-I and Lp(a) lipoprotein. As reported previ-
ously,
 
16
 
 increasing levels of homocysteine were also
associated with increased risk.
Levels of several markers of inflammation were
highly correlated. For example, the correlation coef-
ficient for the relation between hs-CRP and serum
 
*Because of rounding, not all percentages total 100.
†P values were not calculated for variables used in matching of case and
control subjects, since the distribution of these variables was identical in the
two groups.
‡The body-mass index is the weight in kilograms divided by the square
of the height in meters.
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Mean age (yr) 59.3 59.3 —
Mean body-mass index‡ 27.1 26.0 0.04
History of hypertension (%) 55.5 31.3 0.001
History of diabetes (%) 9.8 2.1 0.001
Parental history of myocardial
infarction before 60 yr (%)
21.3 12.7 0.04
Smoking status (%) —
Former smoker 29.5 29.5
Current smoker 27.9 27.9
Nonsmoker 42.6 42.6
Frequency of exercise (%) 0.9
>3 times/wk 6.6 8.2
1–3 times/wk 27.9 27.1
<1 time/wk 21.3 20.1
Rarely or never 44.3 44.5
Frequency of alcohol con-
sumption (%)
0.6
Daily 12.3 8.2
Weekly 27.9 31.2
Monthly 14.8 13.9
Rarely or never 45.1 46.7
Current use of hormone-
replacement therapy (%)
44.3 41.0 0.1
*Plus–minus values are means ±SD. For normally distributed variables,
P values were computed with t-tests; for non-normally distributed variables,
P values were computed with the Wilcoxon rank-sum test for the difference
in medians. LDL denotes low-density lipoprotein, and HDL high-density
lipoprotein. To convert values for cholesterol to millimoles per liter, multi-
ply by 0.02586.
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High-sensitivity C-reactive 
protein (mg/dl)
<0.001
Median 0.42 0.28
Interquartile range 0.21–0.83 0.11–0.55
Serum amyloid A (mg/dl) 0.003
Median 0.63 0.52
Interquartile range 0.45–1.01 0.35–0.78
Soluble intercellular adhesion
molecule type 1 (ng/ml)
349.7±121.3 321.3±107.4 0.03
Interleukin-6 (pg/ml) 0.003
Median 1.65 1.30
Interquartile range 1.14–2.62 1.00–2.03
Total cholesterol (mg/dl) 230.5±41.2 219.2±37.5 0.01
LDL cholesterol (mg/dl) 132.2±34.6 121.5±30.2 0.003
HDL cholesterol (mg/dl) 45.4±14.6 51.1±15.4 <0.001
Apolipoprotein A-I (mg/dl) 163.8±40.3 168.5±36.1 0.3
Apolipoprotein B-100 (mg/dl) 128.5±31.0 115.0±26.7 <0.001
Lp(a) lipoprotein (mg/liter) 0.3
Median 79 74
Interquartile range 34–247 29–203
Ratio of total cholesterol to 
HDL cholesterol
5.5±1.9 4.6±1.4 <0.001
Homocysteine (µmol/liter) 14.1±8.0 12.4±5.8 0.02
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amyloid A was 0.81 (P<0.001). In contrast, corre-
lations between markers of inflammation and lipid
measures were low; less than 10 percent of the vari-
ance in any marker of inflammation was explained by
any of the lipid measures.
To determine the independent predictive value
of each of the 12 measures, we performed a series of
logistic-regression analyses that simultaneously con-
trolled for increasing quartiles of hs-CRP, serum amy-
loid A, sICAM-1, interleukin-6, homocysteine, and
Lp(a) lipoprotein and the ratio of total cholesterol
to HDL cholesterol (because of colinearity with this
ratio, levels of apolipoprotein A-I, apolipoprotein
B-100, and LDL cholesterol were not included in
these analyses). As shown in Table 4, only the level
of hs-CRP and the ratio of total cholesterol to HDL
cholesterol were found to be independent predictors
of risk in models in which women were matched for
smoking status and age or in models that included
further adjustments for body-mass index, hyperten-
sion, diabetes, and parental history of premature cor-
onary artery disease. In similar models that were lim-
ited to markers of inflammation, hs-CRP remained an
independent predictor of the risk of future cardio-
vascular events. In contrast, the beta coefficients asso-
ciated with serum amyloid A, sICAM-1, and inter-
leukin-6 decreased substantially and were no longer
statistically significant in analyses that included con-
trol for the quartile of hs-CRP.
To explore whether any of the markers of inflam-
 
*P values were calculated by logistic-regression analyses. In all models, subjects were matched ac-
cording to age and smoking status, and all models were adjusted for random assignment to aspirin
or vitamin E. CI denotes confidence interval, LDL low-density lipoprotein, and HDL high-density
lipoprotein. To convert values for cholesterol to millimoles per liter, multiply by 0.02586.
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1 2 3 4
High-sensitivity C-reactive 
protein
Median — mg/dl 0.06 0.19 0.38 0.85
Relative risk (95% CI) 1.0 2.1 (1.0–4.5) 2.1 (1.0–4.4) 4.4 (2.2–8.9) <0.001
Serum amyloid A
Median — mg/dl 0.25 0.43 0.62 1.17
Relative risk (95% CI) 1.0 1.8 (0.9–3.6) 1.9 (0.9–3.8) 3.0 (1.5–6.0) 0.002
Soluble intercellular adhesion 
molecule type 1
Median — ng/ml 228.7 273.9 319.1 439.3
Relative risk (95% CI) 1.0 1.5 (0.7–3.1) 2.0 (1.0–4.1) 2.6 (1.3–5.1) 0.004
Interleukin-6
Median — pg/ml 0.82 1.15 1.58 2.70
Relative risk (95% CI) 1.0 1.3 (0.6–2.7) 1.4 (0.7–2.8) 2.2 (1.1–4.3) 0.02
Total cholesterol 
Median — mg/dl 176 206 224 267
Relative risk (95% CI) 1.0 1.2 (0.6–2.3) 1.7 (0.9–3.3) 2.4 (1.3–4.7) 0.003
LDL cholesterol
Median — mg/dl 88.4 108.9 127.4 156.6
Relative risk (95% CI) 1.0 0.9 (0.4–1.9) 1.7 (0.9–3.3) 2.4 (1.3–4.6) 0.001
HDL cholesterol
Median — mg/dl 34.5 44.5 54.9 68.5
Relative risk (95% CI) 1.0 0.5 (0.3–0.8) 0.5 (0.2–0.8) 0.3 (0.2–0.6) 0.001
Apolipoprotein A-I
Median — mg/dl 127 152 176 212
Relative risk (95% CI) 1.0 0.8 (0.4–1.4) 0.4 (0.2–0.8) 0.8 (0.4–1.4) 0.1
Apolipoprotein B-100
Median — mg/dl 86 104 121 149
Relative risk (95% CI) 1.0 1.1 (0.5–2.3) 1.6 (0.8–3.3) 3.4 (1.8–6.8) <0.001
Lp(a) lipoprotein
Median — mg/liter 16 55 107 329
Relative risk (95% CI) 1.0 1.0 (0.5–1.9) 1.1 (0.6–2.1) 1.3 (0.7–2.4) 0.4
Ratio of total cholesterol to 
HDL cholesterol
Median 3.06 4.00 4.80 6.34
Relative risk (95% CI) 1.0 0.8 (0.3–1.5) 1.7 (0.9–3.4) 3.4 (1.8–5.9) <0.001
Homocysteine
Median — µmol/liter 8.2 10.3 12.1 15.7
Relative risk (95% CI) 1.0 1.1 (0.6–2.2) 1.1 (0.5–2.1) 2.0 (1.1–3.8) 0.02
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mation added to the predictive value of lipid-based
screening, several additional analyses were performed.
First, we computed the relative risk of cardiovascular
events in analyses in which study participants were
stratified into nine groups according to total choles-
terol level as well as each marker of inflammation. As
shown in Figure 1, for each marker of inflammation
included in this analysis, the risk of cardiovascular
events was lowest among women with low total cho-
lesterol levels and low levels of the marker in ques-
tion. In contrast, the risk tended to be highest among
women with high total cholesterol levels and high
levels of a marker of inflammation. However, even
among the women with low total cholesterol levels,
the risk of cardiovascular events was significantly high-
er among those with high levels of hs-CRP and serum
amyloid A than among those with low levels of these
markers (Fig. 1). These associations were also evident,
but to a lesser extent, for interleukin-6 and sICAM-1.
In all of the analyses, these additive effects were ro-
bust with respect to the choice of cutoff point and the
choice of the lipid variable analyzed. For example,
the addition of hs-CRP to lipid screening produced a
significant and additive predictive effect when regres-
sion analyses were based on cutoff points for quartiles
(rather than cutoff points for the division of the study
group into thirds) and on analysis of the ratio of to-
tal cholesterol to HDL cholesterol (rather than on
total cholesterol alone).
Second, likelihood-ratio tests were used to com-
pare the fit of predictive models that were based on
measurement of a marker of inflammation in combi-
nation with lipids to the fit of models based on lipid
measurements alone. In these analyses, each of the
markers of inflammation significantly improved the
usefulness of lipid screening in predicting risk. For
example, models including both hs-CRP and total
cholesterol were significantly better in the prediction
of the risk of cardiovascular events than were models
including only total cholesterol (P<0.001). Likewise,
models involving both hs-CRP and the ratio of total
cholesterol to HDL cholesterol allowed significantly
better prediction of risk than did models based solely
on this lipid ratio alone (P<0.001). Similar additive
effects were seen for serum amyloid A, sICAM-1, and
interleukin-6 when these markers were added to mod-
els based on total cholesterol or the ratio of total cho-
lesterol to HDL cholesterol alone (P<0.01 for all
comparisons).
Third, as a measure of clinical usefulness, we com-
puted the area under the receiver-operating-character-
istic curve associated with risk-prediction models based
on lipid screening alone and compared it with those
based on a combination of lipids and markers of in-
flammation. In these analyses, the use of hs-CRP lev-
els in addition to total cholesterol increased the area
under the receiver-operating-characteristic curve from
0.59 to 0.66 (P<0.001) and in addition to the ratio
of total cholesterol to HDL cholesterol increased the
area under the curve from 0.64 to 0.68 (P<0.001).
Similar effects were observed for analyses that included
serum amyloid A, sICAM-1, and interleukin-6: the
addition of these markers to screening based on total
cholesterol increased the area under the curve from
0.59 to 0.63, 0.63, and 0.64, respectively (P<0.003
for all three comparisons). Use of the serum amy-
loid A level in addition to the ratio of total cholesterol
to HDL cholesterol increased the area under the curve
from 0.64 to 0.67 (P=0.007); the use of sICAM-1 in
addition to this ratio led to a smaller change (area un-
der the curve, 0.65; P=0.01), as did the use of inter-
leukin-6 (area under the curve, 0.65; P=0.01).
Finally, to address the clinical observation that many
persons with “safe” lipid levels nonetheless have car-
diovascular events, we performed a subgroup analysis
limited to women whose levels of LDL cholesterol
were less than 130 mg per deciliter, the target level
currently recommended for primary prevention of cor-
onary heart disease by the National Cholesterol Ed-
ucation Program.
 
17
 
 In this analysis, women with in-
creased base-line levels of hs-CRP, serum amyloid A,
interleukin-6, or sICAM-1 were found to be at in-
creased risk for future cardiovascular events. This ef-
fect was strongest for hs-CRP and serum amyloid A.
In this subgroup, the relative risks of cardiovascular
events for women in the lowest to the highest quar-
tiles of hs-CRP were 1.0, 2.4, 2.9, and 4.1 (95 percent
confidence interval for women in the highest as com-
pared with the lowest quartile, 1.7 to 11.3; P=0.002;
P for trend across quartiles, 0.005). After adjustment
 
*In all models, subjects were matched according to age and smoking sta-
tus, and all models were adjusted for random assignment to aspirin or vita-
min E. CI denotes confidence interval, and HDL high-density lipoprotein.
†These models were adjusted for the following additional risk factors:
body-mass index (the weight in kilograms divided by the square of the height
in meters), a history of hypertension, a history of diabetes, and a parental
history of myocardial infarction.
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ADJUSTED FOR OTHER 
PLASMA MARKERS AND 
RISK FACTORS†
RELATIVE RISK
(95% CI) P VALUE
RELATIVE RISK
(95% CI) P VALUE
High-sensitivity C-reac-
tive protein
1.4 (1.1–1.9) 0.02 1.5 (1.1–2.1) 0.02
Serum amyloid A 1.1 (0.8–1.4) 0.5 1.1 (0.8–1.6) 0.4
Soluble intercellular ad-
hesion molecule type 1
1.1 (0.9–1.4) 0.4 1.1 (0.8–1.4) 0.6
Interleukin-6 0.9 (0.7–1.2) 0.6 0.8 (0.6–1.1) 0.2
Homocysteine 1.1 (0.9–1.4) 0.2 1.1 (0.8–1.4) 0.6
Lp(a) lipoprotein 1.1 (0.9–1.3) 0.6 1.0 (0.8–1.2) 0.8
Ratio of total cholesterol 
to HDL cholesterol
1.4 (1.1–1.7) 0.01 1.4 (1.1–1.9) 0.02
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for body-mass index, the presence or absence of hy-
pertension, diabetes, or a parental history of premature
myocardial infarction, and the level of HDL choles-
terol, the increased risk for women in the highest
quartile of hs-CRP at base line remained statistically
significant (relative risk, 3.1; 95 percent confidence in-
terval, 1.1 to 8.3; P=0.03). Thus, even among women
with “safe” levels of LDL cholesterol, the adjusted
relative risk of cardiovascular events increased approx-
imately 39 percent with each increasing quartile for
hs-CRP (95 percent confidence interval, 13 to 89
percent; P=0.03). The mean LDL cholesterol level
in this subgroup analysis was 104 mg per deciliter
(2.7 mmol per liter).
DISCUSSION
In this prospective study of apparently healthy post-
menopausal women, four markers of inflammation
— hs-CRP, serum amyloid A, interleukin-6, and
sICAM-1 — were found to be significant predictors
of the risk of future cardiovascular events. In addition,
measurement of these markers increased the pre-
dictive value of models based only on standard lipid
screening. Of the 12 plasma measures evaluated in this
study, hs-CRP was the most significant predictor of
the risk of cardiovascular events; when measured with
a widely available, standardized commercial assay,18
this marker distinguished between women at high risk
and those at low risk, even in the subgroup of wom-
en with LDL cholesterol levels below 130 mg per dec-
iliter (mean, 104 mg per deciliter), the target consid-
ered safe in the current guidelines of the National
Cholesterol Education Program.17
The results of the current study have several im-
portant implications. First, the findings confirm that
in women, markers of inflammation are important
predictors of the risk of cardiovascular events. Previ-
ous data on this issue have been derived largely from
Figure 1. Relative Risk of Cardiovascular Events among Apparently Healthy Postmenopausal Women According to Base-Line Levels
of Total Cholesterol and Markers of Inflammation.
Each marker of inflammation improved risk-prediction models based on lipid testing alone, an effect that was strongest for hs-CRP
and serum amyloid A.
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studies of middle-aged men.4-11 Thus, from a patho-
physiologic perspective, the current data support the
hypothesis that atherosclerosis is, in part, an inflam-
matory disease.3
Second, because we used a commercially available
assay to measure plasma hs-CRP,18 our results pro-
vide clinically relevant confirmation of previous find-
ings in this cohort, which were obtained with use of
an experimental assay.13 The commercial assay is in-
expensive and can be used with standard hospital and
outpatient laboratory equipment; thus, screening for
this predictor of cardiovascular risk would be practi-
cal in many clinical settings.
Third, we believe the current results have public
health implications both in terms of the prediction of
the risk of cardiovascular events and in terms of the
use of inhibitors of 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase for primary preven-
tion. Although the results of large-scale randomized
trials have indicated that HMG-CoA reductase inhi-
bition is effective even among persons at low-to-mod-
erate risk as defined by standard lipid screening,19,20
the large number of patients who would need to be
treated and the high cost of this approach have lim-
ited the clinical application of those findings. Thus,
our observation that measurement of markers of in-
flammation such as hs-CRP can significantly improve
models for the prediction of cardiovascular risk may
lead to better clinical identification of patients who
might benefit from primary prevention and for whom
the cost-to-benefit ratio for long-term use of statins
would be improved. This issue is particularly intrigu-
ing because recent data from the Cholesterol and Re-
current Events trial indicate that long-term therapy
with pravastatin significantly lowers plasma levels of
hs-CRP21 and that the efficacy of pravastatin in low-
ering the rate of cardiovascular events is greatest in
those with increased levels of hs-CRP.22 As in the cur-
rent findings, which indicate that hs-CRP is a potent
predictor of risk regardless of the LDL cholesterol
level, data from the Cholesterol and Recurrent Events
trial indicate that use of pravastatin resulted in de-
creased levels of hs-CRP in a manner largely independ-
ent of LDL cholesterol.21
Several limitations of these analyses merit consider-
ation. First, our cohort comprised apparently healthy
postmenopausal women, and thus the results may
not apply to younger women, who may also be at
increased risk for cardiovascular events. Second, we
measured each marker of inflammation at study entry
and thus could not evaluate the effects of changes in
the levels of these markers over time. However, follow-
up studies have found that levels of hs-CRP are stable
over long periods, as long as measurements are not
made within two to three weeks of an acute infec-
tion.21,23 Moreover, with respect to the current results,
variation over time in levels of these markers and re-
gression dilution bias would tend, if anything, to lead
to an underestimation of net effects. Finally, although
base-line levels of several markers of inflammation
were greater than normal among women at risk for
future cardiovascular events, the mechanisms under-
lying these elevations remain uncertain. In this study,
we did not find significant associations between car-
diovascular risk and titers of IgG antibodies against
Chlamydia pneumoniae, Helicobacter pylori, herpes sim-
plex virus, or cytomegalovirus or between titers of
these antibodies and plasma levels of hs-CRP.24 On
the other hand, markers of inflammation, including
hs-CRP, interleukin-6, and interleukin-1–receptor
antagonist,25-31 have proved to have predictive value
among persons with unstable angina or acute coro-
nary syndromes. Thus, it is also possible that the in-
flammation that we detected in apparently healthy
women who were at risk for future cardiovascular
events may be an indirect marker of an enhanced cy-
tokine response to a variety of inflammatory stim-
uli that ultimately prove critical at the time of acute
plaque rupture.32
In conclusion, in this prospective evaluation of 12
plasma variables, hs-CRP proved to be the strongest
and most significant predictor of the risk of future
cardiovascular events. As in previous population-based
epidemiologic studies, half of all cardiovascular events
in our cohort occurred among women without overt
hyperlipidemia. Thus, these data raise the possibility
that the addition of hs-CRP to standard lipid screen-
ing will generate an improved method for identifying
persons at high risk for future cardiovascular events,
who would thus be candidates for primary-prevention
interventions such as the use of HMG-CoA reduc-
tase inhibitors.
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THEROSCLEROSIS is an inflammatory dis-
ease. Because high plasma concentrations of
cholesterol, in particular those of low-density
lipoprotein (LDL) cholesterol, are one of the prin-
cipal risk factors for atherosclerosis,
 
1
 
 the process of
atherogenesis has been considered by many to con-
sist largely of the accumulation of lipids within the
artery wall; however, it is much more than that. De-
spite changes in lifestyle and the use of new phar-
macologic approaches to lower plasma cholesterol
concentrations,
 
2,3
 
 cardiovascular disease continues
to be the principal cause of death in the United
States, Europe, and much of Asia.
 
4,5
 
 In fact, the le-
sions of atherosclerosis represent a series of highly
specific cellular and molecular responses that can
best be described, in aggregate, as an inflammatory
disease.
 
6-10
 
The lesions of atherosclerosis occur principally in
large and medium-sized elastic and muscular arteries
and can lead to ischemia of the heart, brain, or ex-
tremities, resulting in infarction. They may be present
throughout a person’s lifetime. In fact, the earliest
type of lesion, the so-called fatty streak, which is
common in infants and young children,
 
11 
 
is a pure in-
flammatory lesion, consisting only of monocyte-de-
rived macrophages and T lymphocytes.
 
12
 
 In persons
with hypercholesterolemia, the influx of these cells is
preceded by the extracellular deposition of amor-
phous and membranous lipids.
 
11,13
 
 By asking ques-
tions about arterial inflammation, we may be able to
gain insight into the process of atherogenesis.
A
 
FACTORS THAT INDUCE AND PROMOTE 
INFLAMMATION OR ATHEROGENESIS
 
Numerous pathophysiologic observations in hu-
mans and animals led to the formulation of the re-
sponse-to-injury hypothesis of atherosclerosis, which
initially proposed that endothelial denudation was
the first step in atherosclerosis.
 
6
 
 The most recent ver-
sion of this hypothesis emphasizes endothelial dys-
function rather than denudation. Whichever process
is at work, each characteristic lesion of atherosclero-
sis represents a different stage in a chronic inflamma-
tory process in the artery; if unabated and excessive,
this process will result in an advanced, complicated
lesion. Possible causes of endothelial dysfunction
leading to atherosclerosis include elevated and mod-
ified LDL; free radicals caused by cigarette smoking,
hypertension, and diabetes mellitus; genetic altera-
tions; elevated plasma homocysteine concentrations;
infectious microorganisms such as herpesviruses or
 
Chlamydia pneumoniae
 
; and combinations of these
or other factors. Regardless of the cause of endothe-
lial dysfunction, atherosclerosis is a highly character-
istic response of particular arteries.
 
6-9,14
 
The endothelial dysfunction that results from the
injury leads to compensatory responses that alter the
normal homeostatic properties of the endothelium.
Thus, the different forms of injury increase the adhe-
siveness of the endothelium with respect to leuko-
cytes or platelets, as well as its permeability. The injury
also induces the endothelium to have procoagulant
instead of anticoagulant properties and to form vaso-
active molecules, cytokines, and growth factors. If the
inflammatory response does not effectively neutralize
or remove the offending agents, it can continue indef-
initely. In doing so, the inflammatory response stim-
ulates migration and proliferation of smooth-muscle
cells that become intermixed with the area of inflam-
mation to form an intermediate lesion. If these re-
sponses continue unabated, they can thicken the ar-
tery wall, which compensates by gradual dilation, so
that up to a point, the lumen remains unaltered,
 
15
 
 a
phenomenon termed “remodeling.” As for the in-
flammatory cells, granulocytes are rarely present dur-
ing any phase of atherogenesis.
 
16
 
 Instead, the response
is mediated by monocyte-derived macrophages and
specific subtypes of T lymphocytes at every stage of
the disease.
 
17,18
 
Continued inflammation results in increased num-
bers of macrophages and lymphocytes, which both
emigrate from the blood and multiply within the
lesion. Activation of these cells leads to the release
of hydrolytic enzymes, cytokines, chemokines, and
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growth factors,
 
19,20
 
 which can induce further damage
and eventually lead to focal necrosis.
 
21 
 
Thus, cycles of
accumulation of mononuclear cells, migration and
proliferation of smooth-muscle cells, and formation
of fibrous tissue lead to further enlargement and re-
structuring of the lesion, so that it becomes covered
by a fibrous cap that overlies a core of lipid and ne-
crotic tissue — a so-called advanced, complicated
lesion. At some point, the artery can no longer com-
pensate by dilation; the lesion may then intrude into
the lumen and alter the flow of blood.
 
Hypercholesterolemia and Modified Lipids
and Lipoproteins
 
LDL, which may be modified by oxidation, glyca-
tion (in diabetes), aggregation, association with pro-
teoglycans, or incorporation into immune complex-
es,
 
22-25
 
 is a major cause of injury to the endothelium
and underlying smooth muscle.
 
25-27 
 
When LDL par-
ticles become trapped in an artery, they can undergo
progressive oxidation and be internalized by macro-
phages by means of the scavenger receptors on the
surfaces of these cells.
 
22,24-28
 
 The internalization
leads to the formation of lipid peroxides and facili-
tates the accumulation of cholesterol esters, result-
ing in the formation of foam cells. The degree to
which LDL is modified can vary greatly.
 
25,27,29
 
 Once
modified and taken up by macrophages, LDL acti-
vates the foam cells. Removal and sequestration of
modified LDL are important parts of the initial,
protective role of the macrophage in the inflamma-
tory response
 
28-30
 
 and minimize the effects of mod-
ified LDL on endothelial and smooth-muscle cells.
Antioxidants such as vitamin E can also reduce free-
radical formation by modified LDL.
 
31
 
 In addition to
its ability to injure these cells,
 
25,27
 
 modified LDL is
chemotactic for other monocytes and can up-regu-
late the expression of genes for macrophage colony-
stimulating factor
 
32,33
 
 and monocyte chemotactic
protein
 
34
 
 derived from endothelial cells. Thus, it may
help expand the inflammatory response by stimulat-
ing the replication of monocyte-derived macrophag-
es and the entry of new monocytes into lesions.
The inflammatory response itself can have a pro-
found effect on lipoprotein movement within the ar-
tery. Specifically, mediators of inflammation such as
tumor necrosis factor 
 
a
 
, interleukin-1, and macro-
phage colony-stimulating factor increase binding of
LDL to endothelium and smooth muscle and increase
the transcription of the LDL-receptor gene.
 
35,36
 
 Af-
ter binding to scavenger receptors in vitro, modified
LDL initiates a series of intracellular events
 
36
 
 that in-
clude the induction of urokinase
 
30
 
 and inflammatory
cytokines such as interleukin-1.
 
37-39
 
 Thus, a vicious
circle of inflammation, modification of lipoproteins,
and further inflammation can be maintained in the
artery by the presence of these lipids.
Oxidized LDL is present in lesions of atheroscle-
rosis in humans.
 
40
 
 In animals with hypercholesterole-
mia, antioxidants can reduce the size of lesions,
 
25,41-44
 
and they reduce fatty streaks in nonhuman pri-
mates.
 
44
 
 The latter observation suggests that the an-
tioxidants have an antiinflammatory effect, perhaps
by preventing the up-regulation of adhesion mole-
cules for monocytes.
 
45
 
 Antioxidants increase the re-
sistance of human LDL to oxidation ex vivo
 
46
 
 in
proportion to the vitamin E content of the plasma.
Vitamin E intake is inversely correlated with the in-
cidence of myocardial infarction, and vitamin E sup-
plementation reduced coronary events in a prelimi-
nary clinical trial.
 
47-49
 
 In contrast, other antioxidants,
such as beta carotene, have no benefit.
 
46,50,51
 
Homocysteine
 
High plasma homocysteine concentrations were
initially thought to be associated with advanced ath-
erosclerosis on the basis of autopsy findings in patients
with homozygous defects in enzymes necessary for
homocysteine metabolism, such as cystathionine beta-
synthase or methylenetetrahydrofolate reductase.
 
52-56
 
In patients with such defects, severe atherosclerosis
develops in childhood, and many have their first my-
ocardial infarction by the age of 20 years.
 
55,56
 
 Ho-
mocysteine is toxic to endothelium
 
57
 
 and is prothrom-
botic,
 
58
 
 and it increases collagen production
 
59
 
 and
decreases the availability of nitric oxide.
 
60
 
Plasma homocysteine concentrations are slightly
elevated in many patients who have no enzymatic de-
fects in homocysteine metabolism.
 
61
 
 These patients
have an increased risk of symptomatic atherosclerosis
of the coronary, peripheral, and cerebral arteries.
 
61
 
Treatment with folic acid can return their plasma ho-
mocysteine concentrations to normal. Trials are under
way to determine whether folic acid will prevent the
progression or possibly even induce the regression of
atherosclerotic lesions.
 
62
 
Hypertension
 
Concentrations of angiotensin II, the principal
product of the renin–angiotensin system, are often
elevated in patients with hypertension; angiotensin
II is a potent vasoconstrictor. In addition to causing
hypertension, it can contribute to atherogenesis by
stimulating the growth of smooth muscle.
 
63
 
 Angio-
tensin II binds to specific receptors on smooth mus-
cle, resulting in the activation of phospholipase C,
which can lead to increases in intracellular calcium
concentrations and in smooth-muscle contraction,
 
63
 
increased protein synthesis, and smooth-muscle hy-
pertrophy.
 
64
 
 It also increases smooth-muscle lipoxy-
genase activity, which can increase inflammation and
the oxidation of LDL. Hypertension also has proin-
flammatory actions, increasing the formation of hy-
drogen peroxide and free radicals such as superoxide
anion and hydroxyl radicals in plasma.
 
27,65,66 
 
These sub-
stances reduce the formation of nitric oxide by the
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endothelium,
 
67
 
 increase leukocyte adhesion,
 
66
 
 and in-
crease peripheral resistance. Thus, free-radical forma-
tion mediates some of the effects of both hyperten-
sion and hypercholesterolemia.
 
Infection
 
Several reports have shown a correlation between
the incidence of atherosclerosis and the presence of
at least two types of infectious microorganisms, her-
pesviruses and 
 
C. pneumoniae.
 
68-70
 
 Both organisms
have been identified in atheromatous lesions in cor-
onary arteries and in other organs obtained at au-
topsy.
 
69,70
 
 Increased titers of antibodies
 
71
 
 to these
organisms have been used as a predictor of further
adverse events in patients who have had a myocardial
infarction.
 
72,73
 
 Nonetheless, there is no direct evi-
dence that these organisms can cause the lesions of
atherosclerosis.
 
68,74,75
 
 Although these organisms are
ubiquitous in many tissues and organs, the fact that
lesions cannot be induced experimentally in animals
by injection of the organisms leaves their role as eti-
ologic agents in question. It is nevertheless possible
that infection, combined with other factors, may be
responsible for the genesis of the lesions of athero-
sclerosis in some patients.
 
68,76
 
THE NATURE OF THE INFLAMMATORY 
RESPONSE
 
Interactions among Endothelial Cells, Monocytes, 
and T Cells
 
Specific arterial sites, such as branches, bifurca-
tions, and curvatures, cause characteristic alterations
in the flow of blood, including decreased shear stress
and increased turbulence.
 
77
 
 At these sites, specific
molecules form on the endothelium that are respon-
sible for the adherence, migration, and accumulation
of monocytes and T cells. Such adhesion molecules,
which act as receptors for glycoconjugates and inte-
grins present on monocytes and T cells, include sever-
al selectins, intercellular adhesion molecules, and vas-
cular-cell adhesion molecules.
 
78
 
 Molecules associated
with the migration of leukocytes across the endothe-
lium, such as platelet–endothelial-cell adhesion mol-
ecules,
 
79
 
 act in conjunction with chemoattractant mol-
ecules generated by the endothelium, smooth muscle,
and monocytes — such as monocyte chemotactic
protein 1, osteopontin,
 
80
 
 and modified LDL — to at-
tract monocytes and T cells into the artery (Fig. 1).
 
33
 
The nature of the flow — that is, whether shear
stress or turbulence is high or low — appears to be
 
Figure 1.
 
 Endothelial Dysfunction in Atherosclerosis.
The earliest changes that precede the formation of lesions of atherosclerosis take place in the endo-
thelium. These changes include increased endothelial permeability to lipoproteins and other plasma
constituents, which is mediated by nitric oxide, prostacyclin, platelet-derived growth factor, angioten-
sin II, and endothelin; up-regulation of leukocyte adhesion molecules, including L-selectin, integrins, and
platelet–endothelial-cell adhesion molecule 1, and the up-regulation of endothelial adhesion molecules,
which include E-selectin, P-selectin, intercellular adhesion molecule 1, and vascular-cell adhesion mol-
ecule 1; and migration of leukocytes into the artery wall, which is mediated by oxidized low-density
lipoprotein, monocyte chemotactic protein 1, interleukin-8, platelet-derived growth factor, macrophage
colony-stimulating factor, and osteopontin.
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important in determining whether lesions occur at
these vascular sites. Changes in flow alter the expres-
sion of genes that have elements in their promoter
regions that respond to shear stress. For example, the
genes for intercellular adhesion molecule 1,
 
81
 
 platelet-
derived growth factor B chain,
 
82
 
 and tissue factor
 
83
 
in endothelial cells have these elements, and their ex-
pression is increased by reduced shear stress.
 
84
 
 Thus,
alterations in blood flow appear to be critical in de-
termining which arterial sites are prone to have le-
sions.
 
77,85,86
 
 Rolling and adherence of monocytes and
T cells occur at these sites as a result of the up-reg-
ulation of adhesion molecules on both the endothe-
lium and the leukocytes.
Chemokines may be responsible for the chemo-
taxis and accumulation of macrophages in fatty streaks
(Fig. 2).
 
87,88
 
 Activation of monocytes and T cells
leads to up-regulation of receptors on their surfaces,
such as the mucin-like molecules that bind selectins,
integrins that bind adhesion molecules of the im-
munoglobulin superfamily, and receptors that bind
chemoattractant molecules.
 
78
 
 These ligand–recep-
tor interactions further activate mononuclear cells,
induce cell proliferation, and help define and lo-
calize the inflammatory response at the sites of le-
sions (Fig. 1).
In genetically modified mice that are deficient in
apolipoprotein E (and have hypercholesterolemia),
intercellular adhesion molecule 1 is constitutively in-
creased at lesion-prone sites.
 
86
 
 In fact, it is present on
the surface of the endothelium at these sites in normal
mice and is increased in mice with apolipoprotein E
deficiency. In contrast, vascular-cell adhesion mole-
cule 1 is absent in normal mice but is present at the
same sites as intercellular adhesion molecule 1 in mice
with apolipoprotein E deficiency.
 
86
 
 Thus, adherence
of monocytes and T cells may occur after an increase
in one or more of the adhesion molecules, which
may act in concert with chemotactic molecules such
as monocyte chemotactic protein 1, interleukin-8, or
modified LDL. Would interference with only one of
the several adhesion molecules be sufficient to de-
crease inflammation and thus slow or counteract the
process of atherogenesis? In mice that are completely
deficient in intercellular adhesion molecule 1, P-selec-
tin, CD18, or combinations of these molecules, lipid
 
Figure 2.
 
 Fatty-Streak Formation in Atherosclerosis.
Fatty streaks initially consist of lipid-laden monocytes and macrophages (foam cells) together with
T lymphocytes. Later they are joined by various numbers of smooth-muscle cells. The steps involved
in this process include smooth-muscle migration, which is stimulated by platelet-derived growth factor,
fibroblast growth factor 2, and transforming growth factor 
 
b
 
; T-cell activation, which is mediated by
tumor necrosis factor 
 
a
 
, interleukin-2, and granulocyte–macrophage colony-stimulating factor; foam-
cell formation, which is mediated by oxidized low-density lipoprotein, macrophage colony-stimulating
factor, tumor necrosis factor 
 
a
 
, and interleukin-1; and platelet adherence and aggregation, which are
stimulated by integrins, P-selectin, fibrin, thromboxane A
 
2
 
, tissue factor, and the factors described in
Figure 1 as responsible for the adherence and migration of leukocytes.
3
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feeding leads to smaller lesions of atherosclerosis.
 
89
 
Comparison of the relative roles of these molecules
in inflammation in the arteries and the microvascu-
lature may provide clues to the relative feasibility of
modifying the inflammatory process at these sites,
and thus of modifying atherosclerosis.
A recently discovered class of molecules, the disin-
tegrins, sometimes called metalloproteinase-like, dis-
integrin-like, cysteine-rich proteins (MDCs), has been
identified in endothelium, smooth muscle, and mac-
rophages.
 
90
 
 These transmembrane proteins, which
appear to be involved in cell–cell interactions,
 
90
 
 con-
tain a metalloproteinase sequence in their extracellu-
lar segment that permits them to activate molecules
such as tumor necrosis factor 
 
a
 
.
 
91,92
 
 They are not
found in normal arteries, but one of them, MDC15,
is present in lesions of atherosclerosis.
 
90
 
 Adhesion
molecules such as L-selectin can be cleaved from the
surface of leukocytes by a metalloproteinase (L-selec-
tin sheddase), which suggests that in situations of
chronic inflammation it may be possible to measure
the “shed” molecules, such as the different adhesion
molecules, in plasma, as markers of a sustained in-
flammatory response.
 
93,94
 
 Disintegrins may partici-
pate in these shedding processes. If shedding occurs,
it may be detectable in different types of inflamma-
tory responses. Increased plasma concentrations of
shed molecules might then be used to identify pa-
tients at risk for atherosclerosis or other inflamma-
tory diseases.
 
Monocytes and Immunity
 
The ubiquitous monocyte, the precursor of macro-
phages in all tissues, is present in every phase of ather-
ogenesis. Monocyte-derived macrophages are scav-
enging and antigen-presenting cells, and they secrete
cytokines, chemokines, growth-regulating molecules,
and metalloproteinases and other hydrolytic enzymes.
The continuing entry, survival, and replication of
mononuclear cells in lesions depend in part on factors
such as macrophage colony-stimulating factor and
granulocyte–macrophage colony-stimulating factor
for monocytes and interleukin-2 for lymphocytes.
Continued exposure to macrophage colony-stimulat-
ing factor permits macrophages to survive in vitro
and possibly to multiply within the lesions. In con-
 
Figure 3.
 
 Formation of an Advanced, Complicated Lesion of Atherosclerosis.
As fatty streaks progress to intermediate and advanced lesions, they tend to form a fibrous cap that
walls off the lesion from the lumen. This represents a type of healing or fibrous response to the injury.
The fibrous cap covers a mixture of leukocytes, lipid, and debris, which may form a necrotic core.
These lesions expand at their shoulders by means of continued leukocyte adhesion and entry caused
by the same factors as those listed in Figures 1 and 2. The principal factors associated with macro-
phage accumulation include macrophage colony-stimulating factor, monocyte chemotactic protein 1,
and oxidized low-density lipoprotein. The necrotic core represents the results of apoptosis and necrosis,
increased proteolytic activity, and lipid accumulation. The fibrous cap forms as a result of increased
activity of platelet-derived growth factor, transforming growth factor 
 
b
 
, interleukin-1, tumor necrosis
factor 
 
a
 
, and osteopontin and of decreased connective-tissue degradation.
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trast, inflammatory cytokines such as interferon-g ac-
tivate macrophages and under certain circumstances
induce them to undergo programmed cell death (ap-
optosis). If this occurs in vivo, macrophages may be-
come involved in the necrotic cores characteristic of
advanced, complicated lesions (Fig. 3).
Initially, the only cells thought to proliferate during
expansion of atherosclerotic lesions were smooth-mus-
cle cells. However, replication of monocyte-derived
macrophages and T cells is probably of equal impor-
tance.95 The ability of macrophages to produce cyto-
kines (such as tumor necrosis factor a, interleukin-1,
and transforming growth factor b), proteolytic en-
zymes (particularly metalloproteinases), and growth
factors (such as platelet-derived growth factor and
insulin-like growth factor I) may be critical in the
role of these cells in the damage and repair that en-
sue as the lesions progress (Fig. 2).
Activated macrophages express class II histocom-
patibility antigens such as HLA-DR that allow them
to present antigens to T lymphocytes.20 Thus, it is
not surprising that cell-mediated immune responses
may be involved in atherogenesis, since both CD4
and CD8 T cells are present in the lesions at all stag-
es of the process.96,97 T cells are activated when they
bind antigen processed and presented by macro-
phages. T-cell activation results in the secretion of
cytokines, including interferon-g and tumor necrosis
factor a and b, that amplify the inflammatory re-
sponse.97 Smooth-muscle cells from the lesions also
have class II HLA molecules on their surfaces, pre-
sumably induced by interferon-g, and can also present
antigens to T cells.97 One possible antigen may be
oxidized LDL,98 which can be produced by macro-
phages.99 Heat-shock protein 60 may also contribute
to autoimmunity. This and other heat-shock pro-
teins perform several functions, including the assem-
bly, intracellular transport, and breakdown of pro-
teins and the prevention of protein denaturation.
These proteins may be elevated on endothelial cells
and participate in immune responses.100
An immunoregulatory molecule, CD40 ligand,101
can be expressed by macrophages, T cells, endothe-
lium, and smooth muscle in atherosclerotic lesions
in vivo, and its receptor, CD40, is expressed on the
same cells. Both are up-regulated in lesions of ath-
erosclerosis, providing further evidence of immune
activation in the lesions.102,103 Furthermore, CD40
ligand induces the release of interleukin-1b by vas-
cular cells, potentially enhancing the inflammatory
response.104 Inhibition of CD40 with blocking anti-
bodies reduces lesion formation in apolipoprotein
E–deficient mice.105
Platelets
Platelet adhesion and mural thrombosis are ubiq-
uitous in the initiation and generation of the lesions
of atherosclerosis in animals and humans (Fig. 2).9
Platelets can adhere to dysfunctional endothelium,
exposed collagen, and macrophages. When activated,
platelets release their granules, which contain cyto-
kines and growth factors that, together with throm-
bin, may contribute to the migration and proliferation
of smooth-muscle cells and monocytes.106 Activation
of platelets leads to the formation of free arachidonic
acid, which can be transformed into prostaglandins
such as thromboxane A2, one of the most potent
vasoconstricting and platelet-aggregating substances
known, or into leukotrienes, which can amplify the
inflammatory response. 
Plaque rupture and thrombosis are notable com-
plications of advanced lesions that lead to unstable
coronary syndromes or myocardial infarction (Fig.
4).9,21,107 Platelets are important in maintaining vas-
cular integrity in the absence of injury and protect-
ing against spontaneous hemorrhage. Activated plate-
lets can accumulate on the walls of arteries and recruit
additional platelets into an expanding thrombus. An
important component of the platelets is the glyco-
protein IIb/IIIa receptor, which belongs to the in-
tegrin superfamily of adhesion-molecule receptors
and appears on the surface of platelets during plate-
let activation and thrombus formation. These recep-
tors serve an important hemostatic function, and an-
tagonists to them prevent thrombus formation in
patients who have had a myocardial infarction.108
ATHEROSCLEROSIS IN RELATION TO 
OTHER CHRONIC INFLAMMATORY 
DISEASES
The cellular interactions in atherogenesis are fun-
damentally no different from those in chronic inflam-
matory–fibroproliferative diseases such as cirrhosis,
rheumatoid arthritis, glomerulosclerosis, pulmonary
fibrosis, and chronic pancreatitis (Table 1). In the ex-
amples in Table 1, the response of each particular tis-
sue or organ depends on its characteristic cells and
architecture, its blood and lymph supply, and the
nature of the offending agents. Thus, the cellular re-
sponses in the arteries (atherosclerosis), liver (cirrho-
sis), joints (rheumatoid arthritis), kidneys (glomeru-
losclerosis), lungs (pulmonary fibrosis), and pancreas
(pancreatitis) are similar yet are characteristic of each
tissue or organ.
Inflammatory Response
Does the inflammatory response in arteries differ
from that in other tissues? Granulocytes are rare in
atherosclerosis, and among the other disorders in Ta-
ble 1, they are present only in rheumatoid arthritis and
pulmonary fibrosis. In the case of arthritis, although
the early response begins with granulocytes, they are
found primarily within the joint cavity. Macrophages
and lymphocytes predominate in the synovium, lead-
ing to erosion of cartilage and bone, which is re-
placed by fibrous tissue (pannus). In pulmonary fi-
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brosis, granulocytes initially appear in the alveolar
spaces; however, the lung parenchyma, where fibrosis
ultimately occurs, is infiltrated by macrophages and
lymphocytes. Thus, there are parallels between ath-
erosclerosis and these other inflammatory diseases.
Are there particular aspects of the chronic inflam-
matory response in atherosclerosis that can be used
to advantage? At least three different types of mac-
rophages, each regulated by different T-cell cyto-
kines (interferon-g, interleukin-2, interleukin-4, and
interleukin-10) have been identified.122 These differ-
ences raise the question whether there are subgroups
of monocytes that “home” to a specific tissue or or-
gan. Are there differences in arterial endothelium
and microvascular endothelium such that different
types of monocytes are attracted to each, and could
one take advantage of such differences?123 One might
try to use such differences to modify the inflamma-
tory response so as to emphasize its protective rather
than its destructive characteristics.
If the injurious agent or agents are not removed
or nullified by the inflammatory response and the
inflammation progresses, the response changes from
a protective to an injurious response. Such constant
or repetitive injury can stimulate each tissue to re-
pair or wall off the damage by means of a fibropro-
liferative response, which, when excessive, diminish-
es the functional capacity of the tissue or organ and
becomes part of the disease process (Table 1).
Instability and Rupture of Plaque
Chronic inflammatory responses are often associ-
ated with specific types of injurious or granuloma-
inducing agents. In most patients myocardial infarc-
tions occur as a result of erosion or uneven thinning
and rupture of the fibrous cap, often at the shoulders
of the lesion where macrophages enter, accumulate,
and are activated and where apoptosis may occur.124,125
Degradation of the fibrous cap may result from elab-
oration of metalloproteinases such as collagenases,
elastases, and stromelysins (Fig. 4).126 Activated T cells
may stimulate metalloproteinase production by mac-
rophages in the lesions, which promotes plaque insta-
bility and further implicates an immune response.103
These changes may also be accompanied by the pro-
duction of tissue-factor procoagulant and other he-
mostatic factors,102,127 further increasing the possibil-
ity of thrombosis.
Stable advanced lesions usually have uniformly
dense fibrous caps. The potentially dangerous lesions
are often nonocclusive and thus difficult to diagnose
by angiography, yet at autopsy active inflammation is
evident in the accumulation of macrophages at sites
of plaque rupture.107 Macrophage accumulation may
Figure 4. Unstable Fibrous Plaques in Atherosclerosis.
Rupture of the fibrous cap or ulceration of the fibrous plaque can rapidly lead to thrombosis and usually
occurs at sites of thinning of the fibrous cap that covers the advanced lesion. Thinning of the fibrous
cap is apparently due to the continuing influx and activation of macrophages, which release metallo-
proteinases and other proteolytic enzymes at these sites. These enzymes cause degradation of the ma-
trix, which can lead to hemorrhage from the vasa vasorum or from the lumen of the artery and can
result in thrombus formation and occlusion of the artery.
Plaque rupture Thinning of fibrous cap Hemorrhage from plaque3
microvessels
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be associated with increased plasma concentrations
of both fibrinogen and C-reactive protein,128-130 two
markers of inflammation thought to be early signs of
atherosclerosis.128,131,132 Plaque rupture and throm-
bosis may be responsible for as many as 50 percent
of cases of acute coronary syndromes and myocar-
dial infarction.21
NEW PERSPECTIVES ON THE FORMATION 
AND PROGRESSION OF LESIONS
Smooth Muscle
To understand the factors that are important in
the proliferative and migratory responses that lead to
differences in the organization and enlargement of
the lesions in different parts of the arterial tree, it
may be helpful to understand the embryonic deriva-
tion of the smooth-muscle cells that make up the ar-
teries in different regions. Smooth-muscle cells have
different embryonic origins, depending on the seg-
ment of the arterial system involved. In some verte-
brates, smooth-muscle cells in the upper portion of
the thoracic aorta are derived from a neuroectoder-
mal source, whereas those in the abdominal aorta
are derived from a mesenchymal source.133 Although
likely, this has not been confirmed in humans. The
smooth-muscle cells of coronary arteries appear to
originate from a third precursor population in the
intracardiac mesenchyme. The existence of these dif-
ferent lineages suggests that smooth muscle in dif-
ferent parts of the arterial tree may respond differ-
ently to the stimuli that generate atherosclerotic
lesions at each of these sites. To complicate matters
further, smooth-muscle cells within the media of
large arteries may be heterogeneous, with different
proliferative and matrix-producing capabilities.134
These differences in the origin of smooth-muscle
cells raise questions about whether these cells, on
the basis of their lineage, respond differently to dif-
ferent cytokines, mitogens, chemotactic factors, or
extracellular matrixes.135-137 Is there selection of a
particular lineage based on the cells’ responses to
these different substances? Does cell lineage help to
explain why lesions in peripheral arteries differ from
those in the carotid and coronary arteries?
The Role of the Matrix
Smooth-muscle cells in the media of arteries, as
well as in lesions, are surrounded by different types
of connective tissue. In the media of arteries, the
matrix consists largely of type I and III fibrillar col-
lagen, whereas in the lesions of atherosclerosis it con-
sists largely of proteoglycan, intermixed with loosely
scattered collagen fibrils.
When cultured human arterial smooth-muscle cells
are plated on collagen in fibrillar form, the collagen
inhibits cell proliferation by up-regulating specific
inhibitors of the cell cycle.137 In vivo degradation of
the collagen by collagenase, or migration away from
this inhibitory environment, may allow the smooth-
muscle cells to respond to mitogenic stimuli and rep-
*Plus signs denote the presence of a cell type, and minus signs its absence.
TABLE 1. CHARACTERISTICS OF ATHEROSCLEROSIS AND OTHER CHRONIC INFLAMMATORY DISEASES.*
DISEASE
MONOCYTES
AND MACRO-
PHAGES
LYMPHO-
CYTES
GRANU-
LOCYTES
CONNECTIVE-TISSUE
CELLS
EXTRACELLULAR
MATRIX PATHOGENETIC MECHANISMS STUDIES
Atherosclerosis + + ¡ Smooth-muscle cells Collagen types I, III, 
and IV, elastin, fibro-
nectin, proteoglycan
Endothelial-cell injury and dys-
function; fibrous cap; new 
matrix formation and degra-
dation; necrotic core
Ross,9 Libby and 
Hansson,109 
Ross and 
Fuster110
Cirrhosis + + ¡ Fibroblasts, Ito cells Collagen types I and 
III
Parenchymal-cell injury; new 
matrix and scarring replacing 
necrotic parenchyma
Maher,111 Antho-
ny et al.112
Rheumatoid
arthritis
+ + +/¡ Synovial fibroblasts Collagen types I and 
III, fibronectin, pro-
teoglycan
Synovial-cell injury; erosion of 
cartilage; new matrix scarring 
(pannus)
Sewell and 
Trentham,113
Harris 114
Glomerulosclerosis + + ¡ Mesangial cells Collagen types I and 
IV, fibronectin
Epithelial- and endothelial-cell 
injury and dysfunction; de-
crease in glomerular filtra-
tion; new matrix formation
Johnson,115 Magil 
and Cohen116
Pulmonary fibrosis + + +/¡ Smooth-muscle cells, 
fibroblasts
Collagen types III and 
IV, fibronectin
Inflammatory exudate in alveoli 
and bronchi, organized by ex-
tensive matrix deposition and 
scarring
Kuhn et al.,117 
Lukacs and 
Ward,118 Brody 
et al.119
Chronic pancreatitis + + ¡ Fibroblasts Collagen, fibronectin, 
proteoglycan
Epithelial (ductal) injury; peri-
ductal inflammation; intersti-
tial fat necrosis; new matrix 
formation
1
2
Sarles et al.,120 
DiMagno 
et al.121
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licate, as they do when they are cultured on non-
fibrillar, monomeric collagen. Other matrix molecules,
such as fibronectin and heparan sulfate, may be in-
volved, because they can also inhibit the cell cycle, and
cell–matrix interactions can lead to the expression of
chemokines by macrophages.138-140 If these interac-
tions were to occur in arteries, they could profound-
ly influence the inflammatory and fibroproliferative
response.141 Thus, the matrix that surrounds the cells
is not neutral and may determine whether they re-
main quiescent or multiply in response to growth
factors.
CONCLUSIONS
Cells may express different constellations of genes
and therefore vary phenotypically, depending on their
environment. New techniques have been developed
to identify DNA that should yield a vast amount of
information about which genes are expressed and in
what patterns, information that should help decipher
the complex nature of atherogenesis.142-144 Because
atherosclerosis is a multigenic disease, understanding
patterns of gene expression may help to explain dif-
ferences in susceptibility to agents that cause disease.
Furthermore, the patterns of gene expression may
vary in lesions from different persons and at different
sites and may provide clues regarding genetic differ-
ences in susceptibility as well as response to therapy.
Advances in molecular genetics have made it pos-
sible to remove or insert genes and to determine the
roles of their products in disease.145 Numerous ani-
mal models that are useful in studying the genetics
of atherogenesis have been produced, such as apo-
lipoprotein E–deficient mice.146,147 In the absence of
apolipoprotein E, lipoprotein remnants are not car-
ried to the liver, where they are normally metabo-
lized, and the mice become hypercholesterolemic and
lesions of atherosclerosis develop that are similar to
those in humans. To explore the role of monocytes
and platelets and of platelet-derived growth factor in
atherogenesis, studies are under way in which apo-
lipoprotein E–deficient mice have been made chi-
meric for a deficiency of platelet-derived growth fac-
tor in circulating monocytes and platelets.
Studies in transgenic mice have revealed that
Lp(a) lipoprotein, cholesterol ester transfer protein,
apolipoprotein A (the principal apoprotein of high-
density lipoprotein), and other molecules have little
effect on atherogenesis, whereas macrophage colo-
ny-stimulating factor appears to be important in the
regulation of the numbers of monocytes and macro-
phages and in lesion formation.148,149
Thus, although hypercholesterolemia is important
in approximately 50 percent of patients with cardio-
vascular disease,5 other factors need to be taken into
consideration. Atherosclerosis is clearly an inflamma-
tory disease and does not result simply from the ac-
cumulation of lipids. If we can selectively modify the
harmful components of inflammation in the arteries
and leave the protective aspects intact, we may create
new avenues for the diagnosis and management of
disease in the 50 percent of patients with cardiovas-
cular disease who do not have hypercholesterolemia.
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Clinical Application of C-Reactive Protein for
Cardiovascular Disease Detection and Prevention
Paul M Ridker, MD
In an attempt to improve global cardiovascular riskprediction, considerable interest has focused onC-reactive protein (CRP), a marker of inflammation that
has been shown in multiple prospective epidemiological
studies to predict incident myocardial infarction, stroke,
peripheral arterial disease, and sudden cardiac death. CRP
levels have also been shown to predict risk of both recurrent
ischemia and death among those with stable and unstable
angina, those undergoing percutaneous angioplasty, and those
presenting to emergency rooms with acute coronary syn-
dromes. These highly consistent clinical data are supported
by abundant laboratory and experimental evidence that dem-
onstrate that atherothrombosis, in addition to being a disease
of lipid accumulation, also represents a chronic inflammatory
process. In terms of clinical application, CRP seems to be a
stronger predictor of cardiovascular events than LDL choles-
terol, and it adds prognostic information at all levels of
calculated Framingham Risk and at all levels of the metabolic
syndrome. Using widely available high-sensitivity assays,
CRP levels of 1, 1 to 3, and 3 mg/L correspond to low-,
moderate-, and high-risk groups for future cardiovascular
events. Individuals with LDL cholesterol below 130 mg/dL
who have CRP levels 3 mg/L represent a high-risk group
often missed in clinical practice. The addition of CRP to
standard cholesterol evaluation may thus provide a simple
and inexpensive method to improve global risk prediction and
compliance with preventive approaches.
Evidence Supporting CRP Use in
Primary Prevention
Composed of five 23 kDa subunits, C-reactive protein
(CRP) is an hepatically derived pentraxin that plays a key
role in the innate immune response. CRP has a long plasma
half-life and is now understood to be a mediator as well as
a marker of atherothrombotic disease. To date, over a
dozen prospective epidemiological studies carried out
among individuals with no prior history of cardiovascular
disease demonstrate that a single, non-fasting measure of
CRP is a strong predictor of future vascular events1–14
(Figure 1). The relationship between a patient’s baseline
level of CRP and future vascular risk has been consistent
in studies from the United States and Europe, and in most
cases has proven independent of age, smoking, cholesterol
levels, blood pressure, and diabetes, the major “tradition-
al” risk factors evaluated in daily practice. These effects
are present among women as well as men, among the
elderly as well as those in middle age, among smokers and
non-smokers, and among those with and without diabetes.
CRP levels have long-term predictive value. In one recent
study, CRP was a strong predictor of risk even 20 years
after initial blood samples were obtained.15
Very recently, event-free survival data have become avail-
able that allow clinicians to interpret CRP levels either in
terms of population-based quintiles (Figure 2, left) or in terms
of simple clinical cut-points (Figure 2, right).6 Although the
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former approach demonstrates the robust linear relationship
between inflammation and vascular disease, the latter ap-
proach (in which levels of1, 1 to 3, and3 mg/L represent
low-, moderate-, and high-risk groups) is likely to have
greater clinical appeal.
Prospective data also demonstrate that CRP is a stronger
predictor of risk than is low-density lipoprotein (LDL)
cholesterol. In the largest study to date, both the area under
the receiver operator characteristic (ROC) curve (0.64 versus
0.60) and the population attributable risk percent (40 versus
19) were significantly greater for CRP than for LDL
cholesterol.6
CRP levels minimally correlate with lipid levels and there
is virtually no way to predict CRP levels on the basis of either
total cholesterol, high-density lipoprotein cholesterol, or LDL
cholesterol. In evaluations including over 25 000 patients, the
variance in CRP that can be ascribed to LDL cholesterol has
consistently been less than 3% to 5%.4,6,16 Thus, CRP levels
do not supplant lipid evaluation, but must be considered as an
adjunct to lipid evaluation. The additive value of CRP to lipid
screening in terms of coronary risk prediction has been
demonstrated in several settings.1,3,4,6,17 A simplified clinical
approach to this issue based on the Adult Treatment Panel III
(ATP III) cut-points for LDL of130, 130 to 160, and160
mg/dL and on CRP levels of 1, 1 to 3, and 3 mg/L is
shown in Figure 3, as is evidence that CRP adds prognostic
information at all levels of the Framingham Risk Score.
CRP, the Metabolic Syndrome, and
Type 2 Diabetes
A unique feature of CRP that further distinguishes it from
LDL cholesterol is the fact that inflammation (but not
elevated LDL) plays a major role in almost all processes
associated with the metabolic syndrome, another group high-
lighted as being at increased risk according to current ATP III
guidelines. That CRP reflects the metabolic syndrome is not
surprising, as CRP levels not only correlate with triglycer-
ides, obesity, blood pressure, and fasting glucose (all of
which are components of the ATP III metabolic syndrome
definition), but also correlate with insulin sensitivity, endo-
thelial dysfunction, and impaired fibrinolysis (factors addi-
tionally associated with the metabolic syndrome that are not
easily discerned in usual clinical practice).18 Although cardiac
event-free survival is similar for those with CRP levels above
or below 3.0 mg/L and for those with and without the
metabolic syndrome, it is also clear that CRP adds indepen-
dent prognostic information on risk at all levels of severity of
the metabolic syndrome.18 Thus, the metabolic syndrome is a
heterogenous condition; as shown in Figure 4, CRP levels of
1, 1 to 3, and 3 mg/L differentiate low, moderate, and
high risk even when applied to those already defined as
having the metabolic syndrome.18
Several prospective studies demonstrate that CRP levels
additionally predict incident type II diabetes.19,20 These data
further link inflammation, atherothrombosis, and diabetes as
tightly interrelated disorders of the innate immune system and
may help to explain why diet and exercise are so important to
the prevention of both diseases.
The Population Distribution of CRP
When measured with high-sensitivity assays, the population
distribution of CRP has generally been consistent across sex
and ethnic groups, and values of 0.3, 0.6, 1.5, 3.5, and 6.6
mg/L have been reported as estimates of the 10th, 25th, 50th,
75th, and 90th percentile cut-points for middle-aged Ameri-
cans.6 In 4 major cohort studies performed in the United
States, the Physicians Health Study, the Women’s Health
Study, the Women’s Health Initiative, and the Air Force/
Texas Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS),2,3,4,6,10 the quintile distributions of CRP for men
and for women not taking hormone replacement therapy
(HRT) are remarkably similar, and in practice approximate
quintile cut-points of 0.5, 0.5 to 1.0, 1.0 to 2.0, 2.0 to 4.0,
and 4.0 mg/L have been suggested for use. An alternative
approach, as suggested above, is simply one that emphasizes
levels 1, 1 to 3, and 3.0 mg/L as low-, moderate-, and
high-risk groups.
Because women taking HRT will have higher levels of
CRP,21,22 risk estimates for such women may need to be
calibrated downward. As recently demonstrated in analyses
of CRP and HRT in the Women’s Health Initiative,10 how-
ever, these effects in terms of actual event prediction are not
as large as anticipated. Further, these data suggest that it is the
Figure 1. Prospective studies relating baseline CRP levels to the
risk of first cardiovascular events. CHD indicates coronary heart
disease; MI, myocardial infarction; PAD, pulmonary artery dis-
ease; CV, cardiovascular; MRFIT, Multiple Risk Factor Interven-
tion Trial; PHS, Physicians’ Health Study; CHS, Cardiovascular
Health Study; RHPP, Rural Health Promotion Project; WHS,
Women’s Health Study; MONICA, MONItoring trends and deter-
minants In CArdiovascular disease; HELSINKI, Helsinki Heart
Study; CAERPHILLY, Caerphilly Heart Study; BRHS, British
Regional Heart Study; LEIDEN, Leiden Heart Study; SPEED-
WELL, Speedwell Heart Study; WOSCOPS, West of Scotland
Coronary Prevention Study; AFCAPS, Air Force Coronary Ath-
erosclerosis Prevention Study; FHS, Framingham Heart Study;
WHI, Women’s Health Initiative; and HHS, Honolulu Heart
Study.
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expressed level of CRP that determines a given woman’s
vascular risk. Finally, in the Women’s Health Study,3,6 there
was no substantive difference in risk estimates for women
taking HRT when cut-points were determined among users of
HRT rather than non-users. Taken together, these large
outcome analyses suggest little value in having separate
clinical cut-points for CRP either by sex or by HRT use.
The sparse population data available for blacks is consis-
tent with these findings. However, the total number of
individuals evaluated in this group remains small.
Interpreting CRP Assays, Cost-Effectiveness,
and Serial Assessment
In most clinical settings, a single CRP assessment is likely to
be adequate as long as levels less than 10 mg/L are observed.
Because major infections, trauma, or acute hospitalizations
can elevate CRP levels (usually 100-fold or more), levels
greater than 10 mg/L should initially be ignored and the test
repeated at a future date when the patient is clinically stable.
Many investigators have recommended 2 measures of CRP,
with the lower value or the average being used to determine
vascular risk, a practice consistent with recommendations for
cholesterol evaluation. In rare instances where levels of CRP
are markedly elevated, alternative sources of systemic inflam-
mation such as lupus, inflammatory bowel disease, or endo-
carditis should be considered. In such cases, there is usually
an accompanying elevation in the erythrocyte sedimentation
rate. Accumulated experience in outpatient settings has
shown such values to be infrequent.
Because CRP levels are stable over long periods of time,
are not affected by food intake, and demonstrate almost no
circadian variation, there is no need to obtain fasting blood
samples for CRP assessment. Despite being an acute phase
reactant, the variability in CRP levels in given individuals is
Figure 2. Cardiovascular event-free survival among apparently healthy individuals according to baseline CRP levels. Data are shown
using population-based quintiles for CRP (left) and using 3 simple clinical cut-points for CRP, 1, 1 to 3, and 3 mg/L (right). Adapted
from reference 6.
Figure 3. CRP provides prognostic infor-
mation at all levels of LDL cholesterol
and at all levels of the Framingham Risk
Score. Data adapted from reference 6.
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quite similar to that associated with cholesterol screening, as
long as the CRP levels are within the clinical range defined
above.23
Traditional assays for CRP do not have adequate sensitiv-
ity to detect levels required for vascular disease prediction.
To alleviate this problem, high-sensitivity CRP assays have
been developed and are now widely available.24 The cost of
CRP screening is comparable to that of standard cholesterol
evaluation and far less than almost all other alternative
approaches to cardiovascular screening under consideration.
Both in terms of years of life saved and cost-to-benefit ratios,
CRP screening seems to be highly effective.25 In many
settings, the inexpensive approach of adding CRP to LDL
screening may yield immediate cost-savings in terms of
negative predictive value and the subsequent avoidance of
unnecessary clinical testing, particularly when compared with
far more expensive screening approaches such as electron
beam calcium tomography or MRI.
CRP levels within the range detected with high-sensitivity
assays have demonstrated specificity for vascular events.26
Although it has not been determined whether serial CRP
assessment provides incremental clinical value, some physi-
cians have elected to use CRP as part of their annual physical
examination.
Comparison of CRP to Other Novel Risk Factors
CRP is not the only inflammatory biomarker that has been
shown to predict myocardial infarction and stroke. More sophis-
ticated measures of cytokine activity, cellular adhesion, and
immunologic function (such as interleukin-6, intercellular adhe-
sion molecule-1, macrophage inhibitory cytokine-1, and soluble
CD40 ligand) have all been shown to be elevated among those
at increased vascular risk.27 These approaches, however, are
unlikely to have clinical utility because the assays required for
their assessment are either inappropriate for routine clinical use
or the protein of interest has too short a half-life for clinical
evaluation. Measures for fibrinogen, a biomarker involved in
both inflammation and thrombosis, remain poorly standardized,
and methodological issues limit use of this parameter despite
consistent population-based data. Other broad measures of
systemic inflammation, such as the white blood cell count or the
erythrocyte sedimentation rate, have proven unreliable in clinical
settings. By contrast, high-sensitivity assays for CRP have been
standardized across many commercial platforms. Moreover,
CRP is highly stable, allowing measures to be made accurately
in both fresh and frozen plasma without requirements for special
collection procedures. This is due in part to the stable pentraxin
structure of CRP and its long plasma half-life of 18 to 20 hours.
In selected patients, such as those with markedly premature
and unexplained atherosclerosis, evaluation of other markers,
such as lipoprotein(a) and homocysteine, may have clinical
utility. In available population-based studies, however, the rela-
tive magnitude of these biomarkers has been small in direct
comparison to CRP (Figure 5). Recent data also indicate that
CRP is a stronger predictor of risk than nuclear magnetic
resonance-based evaluation of LDL particle size and
concentration.28
Goals of Screening and Therapeutic Options
The primary goal of cardiovascular screening programs should
be the identification of high-risk individuals who can be targeted
for smoking cessation, diet, exercise, and blood pressure control.
It is well established that compliance with lifestyle recommen-
dations is directly related to the absolute risk perceived by
individual patients. Thus, because the addition of CRP to lipid
evaluation provides an improved prediction tool, consideration
of CRP may have usefulness for this reason alone.
There is currently no definitive evidence that lowering CRP
will necessarily reduce cardiovascular event rates; studies ad-
dressing this issue are only now being designed. However, many
interventions known to reduce cardiovascular risk have been
Figure 4. Cardiovascular event-free survival according to base-
line CRP levels among individuals already defined as having the
metabolic syndrome. Adapted from reference 18.
Figure 5. Direct comparison of CRP to several other lipid and
non-lipid risk factors for cardiovascular disease. SICAM-1 indi-
cates soluble intercellular adhesion molecule-1; hs-CRP, high-
sensitivity CRP; HDL, high-density lipoprotein; and HDLC, high-
density lipoprotein cholesterol. Adapted from reference 3.
366 Circulation January 28, 2003
linked to lower CRP levels. In particular, weight loss, diet,
exercise, and smoking cessation all lead to both reduced CRP
levels and reduced vascular risk.
Several pharmacological agents proven to reduce vascular
risk influence CRP levels. Of these, the statin drugs are the
most important, and studies with pravastatin, lovastatin,
cerivastatin, simvastatin, and atorvastatin have all shown that,
on average, median CRP levels decline 15% to 25% as early
as 6 weeks after initiation of therapy. As shown in the
large-scale Cholesterol And Recurrent Events (CARE)29 and
PRavastatin INflammation/CRP Evaluation (PRINCE)16 tri-
als and subsequently confirmed in other settings, there is little
evidence that the magnitude of LDL reduction predicts the
magnitude of CRP reduction. On the other hand, aggressive
LDL reduction remains a critical therapeutic goal, and thus
serial LDL evaluation should remain the primary method to
monitor statin compliance. However, whereas all subjects
taking statins achieve a beneficial reduction in LDL levels,
there seems to be responders and non-responders for statins in
terms of CRP reduction. Whether this latter observation is
important in terms of clinical event reduction is currently
unknown.
Analyses of 2 randomized trials suggest that the magnitude
of risk reduction attributable to statin therapy is particularly
large for those with elevated CRP levels. In the CARE trial of
secondary prevention, the magnitude of benefit associated
with pravastatin use was nearly 55% for those with elevated
CRP levels as compared with 30% for those with low CRP
levels.30 Similarly, in the AFCAPS/TexCAPS primary pre-
vention trial, lovastatin use was highly effective among those
with elevated CRP levels, even when LDL levels were below
thresholds set by the ATP III guidelines.4 Although per-
formed on a post hoc basis and limited by relatively low event
rates, the AFCAPS/TexCAPS analysis suggests that the
benefit of statin therapy among those with low LDL but high
CRP may be just as large as the benefit observed among those
with overt hyperlipidemia.
That patients with elevated CRP but low LDL are at high
vascular risk is demonstrated in Figure 6, which shows
survival data from the Women’s Health Study for those with
LDL cholesterol above or below the study median of 124
mg/dL and CRP above or below the study median of 1.52
mg/L.6 As expected, overall event-free survival was poorest
for those with elevated CRP and elevated LDL, whereas the
best survival was observed for those with low CRP and low
LDL levels. However, event-free survival was actually worse
for those with elevated CRP and low LDL when compared
with those with elevated LDL and low CRP. Because of the
public health implications of these data, a large-scale statin
prevention trial of 15 000 patents is scheduled to begin in
early 2003 specifically targeting those with native LDL130
but a CRP above 2.0 mg/L.31
Although data are less robust, other lipid-lowering agents
reported to reduce CRP include niacin, fibrates, and gemfi-
brozil. Aspirin also has an intriguing interaction with CRP in
that the magnitude of relative risk reduction attributable to
aspirin in primary prevention appears to be greatest among
those with elevated CRP and declines proportionately in
direct relation to CRP levels.2 Observational data suggest
possible differential benefits for clopidogrel and abciximab
on the basis of CRP levels before percutaneous coronary
interventions.32–34 Thiazolidinediones also reduce CRP
levels.35
Clinical Recommendations
As documented above for primary prevention, CRP is an
independent predictor of future cardiovascular events that
adds prognostic information to lipid screening, to the meta-
bolic syndrome, and to the Framingham Risk Score.
In outpatient settings, the primary use of CRP should be at
the time of cholesterol screening, when knowledge of CRP
can be used as an adjunct for global risk assessment.1 For
individuals with LDL levels above 160 mg/dL and for whom
the ATP III guidelines already call for therapeutic interven-
tion, an elevated CRP level should aggressively encourage
physicians and patients to institute pharmacological therapy
in those instances where none is currently being used or
where compliance is poor.
For individuals with LDL levels between 130 and 160
mg/dL, the additional finding of an elevated CRP indicates an
elevated global risk. In almost all cases, this information
should lead to better compliance and adherence with current
ATP III treatment guidelines.
For individuals with LDL levels below 130 mg/dL, the
finding of an elevated CRP implies substantially higher risk
than predicted on the basis of LDL alone. As shown in
Figures 3 and 6, such individuals will have risk estimates as
high as some individuals with overt hyperlipidemia. Patients
with this profile should be advised to adhere carefully with
ATP III lifestyle interventions, despite “low” LDL cholester-
ol levels. Individuals with the low LDL/high CRP phenotype
Figure 6. Cardiovascular event-free survival according to base-
line levels of CRP and LDL. Adapted from reference 6.
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are at elevated risk of having the metabolic syndrome and
should have fasting glucose levels measured. Large-scale,
randomized trial evidence is critically needed before such
patients should be considered for statin therapy.31
An alternative approach in primary prevention is to mea-
sure CRP only among those at intermediate risk as defined by
the Framingham Risk Score. For example, clinicians might
conservatively choose to evaluate CRP only among those
with a calculated 10-year Framingham risk between 5% and
20% (see Figure 3). Although this strategy has epidemiolog-
ical appeal, such an approach requires a second office visit
and a second phlebotomy and thus is likely to be less efficient
and perhaps less cost-effective.
In secondary prevention, the potential utility of CRP is less
certain, as aggressive therapies should already be instituted
and LDL evaluation provides an excellent method to assess
statin efficacy.
In the setting of acute coronary ischemia and unstable
angina, the role of CRP is rapidly evolving. Multiple studies
demonstrate that CRP levels predict early and late mortality
in acute coronary ischemia and add to the predictive value of
cardiac troponin.36–41 Further, knowledge of inflammatory
status has been shown effective in distinguishing patient
subgroups more or less likely to benefit from an aggressive
versus conservative management approach.40 However, ap-
propriate clinical cut-points for CRP in the setting of acute
ischemia remain uncertain, as does the timing of CRP
evaluation in relation to the onset of ischemia. The most
foreseeable use of CRP in the emergency room setting is thus
likely to be among those with chest pain syndromes who have
negative troponin levels. An elevated CRP in this setting is
associated with increased short-term as well as long-term
risks,39–41 and thus additional evaluation modalities may be
warranted. By contrast, current data suggest that patients with
negative troponin and negative CRP levels in the emergency
room setting are unlikely to have flow limiting coronary
disease.39,40
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Abstract
 
Background.
 
Lowering the blood cholesterol
level may reduce the risk of coronary heart disease. This
double-blind study was designed to determine whether
the administration of pravastatin to men with hypercho-
lesterolemia and no history of myocardial infarction re-
duced the combined incidence of nonfatal myocardial in-
farction and death from coronary heart disease.
 
Methods.
 
We randomly assigned 6595 men, 45 to 64
years of age, with a mean (
 

 
SD) plasma cholesterol lev-
el of 272
 

 
23 mg per deciliter (7.0
 

 
0.6 mmol per liter) to
receive pravastatin (40 mg each evening) or placebo.
The average follow-up period was 4.9 years. Medical rec-
ords, electrocardiographic recordings, and the national
death registry were used to determine the clinical end
points.
 
Results.
 
Pravastatin lowered plasma cholesterol lev-
els by 20 percent and low-density lipoprotein cholesterol
levels by 26 percent, whereas there was no change with
placebo. There were 248 deﬁnite coronary events (speci-
ﬁed as nonfatal myocardial infarction or death from coro-
nary heart disease) in the placebo group, and 174 in the
pravastatin group (relative reduction in risk with prava-
statin, 31 percent; 95 percent conﬁdence interval, 17 to
43 percent; P
 

 
0.001). There were similar reductions
in the risk of deﬁnite nonfatal myocardial infarctions (31
percent reduction, P
 

 
0.001), death from coronary heart
disease (deﬁnite cases alone: 28 percent reduction,
P
 

 
0.13; deﬁnite plus suspected cases: 33 percent reduc-
tion, P
 

 
0.042), and death from all cardiovascular causes
(32 percent reduction, P
 

 
0.033). There was no excess of
deaths from noncardiovascular causes in the pravastatin
group. We observed a 22 percent reduction in the risk of
death from any cause in the pravastatin group (95 percent
conﬁdence interval, 0 to 40 percent; P
 

 
0.051).
 
Conclusions.
 
Treatment with pravastatin signiﬁcantly
reduced the incidence of myocardial infarction and death
from cardiovascular causes without adversely affecting
the risk of death from noncardiovascular causes in men
with moderate hypercholesterolemia and no history of
myocardial infarction. (N Engl J Med 1995;333:1301-7.)
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ARLIER trials of lipid-lowering drugs in the pri-
mary prevention of coronary heart disease have
demonstrated that lowering cholesterol levels in mid-
dle-aged men with hypercholesterolemia reduces the
incidence of myocardial infarction.
 
1-4
 
 However, these
studies, because of their design and low rates of ob-
served events, were unable to show a clear effect of
therapy on the risk of death from coronary heart dis-
ease or death from any cause. A meta-analysis of the
trials provided support for the likelihood that therapy
lowered the risk of death from coronary heart disease,
but it also aroused concern that the risk of death from
noncardiovascular causes might be increased by treat-
ment.
 
5-8
 
 Whether this latter association was due to
chance, to the reduction in cholesterol itself, or to an ad-
verse effect of the drugs is not clear.
Recently, a new class of lipid-lowering drug, the
3-hydroxy-3-methylglutaryl–coenzyme A reductase in-
hibitors, has been introduced into clinical practice.
These drugs block endogenous synthesis of cholesterol
and reduce the levels of low-density lipoprotein (LDL)
cholesterol. They slow the progression of coronary dis-
ease and reduce the incidence of death from coronary
causes and death from any cause in men with manifest
coronary heart disease.
 
9-15
 
 The present study was de-
signed to evaluate the effectiveness of a reductase in-
hibitor, pravastatin (Pravachol), in preventing coronary
events in men with moderate hypercholesterolemia and
no history of myocardial infarction.
 
M
 
ETHODS
 
Design
 
The objective was to enroll approximately 6000 middle-aged men,
randomly assigned in a double-blind fashion to receive either prava-
statin (40 mg each evening) or placebo and to record their clinical
progress over a period of ﬁve years. The details of the study design,
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including the deﬁnitions of the end points, have been described pre-
viously.
 
16
 
 Brieﬂy, the primary end point of the study was the occur-
rence of nonfatal myocardial infarction or death from coronary heart
disease as a ﬁrst event; these two categories were combined. Other
principal end points were the occurrence of death from coronary
heart disease and nonfatal myocardial infarction. In all categories, the
events were classiﬁed as either deﬁnite or suspected. In addition to the
main end points, the effect of treatment on death from cardiovascular
causes, death from any cause, and the frequency of coronary revascu-
larization procedures was analyzed.
All subjects provided written informed consent. The study was ap-
proved by the ethics committees of the University of Glasgow and all
participating health boards.
 
Recruitment and Follow-up
 
Coronary screening clinics were established in primary medical
care facilities throughout the West of Scotland district. Approximately
160,000 men ranging in age from 45 to 64 years were invited to attend
the clinics to assess their coronary risk factors. A total of 81,161 ap-
peared for the ﬁrst visit, and those whose nonfasting plasma choles-
terol level was at least 252 mg per deciliter (6.5 mmol per liter) but
who had no history of myocardial infarction were given lipid-lowering
dietary advice
 
17
 
 and asked to return four weeks later. A total of 20,914
men returned for the second visit, at which time a lipoprotein proﬁle
was obtained that measured plasma cholesterol, the cholesterol con-
tent of LDL and high-density lipoprotein (HDL), and plasma triglyc-
erides while the subjects were fasting. If on this occasion the LDL
cholesterol level was at least 155 mg per deciliter (4.0 mmol per liter)
and the subject had no exclusion criteria,
 
16
 
 he was advised to stay on
the lipid-lowering diet for a further four weeks and then to return for
a third visit (13,654 attended), at which time a second lipoprotein pro-
ﬁle and a 12-lead electrocardiogram (ECG) were obtained. On the
fourth visit the patients underwent randomization if they met the fol-
lowing criteria: fasting LDL cholesterol level of at least 155 mg per
deciliter during the second and third visits, with at least one value of
174 mg per deciliter or above (4.5 mmol per liter) and one value of
232 mg per deciliter or below (6.0 mmol per liter); no serious ECG
abnormalities according to Minnesota code
 
18
 
 1 (pathologic Q waves),
4-1, 5-1, or 7-1-1 or arrhythmia such as atrial ﬁbrillation; and no his-
tory of myocardial infarction or other serious illness, although men
with stable angina who had not been hospitalized within the previous
12 months were eligible. Further details of the inclusion and exclusion
criteria were described previously.
 
16
 
 
The subjects were seen at three-month intervals, and dietary advice
was reinforced on each occasion. A fasting lipoprotein proﬁle was ob-
tained every six months, and an ECG was recorded annually or as re-
quired clinically. The subjects received a full medical examination by
a physician each year.
 
Laboratory Analyses
 
The cholesterol measurement during the ﬁrst visit was performed
on a Reﬂotron bench-top analyzer (Boehringer–Mannheim, Lewes,
Kent, United Kingdom). All subsequent laboratory analyses, includ-
ing biochemical, hematologic, and lipoprotein proﬁles, were conduct-
ed at the central laboratory at the Glasgow Royal Inﬁrmary. Lipopro-
tein proﬁles were determined according to the Lipid Research Clinics
protocol
 
19
 
 with enzymatic cholesterol and triglyceride assays. The lab-
oratory was certiﬁed through the Lipid Standardization Program of
the Centers for Disease Control and Prevention in Atlanta. Abnormal-
ities in the results of blood tests were identiﬁed with the use of pub-
lished reference ranges.
 
16
 
 
Siemens Sicard 440 electrocardiographs were used to record the
12-lead ECGs, and the data were transmitted by telephone to the
ECG core laboratory at the Glasgow Royal Inﬁrmary for storage on
a central Mingocare data base (Siemens Elema, Stockholm, Sweden)
and subsequent automated classiﬁcation according to the Minnesota
code, including serial comparisons.
 
18,20-22
 
 All ECG results were veri-
ﬁed by visual inspection.
 
Identiﬁcation and Classiﬁcation of End Points
 
At each follow-up visit, adverse events were documented on the ba-
sis of the subjects’ recall, and if appropriate, further information was
obtained from hospital records. All data on randomized subjects were
ﬂagged electronically on national computer data bases so that the
numbers of deaths, incident cancers, hospitalizations, and cardiac sur-
geries could be monitored according to previously described meth-
ods.
 
23
 
 Potential end points were reviewed and classiﬁed according to
predeﬁned criteria
 
16
 
 by the End-Points Committee, whereas non–cor-
onary heart disease events were reviewed and classiﬁed by the Ad-
verse-Events Committee. The progress and conduct of the study were
monitored regularly by the independent, unblinded Data and Safety
Monitoring Committee. Except for the trial statistician and his assist-
ant, all trial personnel remained unaware of the subjects’ treatment
assignments throughout the study.
 
Statistical Analysis
 
All data were analyzed according to the intention-to-treat princi-
ple. The results of the two fasting lipoprotein proﬁles obtained during
visits 2 and 3 were averaged to produce base-line values. The LDL
cholesterol results were analyzed according to both the treatment
actually received and the intention-to-treat principle. The analysis
based on actual treatment used only the measured lipid levels in sub-
jects who had attended the previous scheduled visit and who had been
issued with trial medication at that visit. For the intention-to-treat
analysis, all recorded levels were included, without reference to the
subjects’ degree of compliance at previous visits. In addition, in cases
in which no lipid value was available for a scheduled visit and no med-
ication had been issued at the previous visit, the subject’s base-line
level was used. For each end-point category, the lengths of time to a
ﬁrst event were compared with use of the log-rank test, and the rela-
tive reduction in risk resulting from pravastatin treatment, with 95
percent conﬁdence intervals, was calculated with the Cox proportion-
al-hazards model.
 
24
 
 In addition, Kaplan–Meier time-to-event curves
were used to estimate the absolute risk of each event at ﬁve years for
each treatment group. When a silent myocardial infarction was de-
tected on the basis of serial comparison of ECGs, the event was con-
 
*Plus–minus values are means 
 

 
SD. To convert values for cholesterol to millimoles per
liter, multiply by 0.026, and to convert values for triglycerides to millimoles per liter, multiply
by 0.011.
†The weight in kilograms divided by the square of the height in meters.
‡A unit was deﬁned as 1 measure (60 ml) of liquor, 1 glass (170 ml) of wine, or a half pint
(300 ml) of beer.
§As indicated by positive responses on the Rose questionnaire.
 
Table 1. Base-Line Characteristics of the Randomized Subjects,
According to Treatment Group.
 
*
 
C
 
HARACTERISTIC
 
P
 
LACEBO
 
(N
 

 
3293)
P
 
RAVASTATIN
 
(N
 

 
3302)
 
Continuous variables
 
Age — yr 55.1
 

 
5.5 55.3
 

 
5.5
Body-mass index† 26.0
 

 
3.1 26.0
 

 
3.2
Blood pressure — mm Hg
Systolic 136
 

 
17 135
 

 
18
Diastolic 84
 

 
10 84
 

 
11
Cholesterol — mg/dl
Total 272
 

 
22 272
 

 
23
LDL 192
 

 
17 192
 

 
17
HDL 44
 

 
10 44
 

 
9
Triglycerides — mg/dl 164
 

 
68 162
 

 
70
Alcohol consumption — units/wk‡ 11
 

 
13 12
 

 
14
 
Categorical variables 
 
— no. of subjects (%)
Angina§ 174 (5) 164 (5)
Intermittent claudication§ 96 (3) 97 (3)
Diabetes 35 (1) 41 (1)
Hypertension (self-reported) 506 (15) 531 (16)
Minor ECG abnormality 259 (8) 275 (8)
Smoking status
Never smoked
Exsmoker
Current smoker
705 (21)
1127 (34)
1460 (44)
717 (22)
1138 (34)
1445 (44)
Employment status
Employed
Unemployed
Retired
Disabled
2324 (71)
459 (14)
338 (10)
171 (5)
2330 (71)
430 (13)
330 (10)
210 (6)
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sidered to have occurred midway between the ﬁrst diagnostic ECG
and the previous ECG. Two-tailed P values were used throughout.
For the primary end point, an analysis was performed for pre-
deﬁned subgroups
 
16
 
 characterized at base line according to age (
 

 
55
years or 
 

 
55 years), smoking status (smoker or nonsmoker of ciga-
rettes, cigars, or pipes), and whether at least two of the following risk
factors were present: smoking, hypertension, a history of chest pain or
intermittent claudication (as indicated by positive responses on the
Rose questionnaire), diabetes, and a minor ECG abnormality associ-
ated with coronary heart disease (Minnesota code 4-2, 4-3, 5-2, or 5-3).
In addition, the effect of treatment was examined in a subgroup
with and a subgroup without vascular disease
at base line. Vascular disease was considered
to be present if there was evidence of angina,
intermittent claudication, stroke, transient is-
chemic attack, and ECG abnormalities ac-
cording to the Minnesota code. Finally, the
inﬂuence of base-line lipid levels on the effect
of treatment was assessed by dividing the ran-
domized population according to the median
plasma cholesterol, LDL or HDL cholesterol,
or plasma triglyceride concentration.
The Data and Safety Monitoring Commit-
tee conducted annual reviews of the main end
points according to the O’Brien and Fleming
criteria for stopping the trial prematurely.
 
25
 
The overall P value indicating statistical sig-
niﬁcance was set at 0.01.
 
R
 
ESULTS
 
A total of 6595 subjects underwent
randomization. The clinical charac-
teristics of the subjects who were
screened and those who were ran-
domized have been described previ-
ously.
 
26
 
 The ﬁrst patient was enrolled
on February 1, 1989, and recruitment
was completed by September 30,
1991. The ﬁnal visits were made be-
tween February and May 1995, by
which time the study population had
accrued 32,216 subject-years of fol-
low-up (an average of 4.9 years per
subject). At the end of the study, the
vital and clinical status of all ran-
domized subjects was ascertained.
The base-line characteristics of the pravastatin and pla-
cebo groups are summarized in Table 1. As expected in
a trial of this size, the groups were well balanced. For
the study population as a whole, the average (
 

 
SD)
plasma cholesterol level was 272
 

 
23 mg per deciliter
(7.0
 

 
0.6 mmol per liter), the LDL cholesterol level was
192
 

 
17 mg per deciliter (5.0
 

 
0.5 mmol per liter), and
the HDL cholesterol level was 44
 

 
9 mg per deciliter
(1.14
 

 
0.26 mmol per liter). On the basis of positive re-
sponses on the Rose questionnaire, evidence of angina
was present in 5 percent of the men, whereas 8 percent
had ECG ST-T wave changes (Minnesota codes 4-2,
4-3, 5-2, and 5-3). The prevalence of self-reported dia-
betes mellitus was 1 percent, and that of hypertension
was 16 percent; 44 percent of the subjects were current
smokers.
 
Withdrawals
 
The cumulative rates of withdrawal from treatment
in the placebo and pravastatin groups were 14.9 per-
cent and 15.5 percent, respectively, at year 1, 19.1 per-
cent and 19.4 percent at year 2, 22.5 percent and 22.7
percent at year 3, 25.2 percent and 24.7 percent at year
4, and 30.8 percent and 29.6 percent at year 5. There
was no signiﬁcant difference in the withdrawal rates be-
tween the two groups at any time. The disproportionate
increase from year 4 to year 5 can be attributed to the
withdrawal from the study of some subjects who had
 
Figure 1. Effects of Pravastatin Therapy on Plasma LDL Choles-
LD
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terol Levels.
To convert values for cholesterol to millimoles per liter, multiply
by 0.026.
 
*The P values are based on the log-rank test. No formal analysis was carried out for events with a low incidence. CI
denotes conﬁdence interval, CHD coronary heart disease, MI myocardial infarction, PTCA percutaneous transluminal cor-
onary angioplasty, and CABG coronary-artery bypass graft.
 
Table 2. End Points of the Study.
 
*
 
V
 
ARIABLE
 
P
 
LACEBO
 
(N
 

 
3293)
P
 
RAVASTATIN
 
(N
 

 
3302) P V
 
ALUE
 
R
 
ISK
 
 R
 
EDUCTION
 
 
 
WITH
 
 
P
 
RAVASTATIN
 
 (95% CI)
 
no. of events (absolute % risk at 5 yr) %
 
Deﬁnite coronary events
 
Nonfatal MI or death from CHD
Nonfatal MI (silent MIs omitted) or
death from CHD
Nonfatal MI
Death from CHD
248 (7.9)
218 (7.0)
204 (6.5)
52 (1.7)
174 (5.5)
150 (4.7)
143 (4.6)
38 (1.2)
 

 
0.001
 

 
0.001
 

 
0.001
0.13
31 (17 to 43)
33 (17 to 45)
31 (15 to 45)
28 (
 

 
10 to 52)
 
Deﬁnite
 

 
suspected coronary events
 
Nonfatal MI or death from CHD
Nonfatal MI (silent MIs omitted) or 
death from CHD
Nonfatal MI
Death from CHD
295 (9.3)
240 (7.6)
246 (7.8)
61 (1.9)
215 (6.8)
166 (5.3)
182 (5.8)
41 (1.3)
 

 
0.001
 

 
0.001
0.001
0.042
29 (15 to 40)
32 (17 to 44)
27 (12 to 40)
33 (1 to 55)
 
Other events
 
Coronary angiography
PTCA or CABG
Fatal or nonfatal stroke
Incident cancer
128 (4.2)
80 (2.5)
51 (1.6)
106 (3.3)
90 (2.8)
51 (1.7)
46 (1.6)
116 (3.7)
0.007
0.009
0.57
0.55
31 (10 to 47)
37 (11 to 56)
11 (
 

 
33 to 40)
 

 
8 (
 

 
41 to 17)
 
Death from other causes
 
Other cardiovascular causes (including 
stroke)
Suicide
Trauma
Cancer
All other causes
12
1
5
49 (1.5)
7
9
2
3
44 (1.3)
7
—
—
—
0.56
—
—
—
—
11 (
 

 
33 to 41)
—
 
Death from all cardiovascular causes
 
73 (2.3) 50 (1.6) 0.033 32 (3 to 53)
 
Death from noncardiovascular causes
 
62 (1.9) 56 (1.7) 0.54 11 (
 

 
28 to 38)
 
Death from any cause
 
135 (4.1) 106 (3.2) 0.051 22 (0 to 40)
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completed the ﬁve years of follow-up and who could
have proceeded further but did not wish to do so.
 
Reduction in Lipid Levels
 
When the data were analyzed according to the treat-
ment actually received, pravastatin was found to have
lowered plasma levels of cholesterol by 20 percent, LDL
cholesterol by 26 percent (Fig. 1), and triglycerides
by 12 percent, whereas HDL cholesterol was increased
by 5 percent. There were no such changes with placebo.
When the data were analyzed according to the inten-
tion-to-treat principle, because such analysis includes
subjects who withdrew and noncompliant subjects,
there was an apparent reduction in the observed dif-
ference in LDL cholesterol levels between treatment
groups over time. This result is in contrast to that based
on actual treatment, which showed that the differnce
was maintained.
 
End Points
 
As compared with placebo, pravastatin produced a
signiﬁcant reduction in the risk of the combined pri-
mary end point of deﬁnite nonfatal myocardial infarc-
tion and death from coronary heart disease (reduction,
31 percent; 95 percent conﬁdence interval, 17 to 43 per-
cent; P0.001; absolute difference in the risk at ﬁve
years, 2.4 percentage points) (Table 2 and Fig. 2). The
effects of pravastatin on other principal end points
are given in Table 2 and Figure 3. The reduction in the
risk of nonfatal myocardial infarction was signiﬁcant
(P0.001) whether the deﬁnite cases of myocardial in-
farction were considered alone or in combination with
suspected cases. Excluding silent myocardial infarc-
tions from the analysis of the primary end point did not
affect the outcome (Table 2). For the end point of death
from coronary heart disease, there was a signiﬁcant
treatment effect in the analysis of both deﬁnite and sus-
pected cases (risk reduction, 33 percent; 95 percent
conﬁdence interval, 1 to 55 percent; P0.042), but not
in the analysis of deﬁnite cases alone, probably because
of the smaller number of events in this group. However,
there was a similar reduction in risk (28 percent). When
the effect of treatment with pravastatin on death from
all cardiovascular causes was analyzed, a 32 percent re-
duction in risk (95 percent conﬁdence interval, 3 to 53
percent; P0.033) was observed. Treatment with pra-
vastatin was associated with similar reductions in the
frequency of coronary angiography (31 percent; 95 per-
cent conﬁdence interval, 10 to 47 percent; P0.007)
Figure 2. Kaplan–Meier Analysis of the Time to a Deﬁnite Non-
fatal Myocardial Infarction or Death from Coronary Heart Dis-
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Figure 3. Kaplan–Meier Analysis of the
Time to a Deﬁnite Nonfatal Myocardial In-
farction (Panel A), Death Deﬁnitely from
Coronary Heart Disease (Panel B), Death
from All Cardiovascular Causes (Panel
C), Death from Noncardiovascular Causes
(Panel D), and Death from Any Cause (Pan-
el E), According to Treatment Group.
P
er
ce
nt
ag
e 
w
ith
 E
ve
nt
10
8
6
4
2
0
0 1 2 3 4 5 6
P0.001
Placebo
Pravastatin
Year
Definite Nonfatal Myocardial
Infarction
A
P
er
ce
nt
ag
e 
w
ith
 E
ve
nt
2.5
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5 6
P  0.13
Placebo
Pravastatin
Year
 Death Definitely from
Coronary Heart Disease
B
P
er
ce
nt
ag
e 
w
ith
 E
ve
nt
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5 6
P  0.033
Placebo
Pravastatin
Year
Death from
All Cardiovascular Causes
C
P
er
ce
nt
ag
e 
w
ith
 E
ve
nt
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5 6
P  0.54
Placebo
Pravastatin
Year
Death from
Noncardiovascular Causes
D
P
er
ce
nt
ag
e 
w
ith
 E
ve
nt
6
5
4
3
2
1
0
0 1 2 3 4 5 6
P  0.051
Placebo
Pravastatin
Year
All DeathsE
Downloaded from www.nejm.org on January 26, 2008 . Copyright © 1995 Massachusetts Medical Society. All rights reserved. 
Vol. 333 No. 20 PRAVASTATIN TO PREVENT CORONARY HEART DISEASE 1305
and revascularization procedures (37
percent; 95 percent conﬁdence inter-
val, 11 to 56 percent; P0.009).
There were 56 deaths from non-
cardiovascular causes in the prava-
statin group and 62 in the placebo
group (P0.54). There was no sig-
niﬁcant difference between treat-
ment groups in the numbers of
deaths from cancer, suicide, or trau-
ma. There were 46 strokes (6 of
which were fatal) in the pravastatin
group and 51 (4 fatal) in the placebo
group. In the pravastatin group, the
reduction in the number of deaths
from cardiovascular causes in the
absence of any increase in the num-
ber of deaths from noncardiovascu-
lar causes resulted in a 22 percent
reduction in the overall risk of death
(95 percent conﬁdence interval, 0 to
40 percent; P0.051).
The beneﬁcial effects of pravastat-
in therapy were evident in all sub-
groups (Table 3). The numbers of
subjects in the subgroups with either
multiple risk factors at base line or vascular disease at
base line were too small to show a statistically signiﬁ-
cant effect.
Other Adverse Events
In the pravastatin group 116 subjects had incident
(fatal or nonfatal) cancers, as compared with 106 in the
placebo group (P0.55). These ﬁgures include cases
of malignant melanoma but not minor skin cancers.
For the placebo and pravastatin groups, respectively,
there were 30 and 31 gastrointestinal cancers, 26 and
32 genitourinary cancers, 28 and 27 respiratory tract
cancers, and 22 and 26 other cancers. Twenty subjects
in the pravastatin group reported myalgia, and 97 mus-
cle aches. The corresponding numbers in the placebo
group were 19 and 102 (P not signiﬁcant). Four subjects
(three in the pravastatin group and one in the placebo
group) had asymptomatic episodes of elevated creatine
kinase concentrations (10 times the upper reference
limit). Elevations in aspartate aminotransferase and
alanine aminotransferase values (3 times the upper
reference limits) were recorded for 26 and 16 subjects,
respectively, in the pravastatin group, as compared
with 20 and 12 subjects in the placebo group (P not sig-
niﬁcant).
DISCUSSION
As compared with placebo, pravastatin reduced the
risk of fatal or nonfatal coronary events in middle-aged
men with hypercholesterolemia and no history of myo-
cardial infarction by approximately 30 percent. The
beneﬁcial effects of treatment were remarkably consis-
tent across a variety of coronary end points. In contrast
to the results of studies using resins, ﬁbrates, or other
3-hydroxy-3-methylglutaryl–coenzyme A reductase in-
hibitors,1-4,9 the time-to-event curves began to diverge
within six months of the initiation of treatment and
continued to do so at the same rate throughout the tri-
al. The frequency of the need for coronary angiography
and revascularization procedures was signiﬁcantly low-
er in the pravastatin group than in the placebo group.
The subjects in this study were representative of the
general population in terms of socioeconomic status
and risk factors (Table 1). Their plasma cholesterol lev-
els were in the highest quartile of the range found in
the British population.27 A number had evidence of mi-
nor vascular disease, and in order to make the ﬁndings
of the trial applicable to typical middle-aged men with
hypercholesterolemia, they were not excluded.
In line with accepted guidelines,28 the LDL cholester-
ol level was used as a criterion for entry into the study.
As compared with placebo, pravastatin produced a ma-
jor reduction in this lipoprotein fraction (Fig. 1) and
moderate decreases in plasma triglycerides, as well as
an increase in HDL cholesterol. These changes are in
line with the expected response to pravastatin,29 and all
could potentially result in clinical beneﬁt. The changes
in the LDL cholesterol level are more substantial than
those observed in earlier primary prevention studies.1-4
When the subjects were divided into two groups ac-
cording to their lipid levels at base line, we found that
coronary risk was related to higher plasma LDL choles-
terol and triglyceride levels (i.e., levels above the medi-
an values) and lower HDL cholesterol levels (i.e., levels
below the median value) (Table 3). The plasma choles-
terol level was not a signiﬁcant factor, principally be-
cause of the narrow range of cholesterol values used as
a criterion for entry into the study. The relative reduc-
*The P values are based on the log-rank test.
†The presence of two or more of the following risk factors: smoking, hypertension, a history of chest pain or intermittent
claudication (as indicated by positive responses on the Rose questionnaire), diabetes, and a minor ECG abnormality asso-
ciated with coronary heart disease (Minnesota code 4-2, 4-3, 5-2, or 5-3).
‡To convert values for cholesterol to millimoles per liter, multiply by 0.026.
§To convert values for triglycerides to millimoles per liter, multiply by 0.011.
Table 3. Incidence of the Primary End Point, According to Subgroup.
VARIABLE SUBGROUP
NO. OF
SUBJECTS PLACEBO PRAVASTATIN P VALUE*
RISK REDUCTION 
WITH PRAVASTATIN 
(95% CI)
no. of events
(absolute % risk at 5 yr) %
Age 55 yr
	55 yr
3225
3370
96 (6.1)
152 (9.8)
57 (3.5)
117 (7.3)
0.0024
0.0089
40 (16 to 56)
27 (8 to 43)
Current smoking status Nonsmoker
Smoker
3687
2905
104 (6.0)
144 (10.4)
74 (4.3)
100 (7.0)
0.016
0.0035
31 (6 to 48)
31 (12 to 47)
Multiple risk factors† Absent
Present
5401
1194
178 (6.9)
70 (12.7)
114 (4.4)
60 (10.2)
0.001
0.20
37 (20 to 50)
20 (13 to 43)
Cholesterol level‡ 269 mg/dl
	269 mg/dl
3192
3403
122 (8.1)
126 (7.8)
80 (5.4)
94 (5.6)
0.0019
0.021
36 (15 to 51)
27 (4 to 44)
LDL cholesterol level‡ 189 mg/dl
	189 mg/dl
3211
3384
110 (7.6)
138 (8.3)
71 (4.9)
103 (6.1)
0.0025
0.016
37 (15 to 53)
27 (6 to 43)
HDL cholesterol level‡ 	43 mg/dl
43 mg/dl
3304
3291
99 (6.2)
149 (9.7)
66 (4.3)
108 (6.7)
0.011
0.0035
33 (9 to 51)
31 (11 to 46)
Triglyceride level§ 148 mg/dl
	148 mg/dl
3239
3356
98 (6.3)
150 (9.4)
72 (4.4)
102 (6.6)
0.024
0.0025
29 (4 to 48)
32 (12 to 47)
Prior vascular disease Absent
Present
5529
1066
183 (7.0)
65 (12.8)
125 (4.7)
49 (9.6)
0.001
0.075
33 (15 to 46)
29 (4 to 51)
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tion in risk with pravastatin therapy was statistically
signiﬁcant and of a similar magnitude in subjects with
lipid values above and below the median.
The relative reductions in risk attributable to prava-
statin therapy were not affected by age (55 years vs.
55 years) or smoking status. Furthermore, a signiﬁcant
treatment effect was seen in the subgroup without mul-
tiple risk factors and the subgroup without preexisting
vascular disease. Thus, it is possible to conclude that in
the subjects who might be considered to fall strictly into
the primary-prevention category, pravastatin therapy
produced a signiﬁcant reduction in the relative risk of
a coronary event.
Pravastatin therapy was well tolerated and resulted
in no more study withdrawals than placebo. In particu-
lar, as in an earlier study,15 there was no evidence that
pravastatin adversely affected liver function or caused
myopathy. Our results support those of a recent sec-
ondary-prevention trial9 that found that lipid lowering
with a 3-hydroxy-3-methylglutaryl–coenzyme A reduc-
tase inhibitor is not associated with an increased risk
of death from noncardiovascular causes. As in that ear-
lier trial,9 a comparison of the treatment and placebo
groups showed no signiﬁcant increase in the incidence
of fatal or incident cancers or deaths due to suicide or
trauma. More data on the adverse-event proﬁle of this
class of drugs will become available as the results of
other prevention trials are published. In the current
study, the beneﬁt of pravastatin therapy with respect to
fatal coronary events and the absence of any increase
in the number of deaths from other causes led to a 22
percent reduction in the relative risk of death from any
cause (P0.051).
From the data in Table 2, it can be estimated that
treating 1000 middle-aged men with hypercholesterole-
mia and no evidence of a previous myocardial infarc-
tion with pravastatin for ﬁve years will result in 14
fewer coronary angiograms, 8 fewer revascularization
procedures, 20 fewer nonfatal myocardial infarctions,
7 fewer deaths from cardiovascular causes, and 2 fewer
deaths from other causes than would be expected in the
absence of treatment. Since these ﬁgures are based on
an intention-to-treat analysis, the magnitude of the ben-
eﬁt in fully compliant subjects is likely to be greater.
These ﬁndings can be compared favorably with the re-
sults of the Medical Research Council trial30,31 of the
treatment of mild hypertension in middle-aged sub-
jects. In that study, it was estimated that ﬁve years of
active treatment of 1000 men ranging in age from 35 to
64 years would result in six fewer strokes and two fewer
cardiovascular events than would be expected. Thus,
our results indicate that reducing cholesterol levels with
pravastatin reduces the risk of coronary events in
asymptomatic subjects with hypercholesterolemia.
APPENDIX
The members of the West of Scotland Coronary Prevention Study
are as follows: Executive Committee (Voting Members) — J. Shepherd
(chairman), S.M. Cobbe, A.R. Lorimer, J.H. McKillop, I. Ford, C. J.
Packard, P.W. Macfarlane, and G.C. Isles; Data and Safety Monitoring
Committee — M.F. Oliver (chairman), A.F. Lever, B.W. Brown, J.G.G.
Ledingham, S. J. Pocock, and B.M. Rifkind; End-Points Committee —
S.M. Cobbe, B.D. Vallance, P.W. Macfarlane; Adverse-Events Committee
— A.R. Lorimer, J.H. McKillop, and D. Ballantyne; Data-Center Staff
— L. Anderson, D. Duncan, J. McGrath, S. Kean, A. Lawrence,
V. Montgomery, and J. Norrie; Population Screening — M. Percy; Clin-
ical Coordination, Monitoring, and Administration — E. Pomphrey,
A. Whitehouse, P. Cameron, P. Parker, F. Porteous, L. Fletcher, and
C. Kilday; Computerized ECG Analysis — D. Shoat (deceased), S. Latif,
and J. Kennedy; Laboratory Operations — M.A. Bell and R. Birrell; and
Company Liaison and General Support — M. Mellies, J. Meyer, and
W. Campbell.
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High-Sensitivity C-Reactive Protein: A Novel and
Promising Marker of Coronary Heart Disease
Nader Rifai1,2,4* and Paul M. Ridker2,3,5
Background: Coronary heart disease remains the lead-
ing cause of morbidity and mortality in the industri-
alized world. Clinical and laboratory studies have
shown that inflammation plays a major role in the
initiation, progression, and destabilization of athero-
mas. C-Reactive protein (CRP), an acute phase reac-
tant that reflects low-grade systemic inflammation,
has been studied in a variety of cardiovascular dis-
eases.
Approach: Findings from prospective clinical trials
were examined to determine the prognostic utility of
CRP in acute coronary syndromes, and observations
from epidemiological studies were reviewed to deter-
mine the ability of CRP to predict future first coronary
events. The analytical considerations of CRP measure-
ment in these clinical applications were also examined.
Content: In patients with established coronary disease,
CRP has been shown to predict adverse clinical
events. In addition, prospective studies have consis-
tently shown that CRP is a strong predictor of future
coronary events in apparently healthy men and
women. The relative risk associated with CRP is
independent of other cardiovascular disease risk fac-
tors. High-sensitivity CRP (hs-CRP) assays are needed
for risk assessment of cardiovascular disease. Such
assays are currently available but may require further
standardization because patients’ results will be in-
terpreted using population-based cutpoints. Preven-
tive therapies to attenuate coronary risk in individu-
als with increased hs-CRP concentrations include
aspirin and statin-type drugs.
Summary: hs-CRP has prognostic utility in patients
with acute coronary syndromes and is a strong indepen-
dent predictor of future coronary events in apparently
healthy subjects.
© 2001 American Association for Clinical Chemistry
Coronary heart disease (CHD)6 is the major cause of death
in the developed world. Atherosclerosis, the underlying
cause of most CHD, is a process that starts early in life and
progresses slowly and silently for decades. The clinical
manifestation usually occurs in the form of myocardial
infarction (MI), stroke, angina, or sudden death between
ages 50 and 60 years in men and between 60 and 70 years
in women. Cholesterol screening has been used as a tool
to identify individuals who are at increased risk of devel-
oping future coronary events. Although this approach has
been useful, it fails to identify almost one-half of the 1.3
million individuals who develop MI in the US each year
who have either normal or only moderately increased
serum cholesterol concentrations.
Laboratory and clinical evidence has demonstrated
that atherosclerosis is not simply a disease of lipid depos-
its. Rather, systemic inflammation also plays a pivotal role
in atherothrombotic inception and progression (1–3).
Mononuclear cells, macrophages, and T lymphocytes are
prominent in atheromatous plaques in the arterial wall
(4–7). Furthermore, the shoulder region of a plaque, the
most vulnerable site for rupture in acute coronary syn-
dromes, is heavily infiltrated with inflammatory cells
(8–10). Cytokines, which cause the de novo hepatic
production of acute phase reactants such as C-reactive
protein (CRP) (11 ), have been shown to increase in acute
coronary syndromes even in the absence of myocardial
necrosis (12 ). Therefore, CRP has been examined as a
surrogate marker of other inflammatory mediators such
as interleukin-6 and tumor necrosis factor-a to better
understand the inflammatory component of atherosclero-
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sis (13, 14). Current knowledge, however, suggests that
the CRP concentration might reflect the vulnerability of
the atheromatous lesion and the likelihood of a plaque to
rupture (2, 3, 15). This acute phase reactant has been
studied over the last several years in a wide variety of
atherosclerotic diseases (12, 16–20). Its prognostic utility
in acute coronary syndromes (12, 16–20) and its ability to
predict future coronary events in apparently healthy men
and women (21–30) have been demonstrated. The devel-
opment of high-sensitivity CRP (hs-CRP) assays has been
instrumental in exploration of the role of this acute phase
reactant in predicting first cardiovascular events. Prospec-
tive studies have consistently demonstrated a positive
association between hs-CRP and future coronary events.
For hs-CRP to make the transition from clinical research
to the routine clinical setting, however, several important
issues must be satisfactorily addressed: (a) the availability
of population-based cutpoints for interpretation and risk
assessment; (b) the existence of potential therapeutic mo-
dalities; and (c) the reliability of the analytical systems
used for measurement.
hs-CRP as a Prognostic Indicator in
Acute Coronary Syndromes
Several studies have demonstrated that hs-CRP, mea-
sured at either presentation or discharge, may have prog-
nostic value in patients with acute coronary syndromes.
Some reports have also examined the risk stratification of
patients by hs-CRP alone or in combination with cardiac
troponins.
Liuzzo et al. (12 ) showed that in 31 patients with
severe unstable angina and no evidence of myocardial
necrosis, as documented by the absence of increased
cardiac troponin T, hs-CRP concentrations .3 mg/L at
admission were associated with an increased incidence of
recurrent angina, coronary revascularization, MI, and
cardiovascular death. The same group later demonstrated
that hs-CRP .3 mg/L at discharge in 53 unstable angina
patients was associated with increased readmission for
recurrent instability and MI (16 ). In a similar study of
unstable angina, Ferreiros et al. (18 ) concluded that the
prognostic value of hs-CRP measured at discharge was
better than that determined at admission in predicting
adverse outcome at 90 days. Furthermore, hs-CRP was the
strongest independent predictor of adverse events in
multivariate analysis. Data from the Thrombolysis In
Myocardial Infarction 11A (TIMI 11A), a study of unstable
angina and non-Q-wave MI, showed that markedly in-
creased hs-CRP (15.5 mg/L) at presentation in 437 pa-
tients was a good predictor of 14-day mortality in that
population (19 ). Furthermore, hs-CRP helped to identify
those patients with negative cardiac troponin T (qualita-
tive rapid bedside method with cutoff of ,0.2 mg/L) who
were at increased risk of mortality (19 ). Morrow et al. (19 )
concluded from that study that a strategy for risk strati-
fication using both cardiac troponin T and hs-CRP should
be considered. Similar conclusions were reported in a
follow-up report by the same group using serum amy-
loid A, another acute phase reactant, instead of hs-CRP
(31 ). A recent report by de Winter et al. (17 ) showed
that hs-CRP concentrations .5 mg/L at admission in
150 patients with non-ST-elevation acute coronary syn-
dromes were associated with an increased incidence of
major cardiac events within 6 months, regardless of
cardiac troponin I values.
hs-CRP as a Predictor of Future Coronary Events
Over the last 6 years, several prospective studies have
demonstrated that hs-CRP is a predictor of future cardio-
vascular morbidity and mortality among individuals with
known cardiovascular disease. Data from the European
Concerted Action on Thrombosis and Disabilities (ECAT)
Angina Pectoris Study Group, a study of 2121 men and
women with stable and unstable angina, demonstrated
that each standard deviation increase in hs-CRP was
associated with a 45% increase in the relative risk (RR) of
nonfatal MI or sudden cardiac death [95% confidence
interval (95% CI), 1.15–1.83] (20 ). Similarly, in the Choles-
terol and Recurrent Events (CARE) trial, hs-CRP was a
predictor of recurrent coronary events in men and women
who had already suffered a MI (32 ). Those with hs-CRP
concentrations in the highest quintile had an 80% higher
chance of developing another coronary event within the
5-year study period (RR 5 1.77; 95% CI, 1.1–2.9). There-
fore, hs-CRP has the potential to be used in the stratifica-
tion of patients into high- and low-risk groups.
Perhaps of greater clinical importance is the demon-
stration that hs-CRP concentrations predict first MI and
stroke. To date, 10 prospective studies, 6 in the US and 4
in Europe, have consistently shown that hs-CRP is a
powerful predictor of future first coronary event in ap-
parently healthy men and women (Fig. 1). Findings from
the Multiple Risk Factors Intervention Trial (MRFIT)
demonstrated a direct positive association between hs-
CRP and CHD mortality in men followed over a 17-year
period (RR 5 2.8; 95% CI, 1.4–5.4) (22 ). This relationship,
however, was evident only among smokers. A similar
association between hs-CRP and future coronary events
was noted in the Cardiovascular Health Study and Rural
Health Promotion Project, which included men and
women over 65 years of age with subclinical cardiovas-
cular disease (26 ). The Physicians’ Health Study (PHS)
demonstrated similar positive association between hs-
CRP and future coronary events in apparently healthy
men (23 ). Unlike the observation in MRFIT, however, this
association was evident in both smokers and nonsmokers.
This study showed that those in the highest quartile of
hs-CRP had a twofold higher risk of future stroke (RR 5
1.9; 95% CI, 1.1–3.3), threefold higher risk of future MI
(RR 5 2.9; 95% CI, 1.8–4.6), and fourfold higher risk of
future peripheral vascular disease (PVD; RR 5 4.1; 95%
CI, 1.2–6.0) (23, 28). The RRs were stable over a long
period of time ($6 years) and independent of other CHD
risk factors. The European MONICA (Monitoring Trends
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study showed that an increase of one standard deviation
in the log-transformed value of hs-CRP was associated
with a 50% increase in coronary risk and that subjects
with hs-CRP concentrations in the highest quintile had a
2.6-fold higher risk of developing future coronary events
(21 ). A recent report from the Helsinki Heart Study
confirmed these observations and demonstrated that
those in the highest quartile of hs-CRP had a more than
threefold higher risk of future MI or cardiac death (RR 5
3.56; 95% CI, 1.93–6.57) (27 ).
Two reports from the Women’s Health Study (WHS)
showed that hs-CRP is a strong predictor of future car-
diovascular events in women (RR 5 4.4; 95% CI, 2.2–8.9)
(24, 25). In stratified analyses, hs-CRP continued to be a
strong predictor of future cardiovascular events even
among subgroups of women with no history of hyperlip-
idemia, hypertension, smoking, diabetes, or family his-
tory of CHD (25 ). The hs-CRP concentrations seen in
these postmenopausal women were somewhat higher
than those reported previously in men. Although no
difference in hs-CRP values was noted between premeno-
pausal women and age-matched males, recent reports
showed that hormone replacement therapy (estrogen
alone or estrogen and progestin) is associated with in-
creased hs-CRP concentrations (33, 34 ). These findings
suggest that the increased hs-CRP seen in the WHS
subjects may reflect the influence of hormone replacement
therapy rather than the effect of gender.
Predictive Value of hs-CRP and Other Biochemical Markers
for CHD Risk
The RR estimates derived from most of the above-men-
tioned prospective studies were independent of other
recognized cardiovascular risk factors. Data from both the
PHS (35 ) and WHS (24 ) showed that the predictive value
of hs-CRP was significantly higher than that associated
with traditional biochemical CHD risk markers [total
cholesterol (TC), HDL-cholesterol (HDL-C), and LDL-
cholesterol (LDL-C)] or novel markers [lipoprotein(a),
homocysteine, apolipoproteins AI and B]. In women, for
example, the univariate RR of future cardiovascular
events presented in Fig. 2 demonstrate that hs-CRP was
the single strongest predictor of risk (RR 5 4.4; 95% CI,
2.2–8.9). In comparison, LDL-C, a well-established
marker of CHD, was a lesser predictor of future risk
(RR 5 2.4; 95% CI, 1.3–4.6). Furthermore, in a multivariate
analysis that accounted for other CHD risk factors (obe-
sity, hypertension, diabetes, family history), only hs-CRP
and the ratio of TC to HDL-C had independent predictive
value. In the same study of postmenopausal women (24 ),
hs-CRP was shown to predict risk among those with
LDL-C values ,1300 mg/L, a concentration deemed
“desirable” by the current National Cholesterol Education
Program guidelines for primary prevention. In this sub-
group (mean LDL-C, 1040 mg/L), the RRs of future MI,
stroke, and coronary revascularization in the lowest to the
highest quartiles of hs-CRP were 1.0, 2.4, 2.9, and 4.1,
respectively (95% CI for the 4th vs 1st quartile, 1.7–11.3).
Fig. 1. Prospective studies of hs-CRP as a risk factor for future cardiovascular disease in populations of apparently healthy men and women.
RR estimates (f) and 95% CIs (lines) are computed for those in the top compared with the bottom quartile. Data from Refs. (21–30).
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After adjustment for other CHD risk factors and concen-
tration of HDL-C, the RR associated with hs-CRP re-
mained highly significant (RR 5 3.1; 95% CI, 1.1–8.3) and
increased ;39% with each increasing quartile of hs-CRP.
This study thus demonstrated that hs-CRP can identify
individuals at increased risk of developing future coro-
nary events who otherwise would be missed if only lipid
measurements were used. Other examined markers of
inflammation, e.g., serum amyloid A, interleukin-6, and
soluble intercellular adhesion molecule-1, showed consis-
tent association but a slightly weaker RR of future coro-
nary events.
The predictive value of hs-CRP in men and women
increased considerably when evaluated in models that
included lipid values. Data from the PHS demonstrated
that, compared with those with TC and hs-CRP below the
75th percentile, those with increased TC alone had a
2.3-fold increase in risk (95% CI, 1.5–3.7), whereas those
with increased hs-CRP alone had a 1.5-fold increase in
risk (95% CI, 0.9–2.4) (35 ). In contrast, the risk of devel-
oping coronary events increased 5-fold (95% CI, 2.5–9.8)
among those with high concentrations of both TC and
hs-CRP. Therefore, the joint effects of both risk factors are
greater than the product of the individual effects of each
risk factor considered alone. Furthermore, when the study
participants were stratified according to quintile of hs-
CRP and quintile of TC:HDL-C ratio, the RR of first
coronary event in those in the highest quintiles of both
hs-CRP and TC:HDL-C ratio was approximately ninefold
higher than that of men in the lowest quintiles of these
analytes. Data from the WHS demonstrated similar find-
ings such that women in the highest quintile of both
hs-CRP and TC:HDL-C ratio had a RR more than eight-
fold higher than that of women in the lowest quintiles
(Fig. 3). In all of these analyses, risk prediction models
that incorporated lipids were significantly better (P
,0.001) than those based on hs-CRP alone (24 ).
Interpretation of hs-CRP Values
For the purpose of assessing risk of future first coronary
events, hs-CRP concentration should be interpreted using
cut points established by prospective clinical studies. Each
patient will be classified into a quintile of risk, depending
on the hs-CRP concentration. Therefore, the reporting of
hs-CRP results focuses on the quintile of risk and not on
the actual mass concentration.
The within-person biologic variability of hs-CRP is low
over a long period of time (36 ). Laboratory measurements
on paired samples obtained from 236 subjects at baseline
and 5 years later showed that an individual’s log-normal-
ized hs-CRP concentrations are highly correlated (r 5
0.60). Somewhat comparable correlation coefficients were
noted for TC (r 5 0.37), LDL-C (r 5 0.32), HDL-C (r 5
0.74), and triglycerides (r 5 0.49) over the 5-year fol-
low-up period. This finding lends further support to the
fact that hs-CRP is a good and biologically stable predic-
tor of future MI despite the fact that it is an acute phase
reactant, providing that the patient is not suffering from
an active infection or using a drug that affects hs-CRP
concentration. hs-CRP values .15 mg/L (;99th percen-
tile of the general population) indicate an active inflam-
mation; patients should be advised to have a repeat
measurement in 2–3 weeks or after the infection in re-
solved.
As indicated earlier, models containing both hs-CRP
and TC or the TC:HDL-C ratio were better able to predict
future first coronary events than those containing hs-CRP
alone. The RRs of future first coronary events for men and
women as well as lipid concentrations were computed in
quintiles from the PHS and WHS databases, respectively,
Fig. 2. RRs for future cardiovascular events among
apparently healthy women in the WHS according to
baseline values of several biochemical markers.
For consistency, risk estimates (f) and 95% CIs (lines) are
computed for those in the top compared with the bottom
quartile for each marker. Lp(a), lipoprotein(a); tHCY, total
homocysteine; IL-6, interleukin-6; sICAM-1, soluble intercel-
lular adhesion molecule-1; LDLC, LDL-C; SAA, serum amy-
loid A; Apo B, apolipoprotein B; HDLC, HDL-C. Adapted from
Ridker et al. (24).
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and are presented in Fig. 3. Because the computed RRs
did not vary significantly between men and women, a
single risk assessment algorithm is suggested for both
genders (Table 1) (37 ). The hs-CRP concentrations were
derived from ongoing population-based surveys. It is
important to note that it is not necessary in this case to
report the actual hs-CRP concentration to the clinician but
only the patient’s RR. The clinical laboratory should play
an active role in the interpretation and implementation of
this clinical application. Providing incomplete informa-
tion or just the actual hs-CRP concentration will only
frustrate and prevent the clinician from correctly inter-
preting the data and managing the patient.
Potential Preventive Therapies
Although no specific therapies have been developed to
decrease hs-CRP and there is no direct evidence that risk
of future cardiovascular events is diminished by reducing
hs-CRP, studies have shown that aspirin (23 ) and prava-
statin (32 ) are effective in decreasing the incidence of
future coronary events in those with increased hs-CRP
concentration. These studies suggest that the two exam-
ined drugs possess antiinflammatory characteristics.
Among apparently healthy men in the PHS with in-
creased hs-CRP (.2.1 mg/L), aspirin use decreased the
risk of future MI by almost 60% (23 ). In contrast, aspirin
use was associated with a much smaller, although statis-
tically significant, 14% decrease in future MI among men
with low hs-CRP (,0.55 mg/L). Although the magnitude
of reduction in future risk of MI depended on the concen-
tration of hs-CRP, it is important to note that all subjects
benefited from aspirin use. These findings suggest that
aspirin was acting not only as an antiplatelet agent but
also as an antiinflammatory drug.
Similar findings were also noted with pravastatin use
in the CARE study (32 ). As indicated earlier, CARE is a
prospective study of men and women with average lipid
concentrations who have suffered an MI. Participants
Fig. 3. RRs of first coronary event among apparently healthy men (left) and women (right) associated with different hs-CRP concentrations and
TC:HDL-C ratios.
Adapted from Ridker and co-workers (23, 24).
Table 1. RR estimates for future coronary events in men and women associated with quintiles of
hs-CRP and TC:HDL-C ratio.a
Men Women
Quintile of hs-CRP, mg/L
1
(<0.7)
2
(0.7–1.1)
3
(1.2–1.9)
4
(2.0–3.8)
5
(3.9–15.0)
Quintile of TC:HDL-C ratio
1 <3.4 <3.4 1 1.2 1.4 1.7 2.2
2 3.4–4.0 3.4–4.1 1.4 1.7 2.1 2.5 3
3 4.1–4.7 4.2–4.7 2 2.5 2.9 3.5 4.2
4 4.8–5.5 4.8–5.8 2.9 3.5 4.2 5.1 6
5 >5.5 >5.8 4.2 5 6 7.2 8.7
a RR estimates and TC:HDL-C ratio were derived from the PHS (23) and the WHS (24) databases. hs-CRP concentrations were derived from ongoing population-based
surveys.
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were randomized between 40 mg of pravastatin per day
and placebo and followed for 5 years (38 ). Study partici-
pants with high hs-CRP (.9.9 mg/L or 90th percentile) at
baseline experienced a reduction of 54% in the incidence
of recurrent coronary events compared with a reduction
of 25% in those with low hs-CRP (,9.9 mg/L or 90th
percentile), although baseline lipid values were almost
identical in the two groups. Moreover, during the 5-year
follow-up, pravastatin lowered mean hs-CRP by almost
40%. This represented a 22% difference at 5 years in
median hs-CRP between the pravastatin and placebo
groups. Furthermore, the magnitude of change in hs-CRP
appeared to be unrelated to that of LDL-C in both the
pravastatin and placebo groups. These findings suggest
that pravastatin may have antiinflammatory characteris-
tics that are independent from its lipid-lowering property.
Clinical trials are currently ongoing to further explore the
interaction between pravastatin, aspirin, and the inflam-
matory response in primary and secondary prevention
settings.
Interrelationships with Other CHD Risk Factors
Several CHD risk factors appear to modulate the inflam-
matory response and affect hs-CRP concentration. Obe-
sity, for example, is directly associated with increased
hs-CRP concentrations, an intriguing observation consid-
ering that interleukin-6, the primary stimulant of the de
novo hepatic synthesis of CRP, is secreted by adipose
tissue (39, 40). Therefore, the attenuation of the inflamma-
tory response may represent a mechanism by which diet
and weight loss reduce cardiovascular risk. Cigarette
smoking has also been shown to increase the concentra-
tion of several inflammatory markers, including hs-CRP,
interleukin-6, and soluble intercellular adhesion mole-
cule-1. Increases of both interleukin-6 (41 ) and soluble
intercellular adhesion molecule-1 (42 ) were shown to be
associated with increased risk of future first coronary
events in both men and women. Smoking cessation de-
creases these markers. Diabetic patients are reported to
have increased hs-CRP values (43 ); In this regard, links
between hs-CRP and the insulin resistance syndrome
have also been reported (44 ). In addition, experimental
findings suggest that increased blood pressure promotes
endothelial expression of cytokines and inflammatory
activation (6, 45, 46). These observations suggest that per-
haps better control of diabetes and hypertension may
attenuate the contribution of the inflammatory response
to overall cardiovascular risk. Finally, physical exercise
has been shown to have a beneficial effect in terms of
reducing the concentration of several inflammatory mark-
ers (47, 48). Taken together, the available evidence thus
supports the hypothesis that hs-CRP concentrations cor-
relate with endothelial dysfunction (49 ).
Analytical Considerations in the Measurement of hs-CRP
Historically, CRP has been measured in clinical laborato-
ries by immunoturbidimetric and immunonephelometric
assays designed to detect active inflammation and infec-
tion. The dynamic range of these assays spans from 3
mg/L (;90th percentile of the general population) to well
over 200 mg/L. Such traditional assays, however, do not
have appropriate sensitivity in the range required for the
determination of cardiovascular risk in apparently
healthy men and women.
To achieve the desired limit of quantification, manu-
facturers and investigators have continued to use immu-
nochemical techniques in their attempts to measure hs-
CRP, but with modifications to increase the detectable
signal. Several approaches have been used, including the
labeling of anti-CRP antibodies with either an enzyme
(ELISA) or a fluorescent compound, and attaching the
antibodies, either monoclonal or polyclonal, to polysty-
rene beads (50–55). The latter approach was popular
among manufacturers because it enabled the adaptation
to commonly used automated analyzers in clinical chem-
istry laboratories. Currently, hs-CRP concentrations as
low as 0.15 mg/L (,2.5th percentile of the general pop-
ulation) can be reliably measured. It is important to note,
however, that not all hs-CRP assays possess a similar
sensitivity or lower limit of quantification (56 ). For prac-
tical considerations, it is advisable to have a single CRP
assay in the clinical laboratory that is capable of measur-
ing low and high concentrations. However, if that is
impossible, clinicians should be aware of the availability
of two different CRP assays and request hs-CRP for
cardiovascular risk prediction purpose.
Because the hs-CRP value of an individual patient is
interpreted in the context of cutpoints established by
prospective clinical studies, standardization of hs-CRP
assays is crucial. Poor agreement among methods will
lead to misclassification and mismanagement of patients.
Recent reports have indicated that the measurement of
low hs-CRP concentrations is not consistent among vari-
ous methods, suggesting that standardization efforts are
needed (51, 56). In one case where a significant bias was
noted between two methods (51 ), the manufacturers of
both reagent systems claimed to have their calibrators
traceable to the WHO reference materials. Unfortunately,
this is not an unusual occurrence. Although manufactur-
ers attempt to standardize their assays using the WHO
calibrators, they often fail to follow the appropriate value
transfer protocol from the reference materials to their own
calibrators (57 ). Invariably, this leads to suboptimal stan-
dardization.
An in-house hs-CRP ELISA method (52 ), utilizing
polyclonal antibodies from Calbiochem, was used in
MRFIT, the Cardiovascular Health Study, and the Rural
Health Promotion Project as well as in the early work
from the PHS. The analytical performance and clinical
efficacy of the ELISA assay were compared with those of
an automated and commercially available latex-enhanced
method (Dade Behring) (51 ) used at present in several
prospective studies, including the PHS, WHS, Women’s
Health Initiative, Nurses’ Health Study, Health Profes-
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sionals’ Study, and Texas/Air Force Coronary Atheroscle-
rosis Prevention Study (58 ). The two assays were evalu-
ated using plasma samples from the PVD cohort of the
PHS in a nested case-control design. Excellent analytical
agreement between the two methods was reported
(slope 5 0.99; intercept 5 0.36 mg/L; r 5 0.95) (58 ). In
addition, for both methods, the calculated RRs of devel-
oping future PVD increased significantly with each in-
creasing quartile of hs-CRP. The calculated interquartile
increase in RR of PVD was 31% (95% CI, 5.2–62.2) for the
ELISA and 34% (95% CI, 8.2–66.1) for the latex-enhanced
method. Furthermore, all but two participants were clas-
sified into concordant quartiles or varied by only one
quartile. This study demonstrated comparable clinical
efficacy of the two methods and linked the earlier and the
current data, thus assuring consistency among reported
hs-CRP values. On the basis on this report, the US Food
and Drug Administration approved the use of this latex-
enhanced method in the risk assessment of cardiovascular
disease. Therefore, this latex-enhanced method is usually
used as the reference procedure when comparison studies
of various hs-CRP assays are conducted. At present, only
a few hs-CRP methods are commercially available. How-
ever, several assays are currently under development or
evaluation and are expected to be available for routine
clinical use in the very near future.
conclusion
hs-CRP is a very promising novel biochemical marker for
the prediction of future first or recurrent coronary events.
American and European prospective studies have been
highly consistent regarding the ability of hs-CRP to pre-
dict future CHD risk in both men and women. Potential
preventive therapeutic modalities to attenuate coronary
risk in those with increased hs-CRP concentrations have
been suggested. The potential use of hs-CRP as a means to
improve the cost-to-benefit ratio in statin therapy is
currently under investigation. Although standardization
of hs-CRP measurement at the lower concentration range
among various methods should be addressed, a robust
and Food and Drug Administration-approved method is
currently available. Several other sensitive assays are
under development and are expected to be commercially
available soon.
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Inflammatory Cytokines Stimulated C-Reactive
Protein Production by Human Coronary Artery
Smooth Muscle Cells
Paolo Calabró, MD; James T. Willerson, MD; Edward T.H. Yeh, MD
Background—Serum C-reactive protein (CRP) levels are good predictors of the development of cardiovascular events in
apparently healthy men and women. CRP has been believed to be produced exclusively by hepatocytes during the
acute-phase response. Several lines of evidence have suggested that atherosclerotic arteries can also produce CRP.
However, the cell types that produce CRP locally in the atherosclerotic arterial wall have not been clearly identified.
Methods and Results—Human coronary artery smooth muscle cells (HCASMCs) and human umbilical vein endothelial
cells (HUVECs) were incubated with interleukin-1 (IL-1), IL-6, their combination, tumor necrosis factor- (TNF-),
or lipopolysaccharide (LPS) at different concentrations. The supernatants were concentrated and analyzed by a
high-sensitivity enzyme-linked immunosorbent assay specific for human CRP. RNA was extracted from the HCASMCs
for reverse transcriptase–polymerase chain reaction (RT-PCR) using specific primers for the CRP. Maximal CRP
production was observed in HCASMCs after 48 hours of incubation with the combination of 25 ng/mL of IL-1 and
10 ng/mL of IL-6, whereas incubation with IL-1 or IL-6 alone only modestly induced CRP. Incubation with TNF-
(50 ng/mL) or LPS (1000 EU/mL) resulted in an increase in CRP production comparable to the IL-1 and IL-6
combination. The induction of CRP in HCASMCs was independently confirmed by RT-PCR comparing the relative
CRP mRNA levels. The induction of CRP production by HCASMCs was not reproduced in HUVECs, however.
Conclusions—These results demonstrated that HCASMCs, but not HUVECs, could produce CRP in response to
inflammatory cytokines. The locally produced CRP could directly participate in atherogenesis and the development of
cardiovascular complications. (Circulation. 2003;108:1930-1932.)
Key Words: atherosclerosis  inflammation  muscle, smooth  interleukins  risk factors
C-reactive protein (CRP), a marker of inflammation, is animportant predictor of future cardiovascular events in
apparently healthy men and women1–4 and could directly
participate in the pathogenesis of atherosclerosis through
activation of endothelial cells.5–9 CRP, named for its capacity
to bind to the C-polysaccharide of Streptococcus pneu-
moniae, was the first acute-phase protein to be described.10
CRP, like other acute-phase proteins, is synthesized by the
liver in response to microbial infection, tissue injury, and
autoimmune disorders. It had been shown that interleukin-1
(IL-1) and IL-6 strongly induced the expression of CRP in
human hepatocytes11 and hepatoma cells.12 Recently, human
neuronal cells were found to produce CRP in Alzheimer’s
disease.13 In addition, renal cortical tubular epithelial cells
were shown to produce CRP after inflammatory stimuli.14
Interestingly, CRP has also been found in human atheroscle-
rotic plaques,15 which could be the result of indirect deposit
from circulating cells or direct production by cells in the
arterial wall. We show that human coronary artery smooth
muscle cells (HCASMCs), but not human umbilical vein
endothelial cells (HUVECs), can synthesize CRP after stim-
ulation by inflammatory cytokines.
Methods
Cell Culture
HCASMCs, HUVECs, and endothelial cell supplements were pur-
chased from Cascade Biologics; penicillin, streptomycin, medium
231, medium 199, and smooth muscle cell growth supplement were
from Gibco BRL; and fetal bovine serum, human serum, heparin,
and gelatin were obtained from Sigma. HCASMCs were plated onto
0.1% gelatin-coated culture dishes from Corning, Inc, and grown in
231 medium with growth supplement and 1% penicillin/streptomy-
cin; HUVECs were plated onto 0.1% gelatin-coated culture dishes
and grown in 199 medium with endothelial growth supplement,
heparin, antibiotics, and 15% fetal bovine serum. Cells were used at
passage 5 to 7.
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CRP Assays
CRP level in the cell supernatant was measured using a commercial
enzyme-linked immunosorbent assay (ELISA) kit specific for human
CRP (Diagnostic System Laboratories) according to the manufactur-
er’s directions. The minimum detectable concentration of the assay
was 1.6 ng/mL. All the experiments were performed in triplicate.
Cells were cultured in 6-well plates until 80% to 90% confluent and
were incubated for 48 hours with recombinant human IL-1 (R&D
Systems) (25 ng/mL), recombinant human IL-6 (R&D Systems) (10
ng/mL), their combination, recombinant human tumor necrosis
factor- (TNF-) (R&D Systems) (50 ng/mL), or lipopolysaccharide
(LPS) derived from Escherichia coli O113:H10 (Associates of Cape
Cod, Inc) (1000 EU/mL); the culture supernatants were then con-
centrated (10 times) using centrifugal filter units (Millipore) and
assayed for CRP.
CRP mRNA Expression
Cells cultured in 60-mm plates were incubated for 48 hours with 25
ng/mL IL-1, 10 ng/mL IL-6, their combination, 50 ng/mL TNF-,
and 1000 EU/mL LPS, and total cellular RNA was extracted by
Trizol reagent. Reverse-transcriptase polymerase chain reaction
(RT-PCR) was performed with the Access RT-PCR System (Pro-
mega) according to the manufacturer’s directions. For each reaction,
1 g of total RNA served as a template. For amplification, a primer
pair specific for human CRP (forward, TCGTATGCCACCAA-
GAGACAAGACA; reverse AACACTTCGCCTTGCACT-
TCATACT; GenBank accession No. M11725) was used. These
primers were designed to yield a product of 440 bp after 40
amplification cycles. In all experiments, control reactions were
performed substituting sterile nuclease-free water for the RNA
template in the reaction. Glyceraldehyde-3-phosphate dehydroge-
nase (GADPH) was amplified as a reference for quantification of
CRP mRNA. The RT-PCR products were visualized on 1% agarose
gel with ethidium bromide.
Results
CRP Production by HCASMCs, but Not
by HUVECs
The results of CRP released into the media and the CRP
mRNA levels in HCASMCs after treatment with inflamma-
tory cytokines were shown in Figures 1 and 2, respectively.
As shown in Figure 1A, CRP production was minimal
without stimulation, and incubation of HCASMCs with 50
ng/mL of IL-1 or 10 ng/mL of IL-6 alone led to a small but
significant induction. Maximal CRP production was observed
after the combination of the 2 cytokines (Figure 1B). TNF-
or LPS also induced a similar level of CRP production and
showed a dose-responsive relationship (Figure 1C). In con-
trast, CRP production could not be detected in HUVECs after
similar stimulation protocols (data not shown). To confirm
the results of CRP protein production in HCASMCs, we also
assayed the mRNA levels in HCASMCs by RT-PCR. Figure
2 shows CRP mRNA levels in HCASMCs after the different
treatments. IL-1  plus IL-6 combination caused a significant
increase in CRP mRNA level compared with baseline.
Treatment with LPS and TNF- also upregulates the CRP
mRNA levels. The RT-PCR amplified band was confirmed to
be authentic CRP by direct sequencing.
Discussion
CRP has been shown to be an excellent predictor of future
cardiovascular events in apparently healthy men and wom-
en.3,4 This could be in part the result of some of the biological
properties of CRP such as its stability, lack of diurnal
variation, and lack of influence of gender and age.10 How-
ever, accumulating evidence also points to the possibility that
CRP is a direct participant in vascular inflammation.16 One of
the outstanding unresolved issues in this field is the source of
CRP production in humans. It has been previously assumed
that hepatocytes are the only source of CRP production
during the acute-phase response. During the acute-phase
reaction, serum CRP levels often increase up to 100 or 200
g/mL; however, the level of serum CRP that is useful for
predicting cardiovascular risk is 1 to 3 g/mL. In fact,
patients with serum CRP levels 10 g/mL should have the
test repeated at a late date to exclude infection, autoimmune
diseases, or malignancy.17 Thus, we sought to identify an-
other source of CRP production that could help explain the
lower level of CRP useful for cardiovascular risk prediction.
We show that CRP is produced by HCASMCs, but not by
HUVECs, after exposure to inflammatory cytokines. This
locally produced CRP could play an important role in the
activation of endothelial cells.5–9 Two studies have shown
that both epithelial cells of the respiratory tract and renal
epithelium produce CRP.14,18 Moreover, neuronal cells also
Figure 1. Effect of cytokine and LPS treatment on CRP protein
production in HCASMCs. HCASMCs were incubated with differ-
ent stimuli for 48 hours and supernatants were analyzed for
CRP. Data represent a meanSD. This has also been repeated
3 times. Statistically significant CRP productions (P0.05) were
indicated by an asterisk. The data were analyzed using one-way
analysis of variance followed by the Scheffe test for multiple
comparisons.
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seem to be capable of synthesizing acute-phase reactants
involved in the pathogenesis of neurodegenerative disease.13
These studies expand the variety of cell types that could
participate in CRP production; however, relevance of these
observations to the pathogenesis of atherosclerosis is doubt-
ful. CRP has been observed to colocalize with the terminal
complement complex in atherosclerotic plaques.19 In this
report, however, the authors suggested that CRP is deposited
from circulating CRP produced by the liver instead of local
synthesis. In contrast, work by Yasojima et al.15 suggested
that cells in the arterial wall synthesize CRP. Using in situ
hybridization techniques, the authors showed that elongated
muscle-like cells inside the atherosclerotic plaque were pos-
itive for CRP. Our findings, thus, provide a direct demon-
stration that HCASMCs, but not HUVECs, are a source of
locally produced CRP in the arterial wall. The locally
produced CRP can directly participate in atherogenesis and
the development of cardiovascular complications.
Isolated human hepatocytes can produce 10 times more
CRP compared with control after stimulation.20 Human hep-
atoma cell line HepG2 is able to produce CRP 4-fold
compared with control in conditions similar to those used in
our experiments.21 Another hepatoma cell line Hep3B stim-
ulated with conditioned medium (generated by stimulating
peripheral blood mononuclear cell with LPS at a dose of 1
g/mL for 24 hours) showed an 50-fold increase in CRP
mRNA compared with unstimulated cells.14 Thus, CRP
productions by human coronary artery smooth muscle cells is
less robust than those produced by the liver. This could partly
account for the lower serum level of CRP (1 to 3 mg/L) useful
for cardiovascular risk prediction and the high level of CRP
(10 mg/L) observed during the acute-phase response.
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C-Reactive Protein
A Simple Test to Help Predict Risk of Heart Attack and Stroke
Paul M Ridker, MD, MPH
Of the 1.5 million heart attacksand 600 000 strokes that occurin the United States each year,
almost half will affect apparently
healthy men and women with normal
or even low cholesterol levels. Older
age, smoking, diabetes, and high blood
pressure all contribute to risk of heart
disease. However, you may well have
family members or friends who suffer
from heart disease yet have few, if any,
of these traditional risk factors.
In an effort to better determine risk
of heart disease and prevent clinical
events, many physicians have begun to
measure C-reactive protein (CRP) as a
routine part of global risk assessment.
This inexpensive and simple approach
to heart disease evaluation has recently
been endorsed by both the Centers for
Disease Control and Prevention and by
the American Heart Association.
When measured with new “high sensi-
tivity” CRP assays, levels of CRP less
than 1, 1 to 3, and greater than 3 mg/L
(milligrams per liter) discriminate be-
tween individuals with low, moderate,
and high risk of future heart attack and
stroke. CRP testing, however, is not a
replacement for cholesterol evaluation.
Rather, CRP testing should be used
along with cholesterol and other tradi-
tional risk factors to determine individ-
ual risk. Evidence also indicates that
individuals with high CRP levels are at
increased risk of developing diabetes.
This Cardiology Patient Page explains
the clinical use of CRP and suggests
methods for prevention of heart dis-
ease for patients found to have ele-
vated levels of CRP.
What Is CRP?
CRP is a critical component of the
immune system, a complex set of pro-
teins that our bodies make when faced
with a major infection or trauma. CRP
was discovered nearly 70 years ago by
scientists exploring the human inflam-
matory response. The role CRP plays
in heart disease, however, has only
recently been uncovered.
Everyone makes CRP, but in differ-
ent amounts depending on a variety of
factors, including genetics as well as
lifestyle habits. On average, individu-
als who smoke, have high blood pres-
sure, are overweight, and fail to exer-
cise tend to have high levels of CRP,
whereas thin, athletic individuals tend
to have lower levels. Nonetheless, al-
most half of the variation in CRP
levels between different people is in-
herited and thus reflects levels that
your parents and grandparents have
passed on to you through their genes.
This is not surprising given the funda-
mental role that CRP plays in inflam-
mation, an extremely important pro-
cess for wound healing, for warding
off bacteria and viruses, and for many
key processes critical for survival. Re-
search over the past decade has shown
that too much inflammation in some
circumstances can have adverse ef-
fects, particularly on the blood vessels
that carry oxygen and nutrients to all
the tissues of the body. Scientists now
understand that atherosclerosis (the
process that leads to cholesterol accu-
mulation in the arteries) is in many
ways an inflammatory disorder of the
blood vessels, just as arthritis is an
inflammatory disorder of the bones
and joints.
Many studies have found that
blood markers that reflect the inflam-
matory process are elevated among
individuals at high risk for future
heart disease. Inflammation is impor-
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tant in all phases of heart disease,
including the early initiation of ath-
erosclerotic plaques within the arter-
ies, as well as the acute rupturing of
these plaques that results in heart
attack and, all too often, sudden
death. Until recently, available mark-
ers of inflammation were not suitable
for use in physicians’ offices. By
contrast, CRP is very stable and quite
easy to measure.
CRP and the Risk of
Cardiovascular Disease
Over a dozen major studies demon-
strate that baseline levels of CRP in
apparently healthy men and women
are highly predictive of future risk of
heart attack, stroke, sudden cardiac
death, and the development of pe-
ripheral arterial disease. Doctors also
know that CRP levels predict recur-
rent coronary events among patients
who already suffer from heart dis-
ease and that the prognosis of pa-
tients in the acute phase of a heart
attack is tightly linked to CRP levels.
However, the most important current
use of CRP is in primary prevention,
that is, in the detection of high risk
among individuals not yet known to
have a problem.
Individuals with elevated levels of
CRP have a risk about 2 to 3 times
higher than the risk of those with low
levels. It is important that your physi-
cian request a “high-sensitivity” test
for CRP if he or she is using CRP for
the purpose of cardiovascular risk as-
sessment. This is because older tests
for CRP, which are adequate for mon-
itoring severe inflammatory condi-
tions, do not have the ability to mea-
sure levels accurately within the range
needed for cardiac risk detection. To
remind doctors of this issue, many
outpatient laboratories now specifi-
cally note on the laboratory request
form that the test offered is for “high-
sensitivity CRP” or “hs-CRP.” Like
the cholesterol test, the test for hs-CRP
is nothing more than a simple, inex-
pensive blood test. The easiest way to
assess overall risk—and avoid an ad-
ditional needle stick—is simply to add
a CRP evaluation at the time of cho-
lesterol screening.
Why Do I Need Both CRP
and Cholesterol Measured?
Both cholesterol and CRP predict risk,
but you cannot predict your CRP level
on the basis of your cholesterol level
(or vice versa). That is because each of
these blood tests picks up a different
component of the disease process. This
independent and additive effect is
demonstrated in Figure 1, which shows
cardiovascular event-free survival for
initially healthy individuals according
to levels of both CRP and the so-called
“bad cholesterol” or LDL cholesterol.
As shown, the worst survival (highest
risk) is seen among those with high
levels of both LDL and CRP, while the
best survival (lowest risk) is among
those with low levels of both markers.
However, one person in four will be in
the high CRP/low LDL group. Such
individuals are at a level of risk greater
than that of individuals in the low
CRP/high LDL category. Without
CRP evaluation, such individuals
would be missed if their physicians
relied on cholesterol screening alone.
It is important to recognize that high
levels of LDL cholesterol remain a
critical risk factor and that aggres-
sively lowering LDL cholesterol is a
fundamental goal of cardiovascular
disease prevention. However, as
shown in Figure 2, CRP is actually a
stronger overall predictor of heart dis-
ease and stroke than is LDL cholester-
ol. Thus, recent practice recommenda-
tions have been to measure cholesterol
levels and CRP together and to base
Figure 1. Cardiovascular event-free survival based on combined hs-CRP and LDL cho-
lesterol measurements. Adapted from Ridker et al (N Engl J Med 2002;347:1557–1565).5
Figure 2. hs-CRP is a stronger predictor of heart attack and stroke than LDL cholester-
ol. Adapted with permission from Ridker et al (N Engl J Med. 2002;347:1557–1565).5
Copyright © 2002 Massachusetts Medical Society. All rights reserved.
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interventions on the combined infor-
mation each provides (see below and
Figure 3).
In many ways, a decision to test for
CRP is similar to the decision to test
for cholesterol; knowledge that levels
are high should motivate you to lose
weight, to diet, to exercise, and to stop
smoking. All of these lifestyle changes
are well known to reduce the risk of
ever getting heart disease, and they all
lower CRP levels.
How Does CRP Compare With
Other “Novel Risk Factors”?
CRP is a powerful predictor of risk,
particularly when combined with cho-
lesterol evaluation. Some physicians
choose to measure CRP along with a
panel of other “novel” risk factors
including homocysteine and lipopro-
tein(a). Others may elect to measure
CRP along with more expensive tests
that measure specific cholesterol sub-
fractions. However, in all direct com-
parisons, the predictive value for CRP
has been substantially greater than that
observed for these alternative “novel”
markers of risk. Further, only CRP has
proven to add important prognostic
information to that already available
from standard cholesterol screening.
In some communities, imaging tech-
niques including “whole-body scans”
that detect calcification in the heart
arteries and the aorta have been advo-
cated as screening techniques. While
the presence of calcification does in-
crease cardiovascular risk, such scans
are not recommended by the American
Heart Association and currently are
very expensive. An additional concern
for these imaging techniques is that
results are often misinterpreted by pa-
tients and physicians and can lead to
unnecessary coronary interventions,
including angioplasty and bypass sur-
gery. While CRP levels also have been
shown to add prognostic information
at all levels of coronary calcium, this
information should be used primarily
to motivate at-risk individuals to adopt
more heart-healthy lifestyles, not to
seek aggressive interventional cardiac
procedures.
How Does CRP Affect Diabetes
and the Metabolic Syndrome?
Unlike LDL cholesterol, CRP predicts
not only heart disease, but also the risk
of developing type 2 diabetes. Individ-
uals with CRP levels greater than 3
mg/L have a risk of getting diabetes 4
to 6 times higher than individuals with
lower levels of CRP. Part of the link
between heart disease and diabetes is
due to inflammation, and for many
patients that inflammation in turn is
the result of obesity, particularly “cen-
tral obesity” or the tendency to put on
weight around the stomach. This is
because fat cells or “adipocytes” pro-
duce messenger proteins that turn on
the production of CRP itself.
The metabolic syndrome is a condi-
tion known to predispose patients to
diabetes and heart disease. Physicians
classify patients as having the meta-
bolic syndrome if they have at least 3
of the following 5 conditions: low
HDL cholesterol, central obesity, high
triglycerides, increased blood sugar
levels, and high blood pressure. How-
ever, the metabolic syndrome also en-
tails a number of less easily measured
abnormalities that include insulin re-
sistance and problems with blood clot-
ting. CRP levels increase as the num-
ber of components of the metabolic
syndrome increase. Even among indi-
viduals known to have the metabolic
syndrome, CRP levels add important
prognostic information on risk. Thus,
many physicians now also measure
CRP as part of the process of defining
the metabolic syndrome. This practice
is increasingly common among endo-
crinologists and other physicians inter-
ested in the prevention of diabetes as
well as heart disease.
Is CRP Specific for
Cardiovascular Disease?
Because CRP is an “acute-phase reac-
tant” and goes up during major trauma
and infection, some physicians have
worried that CRP testing might be too
nonspecific for clinical use. However,
multiple studies show that CRP, when
measured appropriately with high-
sensitivity assays in stable individuals,
is quite specific for the prediction of
future cardiovascular events. In one
recent study, elevated CRP levels were
associated with an 8-fold increase in
cardiovascular mortality, but had no
predictive value for death from other
causes. Other studies show that CRP
levels predict heart attack and stroke,
but not cancer or other major disor-
ders. Thus, a persistently elevated CRP
level is indicative of the risk of heart
disease and of the accelerated athero-
sclerosis that affects individuals with
diabetes.
At What Age Should I
Be Tested?
The first time to consider CRP evalu-
ation is probably in your mid-30s, the
same age that most physicians check
cholesterol levels. There is good evi-
dence that CRP levels in your teens
and 20s are very predictive of levels
later in life. Elevated CRP levels pre-
dict risk over the next 30 to 40 years.
This is good news from a prevention
Figure 3. hs-CRP improves risk prediction at all levels of LDL cholesterol. Adapted from
Ridker et al (N Engl J Med 2000;342:836–843).6
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perspective because ample time is
available to institute lifestyle changes
and, where appropriate, initiate phar-
macological interventions to prevent
first-ever heart attack and stroke.
Unlike cholesterol testing, CRP
evaluation does not require you to fast
and can be done at any time of the day.
What Is the Best Way to
Lower CRP?
The role of CRP as a predictor of
future heart attack and stroke has only
recently been described, and it is im-
portant to recognize that there is no
evidence yet that lowering CRP per se
will necessarily lower cardiac risk.
However, it took almost 20 years be-
fore definitive, randomized clinical tri-
als showed that lowering cholesterol
lowered cardiac risk. You and your
physician should keep abreast of ongo-
ing studies concerning this important
issue.
The good news is that the best ways
to lower CRP are already known to
lower cardiovascular risk. These in-
clude diet, exercise, blood pressure
control, and smoking cessation. Thus,
an important role for CRP evaluation
now is to identify high-risk individuals
(even when cholesterol is low) and to
motivate them toward heart-healthy
interventions.
What About Aspirin and the
“Statin” Drugs?
Aspirin is an antiplatelet drug that, at
least in men, has been shown to reduce
the risk of first-ever heart attack. As-
pirin, however, is also an anti-
inflammatory drug, and it has been
shown that the magnitude of benefit of
aspirin in terms of prevention is great-
est among those with high levels of
inflammation as defined by elevated
CRP levels. Any decision to take aspi-
rin needs to balance potential risks and
benefits and should be made in consul-
tation with your physician.
The statin drugs are highly effective
at reducing risk of first heart attacks
and stroke (primary prevention) as
well as reducing recurrent events (sec-
ondary prevention). While these drugs
work primarily by lowering LDL cho-
lesterol, they also reduce CRP levels in
many patients, and it has been sug-
gested that this additional “anti-
inflammatory” effect may also have
clinical benefit. Currently, statin ther-
apy is warranted for those with known
heart disease, those with elevated lev-
els of LDL cholesterol (above 160
mg/dL), and those with diabetes. For
more information about statin drugs,
please see the Cardiology Patient Page
by Gotto (Statins: powerful drugs for
lowering cholesterol: advice for patients,
Circulation 2002;105:1514–1516).
Whether otherwise healthy individu-
als with low levels of LDL but high
levels of CRP should also be on statin
therapy is controversial, and a major
clinical trial called JUPITER has been
designed to address this very question. If
you are interested in participating in this
study, you can call 1-888-660-8254 or
go to http://www.JUPITERstudy.com
on the internet.
Who Should Be Tested
for CRP?
The Centers for Disease Control and
Prevention and the American Heart
Association suggest that CRP evalua-
tion be considered as a part of overall
global risk prediction for individuals
concerned about vascular risk. The test
is most likely to have greatest utility
among those at “intermediate” risk
where additional prognostic informa-
tion is likely to change overall risk
estimates and motivate lifestyle
change. For efficiency of clinical prac-
tice and to avoid unnecessary blood
draws, many physicians simply add
CRP testing to standard cholesterol
evaluation. CRP testing is not consid-
ered mandatory but rather should be
done at the discretion of your
physician.
The Centers for Disease Control and
Prevention and the American Heart
Association also endorsed the use of
CRP evaluation for those with a prior
history of heart attack and among
those admitted to hospital with acute
heart disease syndromes. In the Emer-
gency Room setting, patients coming
in with chest pain syndromes may also
have CRP levels checked in order to
identify those at high risk for coronary
disease.
How Do I Interpret CRP
Test Results?
Interpreting CRP results is straightfor-
ward (Figure 4). All laboratories
should report values in mg/L (milli-
grams per liter). Levels of CRP less
than 1 mg/L are desirable and reflect a
low overall cardiovascular risk. Levels
of CRP between 1 and 3 mg/L are
indicative of moderate risk, while lev-
els of CRP in excess of 3 mg/L suggest
quite elevated vascular risk. As noted
above and described in Figures 1 and
3, this may be true even if your cho-
lesterol levels are low.
It is possible that you will have a
CRP level that is very high (above 10
mg/L). In that case, the test should be
repeated in about 2 to 3 weeks as
levels above 10 mg/L can reflect the
presence of an acute infection (this is
why it is recommended to have CRP
evaluation done when you are feeling
well). If on repeat testing the CRP
level remains high, you are most likely
in the high-risk group.
Postmenopausal women who take
standard estrogen or estrogen plus pro-
gesterone oral hormone replacement
therapy (HRT) tend to have elevated
levels of CRP. Women in this group
should discuss the relative benefits and
risks of HRT since recent studies have
not shown HRT to lower cardiovascu-
Figure 4. Clinical interpretation of hs-CRP for cardiovascular risk prediction. Adapted
from Yeh and Willerson (Circulation 2003;107:370–372).9
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lar risk. Stopping oral HRT will lower
your CRP levels. Topical estrogens
and the selective estrogen receptor
modulators (SERMS) do not seem to
elevate CRP.
Levels of CRP are similar in men and
women. The average CRP in middle-
aged Americans is about 1.5 mg/L. Ap-
proximately 25% of the US population
has levels of CRP greater than 3 mg/L,
the cut point for high risk.
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C-Reactive Protein and Other Inflammatory
Risk Markers in Acute Coronary Syndromes
Gavin J. Blake, MB, MSC, MRCPI, Paul M. Ridker, MD, MPH
Boston, Massachusetts
Markers of myocyte necrosis such as cardiac troponin or creatine kinase-myocardial band are
invaluable tools for risk stratification among patients presenting with acute coronary
syndromes (ACS). Nonetheless, many patients without any evidence of myocyte necrosis may
be at high risk for recurrent ischemic events. In consideration of the important role that
inflammatory processes play in determining plaque stability, recent work has focused on
whether plasma markers of inflammation may help improve risk stratification. Of these
markers, C-reactive protein (CRP) has been the most widely studied, and there is now robust
evidence that CRP is a strong predictor of cardiovascular risk among apparently healthy
individuals, patients undergoing elective revascularization procedures, and patients presenting
with ACS. Moreover, even among patients with troponin-negative ACS, elevated levels of
CRP are predictive of future risk. Other, more upstream markers of the inflammatory cascade,
such as interleukin (IL)-6, have also been found to be predictive of recurrent vascular
instability. A recent report from the second FRagmin during InStability in Coronary artery
disease trial investigators suggests that elevated levels of an inflammatory marker such as IL-6
may indicate which patients may benefit most from an early invasive strategy. Other
inflammatory markers currently under investigation include lipoprotein-associated phospho-
lipase A2, myeloperoxidase, and pregnancy-associated plasma protein A. Of all these novel
markers, CRP appears to meet most of the criteria required for potential clinical application.
Furthermore, the benefits of lifestyle modification and drug therapy with aspirin or statins
may be most marked among those with elevated CRP levels. (J Am Coll Cardiol 2003;41:
37S–42S) © 2003 by the American College of Cardiology Foundation
Approximately 1.4 million patients with acute coronary
syndromes (ACS) without ST-segment elevation are admit-
ted to hospital annually in the U.S. (1). Markers of myocyte
necrosis such as creatine kinase-myocardial band (CK-MB)
and cardiac troponin are invaluable diagnostic tools for such
patients and are routinely used for risk stratification. How-
ever, even troponin, a highly specific marker of cardiac
myocyte necrosis, has relatively low diagnostic sensitivity for
ACS, with only 22% to 50% of patients with unstable
angina having positive troponin (I or T) tests (2–5). More-
over, many patients with troponin-negative ACS who have
vulnerable coronary plaques remain at high risk for future
ischemic events. Thus, an additional test to improve upon
risk stratification based on markers of myocyte necrosis
alone could prove a valuable aid in clinical practice.
INFLAMMATORY MARKERS: C-REACTIVE PROTEIN
Pathophysiology. The past decade has witnessed an in-
creasing recognition that inflammatory mechanisms play a
central role in the pathogenesis of atherosclerosis and its
complications (6). Recently, attention has focused on the
potential role of plasma markers of inflammation as risk
predictors among those at risk for cardiovascular events (7).
Of these potential markers, C-reactive protein (CRP) has
been the most extensively studied. Produced in the liver in
response to interleukin (IL)-6, CRP is an acute phase
reactant that serves as a pattern recognition molecule in the
innate immune system. It was initially thought of as a
downstream bystander marker of vascular inflammation, but
recent data suggest that CRP may play an active role in
atherogenesis. C-reactive protein opsonization of low-
density lipoprotein (LDL) mediates LDL uptake by mac-
rophages (8), and CRP also stimulates monocyte release of
pro-inflammatory cytokines such as IL-1b, IL-6, and tumor
necrosis factor-alpha (9). Furthermore, CRP mediates
monocyte chemotactic protein-1 induction in endothelial
cells (10) and causes expression of intercellular adhesion
molecule-1 and vascular cellular adhesion molecule-1 by
endothelial cells (11). Recent data have shown that CRP
co-localizes with the membrane attack complex in early
atheromatous lesions, and CRP, complement proteins, and
their messenger ribonucleic acid are all substantially upregu-
lated in atheromatous plaque (12).
CRP as a predictor of risk. Numerous large-scale epide-
miological studies among apparently healthy men and
women have found that CRP is a strong independent
predictor of future cardiovascular risk (13–22). In the setting
of ACS, a landmark study by Liuzzo et al. (23) showed that
patients presenting with unstable angina who had elevated
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plasma levels of CRP (3 mg/l) and serum amyloid A had
a higher rate of death, acute myocardial infarction (MI), and
need for revascularization compared with patients without
elevated levels (Table 1).
The Thrombolysis In Myocardial Infarction (TIMI)
investigators have since shown that the increased risk
associated with high CRP levels may be evident as early as
14 days after presentation with an ACS (24). The Chimeric
c7E3 AntiPlatelet Therapy in Unstable angina Refractory to
standard treatment (CAPTURE) trial investigators found
that, although only troponin T was predictive in the initial
72-h period, both CRP and troponin T were independent
predictors of risk at six months (25), while the FRagmin
during InStability in Coronary artery disease (FRISC)
investigators reported that the risk associated with elevated
CRP levels at the time of index event continues to increase
for several years (26). In each of the above studies, the
predictive value of CRP was independent of, and additive
to, troponin (Table 1). Most importantly, CRP has been
found to have prognostic value among patients without
evidence of myocyte necrosis; specifically, even among
patients with negative troponin T, an elevated CRP is
predictive of future adverse events (24–26). Recent data also
confirm that CRP is a strong independent predictor of
short-term and long-term mortality among patients with
ACS who are treated with very early revascularization (27).
The exact source of elevated CRP levels among patients
with unstable coronary syndromes remains unclear. Data
suggest that plaque rupture per se may not be the cause but,
rather, that elevated CRP levels may be a marker of the
hyper-responsiveness of the inflammatory system to even
small stimuli. The CRP levels do not change after balloon
angioplasty in patients with stable or unstable angina who
have normal pre-procedural levels, but they do increase after
angioplasty in unstable patients with elevated CRP at
baseline (28). Moreover, even diagnostic angiography with-
out intervention caused an increase in CRP levels among
patients with elevated levels at baseline.
Other inflammatory markers. Further data regarding up-
stream mediators of CRP production suggest that this
pathway may reflect inflammatory processes that convey
increased cardiovascular risk. Elevated levels of IL-1 recep-
tor antagonist and IL-6 at 48 h after presentation are
associated with an adverse in-hospital prognosis among
patients with ACS, even without a rise in troponin T (29).
A recent report from the FRISC II study group has found
that circulating levels of IL-6 are a strong independent
marker of increased mortality among patients with unstable
coronary artery disease (CAD) and may be useful in
directing subsequent care (30). For example, randomization
to an early invasive strategy led to a 65% relative reduction
in 12-month mortality among patients with elevated IL-6
levels. By contrast, among those with low IL-6 levels, an
early invasive strategy did not confer any significant benefit
over a non-invasive strategy. Furthermore, among patients
randomized to the non-invasive arm, the risk associated
with elevated IL-6 levels was markedly attenuated if they
were assigned to therapy with dalteparin rather than placebo
(30). Similar data were observed for CRP. Thus, the use of
an inflammatory marker for risk stratification appears to
identify patients at high risk for future events, but most
importantly, it appears to identify individuals who might
benefit most from targeted interventional or intensive med-
ical therapy.
Other novel inflammatory markers have been studied in
cardiovascular risk prediction. Lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) circulates in association with
LDL-cholesterol and may contribute to atherogenesis by
hydrolyzing oxidized phospholipids into pro-atherogenic
fragments and by generating lysolecithin, which has pro-
inflammatory properties. The West of Scotland study group
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
BNP  B-type natriuretic peptide
CAD  coronary artery disease
CK-MB  creatine kinase-myocardial band
CRP  C-reactive protein
IL  interleukin
LDL  low-density lipoprotein
Lp-PLA2  lipoprotein-associated phospholipase A2
MI  myocardial infarction
MPO  myeloperoxidase
PAPP-A  pregnancy-associated plasma protein A
Table 1. CRP and Cardiovascular Risk in ACS: Results From Recent Trials
Study/Trial Results
Liuzzo et al. (23)* Increased rate of death, MI, and revascularization in patients with unstable angina
and CRP 3 mg/l plus elevated serum amyloid A.
TIMI IIa substudy (24)* Increased risk associated with higher CRP levels, evident as early as 14 days after
ACS.
CAPTURE (25)* CRP is an independent predictor of increased risk at 6 months.
FRISC (26)* Increased risk associated with higher CRP levels at index event.
Mueller et al. (27) CRP predictive of short- and long-term mortality among ACS patients treated
with early revascularization.
*The predictive value of CRP was independent of, and additive to, that of troponin.
ACS  acute coronary syndromes; CAPTURE  Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to
standard treatment; CRP  C-reactive protein; FRISC  FRagmin during InStability in Coronary artery disease; MI 
myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
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reported that baseline levels of Lp-PLA2 were a strong
independent predictor of risk for incident coronary heart
disease in a cohort of high-risk hyperlipidemic men (31).
Among a lower-risk cohort of normocholesterolemic
women, baseline levels of Lp-PLA2 were also higher among
cases than controls (32). However, in adjusted analyses,
baseline levels of Lp-PLA2 were not a significant predictor
of future cardiovascular risk, while CRP remained a strong
predictor (32). Lp-PLA2 levels are highly correlated with
LDL-cholesterol, which may in part explain these different
results. The predictive value of Lp-PLA2 among patients
with ACS is currently unknown.
Myeloperoxidase (MPO) levels may be elevated among
individuals with CAD (33). Myeloperoxidase is an enzyme
secreted by a variety of inflammatory cells, including acti-
vated neutrophils, monocytes, and certain tissue macro-
phages, such as those found in atherosclerotic plaque. The
enzyme is not released until leukocyte activation and de-
granulation. Myeloperoxidase may convert LDL into a
high-uptake form for macrophages, leading to foam cell
formation, and may also deplete nitric oxide, contributing to
endothelial dysfunction. In a recent case-control study,
increasing levels of leukocyte-MPO and blood-MPO were
significant predictors of the risk for CAD, such that after
adjustment for white blood cell count and Framingham risk
score, individuals in the highest quartile of blood-MPO had
a 20-fold higher risk of CAD than individuals in the lowest
quartile (33). Prospective studies are thus needed to test this
interesting hypothesis directly.
Recent ACS data have also been presented for
pregnancy-associated plasma protein A (PAPP-A) (34).
This zinc-binding metalloproteinase enzyme is a specific
activator of insulin-like growth factor I, a mediator of
atherosclerosis. Among eight patients who died suddenly
from cardiac causes, PAPP-A was abundantly expressed in
ruptured and eroded unstable plaques, but PAPP-A was
absent or minimally expressed in stable plaques. In plaques
with large lipid cores and cap rupture, staining for PAPP-A
revealed that the enzyme occurred mostly in the inflamma-
tory shoulder region. In a small case-control study, circu-
lating levels of PAPP-A were higher among patients with
unstable angina or acute MI than among patients with
stable angina and controls (34). Levels of CRP were also
higher among those with acute MI and unstable angina than
those with stable angina. Among patients with ACS, levels
of PAPP-A and CRP were highly correlated (r 0.61), but
there was no association between PAPP-A and CK-MB
(r 0.07) or troponin I (r 0.1). As with MPO, these data
require assessment in larger cohorts.
Non-inflammatory markers. de Lemos et al. (35) have
also recently reported data regarding the potential prognos-
tic utility of B-type natriuretic peptide (BNP) among
patients with ACS in the Orbofiban in Patients with
Unstable coronary Syndromes (OPUS)-TIMI 16 study.
Unlike inflammatory markers, BNP is a neurohormone
synthesized in ventricular myocardium and released in
response to pressure overload and ventricular dilation. Base-
line levels of BNP, drawn on average 40 h after the onset of
ischemic symptoms, correlated with the risk of death, heart
failure, and MI at 30 days and 10 months. This association
was significant across the full spectrum of ACS, including
patients presenting with ST-segment elevation MI, MI
without ST elevation, and unstable angina. Although it was
statistically significant, the correlation between BNP and
CRP was weak (r  0.2; p  0.001). After being adjusted
for other independent predictors of risk of death, including
the presence or absence of heart failure in patients, the odds
ratio for death at 10 months for the top quartile of BNP
compared with the lowest was 5.8, BNP also remained a
significant predictor of death when analyses were restricted
to an investigation of the presence or absence of elevated
troponin levels. Non-CRP inflammatory and non-
inflammatory biomarker results are summarized in Table 2.
Clinical utility. Three major questions must be answered
before routine clinical application of inflammatory markers
is advocated (36,37). First, does the marker independently
predict risk beyond conventional tools? Second, are specific
therapies available to reduce levels of the inflammatory
Table 2. Other Novel Inflammatory and Non-Inflammatory Biomarkers of Increased
Cardiovascular Risk
Inflammatory Biomarker Predictive Value
IL-6 Associated with adverse in-hospital prognosis in ACS patients (29).
Independent marker of increased mortality in unstable CAD (30).
Associated risk attenuated with dalteparin therapy (30).
Lp-PLA2 Independent predictor of risk for heart disease in a high-risk male
population (31).
MPO Significant predictor of CAD risk in case control studies.
PAPP-A Abundantly expressed in unstable plaques and elevated in unstable angina
and MI patients; absent or minimally expressed in stable plaques or in
stable angina patients or controls (34).
Non-inflammatory biomarker
BNP Baseline levels correlate with risk of death, heart failure, MI in ACS (35).
ACS  acute coronary syndrome; BNP  B-type natriuretic peptide; CAD  coronary artery disease; IL  interleukin;
Lp-PLA2  lipoprotein-associated phospholipase A2, MI  myocardial infarction; MPO  myeloperoxidase; PAPP-A 
pregnancy-associated plasma protein A.
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marker, and third, do therapies that lower plasma levels of
inflammatory markers also reduce cardiovascular risk? To
this list could also be added the need for a widely available
reliable biochemical assay.
Of the inflammatory markers discussed in the previous
text, CRP currently meets most, if not all, of these criteria.
C-reactive protein has been shown to predict risk in a wide
variety of clinical settings; it has incremental value in
addition to standard lipid screening for primary prevention
(18,19,38) and in addition to cardiac troponin testing
among patients with ACS (24–26). Furthermore, a recent
analysis by Chew et al. (39) shows that CRP predicts the
risk of death or MI at 30 days among patients undergoing
percutaneous coronary intervention. In this setting, the risk
associated with elevated CRP was independent of, but
additive to, the effect of an increased American College of
Cardiology/American Heart Association lesion score.
C-reactive protein levels are higher among smokers,
diabetics, and obese subjects. Adipose tissue is a potent
source of IL-6, the main hepatic stimulus for CRP produc-
tion. Thus, intensification of dietary measures and exercise
programs would seem to be appropriate for these individu-
als. Statin therapy may have powerful anti-inflammatory
effects (40), and in recent clinical studies, statin therapy has
been shown to lower CRP levels, an effect that is indepen-
dent of lipid lowering (19,41–44). Recent data suggest that
baseline levels of CRP and IL-6 are strong independent
predictors of the risk of developing type II diabetes (45). In
this regard, intriguing data from the West of Scotland study
suggest that pravastatin therapy, compared with placebo,
reduced the risk of development of type II diabetes (46).
Further data suggest that the benefits of statin therapy
may be greatest among those with elevated CRP levels,
either among post-MI patients (47) or in the primary
prevention setting (19). In the Cholesterol And Recurrent
Events (CARE) trial population, patients with persistent
low-grade vascular inflammation, as evidenced by high CRP
and serum amyloid A levels, were at increased risk of
recurrent events. Randomization to pravastatin therapy
prevented 54% of recurrent events among those with per-
sistent inflammation, compared with 25% among those
without (47). Similarly, in the primary prevention Air
Force/Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS), individuals with low LDL levels
(149 mg/dl) but high CRP levels (0.16 mg/dl) were at
high risk for future cardiovascular events, and they derived
substantial benefit from lovastatin therapy (relative risk
compared with placebo  0.58; 95% confidence interval,
0.34 to 0.98) (19).
Current clinical practice should not be based on these
post-hoc analyses (16,43), and there are currently no pro-
spective data that prove that lowering CRP decreases
cardiovascular events or improves survival, or that establish
defined targets for treatment. Thus, although substantial
gains may be made by targeting statin therapy at those with
heightened vascular inflammation (48), prospective ran-
domized trials to test these hypotheses directly are needed.
The effect of aspirin on CRP levels is controversial
(49,50), but the benefit of aspirin therapy in preventing
future MI appears to be greatest among those with elevated
CRP levels (16). As noted above, data from the FRISC-II
study suggest that the benefits of an early invasive approach
may be greatest among those with evidence of a heightened
inflammatory response (30). In the absence of an elevated
inflammatory response, a less invasive approach may prove
equally effective. Again, prospective randomized studies are
required to test these hypotheses directly. The possibility of
novel anti-inflammatory interventions targeted at specific
mediators of vascular inflammation is also appealing.
The optimal cutoff point for defining high CRP levels
among patients with ACS remains to be determined. The
CAPTURE group found that a threshold of 10 mg/l
maximized the predictive value of CRP (25). Several other
investigators have used a cutoff point of 3 mg/l for patients
with ACS, while the reference ranges for primary preven-
tion populations are lower (16,18,19). The precise cause of
these different thresholds remains unclear, but it is probably
related to heightened vascular inflammation at the time of
presentation with ACS.
CONCLUSIONS
In summary, the use of CRP and other novel inflammatory
markers may significantly add to our ability to correctly
identify patients presenting with ACS who are at high risk
for future cardiovascular events. The predictive value of
CRP appears to be independent of, and in addition to,
troponin. Individuals with evidence of heightened inflam-
mation may benefit most from an aggressive modification of
lifestyle and an intensification of proven preventive thera-
pies such as aspirin and statins. Moreover, the benefits of an
early invasive strategy may also be greatest among those
with elevated levels of inflammatory biomarkers.
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CDC/AHA Workshop on Markers of Inflammation and
Cardiovascular Disease
Application to Clinical and Public Health Practice
Overview
Thomas A. Pearson, MD, PhD, Co-Chair; George A. Mensah, MD, Co-Chair;
Yuling Hong, MD, PhD; Sidney C. Smith, Jr, MD
The Centers for Disease Control and Prevention/AmericanHeart Association (CDC/AHA) Workshop on Markers of
Inflammation and Cardiovascular Disease: Application to
Clinical and Public Health Practice was convened on March
14 and 15, 2002, to examine the use of inflammatory markers
in patients who are at risk for cardiovascular disease (CVD).
The goal of the workshop was to determine which of the
available tests, if any, should be used; what results should be
used to define high risk; which patients should be tested; and
the indications for which the tests would be most useful. To
achieve this goal, the workshop participants set down 5
objectives:
1. To review the growing body of scientific evidence from
diverse sources and examine the association between
several inflammatory markers and CVD, including the
strength, consistency, independence, and generalizabil-
ity of the data
2. To consider the clinical testing and various assays of
inflammatory markers and identify which may be the
best assay to use in identifying individuals at risk
3. To identify areas in which questions persist to foster
additional research
4. To recommend which tests should be performed for
which patients and in which clinical settings for the
purpose of risk stratification, therapeutic monitoring,
and other clinical applications, on the basis of scientific
evidence
5. To explore the public health implications of an associ-
ation between inflammatory markers and CVD
The 11⁄2-day-long workshop consisted of invited lectures
by recognized authorities in the field and 3 concurrent
discussion groups related to laboratory science, clinical sci-
ence, and population science. The major results of this
workshop were synthesized into a Statement for Healthcare
Professionals from the Centers for Disease Control and
Prevention and the American Heart Association, which was
published in Circulation in January 2003.1 That statement
was a distillation of the extensive deliberations of the 3
discussion groups, which continued to examine the evidence
in their respective areas and to refine their conclusions. This
series of reports presents the findings of the 3 discussion
groups in greater detail,2–4 including information that was not
available for the 2003 Circulation report, as well as 3 reports
from the speakers with background information related to the
workshop.5–7 The references for the latter 3 have been
updated.
The purpose of this series is to document for historical
purposes the evidence presented at the workshop. It is
recognized that this field of research is the focus of intense
investigation, and additional relevant studies have been pub-
lished since the workshop. The workshop co-chairs intend to
convene a follow-up conference when additional evidence
becomes sufficient to warrant an update of the database and
a review of the writing groups’ recommendations. Until then,
the 2003 statement will serve as an evidence-based guide for
the use of inflammatory markers in clinical and public health
practice.
A complete list of participants in the discussion groups is
included with each report. This conference was jointly
sponsored by the CDC and the AHA. Specifically, the
National Center for Chronic Disease Prevention and Health
Promotion and the National Center for Environmental Health
This paper represents a summary of a scientific conference sponsored by the American Heart Association. The opinions expressed in this paper are
those of the authors and do not necessarily represent those of the editor or the American Heart Association. The publication of these proceedings was
approved by the American Heart Association Science Advisory and Coordinating Committee on August 4, 2004. All writing group members were
required to complete and submit shortly before the workshop a Faculty Disclosure Questionnaire. These disclosures are available as an online appendix
at http://www.circulationaha.org (Circulation. 2004;110:e577–e578).
A single reprint is available by calling 800-242-8721 (US only) or by writing the American Heart Association, Public Information, 7272 Greenville
Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0306. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax
413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kgray@lww.com. To make photocopies for personal or educational
use, call the Copyright Clearance Center, 978-750-8400.
The reports of the Laboratory Science, the Clinical Practice, and the Population Science Discussion Groups and 3 background papers are
available online at http://www.circulationaha.org (Circulation. 2004;110:e545–e549; e550–e553; e554–e559; e560–e567; e568–e571; and
e572–e576).
(Circulation. 2004;110:e543–e544.)
© 2004 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org DOI: 10.1161/01.CIR.0000148979.11121.6B
e543
AHA Conference Proceedings
provided financial and organizational support. The AHA, its
Expert Panel on Population and Prevention Science, and its
Councils on Atherosclerosis, Thrombosis, and Vascular Bi-
ology, Clinical Cardiology, and Epidemiology and Preven-
tion coordinated the workshop.1 The writing groups, endorsed
by the Science Advisory and Coordinating Committee of the
AHA, included representation from the above-mentioned
agencies and organizations, as well as the American Associ-
ation for Clinical Chemistry and the American College of
Cardiology. The workshop was also supported from unre-
stricted educational grants from industry sponsors (Bristol-
Myers Squibb, Merck, Wyeth/Ayerst, and Kos
Pharmaceuticals).
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C-Reactive Protein, the Metabolic Syndrome, and Risk of
Incident Cardiovascular Events
An 8-Year Follow-Up of 14 719 Initially Healthy American Women
Paul M Ridker, MD; Julie E. Buring, ScD; Nancy R. Cook, ScD; Nader Rifai, PhD
Background—The metabolic syndrome describes a high-risk population having 3 or more of the following clinical
characteristics: upper-body obesity, hypertriglyceridemia, low HDL, hypertension, and abnormal glucose. All of these
attributes, however, are associated with increased levels of C-reactive protein (CRP).
Methods and Results—We evaluated interrelationships between CRP, the metabolic syndrome, and incident cardiovas-
cular events among 14 719 apparently healthy women who were followed up for an 8-year period for myocardial
infarction, stroke, coronary revascularization, or cardiovascular death; 24% of the cohort had the metabolic syndrome
at study entry. At baseline, median CRP levels for those with 0, 1, 2, 3, 4, or 5 characteristics of the metabolic syndrome
were 0.68, 1.09, 1.93, 3.01, 3.88, and 5.75 mg/L, respectively (Ptrend 0.0001). Over the 8-year follow-up,
cardiovascular event-free survival rates based on CRP levels above or below 3.0 mg/L were similar to survival rates
based on having 3 or more characteristics of the metabolic syndrome. At all levels of severity of the metabolic syndrome,
however, CRP added prognostic information on subsequent risk. For example, among those with the metabolic
syndrome at study entry, age-adjusted incidence rates of future cardiovascular events were 3.4 and 5.9 per 1000
person-years of exposure for those with baseline CRP levels less than or greater than 3.0 mg/L, respectively. Additive
effects for CRP were also observed for those with 4 or 5 characteristics of the metabolic syndrome. The use of different
definitions of the metabolic syndrome had minimal impact on these findings.
Conclusions—These prospective data suggest that measurement of CRP adds clinically important prognostic information
to the metabolic syndrome. (Circulation. 2003;107:391-397.)
Key Words: protein, C-reactive  risk factors  prognosis  diabetes mellitus  inflammation
Patients with the metabolic syndrome are at increased riskfor diabetes and cardiovascular events,1–3 and the re-
cently released Third Report of the National Cholesterol
Education Program Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (ATP-III)
stresses the importance of targeting prevention strategies for
such individuals.4 The ATP-III guideline also suggests a
working definition of the metabolic syndrome that includes
the presence of at least 3 of the following characteristics:
abdominal obesity, elevated triglycerides, reduced levels of
HDL cholesterol, high blood pressure, and high fasting
glucose. However, all of these parameters are associated with
elevated levels of C-reactive protein (CRP), an easily mea-
sured inflammatory biomarker that has proven to be a strong,
independent predictor of both incident diabetes5,6 and inci-
dent cardiovascular disease.7–14 CRP levels also correlate
with several other components of the metabolic syndrome
such as fasting insulin, microalbuminuria, and impaired
fibrinolysis that are not easily evaluated in usual clinical
practice.15–20 We therefore sought to evaluate in a large-scale
population cohort the potential interrelationships between
CRP, the metabolic syndrome, and incident cardiovascular
events. We additionally sought evidence as to whether or not
CRP might add prognostic information at all levels of
severity of the metabolic syndrome.
Methods
We evaluated the relationship of CRP with components of the
metabolic syndrome among apparently healthy women participating
in the Women’s Health Study (WHS), an ongoing trial of aspirin and
vitamin E in primary prevention. Details of the WHS and the
methods used to ascertain baseline risk factors and adjudicate clinical
outcomes have been described elsewhere.8,10 In brief, American
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women aged 45 years and over with no prior history of cardiovas-
cular disease or cancer were enrolled between November 1992 and
July 1995, at which time they provided detailed information on
demographic, lifestyle, and behavioral risk factors. Of these women,
28 345 provided baseline blood samples collected in EDTA, which
were stored in liquid nitrogen. Since enrollment, all study partici-
pants have been followed up for incident cardiovascular events,
including nonfatal myocardial infarction, nonfatal ischemic stroke,
coronary revascularization procedures, and cardiovascular death.
Because recent randomized trial evidence indicates a net hazard in
association with hormone replacement therapy (HRT), we elected to
increase the generalizability of our data by limiting our analysis to
the 15 745 WHS participants not using HRT at study entry. Of these,
14 719 were also free of diabetes at study entry and contributed
complete data for all 5 components of the metabolic syndrome.
Baseline blood samples from these women were thawed and assayed
for CRP by a validated high-sensitivity assay (Denka Seiken),
whereas triglyceride and HDL cholesterol levels were ascertained
with direct measurement assays (Roche Diagnostics).
Women with 3 or more of the following attributes are typically
defined as having the metabolic syndrome: (1) triglycerides 150
mg/dL; (2) HDL cholesterol 50 mg/dL; (3) blood pressure 135/
85 mm Hg; (4) obesity as defined by a waist circumference88 cm;
and (5) abnormal glucose metabolism as defined by a fasting glucose
110 mg/dL. In the WHS, triglycerides, HDL cholesterol, and blood
pressure were directly ascertained as outlined above. However, waist
circumference was not measured until year 6 of follow-up. As such,
we elected to use as our cutpoint for obesity a body mass index
(BMI)26.7 kg/m2, a value that corresponded to the same percentile
cutpoint for BMI at year 6 as did a waist circumference of 88 cm
measured at that time. To address whether this choice of BMI
affected our results, we repeated our analyses using a BMI cutpoint
of 30 kg/m2 as suggested in recent European guidelines.21 Because
fasting glucose levels were not available, we elected to conserva-
tively use the diagnosis of incident type II diabetes during study
follow-up as an alternative measure of baseline impairment of
glucose metabolism. To address how closely these definitions
represented the metabolic syndrome, we compared the proportion of
women in the present study categorized according to characteristics
of the metabolic syndrome as defined above to that previously
published for American women in the National Health and Nutrition
Survey (NHANES)22 using categories defined by the ATP-III
guideline.
To evaluate for evidence of association between baseline CRP
levels and the metabolic syndrome, we first compared the distribu-
tion of CRP levels among individuals with or without each of the
individual components of the syndrome as defined above. Because
levels of CRP are skewed, we evaluated the significance of any
differences in median values between groups using the Wilcoxon
rank-sum test. We then classified all study subjects as having 0, 1, 2,
3, 4, or 5 components of the metabolic syndrome and assessed for
evidence of a relation of median CRP levels across these groups
using the Jonckheere-Terpstra test. We then used logistic regression
analysis to discern whether elevated CRP levels added prognostic
information on risk of subsequent cardiovascular events across the
full spectrum of severity of the metabolic syndrome. Consistent with
recent recommendations from the Centers for Disease Control and
Prevention, a CRP cutpoint of 3 mg/L was used to differentiate
high-risk and low-risk groups.23
To directly compare the clinical utility of CRP alone to that of the
metabolic syndrome alone, we constructed 8-year cardiovascular
event-free survival curves for those with CRP levels above or below
3.0 mg/L and compared these to survival curves based on the
presence or absence of 3 or more components of the metabolic
syndrome. Age-adjusted c statistics, analogous to the area under the
receiver operator characteristic (ROC) curve, were used to assess the
discrimination of cardiovascular prediction models based on CRP
alone versus those based on having 3 or more characteristics of the
metabolic syndrome. These analyses were then repeated with con-
tinuous rather than dichotomous definitions used for components of
the metabolic syndrome. Finally, in analysis stratified by those with
and without the metabolic syndrome, we sought evidence in terms of
cardiovascular event-free survival that CRP levels might have
additional prognostic value in the prediction of incident cardiovas-
cular end points.
Results
Mean age of the 14 719 women evaluated in the present study
was 547.6 years. As defined by the proportion of individ-
uals with increasing numbers of characteristics of the meta-
bolic syndrome, the women participating in the present study
were almost identical to those evaluated in the recent
NHANES report22 (Table 1). Specifically, the proportion of
women in the present cohort with 3 or more characteristics of
the metabolic syndrome was 24.4% compared with 23.4% in
NHANES.
Table 2 presents median CRP values (with interquartile
ranges) for those study participants with and without each
individual component of the metabolic syndrome. Consistent
with prior cross-sectional data, CRP levels were significantly
TABLE 1. Prevalence of Metabolic Syndrome Abnormalities
Among Participants in the Women’s Health Study
No. of Metabolic
Abnormalities
Women’s Health Study
(n14 719)
NHANES Survey
(n4549)
1 72.2(0.4) 70.9(1.2)
2 45.9(0.4) 42.7(1.3)
3 24.4(0.4) 23.4(0.9)
4 8.9(0.2) 9.6(0.5)
5 1.2(0.1) 2.9(0.3)
Data are % (SEM). For comparison, data are also shown from the NHANES
survey. See Methods for a description of the criteria used for each component
of the metabolic syndrome.
TABLE 2. Median CRP Levels (Interquartile Range) Among 14 719 American
Women According to the Presence or Absence of Each Component of the
Metabolic Syndrome
Characteristic Present Absent P
Obesity (n5158) 3.13 (1.57–5.63) 0.95 (0.43–2.04) 0.0001
Hypertriglyceridemia (n4297) 2.56 (1.24–4.84) 1.11 (0.48–2.57) 0.0001
Low HDL cholesterol (n7572) 2.02 (0.88–4.26) 1.00 (0.44–2.31) 0.0001
High blood pressure (n4859) 2.38 (1.06–4.78) 1.14 (0.48–2.56) 0.0001
Abnormal glucose metabolism (n568) 4.30 (2.51–7.48) 1.39 (0.57–3.16) 0.0001
3 Characteristics (n3597) 3.38 (1.76–6.01) 1.08 (0.47–2.37) 0.0001
See Methods for a description of the criteria used for each component of the metabolic syndrome.
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higher among women who had each component of the
metabolic syndrome than among women who did not (all
P0.0001).
Figure 1 displays the distribution of CRP levels after
women were classified according to their total number of
components of the metabolic syndrome. As shown, there was
a strong linear increase in CRP levels as the number of
components of the metabolic syndrome increased; median
CRP levels for those with 0, 1, 2, 3, 4, or 5 characteristics of
the metabolic syndrome were 0.68, 1.09, 1.93, 3.01, 3.88, and
5.75 mg/L, respectively (Ptrend0.0001).
As shown in Figure 2, CRP levels 3 mg/L at baseline
added prognostic information at all levels of severity of the
metabolic syndrome. This additive effect was particularly
apparent among those with 3, 4, or 5 characteristics of the
metabolic syndrome (all P0.001).
Figure 3 presents results of the survival analyses directly
comparing CRP with the metabolic syndrome. As shown, the
predictive value of CRP levels above or below 3.0 mg/L in
terms of the development of first-ever cardiovascular events
was quite similar to the predictive value associated with
having or not having 3 or more characteristics of the
metabolic syndrome. In age-adjusted analyses, the area under
the ROC curve associated with CRP alone was 0.77 versus
0.78 for the metabolic syndrome.
As prespecified, we additionally sought evidence that CRP
might have prognostic utility among those with and without
the metabolic syndrome. We therefore first performed an
analysis limited to the 3597 study participants classified as
having 3 or more characteristics of the metabolic syndrome at
study entry. Among these women, we observed significant
increases in rates of future cardiovascular disease as levels of
baseline CRP increased. Specifically, age-adjusted incidence
rates were 3.4 and 5.9 events per 1000 person-years of
exposure for those with baseline CRP levels less than or
greater than 3.0 mg/L, respectively (P0.001).
To further explore these interrelationships, we divided the
study cohort into 4 groups on the basis of the presence or
absence of the metabolic syndrome and on the basis of CRP
levels less than or greater than 3.0 mg/L. As shown in Figure
4 (left), CRP evaluation provided additional prognostic infor-
mation both for those with and without the metabolic syn-
drome. The age-adjusted relative risks of future cardiovascu-
lar events for women in the low-CRP/no metabolic syndrome,
high-CRP/no metabolic syndrome, low-CRP/yes metabolic
syndrome, and high-CRP/yes metabolic syndrome groups
were 1.0 (referent), 1.5 (95% CI 1.0 to 2.2), 2.3 (95% CI 1.6
to 3.3), and 4.0 (95% CI 3.0 to 5.4), respectively.
We performed several additional analyses to address the
robustness of these findings. First, because the concept of the
metabolic syndrome was developed in part to reflect a
secondary target population without hyperlipidemia, we re-
peated our analyses for the 12 453 women with baseline LDL
cholesterol levels 160 mg/dL and for the 8500 women with
LDL cholesterol 130 mg/dL. As shown in Figure 4 (middle
and right), CRP provided prognostic information in addition
to the metabolic syndrome in both of these latter analyses.
The relative risks and associated CIs for these analyses are
presented in Table 3.
Figure 1. Distribution of CRP levels among 14 719 American women according to presence of 0, 1, 2, 3, 4, or 5 components of meta-
bolic syndrome. Box plots demonstrate median, 25th, and 75th percentile values for CRP.
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Second, and as also shown in Table 3, we repeated our
analyses using only the end point of coronary heart disease.
For this end point, overall effects were, if anything, larger
than that observed with the a priori combined end point that
also included thromboembolic stroke.
Third, we repeated our analyses using continuous rather
than dichotomous variables and found similar effects. In the
continuous variable models, the relative risk of future cardio-
vascular events associated with CRP levels 3.0 mg/L was
1.5 (P0.006), and the area under the ROC curve was 0.82.
By contrast, when dichotomous definitions for each compo-
nent of the metabolic syndrome were used, the corresponding
relative risk was 1.6 (P0.0003), and the corresponding area
under the ROC curve was 0.79.
Fourth, we repeated our primary analyses using a BMI
cutpoint of 30 kg/m2 and again found almost identical results
in terms of additive predictive value. Use of this cutpoint,
however, classified only 17% of the present cohort as obese.
By contrast, the use of a BMI cutpoint of 26.7 kg/m2 (as done
in our primary analyses) classified 32% of the cohort as
obese, a value closer to that observed in the NHANES survey.
Finally, we performed an additional analysis limited to
those 3597 participants with the metabolic syndrome at study
entry and found that CRP levels 1, 1 to 3, and 3 mg/L
stratified the population into 3 risk groups such that those
with the metabolic syndrome and the highest CRP levels had
a relative risk 2.1 times that of those with the metabolic
syndrome who had the lowest CRP levels (95% CI 1.1 to 4.2,
P0.001; Figure 5). In all these analyses, virtually identical
results were observed when we excluded incident diabetes as
part of the definition of the metabolic syndrome.
Discussion
Recent guidelines stress the importance of identifying indi-
viduals with the metabolic syndrome as a high-risk group for
Figure 2. Relative risks of future cardiovascular events according to number of components of metabolic syndrome and according to
CRP levels above or below 3.0 mg/L.
Figure 3. Comparison of cardiovascular event-free survival for
those with and without metabolic syndrome to those with base-
line CRP levels above or below 3.0 mg/L. CVD indicates cardio-
vascular disease.
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the development of cardiovascular disease.4 The present
prospective cohort of 14 719 initially healthy women con-
firms this association, because those with the metabolic
syndrome had significantly worse cardiovascular event-free
survival than did those without the metabolic syndrome.
However, the present data also demonstrate that at all levels
of severity of the metabolic syndrome, CRP added important
and independent prognostic information in terms of future
cardiovascular risk. This additive effect was present in all
study groups evaluated and was robust to the several methods
used to define the metabolic syndrome.
That CRP levels correspond with individual components of
the metabolic is consistent with work of other investiga-
tors15–20 and the hypothesized role of inflammation in several
processes critical to the development of both diabetes and
atherothrombosis.24,25 Indeed, in this cohort, we have previ-
ously shown baseline CRP levels to be a strong predictor not
only of myocardial infarction and stroke8,10 but also of
incident type 2 diabetes.5 Rapidly evolving work now dem-
onstrates that in addition to being a marker of innate immu-
nity, CRP also has several direct effects at the level of the
vessel wall.26,27 These observations, along with basic research
into the inflammatory mechanisms of both diabetes and
vascular dysfunction, provide strong evidence that insulin
resistance and atherosclerosis share a common inflammatory
basis.28 CRP, however, is also associated with several aspects
Figure 4. Cardiovascular event-free survival in analyses stratified by both CRP and metabolic syndrome. CVD indicates cardiovascular
disease.
TABLE 3. Relative Risks (95% CIs) of Future Cardiovascular Events According to CRP Levels
Greater Than or Less Than 3.0 mg/L and According to the Presence or Absence of the
Metabolic Syndrome
All Cardiovascular Events
Total
Cohort
(n14 719)
LDL
160 mg/dL
(n12 453)
LDL
130 mg/dL
(n8500)
Coronary Events
Total Cohort
(n14 719)
CRP 3 mg/L, no metabolic syndrome 1.0 1.0 1.0 1.0
CRP 3 mg/L, no metabolic syndrome 1.5 (1.0–2.2) 1.3 (0.8–2.2) 1.2 (0.6–2.3) 1.6 (0.9–2.7)
CRP 3 mg/L, yes metabolic syndrome 2.3 (1.6–3.3) 2.2 (1.4–3.5) 2.5 (1.4–4.4) 3.1 (2.0–4.9)
CRP 3 mg/L, yes metabolic syndrome 4.0 (3.0–5.4) 4.4 (3.1–6.3) 4.4 (2.8–7.1) 5.5 (3.8–8.0)
Data are shown for all cardiovascular events (n255) and for coronary events only (n163).
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of the metabolic syndrome not easily ascertained in usual
clinical practice, including fasting insulin, hypofibrinolysis,
and microalbuminuria.15–20 Our finding that CRP measure-
ment adds important prognostic information to clinical defi-
nitions of the metabolic syndrome is thus consistent with this
hypothesis.
Limitations of this study must be considered. First, the
study included only women. We believe, however, that these
data are likely to generalize to men because other studies have
linked markers of inflammation to individual components of
the metabolic syndrome in men, and many cohort studies
have already shown CRP to independently predict vascular
events in men.7,11–14 Second, because we did not have fasting
glucose levels in all participants, we elected instead to use the
diagnosis of incident diabetes during follow-up as a surrogate
for abnormal baseline glucose metabolism. We believe this
choice to be valid because other work has shown CRP levels
to correlate with fasting glucose level29 and predict incident
type 2 diabetes.5,6 Moreover, as shown in Table 1, this choice
was, if anything, conservative, because it resulted in only
1.2% of the present cohort being defined as having all 5
characteristics of the metabolic syndrome versus 2.9% in the
NHANES survey. We also believe it unlikely that this
decision affected validity, because elevated fasting glucose is
by far the least common abnormality used to define those
with the metabolic syndrome. Finally, these analyses do not
make adjustment for other factors that may affect CRP levels,
such as smoking status.
We recognize that these data have broad implications for
the development of therapies targeting insulin resistance,
diabetes, and atherothrombosis. We have previously shown
that aspirin and statins are relatively more effective in
reducing vascular risk among those with elevated CRP
levels,7,9,30 and we have hypothesized on that basis that CRP
is likely to have utility in the targeting of therapies for the
primary prevention of cardiovascular disease. At the same
time, weight reduction and exercise, the first-line therapies
stressed by ATP-III for the management of the metabolic
syndrome, also reduce CRP levels. Furthermore, a recent
report suggests that rosiglitazone directly reduces CRP levels,
an intriguing observation because this PPAR- inhibitor is
already established as standard therapy for those with type II
diabetes.31
In sum, these data provide clear evidence that the presence
of at least 3 of 5 components of the metabolic syndrome
predicts incident cardiovascular events in apparently healthy
women. However, these data also indicate that among those
with and without the metabolic syndrome, baseline CRP
levels add clinically relevant prognostic information concern-
ing future vascular risk.
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Plasma Concentration of C-Reactive Protein and the
Calculated Framingham Coronary Heart Disease Risk Score
Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH
Background—Although C-reactive protein (CRP) predicts vascular risk, few data are available evaluating the relation
between CRP and the Framingham Coronary Heart Disease Risk Score (FCRS).
Methods and Results—CRP levels were compared with calculated 10-year FCRS in a cross-sectional survey of 1666
individuals free of cardiovascular disease. Among men and women not using hormone replacement therapy (HRT), CRP
levels were significantly related to 10-year Framingham Coronary Heart Disease Risk categories [total cholesterol (TC)
score for men and women: r0.29 and r0.22, respectively; LDL cholesterol score for men and women: r0.29 and
r0.22, respectively, all probability values 0.01]. However, CRP levels correlated minimally with individual
components of the FCRS, which included age (rmen0.17, rwomen0.003), TC (rmen0.02, rwomen0.006), HDL-C
(rmen0.13), LDL-C (rmen0.0002, rwomen0.012), blood pressure (rmen0.18, rwomen0.22), diabetes (rmen0.10,
rwomen0.07), and smoking (rmen0.16, rwomen0.14) status. For women taking HRT, no significant relation was observed
between CRP and the FCRS, although the power to detect effects in this subgroup is limited.
Conclusions—Our data demonstrate that CRP levels significantly correlate with calculated 10-year Framingham Coronary
Heart Disease Risk in men and women not taking HRT but correlate minimally with most individual components of the
FCRS. These data provide additional support for continued evaluation of CRP as a potential adjunct in the global
prediction of cardiovascular risk. (Circulation. 2003;108:161-165.)
Key Words: prevention  inflammation  risk factors
The Framingham Coronary Heart Disease Risk Score(FCRS) is a simplified coronary prediction tool devel-
oped to enable clinicians to estimate cardiovascular risk in
middle-aged individuals.1,2 Although it is an important clin-
ical tool, it is recognized that not all persons at high coronary
heart disease risk are identified by the FCRS. For example,
recent evidence indicates that the c statistic for the area under
the receiver operator characteristic curve associated with the
FCRS varies between 0.63 to 0.83 in different populations.3
In an effort to improve coronary heart disease risk prediction,
several novel cardiovascular risk markers have been evalu-
ated as potential adjuncts to lipid screening in primary
prevention. Of these, C-reactive protein (CRP), a marker of
low-grade inflammation, has been extensively studied in
several large, prospective, epidemiological studies.4–7 How-
ever, few data are available directly comparing CRP levels
with calculated FCRS. Although both CRP and the FCRS
each predict vascular risk, the extent to which CRP reflects
any individual component of the FCRS is unclear.
Methods
We measured CRP levels and calculated the FCRS among 932 men
and 734 women participating in the primary prevention arm of the
Pravastatin Inflammation/CRP Evaluation (PRINCE) Study,8,9 a
multicenter, community-based study of the effect of 40 mg prava-
statin or placebo on CRP levels over a 6-month follow-up period. At
study entry, in addition to providing a blood sample for CRP and
lipid evaluation, 1666 of a total of 1702 participants provided data on
age, gender, smoking status, and diabetes history. Data on weight,
height, and blood pressure were measured by the participant’s
physician at study entry. None of the participants had a history of
myocardial infarction, stroke, or coronary revascularization. Partic-
ipants all provided written informed consent, and all procedures
followed were in accordance with institutional guidelines.
Plasma samples were assayed for CRP by using a clinically
validated high-sensitivity assay10; total cholesterol, HDL cholesterol,
and LDL cholesterol levels were determined in a Centers for Disease
Control and Prevention standardized laboratory. Framingham Coro-
nary Heart Disease risk was calculated by using previously published
algorithms that used baseline cardiac risk factors including age, HDL
cholesterol, LDL cholesterol, total cholesterol, smoking status, blood
pressure, and diabetes history.2
To assess the relation between CRP and individual components of
the FCRS, we first calculated the scores corresponding to the
individual components of the FCRS as well as the total score. Next,
Pearson correlation coefficients relating these individual risk factor
scores and the total score to the natural log of baseline CRP levels
were calculated. Additionally, biserial correlation coefficients were
computed for diabetic and smoking status because both of these
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variables are binary. The components of the FCRS were also divided
into different categories, and median CRP levels were calculated and
plotted per category.
The FCRS was also divided into 5 clinically meaningful categories
to reflect increasing 10-year coronary heart disease risk. Median
CRP levels were then computed for each coronary heart disease risk
category. Separate FCRS calculations were performed for total
cholesterol and LDL cholesterol and for men and women. Addition-
ally, as CRP levels are known to be elevated by estrogen therapy
use,11,12 we performed stratified analyses for women on this basis.
To assess the relation between increasing Framingham Coronary
Heart Disease risk categories and median CRP levels, a linear
regression analysis was performed. All probability values are 2
tailed.
Results
The baseline characteristics of the study participants are
shown in Table 1. Compared with men, women were older
(59.0 versus 53.0 years), more likely to have diabetes (12.3%
versus 9.3%), and had higher total cholesterol (235.0 versus
222.5 mg/dL), HDL cholesterol (43.4 versus 35.8 mg/dL),
and LDL cholesterol levels (143.6 versus 139.4 mg/dL). As
expected, median CRP levels were significantly higher
among women (2.90 mg/L; interquartile range, 1.30 to 5.80
mg/L) than among men (median CRP1.50 mg/L; interquar-
tile range, 0.80 to 3.20 mg/L), an effect largely the result of
HRT use. Specifically, those women who reported current
estrogen therapy use (HRT) had higher baseline CRP levels
(median3.80 mg/L; interquartile range, 2.00 to 6.80 mg/L)
than those women who were not taking HRT (median2.40
mg/L; interquartile range, 1.10 to 5.00 mg/L).
We found a modest correlation between CRP levels and the
FCRS in men and women not taking HRT by using both the
total cholesterol (rmen0.29, P0.01; rwomen0.22, P0.01)
and LDL cholesterol (rmen0.29, P0.01; rwomen0.22,
P0.01) scoring algorithms. As shown in Table 2, although
we also noted modest associations between CRP and HDL
cholesterol (r0.24, P0.01) and blood pressure scores
(r0.22, P0.01) in women not taking HRT, we found
minimal additional evidence of association between CRP
levels and the individual components of the FCRS. For
example, in men and women taking HRT, CRP had the
largest correlation with baseline blood pressure (rmen0.18,
rwomen0.13). Furthermore, except for the relation between
smoking and CRP among men, biserial correlation coeffi-
cients assessing the relation between diabetic status and CRP
(rmen0.11, rwomen hrt0.11, rwomen no hrt0.08) as well as be-
tween smoking status and CRP (rmen0.22, rwomen hrt-0.004,
rwomen no hrt0.14) were almost identical to the corresponding
Pearson correlation coefficients noted in Table 2. Likewise,
plots showing median CRP levels versus individual compo-
nents of the FCRS among men and women not taking HRT
also demonstrate minimal association between CRP levels
and the components of the FCRS (Figures 1 and 2). Specif-
ically, among men, plots of HDL-C and CRP demonstrate a
small decrease in median CRP levels with increasing HDL-C
levels, whereas there is small increase in CRP concentrations
at the highest levels of systolic blood pressure (Figure 1).
Plots for women not taking HRT demonstrate similar findings
(Figure 2).
Figure 3 shows that median CRP levels increased in men
with each increasing calculated Framingham 10-year coro-
nary risk category. This significant positive trend between
increasing CRP levels and progressively higher FCRS was
TABLE 1. Baseline Characteristics of Study Participants
Men (n932) Women (n734)
Age, y 53.0 (47.0, 63.0) 59.0 (52.0, 69.0)
Aspirin use, % 29.6 26.6
Smoking status, %
Never 45.6 54.3
Current 15.2 15.3
Past 39.2 30.4
Body mass index, kg/m2 28.5 (26.0, 31.5) 28.6 (25.0, 33.4)
Blood pressure, mm Hg
Systolic 130.0 (120.0, 140.0) 130.0 (120.0, 140.0)
Diastolic 80.0 (76.0, 86.0) 80.0 (70.0, 84.0)
Diabetes, % 9.3 12.3
hs-CRP, mg/L 1.50 (0.80–3.20) 2.90 (1.30–5.80)
HRT use (n275)    3.80 (2.00, 6.80)
No HRT use (n459)    2.40 (1.10, 5.00)
Alcohol use, %
Daily 14.2 3.8
Weekly 27.9 10.3
Monthly 19.2 17.5
Never/rarely 38.7 68.4
Triglycerides, mg/dL 162.5 (117.0, 235.0) 158.0 (113.0, 231.0)
Cholesterol, mg/dL
Total 222.5 (205.0, 245.0) 235.0 (214.0, 256.0)
LDL-C 139.4 (125.4, 156.4) 143.6 (126.9, 160.5)
HDL-C 35.8 (30.8, 41.5) 43.4 (36.3, 50.4)
Exercise activity, %
Daily 6.9 4.8
2 times/wk 33.0 27.7
Once/wk 12.3 6.5
1 time/wk 10.1 9.5
Never/rarely 37.7 51.5
*Values are percentage or median and associated interquartile range.
TABLE 2. Pearson Correlation Coefficients Relating Baseline
C-Reactive Protein to Individual Components of the
Framingham Coronary Risk Score
Women
Variable
Men
(n932)
HRT Use
(n275)
No HRT Use
(n459)
Age score 0.17 0.09* 0.003*
Total cholesterol score 0.02* 0.06* 0.006*
HDL cholesterol score 0.13 0.0006* 0.24
LDL cholesterol score 0.0002* 0.011* 0.012*
Blood pressure score 0.18 0.13 0.22
Diabetes score 0.10 0.11* 0.07*
Smoking score 0.16 0.003* 0.14
All P values0.01.
*P values 0.05.
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noted with the use of both the total cholesterol (Ptrend0.01)
and LDL cholesterol (Ptrend0.01) scoring algorithms. A
similar pattern was observed for women, but this effect was
attenuated in magnitude as the result of an apparent modifi-
cation effect by HRT use. As shown in Figure 4 (top), among
women not taking HRT, the relation between CRP and FCRS
was similar to that noted in men (Ptrend0.01). By contrast,
among HRT users where as reported, CRP levels were higher,
the relation between CRP and FCRS was not statistically
significant (total cholesterol score computation, Ptrend0.18;
LDL cholesterol score computation, Ptrend0.28; Figure 4,
bottom).
Discussion
These cross-sectional data indicate that plasma concentration
of CRP is significantly associated with calculated FCRS
among middle-aged men and women not taking HRT. Over-
all, individuals in the lowest cardiovascular risk category had
CRP levels that were at least half those of individuals in the
highest CHD risk category. However, despite this positive
association, CRP levels correlated minimally with most
individual components of the FCRS.
The dichotomy observed in our data is intriguing and
suggests that whereas CRP is related to the FCRS, CRP and
the individual components of the FCRS might be reflecting
Figure 1. Comparison of components of
the FCRS with CRP in the PRINCE Pri-
mary Prevention Cohort: Men.
Figure 2. Comparison of components of
the FCRS with CRP in the PRINCE Pri-
mary Prevention Cohort: Female non-
HRT users.
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different aspects of cardiovascular risk. In support of this
hypothesis are previous data from several large prospective
cohorts5–7,13,14 that indicate that CRP predicts risk of incident
cardiovascular events, even after adjustment for other tradi-
tional risk factors. Furthermore, recent data from the Wom-
en’s Health Study (WHS) Cohort15 demonstrate that after
adjustment for all components of the FCRS, CRP remained
an independent predictor of future cardiovascular risk. There-
fore, the current data are consistent with the hypothesis that
the addition of CRP to the FCRS might be useful in the
context of overall cardiovascular risk determination.
As previously described,11,12 we also observed in our
women that median CRP levels were twice as high in HRT
users as compared with non-HRT users. Our data extend this
observation by further demonstrating a discordance between
CRP and FCRS in women taking HRT. The underlying
mechanism for this effect modification by HRT is uncertain
but may relate to first-pass effects of HRT on hepatic CRP
production.16 These issues have clinical importance and
require evaluation in experimental settings.
These data are also important because they have implica-
tions for the design of future trials of statin therapy in the
primary prevention of cardiovascular disease. Previous data
demonstrate that by lowering LDL levels, HMG CoA reduc-
tase inhibitors decrease the risk of future cardiovascular
events.17,18 However, traditional LDL screening, a critical
component of the FCRS, misses many individuals in primary
prevention who are at high risk for coronary events. Because
statins lower CRP levels in an LDL-independent man-
ner,9,14,19 CRP screening in conjunction with lipid screening
might help identify those individuals who may benefit from
prophylactic statin therapy. For example, in AFCAPS/Tex-
CAPS (Air Force/Texas Coronary Atherosclerosis Prevention
Study), individuals with below-median LDL and above-
median CRP levels had a similar risk of future vascular
events as did those with overt hyperlipidemia.14 In addition,
lovastatin was as effective in decreasing cardiovascular event
rates among individuals in the below-median LDL/above-
median CRP group as it was in participants with above-
median LDL levels. Furthermore, assessment of the ability of
CRP and LDL-C to predict cardiovascular risk in the WHS
cohort revealed that CRP was a better predictor than LDL-C
in risk prediction.15 On the basis of these data, we have
initiated a large-scale primary prevention trial of statin
therapy among patients with low LDL but high CRP to
directly test this hypothesis.20 As shown in the current
analysis, such a study must include large numbers of women
and detailed knowledge of HRT status at study initiation and
during follow-up.
In summary, in this cross-sectional survey, whereas CRP
levels were significantly associated with the level of coronary
heart disease risk as calculated by the FCRS in men and
women not taking HRT, CRP levels correlated only mini-
mally with most individual components of the FCRS. These
data imply that CRP may capture different components than
the traditional components of coronary risk reflected in the
FCRS and support the hypothesis that CRP may have an
adjunctive role in the global risk prediction of cardiovascular
disease.4
Appendix
Components of the Framingham Cardiovascular Risk Score include
age, blood pressure, total cholesterol/LDL cholesterol, HDL choles-
terol, diabetes, and smoking status.
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Clinical Usefulness of Very High and Very Low Levels of
C-Reactive Protein Across the Full Range of Framingham
Risk Scores
Paul M Ridker, MD, MPH; Nancy Cook, ScD
Background—High-sensitivity C-reactive protein (hsCRP) is a strong independent risk factor for cardiovascular events,
and levels of hsCRP of1, 1 to3, and3 mg/L have been suggested to define low-, moderate-, and high-risk groups.
However, the positive predictive value of very low (0.5 mg/L) and very high levels of hsCRP (10.0 mg/L) is
uncertain.
Methods and Results—Baseline levels of hsCRP were evaluated among 27 939 apparently healthy women who were
followed up for myocardial infarction, stroke, coronary revascularization, or cardiovascular death. Crude and
Framingham Risk Score (FRS)–adjusted relative risks (RRs) of incident cardiovascular events were calculated across
a full range of hsCRP levels. Cardiovascular risks increased linearly from the very lowest (referent) to the very highest
levels of hsCRP. Crude RRs for those with baseline hsCRP levels of 0.5, 0.5 to 1.0, 1.0 to 2.0, 2.0 to 3.0, 3.0
to 4.0, 4.0 to 5.0, 5.0 to 10.0, 10.0 to 20.0, and 20.0 mg/L were 1.0, 2.2, 2.5, 3.1, 3.7, 4.2, 4.9, 6.3, and 7.6,
respectively (P for trend 0.001). After adjustment for FRS, these risks were 1.0, 1.6, 1.6, 1.7, 1.9, 2.2, 2.3, 2.8, and
3.1 (P for trend 0.001). All risk estimates remained significant in analyses stratified by FRS and after control for
diabetes. Of the total cohort, 15.1% had hsCRP 0.50 mg/L, and 5.4% had hsCRP 10.0 mg/L.
Conclusions—Both very low (0.5 mg/L) and very high (10 mg/L) levels of hsCRP provide important prognostic
information on cardiovascular risk. hsCRP is clinically useful for risk prediction across a full range of values and across
a full range of FRS. (Circulation. 2004;109:1955-1959.)
Key Words: risk factors  prevention  epidemiology  inflammation  C-reactive protein
High-sensitivity C-reactive protein (hsCRP) has emergedas a strong independent risk factor for future cardiovas-
cular events that adds prognostic information at all levels of
LDL cholesterol, at all levels of the Framingham Risk Score
(FRS), and at all levels of the metabolic syndrome.1 On the
basis of published data from large, prospective cohorts,2–9 the
Centers for Disease Control and Prevention and the American
Heart Association (CDC/AHA) in January of 2003 issued the
first set of clinical guidelines for hsCRP as a part of global
risk prediction and suggested that levels of hsCRP of1, 1 to
3, and 3 mg/L be used to represent low, moderate, and
high vascular risk.10 However, as clinicians have begun using
hsCRP on a regular basis, questions about the usefulness of
both very high and very low levels of hsCRP have emerged.
In particular, some physicians have raised concern that very
high levels of hsCRP (10 mg/L) may represent nonspecific
inflammation and therefore lack positive predictive value. At
the same time, others have voiced concern that very low
levels of hsCRP might give patients a false sense of security,
particularly when other traditional risk factors are present.
We addressed these clinical issues in the large-scale Wom-
en’s Health Study, in which baseline levels of hsCRP as well
as FRS were measured among 27 939 apparently healthy
women who were followed up over a 9-year period for the
occurrence of first cardiovascular events.
Methods
The Women’s Health Study is an ongoing trial of aspirin and vitamin
E in primary prevention being conducted among American women
age 45 years with no previous history of cardiovascular disease or
cancer. Participants were enrolled between November 1992 and July
1995, at which time they provided detailed information on demo-
graphic, lifestyle, and behavioral risk factors. Among women en-
rolled, 28 345 provided a baseline blood sample, of which 27 939
underwent successful measurement of LDL cholesterol, HDL cho-
lesterol, and hsCRP.9 As described elsewhere, all women have been
followed up for incident cardiovascular events, including nonfatal
myocardial infarction, nonfatal ischemic stroke, coronary revascu-
larization procedures, and cardiovascular death.9
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Following guidelines issued by CDC/AHA,10 we initially
classified all study participants into 3 groups on the basis of
baseline hsCRP levels of 1, 1 to 3, and 3 mg/L. Cox
proportional-hazards models were then used to compute relative
risks of future cardiovascular events across these 3 study groups.
We then addressed the issue of whether very high or very low
levels of hsCRP have clinical relevance for risk prediction in 2
stages. First, to avoid the possibility of data-derived findings, we
initially reclassified all participants into 1 of 10 groups based on
increasing deciles of the distribution of hsCRP. Second, to
increase clinical usefulness, we repeated these analyses after
classifying all participants into 1 of the following categories of
baseline hsCRP: 0.5, 0.5 to 1.0, 1.0 to 2.0, 2.0 to 3.0, 3.0
to 4.0, 4.0 to 5.0, 5.0 to 10.0, 10.0 to 20.0, and 20.0
mg/L. In each instance, Cox proportional-hazards models were
used to compute relative risks across the full spectrum of hsCRP
levels. For all models, we computed both crude relative risks and
relative risks adjusted for the FRS and additionally for diabetes.
Because hormone replacement therapy (HRT) is known to elevate
hsCRP levels, we repeated all analyses for the subgroup of
women not using these agents at study entry.
Results
The risk factor profile of participants in the Women’s Health
Study is similar to that of the general population in terms of
both lipid levels and the proportion having metabolic syn-
drome.11 Among the 27 939 women evaluated in this analy-
sis, 12% were smokers at study entry, 2.5% had diabetes, and
25% had a history of hypertension. The mean body mass
index was 25.9 kg/m2. Between study initiation and time of
this analysis, 698 first cardiovascular events were reported
and confirmed by the end-points committee.
Table 1 presents the crude and FRS-adjusted relative risks
of future cardiovascular events according to the clinical
cutpoints set by the CDC/AHA guidelines. Compared with
women with baseline levels of hsCRP 1 mg/L, the crude
relative risk for those with baseline hsCRP levels between 1
and 3 mg/L was 1.7 (95% CI, 1.4 to 2.2), whereas the
relative risk for those with baseline hsCRP levels 3 mg/L
was 3.0 (95% CI, 2.4 to 3.7) (P for trend across groups
0.001). As expected, these risks were attenuated but re-
mained statistically significant in models adjusted for FRS
and additionally for diabetes. As also shown in Table 1, these
effects remained statistically significant in the subgroup
analysis of those 15 745 women not taking HRT at study
entry (P for trend across groups 0.001).
Table 2 presents crude and FRS-adjusted relative risks of
future cardiovascular events in analyses in which hsCRP
levels were classified into 10 groups based on exact decile
cutpoints. As shown, there is a strong and highly significant
linear association between baseline hsCRP and future cardio-
vascular risk across the full spectrum of hsCRP levels.
Specifically, crude relative risks from the very lowest (refer-
ent) to very highest deciles of baseline hsCRP were 1.0, 1.3,
2.6, 2.2, 3.0, 3.4, 3.6, 4.2, 5.1, and 6.3 (P for trend across
groups 0.001). After adjustment for FRS, these risk esti-
mates were 1.0, 0.9, 1.7, 1.3, 1.7, 1.6, 1.7, 1.9, 2.1, and 2.4 (P
for trend across groups 0.001). Almost identical findings
were observed in the subgroup not taking HRT at study entry
(P for trend 0.001).
Table 3 presents crude and adjusted relative risks of future
cardiovascular events in analyses in which baseline hsCRP
values were defined according to clinically useful cutpoints
of hsCRP rather than strict deciles. Again, in analyses of both
the total cohort and those not taking HRT, a highly significant
relationship between hsCRP and risk was observed across the
full spectrum of hsCRP values. Specifically, the very lowest
risk was observed among those in the referent group with
hsCRP levels 0.5 mg/L, whereas risk was almost 8-fold
higher among those with levels of hsCRP in excess of 20
mg/L (crude relative risk, 7.6; 95% CI, 4.7 to 12.1). These
effects were even stronger in the non–HRT-using subgroup,
in which the crude relative risk for those with hsCRP levels
20 mg/L was increased nearly 10-fold. All findings re-
mained statistically significant after adjustment for FRS and
additionally for diabetes (P for trend across groups 0.001
for both the total cohort and non–HRT users).
Figure 1 presents the relative impact of both very high and
very low levels of hsCRP on future vascular risk using
clinically relevant cutpoints for hsCRP. For comparison, the
CDC/AHA cutpoints of 1, 1 to 3, and 3 mg/L used to
determine low, moderate, and high risk are also shown.
Figure 2 shows the predictive value of hsCRP levels among
those with calculated 10-year Framingham Risks above and
below 10%.
Finally, because diabetes is often considered a coronary
risk equivalent, we repeated our analyses for those women
free of diabetes at study entry. Among such women, the
relative risks for those with baseline hsCRP levels 0.5, 0.5
to 1.0, 1.0 to 2.0, 2.0 to 3.0, 3.0 to 4.0, 4.0 to 5.0,
5.0 to 10.0, 10.0 to 20.0, and 20.0 mg/L were 1.0, 2.1,
2.6, 3.0, 3.6, 4.0, 4.6, 5.0, and 7.4, respectively (P for trend
0.001).
TABLE 1. Crude and FRS-Adjusted Relative Risks of First Cardiovascular Events According to hsCRP Cutpoints of <1, 1 to <3, and
>3 mg/L
Total Cohort
(n27 939)
No HRT
(n15 745)
hsCRP, mg/L
Events,
n
Crude
RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
Events,
n
Crude Adjusted
RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
1.00 105 1.0 (ref) 1.0 (ref) 1.0 (ref) 75 1.0 (ref) 1.0 (ref) 1.0 (ref)
1.00–3.00 202 1.7 (1.4–2.2) 1.2 (1.0–1.5) 1.2 (0.9–1.5) 120 1.8 (1.4–2.5) 1.2 (0.9–1.6) 1.1 (0.9–1.6)
3.00 391 3.0 (2.4–3.7) 1.7 (1.3–2.2) 1.5 (1.2–1.9) 223 3.9 (3.0–5.0) 1.9 (1.4–2.5) 1.6 (1.2–2.2)
P for trend 0.001 0.001 0.001 0.001 0.001 0.001
RR indicates relative risk; FRS, adjusted for the Framingham Risk Score age; and FRSDM, adjusted for FRS and diabetes mellitus. Values represent RR (95%
CI) compared with the referent (ref) group.
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In all analyses, virtually identical results were obtained
when individual components of the FRS were used.
Discussion
These prospective data indicate that the predictive value of
hsCRP for future cardiovascular events is linear across a full
range of values. Most importantly, these data demonstrate
that both very high (10 mg/L) and very low (0.5 mg/L)
levels of hsCRP provide important prognostic information on
vascular risk across a full range of FRS. These observations
were consistent in analyses using deciles of hsCRP as well as
clinically relevant cutpoints and were present in the total
cohort as well as in the subgroups of those not taking HRT
and those without diabetes.
The present data have both clinical and pathophysiological
relevance. From a clinical perspective, these data demonstrate
that the predictive value of hsCRP is strongly linear across
the full range of values. Thus, not only is there no evidence
in these data of any threshold effect, but there is also no
evidence that unusually low or unusually high values repre-
sent false-positive findings. Quite to the contrary, these data
indicate that there is considerable predictive value of hsCRP
levels beyond the ranges suggested by the recent CDC/AHA
guidelines for use of hsCRP.10 Thus, in addition to the
“high-risk” group defined by the CDC/AHA as having levels
of hsCRP between 3 and 10 mg/L, there appears to be a
“very-high-risk” group with levels of hsCRP in excess of 10
mg/L (which in our study represented 5.5% of the total
TABLE 2. Crude and FRS-Adjusted Relative Risks of First Cardiovascular Events According to Increasing Deciles of hsCRP With
Cutpoints Also Provided
Total Cohort
(n27 939)
No HRT
(n15 745)
Decile
hsCRP,
mg/L
Events,
n
Crude
RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
Events,
n
Crude-Adjusted
RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
1 0.36 22 1.0 (ref) 1.0 (ref) 1.0 (ref) 11 1.0 (ref) 1.0 (ref) 1.0 (ref)
2 0.36–0.64 28 1.3 (0.7–2.2) 0.9 (0.5–1.6) 0.9 (0.5–1.6) 10 0.9 (0.4–2.2) 0.6 (0.2–1.4) 0.6 (0.2–1.4)
3 0.64–1.00 55 2.6 (1.6–4.3) 1.7 (1.0–2.8) 1.7 (1.0–2.8) 22 2.1 (1.0–4.2) 1.1 (0.5–2.4) 1.1 (0.5–2.4)
4 1.00–1.46 49 2.2 (1.4–3.7) 1.3 (0.8–2.2) 1.3 (0.8–2.2) 34 3.3 (1.7–6.4) 1.7 (0.9–3.5) 1.7 (0.9–3.5)
5 1.46–2.02 65 3.0 (1.9–4.9) 1.7 (1.0–2.7) 1.7 (1.0–2.7) 31 2.9 (1.5–5.7) 1.3 (0.6–2.6) 1.3 (0.6–2.6)
6 2.02–2.74 72 3.4 (2.1–5.5) 1.6 (1.0–2.6) 1.6 (1.0–2.6) 38 3.6 (1.8–7.0) 1.6 (0.8–3.1) 1.5 (0.8–3.0)
7 2.75–3.71 76 3.6 (2.2–5.7) 1.7 (1.0–2.7) 1.6 (1.0–2.6) 47 4.4 (2.3–8.6) 1.7 (0.9–3.2) 1.6 (0.8–3.1)
8 3.71–5.17 90 4.2 (2.6–6.7) 1.9 (1.2–3.0) 1.8 (1.1–2.9) 54 5.1 (2.7–9.8) 1.8 (0.9–3.4) 1.7 (0.9–3.3)
9 5.17–7.73 108 5.1 (3.2–8.0) 2.1 (1.3–3.4) 1.9 (1.2–3.1) 77 7.3 (3.9–13.8) 2.4 (1.2–4.5) 2.0 (1.1–3.9)
10 7.73 133 6.3 (4.0–9.8) 2.4 (1.5–3.9) 2.1 (1.3–3.2) 94 9.0 (4.8–16.9) 2.8 (1.5–5.2) 2.3 (1.2–4.3)
P for trend 0.001 0.001 0.001 0.001 0.001 0.001
Abbreviations as in Table 1. Values represent RR (95% CI) compared with the referent (ref) group.
hsCRP cutpoints shown are for the total cohort. Decile cutpoints for hsCRP for the group not taking HRT are 0.29, 0.29–0.49, 0.49–0.75, 0.75–1.08,
1.08–1.52, 1.52–2.09, 2.09–2.93, 2.93–4.19, 4.19–6.61, and 6.61 mg/L.
TABLE 3. Crude and FRS-Adjusted Relative Risks of First Cardiovascular Events Across a Full Range of Clinically Set
hsCRP Cutpoints
Total Cohort
(n27 939)
No HRT
(n15 745)
hsCRP, mg/L
Events,
n Crude RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
Events,
n
Crude Adjusted
RR
FRS-Adjusted
RR
FRSDM-Adjusted
RR
0.50 34 1.0 (ref) 1.0 (ref) 1.0 (ref) 21 1.0 (ref) 1.0 (ref) 1.0 (ref)
0.50–1.0 71 2.2 (1.4–3.2) 1.6 (1.1–2.4) 1.6 (1.1–2.5) 54 3.0 (1.8–5.0) 2.1 (1.3–3.6) 2.1 (1.3–3.5)
1.0–2.0 111 2.5 (1.7–3.7) 1.6 (1.1–2.4) 1.6 (1.1–2.4) 68 3.2 (1.9–5.1) 1.8 (1.1–3.0) 1.8 (1.1–3.0)
2.0–3.0 91 3.1 (2.1–4.6) 1.7 (1.1–2.5) 1.7 (1.1–2.5) 52 4.2 (2.5–7.0) 2.1 (1.2–3.5) 1.9 (1.2–3.3)
3.0–4.0 79 3.7 (2.5–5.6) 1.9 (1.3–2.9) 1.9 (1.2–2.8) 47 5.6 (3.3–9.3) 2.4 (1.4–4.1) 2.3 (1.4–3.9)
4.0–5.0 63 4.2 (2.8–6.4) 2.2 (1.4–3.3) 2.0 (1.3–3.1) 42 7.5 (4.4–12.6) 3.3 (1.9–5.6) 2.9 (1.7–5.1)
5.0–10.0 169 4.9 (3.4–7.1) 2.3 (1.5–3.3) 2.0 (1.4–3.0) 94 7.9 (4.9–12.7) 3.1 (1.9–5.1) 2.6 (1.6–4.3)
10.0–20.0 44 6.3 (4.0–9.8) 2.8 (1.7–4.4) 2.4 (1.5–3.8) 24 10.4 (5.8–18.7) 4.0 (2.2–7.4) 3.3 (1.8–6.1)
20 36 7.6 (4.7–12.1) 3.1 (1.9–5.1) 2.4 (1.5–4.0) 16 9.3 (4.8–17.9) 3.9 (2.0–7.5) 2.9 (1.5–5.6)
P for trend 0.001 0.001 0.001 0.001 0.001 0.002
Abbreviations as in Table 1. Values represent RR (95% CI) compared with the referent (ref) group. Data are shown for the total cohort (n27 939) and for those
women not taking HRT (n15 745).
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population). Moreover, although levels of hsCRP 20 mg/L
were rare (2.2% of the total population), these individuals
were observed to have the very highest risk of future vascular
events. By contrast, risk appeared to be very low for individ-
uals at the other end of the spectrum with hsCRP levels 0.5
mg/L (15.1% of the study population). Indeed, this group
appeared to have very low risk even when compared with
those with hsCRP levels between 0.5 and 1.0 mg/L. As shown
in our multivariate analyses, this was true even when other
risk factors were present and after adjustment for the FRS and
additionally for diabetes.
From a pathophysiological perspective, these analyses also
raise several intriguing issues. First, the observation that
individuals with exceptionally low levels of hsCRP have very
low risks of future cardiovascular events provides clinical
support for the concept that CRP itself may have a direct role
in atherothrombosis and raises the possibility that a virtual
absence of CRP may in fact be protective. For example, mice
transgenic for human CRP not only begin to express elevated
CRP levels for the first time but also have increased rates of
arterial thrombosis, at least compared with wild-type mice
that minimally express CRP.12 Recent work further indicates
that CRP can be produced within the vascular smooth muscle
of diseased coronary arteries13,14 and that this production may
directly lead to the expression of several mediators of the
atherothrombotic process, including adhesion molecule in-
duction, reduced NO production, and altered fibrinolytic
function.15 Thus, individuals without expressed CRP levels
may largely be free of these proatherogenic responses. Con-
versely, our observation that individuals with very high levels
of hsCRP are at very high vascular risk is consistent with the
hypothesis that CRP may have direct arterial effects or be a
surrogate for these effects. In this regard, rather than suggest-
ing that markedly elevated levels of hsCRP represent a
false-positive response, the current clinical data raise the
possibility that chronic inflammation from any of several
causes may well increase vascular risk. As such, these data
are consistent with reports suggesting that several chronic
conditions including arthritis, periodontal disease, and
chronic low-grade infection may all predispose to athero-
thrombotic events.16
Our data also reinforce the need to use high-sensitivity
assays for the evaluation of CRP. Although older assays for
CRP might be able to reliably detect levels in excess of 10
mg/L (the very-high-risk group), it is only with use of hsCRP
assays that clinical detection across a full range can be
assessed. As demonstrated in these data, that range must
include those at high risk (hsCRP between 3 and 10 mg/L) as
well as those at very low risk (0.5 mg/L) and intermediate
risk (hsCRP between 1.0 and 3.0 mg/L), all levels undetect-
able without high-sensitivity assays.
An important limitation of our study is that we evaluated
hsCRP levels only once at baseline and thus cannot eliminate
the possibility that some of the marked elevations observed
might well reflect a clinically silent acute-phase response.
However, this potential misclassification bias among those
with high levels of hsCRP can lead only to an underestima-
tion of true effects, not a falsely high risk estimate. Thus, the
magnitude of predictive values found here for hsCRP are, if
anything, likely to be underestimates of true effects. Clini-
cians can largely avoid this difficulty by simply measuring
hsCRP twice whenever levels are in excess of 10 mg/L. This
Figure 1. Relative risks of future cardiovascular events across a
full clinical range of hsCRP values. Black bars represent crude
relative risks; gray bars, risks adjusted for FRS.
Figure 2. Relative risks of future cardio-
vascular events among those with calcu-
lated 10-year Framingham risks 10%
(left) and between 10% and 20% (right).
1958 Circulation April 27, 2004
practice is consistent with the recent CDC/AHA guidelines
and, as has been found in several reports, greatly reduces any
residual variation in levels that may be observed in outpatient
clinical use.17,18 Finally, absolute event rates within the
Women’s Health Study are low in comparison to the general
population because of the “healthy cohort effect” and the fact
that our participants are healthcare providers. However, the
fact that hsCRP has been shown to predict vascular risk with
similar magnitude in multiple other studies of men and
women suggests that the relative risks described here are
generalizable.
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Should C-Reactive Protein Be Added to Metabolic Syndrome
and to Assessment of Global Cardiovascular Risk?
Paul M Ridker, MD; Peter W.F. Wilson, MD; Scott M. Grundy, MD
Abstract—Of novel risk factors for cardiovascular disease currently under investigation, high-sensitivity C-reactive protein
(hsCRP) is the most promising. To date, more than 20 prospective epidemiologic studies have demonstrated that hsCRP
independently predicts vascular risk, 6 cohort studies have confirmed that hsCRP evaluation adds prognostic
information beyond that available from the Framingham Risk Score, and 8 cohort studies have demonstrated additive
prognostic value at all levels of metabolic syndrome or in the prediction of type 2 diabetes. In contrast to several other
biomarkers that also reflect biological aspects of inflammation, hypofibrinolysis, and insulin resistance, hsCRP
measurement is inexpensive, standardized, widely available, and has a decade-to-decade variation similar to that of
cholesterol. Given the consistency of prognostic data for hsCRP and the practicality of its use in outpatient clinical
settings, we believe the time has come for a careful consideration of adding hsCRP as a clinical criterion for metabolic
syndrome and for the creation of an hsCRP-modified coronary risk score useful for global risk prediction in both men
and women. Toward this end, we believe experts in the fields of epidemiology, prevention, vascular biology, and clinical
cardiology should be convened to begin discussing the merits of this proposal. (Circulation. 2004;109:2818-2825.)
Key Words: inflammation  risk factors  prevention  diabetes mellitus  atherosclerosis
The identification of individuals who are at high risk fordeveloping cardiovascular disease but who currently lack
symptoms is a critical issue in primary prevention. For more
than 30 years, cardiovascular risk prediction algorithms have
relied on blood pressure, smoking status, hyperlipidemia, and
the presence or absence of diabetes. These core traditional
risk factors for heart disease and stroke derive largely from
the groundbreaking Framingham Heart Study that first pro-
vided the conceptual basis for cardiovascular risk factors in
the early 1960s.1 With corroborating evidence from major
cohort studies performed worldwide, these risk factors and
their interactions with age and sex were formally codified in
the 1980s into the Framingham Risk Score.2,3 This scoring
system, along with its European counterpart,4 has been highly
successful and forms the basis for most coronary risk detec-
tion and prevention programs.5 In current practice, those with
10-year Framingham coronary heart disease (CHD) risk
estimates that are less than 5% are considered to be at low
risk, those with 10-year estimates between 6% and 20% are
considered at intermediate risk, and those with 10-year risks
of 20% and higher (or who have diabetes) are considered to
be coronary risk equivalents.6,7
Despite the success of the Framingham Risk Score, there are
limitations to this approach. First, it is widely recognized that
a fifth of all events occur among individuals in whom
traditional risk factors have not been identified.8 Moreover,
the specificity of traditional risk factors is limited.9 Multiple
studies additionally confirm that most vascular events occur
among individuals without evidence of very high cholesterol
levels10 and that the intermediate-risk group is large, hetero-
geneous, and in need of better methods for risk stratifica-
tion.11 Finally, the relationship between Framingham scores
and absolute risk for CHD varies across populations.12–14
For all of these reasons, there has been considerable
interest in developing novel risk factors that might improve
global risk prediction. To be useful in a clinical setting, the
biomarker of interest should provide information on risk or
prognosis beyond that available from standard global assess-
ment tools. Successful screening techniques should also be
inexpensive and available to primary care practitioners to
ensure appropriate interpretation and follow-up. Thus, imag-
ing techniques, including MRI, carotid ultrasonography, and
coronary calcium detection, are unlikely to be useful as
first-level screening tools. Similarly, metabolic evaluations,
such as oral glucose tolerance testing, may be impractical
given the time constraints of daily clinical practice. By
contrast, simple blood tests that can be sent at the time of
cholesterol evaluation are more likely to succeed.
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Review: Current Perspective
Of potential novel risk factors presently available, high-
sensitivity C-reactive protein (hsCRP), a marker of low-grade
vascular inflammation, is among the most promising. Pro-
spective epidemiologic studies consistently demonstrate that
hsCRP adds independent prognostic information at all levels
of LDL cholesterol and at all levels of the Framingham Risk
Score.15 The Centers for Disease Control and Prevention
(CDC) and the American Heart Association (AHA) published
in January of 2003 the first set of guidelines to endorse use of
hsCRP as an adjunct to traditional risk factor screening.16 The
CDC/AHA report also endorsed hsCRP as the only inflam-
matory biomarker currently available with adequate standard-
ization and predictive value to justify use in outpatient
clinical settings. On the basis of data from available investi-
gations, levels of hsCRP 1, 1 to 3, and 3 mg/L have been
defined as lower, moderate, and higher cardiovascular risk.
Taking a conservative approach, the CDC/AHA report sug-
gested that the best use of hsCRP was in patients at interme-
diate Framingham risk.
In the year since publication of the CDC/AHA report,
abundant data have emerged not only confirming the ability
of hsCRP to add prognostic information to the Framingham
Risk Score but also linking hsCRP to metabolic syndrome
and the development of incident type 2 diabetes. Moreover,
accumulating data suggest that both very low and very high
levels of hsCRP seem to provide independent prognostic
information across a full spectrum of Framingham risk.17 At
the same time, cost-effectiveness studies have found that,
given the low cost of screening for hsCRP, simultaneous
evaluation of hsCRP at the time of lipid screening may be
more efficient than a selective policy of hsCRP use that
requires a return visit to the primary care physician as well as
an additional outpatient phlebotomy.18,19
All of these new data raise the possibility that hsCRP
testing may improve CHD risk assessment, and clinicians
within the prevention community have begun considering the
use of hsCRP as a core part of global risk assessment, both in
terms of Framingham risk evaluation and in terms of a
modified metabolic syndrome evaluation. We thus review
here evidence for hsCRP as a potential adjunct to both the
Framingham Risk Score and as an additional clinical criterion
for diagnosis of metabolic syndrome.
Evidence That hsCRP Is Independent of and Adds
Predictive Value to the Framingham Risk Score
To date, 22 prospective studies of hsCRP and risk of future
cardiovascular disease have been presented, and all are
positive. Furthermore, 6 major prospective studies have
demonstrated that hsCRP adds prognostic information on
cardiovascular risk beyond that available using the Framing-
ham Risk Score alone. Four investigations—the Physicians’
Health Study (PHS),20 the Women’s Health Study
(WHS),10,21 the Atherosclerosis Risk in Communities Study
(ARIC),22 and the Air Force/Texas Atherosclerosis Preven-
tion Study (AFCAPS/TexCAPS)23—were performed in the
United States, and 2 studies, the Monitoring of Trends and
Determinants of Cardiovascular disease (MONICA) study24
and the Reykjavik Study,25 were performed in Europe. In
addition, the Framingham Heart Study itself has provided
evidence that hsCRP independently predicts thrombotic
events in the cerebral circulation,26 and the Pravastatin
Inflammation/CRP Evaluation (PRINCE) database has pro-
vided evidence that hsCRP picks up risk information that
cannot be gleaned from the individual Framingham
covariates.27
The largest of the American cohorts is the WHS, a
prospective evaluation of 27 939 initially healthy American
women who underwent hsCRP evaluation along with a full
lipid panel and Framingham risk assessment and were mon-
itored over a period of 8.3 years for the occurrence of
first-ever cardiovascular events.10,21 When this study was first
presented, 571 first-ever nonfatal myocardial infarctions,
nonfatal strokes, coronary revascularizations, or cardiovascu-
lar deaths had accrued. Following the National Cholesterol
Education Program Adult Treatment Panel III (ATP III)
guidelines, the WHS emphasized hard cardiovascular end
points and did not include angina pectoris.10
Overall, baseline hsCRP levels in the WHS were a strong
predictor of future vascular events; the relative risks for those
with lowest to highest quintiles of hsCRP at baseline were
1.0, 1.8, 2.3, 3.2, and 4.5 (P0.001). After adjustment for
age, smoking, diabetes, blood pressure, and hormone replace-
ment therapy, the risk in the top quintile of hsCRP was 2.3
(95% CI, 1.6 to 3.4). The hsCRP levels minimally correlated
with LDL in the WHS, and a combined approach, using both
lipids and hsCRP, provided improved prediction of cardio-
vascular event-free survival (Figure 1).
Most importantly, hsCRP levels remained a highly signif-
icant predictor of risk in the WHS after adjustment for the
Framingham Risk Score.10 After taking into account all
components of the Framingham Risk Score, the relative risks
for those with lowest to highest hsCRP quintiles at baseline
were 1.0, 1.3, 1.4, 1.7, and 1.9 (P0.001) for all participants
and 1.0, 1.6, 1.5, 1.8, and 2.2 (P0.001) for those not taking
Figure 1. Cardiovascular event-free survival among apparently
healthy individuals according to baseline levels of hsCRP and
LDL cholesterol. Reprinted with permission from Reference 10.
Copyright © 2002 Massachusetts Medical Society. All rights
reserved.
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hormone replacement therapy. The addition of data on hsCRP
provided qualitatively important information on risk at all
levels of LDL cholesterol after adjustment for usual risk
factors (Figure 2, right) and at all levels of estimated 10-year
risk based on the Framingham Risk Score (Figure 2, left).
These latter analyses were based on levels of hsCRP 1, 1 to
3, and 3 mg/L, the cut points suggested for use by the
CDC/AHA guidelines.
Since publication of these results, there has been continued
accrual of cardiovascular end points within the WHS as well
as ongoing analysis of the utility of hsCRP as a risk predictor.
For example, within the WHS, evidence is now available that
demonstrates predictive value both for extremely low levels
of hsCRP (0.5 mg/L) and for extremely high levels of
hsCRP (10 mg/L).17 This new analysis is important because
it shows that dividing hsCRP levels into five categories
(0.5, 0.5 to 1.0, 1.0 to 3.0, 3.0 to 10.0, and 10.0
mg/L) may improve risk discrimination at both low and high
levels of the Framingham Risk Score, potentially leading to a
superior way to code hsCRP for use in CRP-modified
algorithms (Figure 3). These data are also consistent with the
hypothesis that very low levels of hsCRP may protect against
acute vascular events. On the other hand, chronic inflamma-
tion from any source leads to excess risk, a hypothesis
consistent with evidence about direct mechanisms by which
CRP may affect both atherosclerotic development and acute
thrombosis.
Data from the WHS demonstrate the additive value of
hsCRP to the Framingham Risk Score and provide confirma-
tion of data that had been presented earlier for men in the
PHS.20 In that cohort of healthy middle-aged men, baseline
levels of hsCRP were independently predictive of future
myocardial infarction and thromboembolic stroke but not of
venous thrombosis. Furthermore, the PHS demonstrated that
the relative benefit of aspirin was greatest in preventing
vascular events among those with the highest hsCRP levels,
an intriguing observation given the antiinflammatory proper-
ties of aspirin.20 That hsCRP is an independent predictor
beyond the Framingham Risk Score is also evident in those
early original data. Specifically, after adjustment for all
components of the Framingham Risk Score, the relative risks
of future myocardial infarction in the PHS for those with
hsCRP levels 1, 1 to 3, and 3 mg/L were 1.0, 1.7, and 2.2
(95% CI for those with hsCRP 3.0 mg/L, 1.2 to 3.8).
Data on hsCRP from the PHS and WHS have been
corroborated by similar analyses from other large cohorts
from the United States and Europe. In a case-cohort analysis
of 12 819 apparently healthy middle-aged men and women
participating in the ARIC study over a 6-year follow-up
period, the relative risks of incident coronary heart disease for
those with baseline hsCRP levels 1.0, 1.0 to 3.0, and 3.0
mg/L were 1.0, 1.6, and 2.5 after adjusting for age, sex, and
ethnicity.22 After full adjustment for the Framingham covari-
ates and additionally for diabetes, these risk estimates were
Figure 2. hsCRP adds prognostic information
at all levels of LDL cholesterol (right) and at all
levels of the Framingham Risk Score (left).
Reprinted with permission from Reference 10.
Copyright © 2002 Massachusetts Medical Soci-
ety. All rights reserved.
Figure 3. Clinical utility of very high (10 mg/L) as
well as very low (0.5 mg/L) levels of hsCRP
among those with 10-year Framingham estimated
risks 10% (left) and between 10% and 20%
(right). Data from Reference 17.
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1.0, 1.2, and 1.8, respectively (95% CI for those with hsCRP
3.0, 1.0 to 3.0). Almost identical data derive from a
prospective evaluation of 3435 German men participating in
the MONICA-Augsberg Cohort Study in which 191 incident
coronary events occurred during 6.6 years of follow-up.24 In
this study of men, as in the WHS study of women, hsCRP
levels at baseline were independently associated with incident
coronary events. These effects remained significant
(P0.001) after adjustment for the Framingham Risk Score,
such that persons with hsCRP levels of 1, 1 to 3, and 3
mg/L had fully adjusted relative risks of 1.0, 1.5, and 2.5,
respectively (95% CI for those with hsCRP 3.0, 1.8 to 3.7).
The exceptional consistency of these Framingham-adjusted
findings for hsCRP across the PHS, WHS, ARIC, and the
MONICA studies using the AHA/CDC established cut points
for hsCRP of 1, 1 to 3, and 3 mg/L are shown in Figure 4.
Strong supportive evidence for the addition of hsCRP to
Framingham risk evaluation also comes from the large
Reykjavik Study that included 2459 incident events during an
18-year follow-up period.25 Although this prospective study
used an hsCRP cut point of 2.0 rather than 3.0 and thus would
tend to underestimate effects compared with other cohorts, a
highly significant fully adjusted odds ratio of 1.5 was none-
theless observed. In fact, this 50% increase in risk associated
with hsCRP was observed not only after control for typical
Framingham covariates but also after additional control for
diabetes, triglycerides, body mass index, and indices of
pulmonary function. Moreover, the odds ratio for hsCRP
observed in the Reykjavik Study was exactly the same as the
adjusted odds ratio observed for hypertension and statistically
similar to that of smoking. Furthermore, the fully adjusted
odds ratio for hsCRP during the initial 10 years of follow-up
was 1.84, a risk estimate consistent with all prior studies.
Although there has been controversy about the relative
importance of hsCRP compared with cholesterol in the
Iceland analysis, it is important to recognize that the Reyk-
javik population studied had a mean total cholesterol of 247
mg/dL compared with the United States average of 213
mg/dL. Thus, the Icelandic data not only confirm prior
reports that hsCRP significantly predicts risk after adjustment
for Framingham covariates but also demonstrate the additive
clinical value of hsCRP in a population with much higher
baseline cholesterol levels than those observed in contempo-
rary American and European studies.
In addition to these 5 major cohorts, supportive evidence
for the addition of hsCRP to Framingham risk evaluation also
comes from other sources. Within the AFCAPS/TexCAPS
analysis of 5742 apparently healthy individuals enrolled in a
randomized primary prevention trial of lovastatin versus
placebo, each quartile increase in baseline hsCRP was asso-
ciated with a 21% increase in the risk of a first cardiovascular
event (95% CI, 4% to 41%), an effect that again persisted
after control for all individual components of the Framing-
ham Risk Score.23 Similarly, in an analysis of 1666 individ-
uals free of cardiovascular disease enrolled in the PRINCE
study, hsCRP levels correlated modestly with 10-year Fra-
mingham Risk Scores yet showed minimal relation to any
individual component of the score itself.27 Thus, as in the
prospective cohort evaluations, the PRINCE data suggest that
hsCRP detects a component of vascular risk not readily
obtained from the Framingham covariates themselves.
Finally, within the Framingham Heart Study, data have
also been presented that demonstrate the ability of hsCRP to
predict stroke risk independently of the Framingham covari-
ates.26 After adjustment for age, smoking, blood pressure,
diabetes, and total and HDL cholesterol, the risk of future
stroke in the Framingham Heart Study increased 25% in men
(P0.036) and 29% in women (P0.008) for each increasing
quartile of hsCRP. These latter data are consistent with
Figure 4. Framingham-adjusted relative risks of
future coronary events according to baseline levels
of hsCRP 1, 1 to 3, and 3 mg/L in 4 major
cohort studies. Data from References 10, 20–22,
24, and 51.
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evidence from several studies showing that hsCRP also predicts
first-ever thromboembolic stroke.10,20,21 With regard to hard
coronary heart disease end points within Framingham, power is
limited because of a small number of events. However, the
age-adjusted relative risks of hard coronary heart disease within
Framingham for those with baseline levels of hsCRP1, 1 to 3,
and 3 mg/L are 1.0, 1.47, and 1.63, data fully consistent with
those from the other larger studies.
Although a predictor of vascular events, hsCRP levels do
not track closely with subclinical atherosclerosis, as measured
by cardiac catheterization, intimal-medial thickness, the
ankle-brachial index, or coronary calcification.28–30 This
observation likely reflects the fact that inflammation is more
tightly associated with plaque vulnerability and rupture than
with total plaque burden per se. Clinically, this observation
also helps to explain why hsCRP levels not only add to the
Framingham Risk Score but also add to coronary risk
prediction based on coronary calcification; in the South Bay
Heart Study, elevated hsCRP levels resulted in a doubling of
risk at low, moderate, and high levels of coronary calcifica-
tion.31 Thus, measures of inflammation such as hsCRP seem
to provide independent and complementary information on
risk beyond that achievable by direct measures of atheroscle-
rotic burden.
Evidence That hsCRP Correlates With and Adds
Prognostic Information to Formal Definitions of
Metabolic Syndrome
Part of the clinical interest in adding hsCRP to current risk
algorithms derives from the fact that inflammation also plays
a major role in the development of diabetes and is intimately
related to several difficult-to-measure components of the
metabolic syndrome.32 In cross-sectional studies, hsCRP
levels have been found to correlate with elevated triglycer-
ides, low HDL levels, midline obesity, elevated blood pres-
sure, and high fasting glucose levels, the key easily measured
components of the ATP III definition of metabolic syn-
drome.33,34 However, hsCRP levels also correlate with insulin
resistance and impaired fibrinolysis, major components of the
metabolic syndrome that are not easily evaluated in an
outpatient practice setting. In one study of women, hsCRP
and body mass index were the only independent correlates of
fasting insulin levels when modeled as a continuous depen-
dent variable.35
In other investigations, hsCRP levels have been found to
correlate with direct measures of insulin resistance and
endothelial dysfunction.36,37 Among nondiabetic participants
in the Insulin Resistance Atherosclerosis Study (IRAS), the
correlation coefficients between hsCRP and fasting glucose,
fasting insulin, and insulin sensitivity were 0.18, 0.33, and
0.37, respectively (all P values 0.001).33 The IRAS
investigators also found correlations between hsCRP and
plasminogen activator inhibitor, indicating interrelationships
between inflammation and hypofibrinolysis.38 Not all of these
effects are attributable to obesity, as insulin resistance per se
appears responsible for higher production of cytokines.39
Thus, because of its relation to these additional pathophysi-
ological components of risk, it has been hypothesized that
hsCRP evaluation might also add prognostic information as
an additional clinical criterion for diagnosis of the metabolic
syndrome.40
Evidence supporting this hypothesis is now available from
several major prospective studies, of which the WHS and the
West of Scotland Coronary Prevention Study (WOSCOPS)
are the largest. In the WHS, levels of hsCRP were shown to
correlate with the major components of the metabolic syn-
drome, and in univariate analyses, the finding of an hsCRP
level greater than 3 mg/L had almost identical prognostic
value in terms of cardiovascular event-free survival, as did a
full assessment of the metabolic syndrome (area under the
receiver-operating characteristic curve, 0.77 for hsCRP alone
and 0.78 for having at least 3 of 5 ATP III components of the
metabolic syndrome).34 More importantly, in this large-scale
prospective evaluation, hsCRP levels were found to add
prognostic information to the metabolic syndrome definition.
As shown in Figure 5, those who had hsCRP levels 3 mg/L
without metabolic syndrome had the best vascular survival,
whereas those who had hsCRP levels 3 mg/L with the
metabolic syndrome had the worst vascular survival.
An almost identical additive interaction between hsCRP,
metabolic syndrome, and subsequent vascular risk was ob-
served in WOSCOPS, a randomized intervention trial of
pravastatin that monitored 6447 middle-aged men over a
5-year period. In WOSCOPS, hsCRP levels above and below
3 mg/L at baseline were highly predictive of incident vascular
events after stratification by the presence or absence of the
metabolic syndrome.41 Specifically, the observed relative
risks of future coronary events in the low CRP/metabolic
syndrome–absent, high CRP/metabolic syndrome–absent,
low CRP/metabolic syndrome–present, and high CRP/meta-
bolic syndrome–present subgroups within WOSCOPS were
1.0 (referent), 1.6, 1.6, and 2.8, respectively (all P values
0.05).
Additional evidence of the interrelationships between in-
flammation and metabolic syndrome derive from 6 prospec-
tive studies that have reported hsCRP levels to predict the
onset of type 2 diabetes, often after controlling for obesity
and other diabetes-related risk factors. In the WHS, those
Figure 5. Cardiovascular event-free survival according to hsCRP
levels above or below 3 mg/L among individuals with and with-
out metabolic syndrome. Reprinted with permission from Refer-
ence 34.
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with hsCRP levels in the top quartile were more than 4 times
as likely to develop diabetes compared with those with
hsCRP levels in the lowest quartile (multivariate adjusted
relative risk, 4.2; 95% CI, 1.2 to 12.0).42 Similarly, in
WOSCOPS, those with the highest levels of hsCRP at study
entry had a 3-fold increase in risk of incident diabetes during
the 5-year follow-up period (multivariate adjusted relative
risk, 3.1; 95% CI, 1.3 to 7.1).43 Smaller but consistent effects
were observed in the Cardiovascular Health Study, which
included 5888 older individuals where the multivariate ad-
justed relative risk of incident diabetes for those with the
highest quartile of baseline hsCRP was 1.8 (95% CI, 1.2 to
2.9).44 Finally, in the MONICA cohort of 2052 middle aged
men, the Insulin Resistance Atherosclerosis Study (IRAS) of
1047 middle-aged men and women, and the Nurses Health
Study of middle-aged women, significant age-adjusted asso-
ciations between baseline hsCRP and incident diabetes were
observed.38,45,46 hsCRP levels have additionally been found to
predict cardiovascular risk among those with diabetes; in a
prospective cohort of 746 men with type 2 diabetes who were
free of cardiovascular disease at study entry, those with
hsCRP levels in the top quartile were 3 times as likely to
develop cardiovascular events even after control for all
available covariates (95% CI, 1.3 to 5.3).47
On the basis of the above observations, an argument can be
made for including hsCRP as one of the clinical criteria for the
diagnosis of the metabolic syndrome. Newly reported clinical
data support this contention. Within the WHS population, 3597
women with the ATP III criteria for the metabolic syndrome
were prospectively followed up over an 8-year period for
first-ever cardiovascular events.34 In that prospective cohort,
cardiovascular event-free survival among patients with metabol-
ic syndrome was markedly different when information on
hsCRP was taken into consideration. As shown in Figure 6,
baseline hsCRP levels 1, 1 to 3, and 3 mg/L differentiated
between low-, moderate-, and higher-risk groups among women
already identified as having metabolic syndrome by ATP III
criteria. Those with metabolic syndrome and the highest levels
of hsCRP had a relative risk of future cardiovascular events
twice that of individuals with metabolic syndrome and low
levels of hsCRP (95% CI, 1.1 to 4.2; P0.001).34
The studies above demonstrate that vascular risk prediction
and the prediction of type 2 diabetes can be improved by
knowledge of hsCRP levels, even among those with meta-
bolic syndrome. Recent studies relating hsCRP to incident
hypertension serve to reinforce the importance of blood
pressure in the metabolic syndrome complex.48,49 Whether to
formally incorporate hsCRP as one criterion for diagnosis of
metabolic syndrome is presently an area of intense debate.
The simplicity of hsCRP evaluation strengthens the argu-
ment, particularly because direct measures of insulin resis-
tance and hypofibrinolysis are difficult and formal oral
glucose tolerance testing impractical in usual outpatient
settings. From a practical standpoint, the measurement of
hsCRP at the time of triglyceride, fasting glucose, and HDL
assessment has appeal for improving metabolic syndrome
diagnosis in daily practice.
Has the Time Come to Consider hsCRP as a
Clinical Criterion for Metabolic Syndrome and as
a Formal Addition to Global Risk Prediction?
Inexpensive evaluation of hsCRP in outpatient settings is now
possible with the availability of standardized commercial
assays capable of detecting the very low levels of CRP
needed for coronary risk prediction. No circadian variation
exists for hsCRP, nor does food consumption alter plasma
levels, so there is no need for a fasting blood sample to be
obtained. Despite being an acute-phase reactant, the decade-
to-decade variation in hsCRP is similar to that of cholester-
ol,25 demonstrating long-term stability for risk prediction.
Because therapy with HMG CoA reductase inhibitors lowers
hsCRP as well as LDL cholesterol,50 many clinicians have
begun measuring hsCRP at the time of cholesterol evaluation,
using information on inflammation both to motivate patients
for lifestyle changes and to better target statin therapy.23,51
After publication of the CDC/AHA guidelines,16 outpatient
use of hsCRP increased in the United States, a change that
reflects the translation of the biology of inflammation into
daily clinical practice. Observations that hsCRP also has
predictive value in unstable angina and acute myocardial
infarction52 have additionally encouraged some emergency
room physicians to obtain hsCRP levels at the time of
hospital admission.53 Multiple clinical trials have specified
hsCRP as part of their entry criteria to identify high–cardio-
vascular risk patients.54
In consideration of the consistency of these data, we
believe the time has come to examine the possibility of incor-
porating hsCRP into the criteria for the diagnosis of metabolic
syndrome and as a risk factor in calculation of global cardiovas-
cular risk. To begin a dialogue on this issue and to better
understand the potential role of hsCRP as an adjunct to the
Framingham Risk Score, we reanalyzed data from 27 939
participants in the prospective WHS using 5 clinically defined
categorical levels of hsCRP (0.5, 0.5 to1, 1 to3, 3 to10,
and10 mg/L) and after dividing the full WHS population into
those with 10-year Framingham risks estimated as being 5%,
Figure 6. Clinical predictive value of hsCRP levels 1, 1 to 3,
and 3 g/L among individuals already defined as having meta-
bolic syndrome by ATP III criteria. Reprinted with permission
from Reference 34.
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5% to 10%, and 10% to 20%. This new analysis also takes
advantage of continued follow-up of the WHS and thus includes
685 incident hard cardiovascular events.
The results of these exploratory analyses are presented in
Figure 7. As shown, a risk gradient exists on the basis of
hsCRP levels across all levels of the Framingham Risk Score,
not only those deemed at intermediate risk as suggested by
the CDC/AHA guidelines. Risk levels increase consistently
for those at estimated 10-year Framingham Risks of 5%
and between 5% and 10% in almost the same manner as for
those with estimated 10-year Framingham risks between 10%
and 20%. These data suggest that an hsCRP-modified CHD
risk score can be calculated that may improve the overall
prediction of vascular events (Figure 7).
Thus, given the consistency of data for hsCRP observed in
analyses from the PHS, WHS, ARIC, AFCAPS/TexCAPS,
MONICA, and Reykjavik studies as well as in the Framing-
ham Heart Study itself, we believe the time has come for a
careful consideration of adding hsCRP as a clinical criterion
for metabolic syndrome and for the creation of an hsCRP-
modified CHD risk score useful for global risk prediction in
both men and women. Toward this end, we believe investi-
gators from the major prospective cohort studies as well as
experts in the fields of epidemiology, prevention, vascular
biology, and clinical cardiology should be convened to begin
discussing the merits of this proposal.
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C-Reactive Protein and the 10-Year Incidence of Coronary
Heart Disease in Older Men and Women
The Cardiovascular Health Study
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Background—High C-reactive protein (CRP) is associated with increased coronary heart disease risk. Few long-term data
in the elderly are available.
Methods and Results—Baseline CRP was measured in 3971 men and women 65 years of age without prior vascular
diseases; 26% had elevated concentrations (3 mg/L). With 10 years of follow-up, 547 participants developed coronary
heart disease (CHD; defined as myocardial infarction or coronary death). With elevated CRP, the 10-year cumulative
CHD incidences were 33% in men and 17% in women. The age-, ethnicity-, and sex-adjusted relative risk of CHD for
CRP 3 mg/L compared with 1 mg/L was 1.82 (95% CI, 1.46 to 2.28). Adjusting for conventional risk factors
reduced the relative risk to 1.45 (95% CI, 1.14 to 1.86). The population-attributable risk of CHD for elevated CRP was
11%. Risk relationships did not differ in subgroups defined by baseline risk factors. We assessed whether CRP improved
prediction by the Framingham Risk Score. Among men with a 10-year Framingham-predicted risk of 10% to 20%, the
observed CHD incidence was 32% for elevated CRP. Among women, CRP discriminated best among those with a
10-year predicted risk 20%; the incidences were 31% and 10% for elevated and normal CRP levels, respectively.
Conclusions—In older men and women, elevated CRP was associated with increased 10-year risk of CHD, regardless of
the presence or absence of cardiac risk factors. A single CRP measurement provided information beyond conventional
risk assessment, especially in intermediate-Framingham-risk men and high-Framingham-risk women. (Circulation.
2005;112:25-31.)
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Older adults are the demographic group at highest risk ofmyocardial infarction (MI). Although cardiovascular
risk factor levels in middle-aged individuals are important in
MI prediction, utility of some risk factors such as lipid
measures has been questioned among older individuals.1,2
The inflammation marker C-reactive protein (CRP) has been
reported as a risk factor for MI in several studies of initially
healthy subjects.3 In 4 studies including middle-aged sub-
jects, CRP measurement added to the predictive value of the
Framingham Risk Score or lipid determination.4–8 A consen-
sus panel reported possible roles of CRP measurement in
primary prevention, suggesting that concentrations of 1 to 3
mg/L indicate intermediate risk, levels 3 mg/L indicate
increased risk, and levels 10 mg/L might indicate other
inflammatory diseases.3 However, a recent large study re-
ported only a modest association of CRP with future coronary
heart disease (CHD), and the investigators questioned these
recommendations.9
Long-term prospective studies assessing CRP and MI in
elderly men and women are not available. In prospective
studies of elderly subjects without baseline coronary disease,
CRP was associated with short-term risk of MI or angina in
the population assessed here10 and with vascular mortality in
2 other studies11,12 but not with MI in older adults in the
Rotterdam Study13 or with acute coronary syndrome in the
Health, Aging and Body Composition cohort.14
In several studies, associations of CRP with MI were
substantially reduced by adjustment for conventional cardio-
vascular risk factors.9,15–20 Measures of subclinical athero-
sclerosis such as carotid intima-media thickness and ankle-
brachial index predict future MI, possibly because they reflect
the lifetime burden of cardiac risk factors or host response to
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risk factors.21 Adjustment for subclinical disease might pro-
vide more complete adjustment for potential confounding,
yielding new information on the independence of the associ-
ation of CRP with MI.
In this report, we analyzed baseline CRP and 10-year
incidence of first MI or CHD death in the Cardiovascular
Health Study (CHS), a cohort of men and women 65 years
of age. We assessed the recommended clinical cut points for
elevated CRP3; independence of CRP associations with CHD
from risk factors, including subclinical disease; and associa-
tions of CRP with CHD in subgroups defined by baseline risk
factors, including subclinical disease and the Framingham
Risk Score.
Methods
The CHS is an observational study of risk factors for cardiovascular
disease in 5888 men and women65 years of age who were enrolled
as 2 cohorts at 4 centers in either 1989 to 1990 or 1992 to 1993. The
first cohort consisted of 5201 primarily white participants; the
second consisted of 687 blacks. Invited participants were a random
sample of Health Care Financing Administration eligibility lists and
their household members.22 Exclusion criteria included institution-
alization, active cancer treatment, or expectation of moving from the
area within 2 years. Participants provided informed consent, and
institutional review committees approved the study methods.
Interview, lipid determination, and testing for subclinical athero-
sclerosis were completed at enrollment.22 Subclinical disease was
measured by carotid ultrasound, ECG, and ankle-brachial blood
pressure index as previously described.21 Previous vascular diag-
noses were confirmed by medical record review. In 1997, CRP was
measured in stored baseline plasma by immunoassay with a coeffi-
cient of variation of 6.2%.23,24
Baseline Definitions
Primary analysis of CHD events categorized CRP as low (1 mg/L),
intermediate (1 to 3 mg/L), or elevated (3 mg/L) to address the
utility of recent guidelines.3 CRP 10 mg/L was assessed in
secondary analyses.3 Diabetes was defined using the American
Diabetes Association criteria. Hypertension was defined as blood
pressure 140/90 mm Hg or self-reported hypertension with the use
of antihypertensive drugs. Hyperlipidemia was defined as cholesterol
6.22 mmol/L (240 mg/dL), LDL cholesterol 4.14 mmol/L (160
mg/dL), or use of medications for hyperlipidemia. Cigarette use was
categorized as never, former, or current and by number of pack-
years. Presence of subclinical vascular disease was defined as any 1
of the following: ankle-brachial index 0.9, internal or common
carotid artery wall thickness 80th percentile, carotid stenosis
25%, major ECG abnormalities, or positive response to the Rose
questionnaires for angina and claudication.21 Regular aspirin use was
defined as use during at least 7 of the previous 14 days or by
prescription. Framingham Risk Score was calculated25 and reported
as low (10%), intermediate (10% to 20%), or high (20%) 10-year
predicted risk of CHD.
Subjects Included in Analysis
We excluded 1536 participants with confirmed prebaseline cardio-
vascular disease (MI, angina, congestive heart failure, stroke, tran-
sient ischemic attack, claudication, coronary artery bypass surgery,
angioplasty, carotid endarterectomy; 715 women, 821 men). Of the
remaining women, 326 using oral postmenopausal hormones were
excluded because users have higher CRP concentrations with uncer-
tain clinical consequence.26,27 Fifty-five subjects did not have CRP
levels available. Exclusions yielded 3971 participants.
Events Ascertainment
Subjects were followed up every 6 months by alternating field center
visits and telephone calls between enrollment and June 30, 2000.
Vascular outcomes were ascertained by self-report and review of
discharge codes for all hospitalizations. For suspected coronary
events, medical records were abstracted and then reviewed and
classified by a committee using standardized criteria.28,29 CHD death
was defined as the absence of nonatherosclerotic cause of death and
1 or both of the following: chest pain within 72 hours of death or
history of chronic ischemic heart disease in the absence of valvular
heart disease or nonischemic cardiomyopathy.
Statistical Analysis
The SPSS package was used for analysis with a CHS database
updated November 18, 2002. Associations of CRP with risk factors
were assessed by tests for trend across categories of CRP through the
use of 2 statistics or ANOVA. When indicated, CRP was log
transformed and described by its geometric mean. Incidence rates of
CHD by CRP category were calculated separately for men and
women and within categories of the Framingham Risk Score. Cox
proportional-hazards models were used to compute hazard ratios as
estimates of relative risk of CHD with increasing category of CRP
with adjustment for age, sex, and race in all participants and in
subgroups defined by known risk factors. Censoring occurred at
death, last follow-up, or June 30, 2000, whichever occurred first.
Differences in findings by sex, race, and presence or absence of
vascular risk factors were evaluated formally by adding interaction
terms of each for these factors with CRP to the model (P0.05
indicated significance). To determine whether CRP remained pre-
dictive after adjustment for known risk factors, 2 additional levels of
adjustment were considered. First, models were additionally adjusted
for field center and the risk factors related to CRP or MI: hyperten-
sion, diabetes, smoking status, pack-years of smoking, body mass
index, waist circumference, total and HDL cholesterol, and regular
aspirin use. Second, subclinical atherosclerosis measures were added
to the models.
Results
Among 3971 participants, 29% had CRP 1.0 mg/L, 45%
had levels of 1 to 3 mg/L, and 26% had elevated values (3
mg/L). The median CRP was 1.76 mg/L (interquartile range,
0.88 to 3.10 mg/L). Associations of CRP with risk factors and
subclinical and clinical cardiovascular disease are shown in
Table 1. CRP was higher among women and blacks and with
obesity, aspirin use, lower HDL cholesterol, hypertension,
diabetes, smoking, and pack-years. CRP was higher with than
without subclinical disease, with geometric mean values of
1.64 mg/L without subclinical disease and 1.98 mg/L with
subclinical disease (P0.001).
With 10 years of follow-up, there were 547 first MI or
CHD deaths (354 nonfatal MI, 41 fatal MI, and 152 CHD
deaths). Incidence rates were 22.2 and 12.0 per 1000 person-
years in men and women, respectively. Figure 1 shows the
cumulative incidence of CHD by gender and baseline CRP.
There was little difference between participants with low and
intermediate CRP levels, but for those with elevated CRP, the
incidence was higher, with a 10-year cumulative incidence of
33% in men and 17% in women. Figure 2 shows the
incidence of CHD over the full range of CRP values,
demonstrating an increase in risk throughout the range.
Incidence rates and relative risks of CHD by baseline CRP
categories are shown in Table 2. Incidence increased with
each higher CRP category. Age, sex, and race-adjusted
relative risks of CHD were slightly increased for intermediate
CRP and were nearly doubled for CRP3 mg/L. Adjustment
for other risk factors attenuated these relative risks, leaving
little association with CHD for CRP 1 to 3 mg/L and a 45%
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increased risk for CRP 3 mg/L. There was no effect of
additional adjustment for baseline statin use. Further adjust-
ment for subclinical disease yielded little attenuation; a 37%
increased risk of CHD for elevated CRP remained. When
CRP was considered a continuous variable, with adjustment
for risk factors, the relative risk associated with a 1-ln-unit-
higher baseline CRP was 1.27 (95% CI, 1.12 to 1.44). There
were no significant differences in associations by sex or race.
The population-attributable risk percentage for elevated CRP
was 11%.
Table 3 shows the relative risks of incident CHD for CRP
3 mg/L compared with CRP 1 mg/L in subgroups based
on the presence or absence of cardiovascular risk factors.
Baseline CRP was associated with CHD in all of these
groups, including those without subclinical disease and those
at low risk by the Framingham Risk Score (P for interaction
0.05 for all). Although the relative risk did not differ by
subclinical disease status, among men and women, the
presence of elevated CRP together with subclinical disease
was associated with a higher incidence of CHD compared
with those with lower CRP and no subclinical disease
(Figure 3).
Figure 4 shows the 10-year sex-specific incidence of CHD
according to CRP concentration in categories of the Framing-
ham Risk Score. In intermediate- and low-risk women, CRP
3 mg/L added little to risk prediction, whereas in high-risk
women, CRP provided additional risk information. Among
women with a 10-year predicted risk 20%, for intermediate
or elevated CRP, the observed incidences were 28%, and
31%, respectively, compared with only 16% for those with
low CRP. In men, CRP provided additional risk information
in intermediate- and high-Framingham-risk groups. Among
men with a 10-year predicted risk 10% to 20%, those with
CRP 3 mg/L had an observed risk of 32%. Among
high-Framingham-risk men, this observed risk was 41%.
We investigated the utility of CRP 10 mg/L for deter-
mining risk of CHD and the impact of hormone replacement
therapy among women. Of participants with elevated CRP,
22% were 10 mg/L. Of these 233 participants, 49 (21%)
developed CHD during follow-up compared with 498 of 3738
(13.3%) with lower CRP. The age-, sex-, and race-adjusted
relative risk of CHD was 2.16 (95% CI, 1.55 to 3.00) for CRP
10 compared with 1 mg/L and 1.78 (95% CI, 1.26 to
2.51) after adjustment for traditional risk factors. Among 326
TABLE 1. Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration
CRP, mg/L
1
(n1144)
1–3
(n1783)
3–10
(n811)
10
(n233)
P for
Trend
Continuous variables
Age, y 72.9 72.4 72.4 72.6 0.16
Body mass index, kg/m2 24.7 26.8 28.6 29.0 0.001
Waist, cm 89.5 94.7 99.1 100.2 0.001
LDL cholesterol, mmol/L (mg/dL) 3.29 (127) 3.47 (134) 3.44 (133) 3.23 (125) 0.21
HDL cholesterol, mmol/L (mg/dL) 1.50 (58) 1.40 (54) 1.35 (52) 1.32 (51) 0.001
Total cholesterol, mmol/L (mg/dL) 5.41 (209) 5.57 (215) 5.54 (214) 5.18 (200) 0.67
Pack-years (among ever smokers) 29.0 32.6 36.8 36.7 0.001
Categorical variables, %
Male sex 43.4 42.5 37.0 41.2 0.02
Black race 10.9 13.5 20.0 29.2 0.001
Hypertension 46.7 56.5 64.6 66.5 0.001
Diabetes
IFG 11.2 14.0 16.9 19.4
Diabetes 8.2 13.7 21.8 25.0 0.001
Smoking status
Former 40.9 38.8 40.8 41.2
Current 8.5 11.9 16.6 20.2 0.001
Regular aspirin use 19.2 19.1 22.5 20.2 0.17
Any subclinical cardiovascular disease 55.8 63.3 67.8 69.1 0.001
Ankle-arm index 0.9 6.7 9.3 14.4 13.2 0.001
Carotid intima-media thickness 80th percentile 23.1 30.3 35.1 36.1 0.001
Major ECG abnormality 19.7 23.9 25.0 25.6 0.004
Carotid stenosis 25% 39.4 43.8 47.7 50.4 0.001
Rose angina positive 3.1 2.4 2.6 4.3 0.78
Rose claudication positive 0.6 1.0 1.7 2.6 0.002
IFG indicates impaired fasting glucose. Values for continuous variables are means.
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women excluded from analysis for hormone replacement
therapy use, the age-adjusted relative risk of CHD for CRP
3 mg/L was 1.35 (95% CI, 0.42 to 4.32).
Discussion
In this 10-year prospective study in men and women 65
years of age, CHD risk increased with increasing CRP. When
recent clinical guidelines were applied, intermediate CRP
concentrations (1 to 3 mg/L) were weakly related to future
CHD, and elevated CRP (3.0 mg/L) was associated with a
1.45-fold increased risk of CHD, with adjustment for other
vascular risk factors. There was little further confounding
with adjustment for the presence of noninvasively assessed
subclinical atherosclerosis. Elevated CRP was associated
with CHD in all subgroups defined by conventional cardiac
risk factors or subclinical disease. Among men with interme-
diate and high Framingham Risk Scores, CRP identified those
with higher-than-predicted risk. Among women, CRP dis-
criminated risk best among those at high Framingham-
predicted risk.
The relative risk of CHD for elevated CRP observed here
was smaller than in most studies of middle-aged subjects and
might seem modest at 1.45. However, event rates were high
in this age group, so the attributable risk percent for elevated
CRP was high at 11%, even given a modest relative risk.30
Thus, a much higher percentage of subjects with elevated
CRP subsequently had events in this study compared with
studies of younger subjects.7,8 In a recent report by Danesh et
Figure 2. Incidence rate per 1000 person-years of MI or CHD
death by baseline CRP. Incidence rates were calculated within
small intervals of CRP values and plotted with a scatterplot
smoother. Association was well fit by a quadratic function of
CRP, plotted with 95% confidence bands.
TABLE 2. Association of Baseline CRP With Incident MI or CHD Death Over 10 Years*
Relative Risk (95% CI) in CRP Categories
1.0 mg/L
(N1144, n135)
1.0–3.0 mg/L
(N1783, n230)
3.0 mg/L
(N1044, n182) P
Incidence rate, %
(n of events)
Men 17.1 (74) 20.6 (127) 33.3 (96)
Women 10.4 (61) 11.0 (103) 15.5 (86)
Model 1 1.0 (ref) 1.18 (0.96–1.46) 1.82 (1.46–2.28) 0.001
Model 2 1.0 (ref) 1.08 (0.86–1.35) 1.45 (1.14–1.86) 0.004
Model 3 1.0 (ref) 1.04 (0.82–1.31) 1.37 (1.06–1.78) 0.01
N is number at risk in given group; n, number of cases in given group; and ref, reference.
*Model 1 is adjusted for age, race, and sex. Model 2 is adjusted for age, sex, race, field center, hypertension,
diabetes, smoking status, log pack-years, body mass index, waist circumference, total cholesterol, HDL cholesterol,
and regular aspirin use. Model 3 is adjusted for model 2 variables plus ankle-arm index 0.9, internal or common
carotid intima-media thickness 80th percentile, positive responses to the Rose angina or claudication question-
naires, major ECG abnormalities, and maximum stenosis of the carotid artery 25%.
Figure 1. Cumulative rate of MI or CHD death. Top, data for
men; bottom, data for women. Unadjusted hazard ratios and
95% CIs for each group compared with reference group (CRP
1 mg/L) are shown. Solid line indicates CRP 1 mg/L; dotted
line, CRP 1 to 3 mg/L; and dashed line, CRP 3 mg/L.
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al,9 a similar adjusted relative risk was observed in a large
population, but in that case-control study, attributable risk
was not estimated. If elevated CRP represents a causal risk
factor as suggested by several experimental studies,31 our
estimate of attributable risk indicates a hypothesis that cor-
rection of elevated CRP could eliminate up to 11% of
incident CHD in this age group.
It has been suggested that novel risk factors or atheroscle-
rosis imaging may identify those at intermediate CHD risk
who might benefit from aggressive risk factor interventions.32
Along with findings in middle-aged populations,7,8 our data
provide evidence that CRP assessment can identify older
patients at higher or lower than their predicted risk of
coronary events. Our findings with regard to women at low
and intermediate risk differ from findings in middle-aged
women in which CRP predicted cardiovascular events across
the entire range of Framingham Risk Scores.33 Further work
is needed to validate our findings in this age group and to
determine appropriate values defining elevated CRP in vari-
ous age and sex groups.
Other studies reported weak or no associations of CRP
with subclinical disease measures.34–38 Here, in the absence
of clinical disease, CRP was higher among those with any
single type of subclinical disease. Moreover, CHD incidence
was higher among those with elevated CRP and subclinical
disease compared with groups with only 1 or neither of these
risk factors. In this cohort, the 10-year stroke risk associated
with elevated CRP was larger among those with higher
compared with lower carotid intima-media thickness.39 In a
short-term study, the risk of MI was higher among those with
higher coronary artery calcium scores if CRP was also
elevated.40 Taken together, findings from these few studies
suggest possible roles for the assessment of both inflamma-
tion and subclinical disease. It is also possible that CRP is a
marker of subclinical disease, and if better measures of
subclinical disease were available, adjustment for subclinical
disease would further lessen the association of CRP with
CHD.
The CDC/AHA guideline for CRP testing suggest that
values 10 mg/L indicate acute inflammation and have
uncertain implications for vascular risk prediction.3 In this
older population, 6% of subjects had CRP 10 mg/L; when
traditional risk factors were accounted for, these subjects had
a 1.8-fold increased risk of CHD, a higher risk estimate than
Figure 3. Incidence rates per 1000
person-years of first MI or CHD death by
baseline CRP, stratified by sex and pres-
ence of subclinical atherosclerosis.
TABLE 3. Relative Risk of CHD for CRP >3 mg/L Compared With <1 mg/L by Categories of Baseline
Risk Factors
Risk Factor Present Risk Factor Absent
Risk Factor n/N RR* (95% CI) n/N RR* (95% CI)
Smoking (formercurrent) 307/2076 1.84 (1.37–2.47) 240/1890 1.68 (1.18–2.40)
Pack-years (median; ever smokers only) 171/967 2.13 (1.40–3.25) 120/1000 1.61 (1.02–2.53)
Hypertension 365/2219 1.74 (1.32–2.29) 182/1748 1.55 (1.04–2.32)
Diabetes or impaired fasting glucose 213/1130 1.49 (1.02–2.18) 334/2833 1.74 (1.30–2.32)
Hyperlipidemia 139/966 1.99 (1.25–3.19) 404/2971 1.74 (1.34–2.26)
Regular aspirin use 123/788 1.89 (1.17–3.05) 423/3176 1.79 (1.39–2.31)
Estimated 10-year Framingham Risk Score 20% 181/772 2.00 (1.28–3.13) 357/3127 1.51 (1.15–1.98)
Subclinical disease 417/2477 1.85 (1.42–2.42) 130/1494 1.42 (0.91–2.22)
Carotid wall thickness 80th percentile 250/1167 1.56 (1.11–2.20) 293/2784 1.71 (1.26–2.32)
Ankle-arm index 0.9 95/381 1.45 (0.82–2.59) 443/3514 1.78 (1.39–2.28)
Carotid stenosis 25% 315/1726 1.68 (1.25–2.25) 230/2223 1.74 (1.22–2.47)
Major ECG abnormality 177/886 1.73 (1.15–2.61) 355/2963 1.81 (1.38–2.38)
n/N indicates number of events/number at risk in all 3 levels of CRP in specified category of each risk factor.
*Adjusted for age, race, and sex.
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for CRP 3.0 mg/L. Our finding agrees with recently
reported results in middle-aged women.33 Thus, CRP values
10 mg/L appear to be important in CHD risk prediction.
Limitations of this study merit consideration. The cohort,
free-living elderly who were willing to enroll in the study,
may not represent the general older population. The observa-
tional study design, even with extensive multivariate analysis,
cannot prove causal relationships. Competing risks may have
diluted associations of CRP with CHD because CRP may be
associated with other disease outcomes. In some cases,
analysis of subgroups was limited by small sample sizes.
Finally, CRP was measured only once at baseline, and it has
been suggested that repeated testing for confirmation be
considered in those with high values.3
Strengths of this study include its large size, extensive
baseline data collection, and long-term event follow-up.
Several new findings were observed on the basis of unique
aspects of the study. First, we confirmed an association of
elevated CRP with CHD incidence in an older age group;
most previous studies included younger subjects or clinical
trial participants. Second, independence of associations from
noninvasively measured subclinical atherosclerosis was doc-
umented. Third, more complete adjustment for smoking
status was made by assessing pack-years, a major determinant
of CRP concentration in smokers.34 Fourth, because CRP was
measured in the whole cohort, incidence rates of CHD by
baseline CRP were calculated, and subgroup analyses could
be done.
In conclusion, we extend previous reports on the associa-
tion of CRP with CHD to men and women 65 years of age.
CRP appears to be useful for risk assessment in this age
group. Because event rates are high overall in older age,
further study is required to determine optimal clinical roles of
CRP measurement, especially as related to interventions for
elevated CRP.
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C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
 
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL LEVELS IN THE PREDICTION
OF FIRST CARDIOVASCULAR EVENTS
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BSTRACT
 
Background
 
Both C-reactive protein and low-den-
sity lipoprotein (LDL) cholesterol levels are elevated
in persons at risk for cardiovascular events. However,
population-based data directly comparing these two
biologic markers are not available.
 
Methods
 
C-reactive protein and LDL cholesterol
were measured at base line in 27,939 apparently
healthy American women, who were then followed
for a mean of eight years for the occurrence of myo-
cardial infarction, ischemic stroke, coronary revascu-
larization, or death from cardiovascular causes. We
assessed the value of these two measurements in pre-
dicting the risk of cardiovascular events in the study
population.
 
Results
 
Although C-reactive protein and LDL cho-
lesterol were minimally correlated (r=0.08), base-line
levels of each had a strong linear relation with the in-
cidence of cardiovascular events. After adjustment for
age, smoking status, the presence or absence of diabe-
tes mellitus, categorical levels of blood pressure, and
use or nonuse of hormone-replacement therapy, the
relative risks of first cardiovascular events according
to increasing quintiles of C-reactive protein, as com-
pared with the women in the lowest quintile, were 1.4,
1.6, 2.0, and 2.3 (P<0.001), whereas the corresponding
relative risks in increasing quintiles of LDL cholesterol,
as compared with the lowest, were 0.9, 1.1, 1.3, and 1.5
(P<0.001). Similar effects were observed in separate
analyses of each component of the composite end
point and among users and nonusers of hormone-
replacement therapy. Overall, 77 percent of all events
occurred among women with LDL cholesterol levels
below 160 mg per deciliter (4.14 mmol per liter), and
46 percent occurred among those with LDL choles-
terol levels below 130 mg per deciliter (3.36 mmol per
liter). By contrast, because C-reactive protein and LDL
cholesterol measurements tended to identify different
high-risk groups, screening for both biologic markers
provided better prognostic information than screen-
ing for either alone. Independent effects were also
observed for C-reactive protein in analyses adjusted
for all components of the Framingham risk score.
 
Conclusions
 
These data suggest that the C-reactive
protein level is a stronger predictor of cardiovascular
events than the LDL cholesterol level and that it adds
prognostic information to that conveyed by the Fra-
mingham risk score. (N Engl J Med 2002;347:1557-65.)
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ECAUSE of its critical importance in ather-
ogenesis, low-density lipoprotein (LDL) cho-
lesterol is the focus of current guidelines for
the determination of the risk of cardiovascu-
lar disease.
 
1
 
 However, atherothrombosis often occurs
in the absence of hyperlipidemia, and recent consen-
sus panels assembled by the National Heart, Lung, and
Blood Institute and the Centers for Disease Control
and Prevention have concluded that population-based
data on other risk factors are urgently needed.
 
2,3
 
Among the biologic markers considered by those
panels, there was particular interest in C-reactive pro-
tein, a marker of inflammation that has been shown in
several prospective, nested case–control studies to be
associated with an increased risk of myocardial infarc-
tion,
 
4-9
 
 stroke,
 
4,6,10,11
 
 sudden death from cardiac caus-
es,
 
12
 
 and peripheral arterial disease.
 
13
 
 Although the
results of these studies are highly consistent, limita-
tions inherent in the design of nested case–control
studies make it difficult to assess the relative merit of
C-reactive protein. In particular, population-based cut-
off points for C-reactive protein remain uncertain,
and reliable data describing receiver-operating-char-
acteristic curves for C-reactive protein have not been
available. Moreover, there are insufficient data from
prospective cohort studies directly comparing the pre-
dictive value of  C-reactive protein with that of LDL
cholesterol.
In a previous hypothesis-generating report limited
to 122 women in whom cardiovascular disease devel-
oped (case patients) and 244 controls who were par-
ticipants in the Women’s Health Study, we observed
that several markers of inflammation, including C-reac-
tive protein, had prognostic value for the detection of
first vascular events over a three-year period.
 
6
 
 Howev-
er, the relatively small number of events and the short
follow-up limit the reliability of those data. Further-
more, because of the matched-pairs case–control study
design, we were unable to define general population-
B
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based cutoff points or to evaluate directly characteris-
tics of C-reactive protein used as a diagnostic test.
To overcome these limitations, we measured
C-reactive protein and LDL cholesterol in all
27,939 participants in the Women’s Health Study
who provided usable base-line blood samples; these
women had been followed for a mean of eight years.
Using these data, we were able to calculate survival
curves associated with C-reactive protein levels, to
compare the predictive value of C-reactive protein and
LDL cholesterol directly in a large, representative pop-
ulation sample, and to define the population distribu-
tion of C-reactive protein levels. We also determined
the predictive value of each biologic marker among
users and nonusers of hormone-replacement therapy;
this is a clinically relevant issue, since hormone-replace-
ment therapy affects levels of both C-reactive protein
and LDL cholesterol.
 
14-16
 
 Finally, we evaluated wheth-
er C-reactive protein provided prognostic information
on risk after adjustment for all components of the Fra-
mingham risk score.
 
METHODS
 
Study Design
 
The Women’s Health Study is an ongoing evaluation of aspirin
and vitamin E for the primary prevention of cardiovascular events
among women 45 years of age or older. Participants were enrolled
between November 1992 and July 1995, at which time they pro-
vided information regarding demographic, behavioral, and lifestyle
factors. All participants were followed for the occurrence of first
cardiovascular events, including nonfatal myocardial infarction, non-
fatal ischemic stroke, coronary revascularization procedures, and
death from cardiovascular causes. The occurrence of myocardial in-
farction was considered confirmed if symptoms met the criteria of
the World Health Organization and if the event was associated with
abnormal levels of cardiac enzymes or diagnostic electrocardio-
graphic criteria. Stroke was confirmed if the participant had new
neurologic deficits that persisted for more than 24 hours. Comput-
ed tomographic scans or magnetic resonance images were available
for the great majority of events and were used to distinguish hem-
orrhagic from ischemic events. The performance of either percuta-
neous coronary revascularization or coronary-artery bypass surgery
was confirmed by a review of hospital records. Deaths from cardio-
vascular causes were confirmed by review of autopsy reports, death
certificates, medical records, and information obtained from family
members.
Before randomization, blood samples were collected in tubes con-
taining EDTA from 28,345 study participants and stored in liquid
nitrogen until the time of analysis. Samples were then transferred
to a core laboratory facility, where they were assayed for C-reactive
protein with a validated, high-sensitivity assay (Denka Seiken) and
for LDL cholesterol with a direct-measurement assay (Roche Di-
agnostics). This laboratory is certified for the  measurement of lip-
ids and is a core facility for ongoing standardization programs re-
garding the measurement of C-reactive protein. Of the samples
received, 27,939 could be evaluated and were assayed for C-reactive
protein and LDL cholesterol.
 
Statistical Analysis
 
Because hormone-replacement therapy affects levels of C-reactive
protein and LDL cholesterol, we first established population-based
distributions for each analyte among the 15,745 women who were
not taking hormone-replacement therapy at study entry — a method
consistent with the guidelines of the Department of Health and Hu-
man Services for lipid standardization.
 
17
 
 We then divided these pop-
ulation data into increasing quintiles with respect to C-reactive pro-
tein and LDL cholesterol and constructed Kaplan–Meier curves for
event-free survival. The relative risks of new cardiovascular events
were computed for quintiles 2 through 5, as compared with the low-
est quintile, in both crude Cox proportional-hazards models and
models adjusted for risk factors. Stratified analyses were used to ad-
dress the predictive value of LDL cholesterol and C-reactive protein
among users and nonusers of hormone-replacement therapy at base
line. To evaluate whether different cutoff points might affect the risk
estimates for users of hormone-replacement therapy, we repeated the
analysis among users with cutoff points for C-reactive protein and
LDL cholesterol defined by the values in the 12,139 women who
were using hormone-replacement therapy at base line. The 55 wom-
en for whom hormone-replacement status was unknown were ex-
cluded from the stratified analyses.
To estimate the discriminative value of predictive models, we cal-
culated the C statistic on the basis of the minimal follow-up time
of six years for both C-reactive protein and LDL cholesterol in
crude and risk-factor–adjusted models. This statistic is analogous
to the area under the receiver-operating-characteristic curve.
 
18
 
 To
compute the C statistic, we compared each woman’s status with re-
spect to cardiovascular disease (present or absent) at six years with
the predicted six-year probability of event-free survival, estimated
from the Cox proportional-hazards model. Subjects whose data
were censored before six years of follow-up (less than 1 percent)
were excluded from this calculation.
We tested for trend across the quintiles of C-reactive protein or
LDL cholesterol by entering a single ordinal term for the quintile
in the Cox regression model. In addition, we tested for deviation
from linearity by comparing models containing quintile indicators
with those containing a linear term in a likelihood-ratio test with
3 degrees of freedom. We also tested the additional prognostic
 
*To convert values for LDL cholesterol to millimoles per liter, multiply
by 0.02586.
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milligrams per liter
 
C-reactive
protein
 
45–54 yr 10,075 0.17 0.25 0.52 1.31 3.18 6.15 8.80
55–64 yr 3,604 0.25 0.39 0.82 1.89 4.12 7.47 9.76
65–74 yr 1,862 0.33 0.46 0.91 1.99 3.92 6.79 8.77
»75 yr 204 0.29 0.43 0.80 1.52 3.55 7.56 13.33
Total 15,745 0.19 0.29 0.61 1.52 3.48 6.61 9.14
 
milligrams per deciliter*
 
LDL
cholesterol
 
45–54 yr 10,075 72.7 82.1 97.6 117.3 139.6 162.5 178.2
55–64 yr 3,604 83.4 94.9 113.4 134.4 158.8 181.9 198.3
65–74 yr 1,862 86.4 97.0 115.1 137.0 157.9 183.5 199.3
»75 yr 204 91.2 100.4 117.3 139.3 159.6 178.4 189.4
Total 15,745 75.8 85.3 102.4 123.7 147.4 170.5 187.2
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contribution of quintiles of C-reactive protein or LDL cholesterol
to models containing the other variable with a likelihood-ratio test
with 4 degrees of freedom.
To evaluate joint effects, we repeated the analyses after classifying
all study participants in one of four groups on the basis of whether
their C-reactive protein and LDL cholesterol levels were above or
below the respective study medians. Finally, using these data, we
assessed whether C-reactive protein had independent predictive
value after simultaneous adjustment for all components of the Fra-
mingham risk score
 
19
 
 (including age, smoking status, categorical lev-
els of blood pressure, presence or absence of diabetes mellitus, and
high-density lipoprotein and LDL cholesterol levels) and whether
C-reactive protein contributed information on risk beyond that
conveyed by the 10-year risk calculated with the Framingham risk
score and beyond the risk associated with LDL cholesterol, as de-
fined by current guidelines.
 
1
 
 All P values are two-tailed, and 95 per-
cent confidence intervals were calculated.
 
RESULTS
 
Base-Line Characteristics
 
The mean age of the 27,939 women at base line was
54.7 years. Forty-four percent were current users of
hormone-replacement therapy, 25 percent had hyper-
tension, 12 percent were current smokers, and 2.5
percent had diabetes mellitus. The mean body-mass
index (the weight in kilograms divided by the square
of the height in meters) was 25.9.
 
Distribution of C-Reactive Protein 
and LDL Cholesterol Levels
 
Table 1 presents data on the distribution of C-reac-
tive protein and LDL cholesterol values among the
 
Figure 1.
 
 Event-free Survival According to Base-Line Quintiles of C-Reactive Protein and LDL Cholesterol.
The range of values for C-reactive protein was as follows: first quintile, «0.49 mg per liter; second quintile, >0.49 to 1.08 mg per liter;
third quintile, >1.08 to 2.09 mg per liter; fourth quintile, >2.09 to 4.19 mg per liter; fifth quintile, >4.19 mg per liter. For LDL cholesterol,
the values were as follows: first quintile, «97.6 mg per deciliter; second quintile, >97.6 to 115.4 mg per deciliter; third quintile,
>115.4 to 132.2 mg per deciliter; fourth quintile, >132.2 to 153.9 mg per deciliter; fifth quintile, >153.9 mg per deciliter. To convert
values for LDL cholesterol to millimoles per liter, multiply by 0.02586. Note the expanded scale on the ordinate.
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15,745 women who were not using hormone-replace-
ment therapy at the time of blood collection. These
distributions are very similar to those reported for men
and women in previous U.S. and European studies. On
the basis of this sample, the cutoff points for quintiles
of C-reactive protein were less than or equal to 0.49,
more than 0.49 to 1.08, more than 1.08 to 2.09, more
than 2.09 to 4.19, and more than 4.19 mg per liter.
 
Event-free Survival
 
The probability of event-free survival for all study
participants is presented in Figure 1 according to base-
line quintiles of C-reactive protein and LDL choles-
terol. Table 2 presents crude relative risks of a first
cardiovascular event according to increasing quintiles
of base-line C-reactive protein and LDL cholesterol,
along with relative risks adjusted for age and other
risk factors. For both C-reactive protein and LDL cho-
lesterol, strong linear risk gradients were observed.
After adjustment for age, smoking status, the presence
or absence of diabetes, blood pressure, and use or non-
use of hormone-replacement therapy, the multivari-
able relative risks of a first cardiovascular event for
women in increasing quintiles of C-reactive protein
were 1.0 (the first quintile was the reference category),
1.4, 1.6, 2.0, and 2.3 (P<0.001), whereas the relative
risks associated with increasing quintiles of LDL cho-
lesterol were 1.0 (the first quintile was the reference
category), 0.9, 1.1, 1.3, and 1.5 (P<0.001). No signif-
icant deviations from linearity in the log relative risks
were detected in either model. The apparent superi-
ority of C-reactive protein over LDL cholesterol in
terms of the prediction of risk was observed in sim-
ilar analyses of the individual components of the com-
posite end point (coronary heart disease, stroke, and
death from cardiovascular causes) (Fig. 2).
 
Predictive Models
 
Table 2 also presents results of the C statistic analy-
ses (area under the receiver-operating-characteristic
curve). In models of crude rates including the entire
cohort (27,939 women), the calculated area under the
receiver-operating-characteristic curve was 0.64 for
C-reactive protein and 0.60 for LDL cholesterol. In
prediction models including age, smoking status, pres-
ence or absence of diabetes, blood pressure, use or
nonuse of hormone-replacement therapy, and treat-
ment assignment, the ability of the model based on
C-reactive protein to discriminate events from non-
events was virtually identical to that of the model
based on LDL cholesterol (C statistic for both mod-
els, 0.81). However, the likelihood-ratio chi-square
statistic was higher for the model based on C-reactive
protein than for that based on LDL cholesterol (716.4
vs. 706.0, both with 16 df ). This statistic, a more sen-
sitive measure of model fit than the rank-based C sta-
tistic, suggests that the model based on C-reactive pro-
tein has better discrimination than the model based
on LDL cholesterol. In addition, in likelihood-ratio
tests of the contribution of each variable, the addition
of C-reactive protein to the model based on LDL
cholesterol was stronger (chi-square=25.4, 4 df;
 
*P values are for tests of trend across quintiles. ROC denotes receiver operating characteristic, and CI confidence interval. Risk-factor–
adjusted relative risks have been adjusted for age, smoking status, the presence or absence of diabetes mellitus, blood pressure, and use or nonuse
of hormone-replacement therapy. All models have been adjusted for treatment assignment. For all relative risks, the reference category is the first
quintile. To convert values for LDL cholesterol to millimoles per liter, multiply by 0.02586.
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VALUE
AREA UNDER
ROC CURVE
Crude relative risk (95% CI) 1.0 1.8 (1.1–2.7) 2.3 (1.5–3.4) 3.2 (2.2–4.8) 4.5 (3.1–6.6) <0.001 0.64
Age-adjusted relative risk (95% CI) 1.0 1.5 (1.0–2.4) 1.8 (1.2–2.8) 2.5 (1.7–3.7) 3.6 (2.5–5.2) <0.001 0.74
Risk-factor–adjusted relative risk
(95% CI)
1.0 1.4 (0.9–2.2) 1.6 (1.1–2.4) 2.0 (1.3–3.0) 2.3 (1.6–3.4) <0.001 0.81
QUINTILE OF LDL CHOLESTEROL
1
(«97.6
mg/dl)
2
(>97.6–115.4
mg/dl)
3
(>115.4–132.2
mg/dl)
4
(>132.2–153.9
mg/dl)
5
(>153.9
mg/dl) P VALUE
AREA UNDER
ROC CURVE
Crude relative risk (95% CI) 1.0 1.0 (0.8–1.4) 1.3 (1.0–1.8) 1.8 (1.4–2.4) 2.2 (1.7–2.9) <0.001 0.60
Age-adjusted relative risk (95% CI) 1.0 0.9 (0.7–1.3) 1.1 (0.9–1.5) 1.5 (1.1–1.9) 1.7 (1.3–2.2) <0.001 0.73
Risk-factor–adjusted relative risk
(95% CI)
1.0 0.9 (0.7–1.2) 1.1 (0.8–1.4) 1.3 (1.0–1.7) 1.5 (1.1–2.0) <0.001 0.81
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P< 0.001) than the addition of LDL cholesterol to
the model based on C-reactive protein (chi-square=
15.0, 4 df; P=0.005).
Effects of Hormone-Replacement Therapy
Table 3 presents stratified analyses according to
the use or nonuse of hormone-replacement therapy
at base line. Among women who did not use hormone-
replacement therapy, the multivariable-adjusted rel-
ative risks of a first cardiovascular event in increasing
quintiles of C-reactive protein were 1.0, 1.8, 1.8, 2.4,
and 3.0 (P<0.001), whereas the multivariable-adjust-
ed relative risks in increasing quintiles of LDL choles-
terol were 1.0, 0.8, 0.9, 1.1, and 1.4 (P=0.002). Among
users of hormone-replacement therapy, risk estimates
were lower for both C-reactive protein and LDL cho-
lesterol but remained significant in crude and age-
adjusted models. Risk estimates based on C-reactive
protein among users of hormone-replacement therapy
were similar regardless of whether the quintiles were
defined by measurements in nonusers or users of hor-
mone-replacement therapy.
Interactions between C-Reactive Protein 
and LDL Cholesterol
Of all events in the study participants, 77 percent
occurred among those with LDL cholesterol levels
below 160 mg per deciliter (4.14 mmol per liter), and
46 percent occurred among those with LDL choles-
terol levels below 130 mg per deciliter (3.36 mmol
per liter). However, C-reactive protein and LDL cho-
lesterol levels were minimally correlated (r=0.08),
suggesting that each biologic marker was detecting
a different high-risk group. We therefore constructed
survival curves after dividing the study participants
into four groups on the basis of whether they were
Figure 2. Age-Adjusted Relative Risk of Future Cardiovascular Events, According to Base-Line C-Reactive Protein Levels (Solid Bars)
and LDL Cholesterol Levels (Open Bars).
5.0
4.0
3.0
2.0
1.0
0.0
53 421
Quintile
All Cardiovascular Events (n=571)
R
el
at
iv
e 
R
is
k
5.0
4.0
3.0
2.0
1.0
0.0
53 421
Quintile
Coronary Heart Disease (n=371)
R
el
at
iv
e 
R
is
k
5.0
4.0
3.0
2.0
1.0
0.0
53 421
Quintile
Ischemic Stroke (n=158)
R
el
at
iv
e 
R
is
k
5.0
4.0
3.0
2.0
1.0
0.0
53 421
Quintile
Cardiovascular Death (n=80)
R
el
at
iv
e 
R
is
k
Downloaded from www.nejm.org on December 18, 2006 . Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
1562 · N Engl J Med, Vol. 347, No. 20 · November 14, 2002 · www.nejm.org
The New England Journal  of  Medicine
above or below the median C-reactive protein value
(1.52 mg per liter) and the median LDL cholesterol
value (123.7 mg per deciliter [3.20 mmol per liter]).
For the entire cohort (Fig. 3), the multivariable-adjust-
ed relative risks were as follows: low C-reactive pro-
tein–low LDL cholesterol, 1.0 (this was the reference
category); low C-reactive protein–high LDL choles-
terol, 1.5 (95 percent confidence interval, 1.0 to 2.1);
high C-reactive protein–low LDL cholesterol, 1.5 (95
percent confidence interval, 1.1 to 2.1); and high
C-reactive protein–high LDL cholesterol, 2.1 (95 per-
cent confidence interval, 1.5 to 2.8).  The correspond-
ing age-adjusted rates of events per 1000 person-years
of follow-up were 1.3, 2.0, 2.6, and 3.9, respectively.
On the assumption that recent evidence from clin-
ical trials will lead to a marked reduction in the use
of hormone-replacement therapy among American
women,20 we sought to increase the generalizability of
our findings by repeating these analyses including only
the 15,745 women who were not using hormone-
replacement therapy at base line. In this analysis, the
multivariable-adjusted relative risks were as follows:
low C-reactive protein–low LDL cholesterol, 1.0 (the
reference category); low C-reactive protein–high LDL
cholesterol, 1.5 (95 percent confidence interval, 1.0 to
2.4); high C-reactive protein–low LDL cholesterol,
1.7 (95 percent confidence interval, 1.1 to 2.6); and
high C-reactive protein–high LDL cholesterol, 2.4
(95 percent confidence interval, 1.6 to 3.6). The cor-
responding age-adjusted rates of events per 1000 per-
son-years were 1.2, 1.9, 3.1, and 4.5, respectively. As
in the total cohort, event-free survival among non-
users of hormone-replacement therapy was worse in
the high C-reactive protein–low LDL cholesterol
group than in the low C-reactive protein–high LDL
cholesterol group (Fig. 3).
C-Reactive Protein, LDL Cholesterol Categories, 
and the Framingham Risk Score
We performed several further analyses to evaluate
the addition of measurements of C-reactive protein to
the Framingham risk score and to the LDL cholester-
ol categories of less than 130, 130 to 160, and more
than 160 mg per deciliter, which are defined in current
guidelines for risk detection.1 After adjustment for
all components of the Framingham risk score,19 quin-
tiles of C-reactive protein remained a strong, independ-
ent predictor of risk in the cohort as a whole (relative
risks of future cardiovascular events in increasing quin-
tiles, 1.0, 1.3, 1.4, 1.7, and 1.9; P<0.001) and among
nonusers of hormone-replacement therapy (relative
risks, 1.0, 1.6, 1.5, 1.8, and 2.2; P=0.001). As shown
in Figure 4, increasing levels of C-reactive protein were
associated with increased risk of cardiovascular events
at all levels of estimated 10-year risk based on the Fra-
mingham risk score.19 Similarly, increasing C-reactive
protein levels were associated with increased risk of car-
diovascular events at LDL cholesterol levels below 130,
130 to 160, and above 160 mg per deciliter (Fig. 4).
DISCUSSION
The current study suggests that C-reactive protein,
a marker of systemic inflammation, is a stronger pre-
dictor of future cardiovascular events than LDL cho-
lesterol. In this study, C-reactive protein was superior
to LDL cholesterol in predicting the risk of all study
end points; this advantage persisted in multivariable
analyses in which we adjusted for all traditional car-
diovascular risk factors and was clear among users as
well as nonusers of hormone-replacement therapy at
base line. However, C-reactive protein and LDL cho-
lesterol levels were minimally correlated. Thus, the
combined evaluation of both C-reactive protein and
LDL cholesterol proved to be superior as a method of
*ROC denotes receiver operating characteristic, and HRT hormone-
replacement therapy. P values are for tests of trend across quintiles. Risk-
factor–adjusted relative risks have been adjusted for age, smoking status,
presence or absence of diabetes mellitus, and blood pressure. All models
have been adjusted for treatment assignment. For all relative risks, the ref-
erence category is the first quintile. For 55 women in the study, status with
regard to hormone-replacement therapy was unknown.
TABLE 3. CRUDE, AGE-ADJUSTED, AND RISK-FACTOR–ADJUSTED 
RELATIVE RISK OF A FIRST CARDIOVASCULAR EVENT, 
ACCORDING TO THE QUINTILE OF C-REACTIVE PROTEIN 
AND LDL CHOLESTEROL AT BASE LINE, AMONG 12,139 WOMEN 
WHO USED POSTMENOPAUSAL HORMONE-REPLACEMENT THERAPY 
AND 15,745 WOMEN WHO DID NOT USE SUCH THERAPY.*
VARIABLE QUINTILE OF C-REACTIVE PROTEIN
1 2 3 4 5 P VALUE
AREA UNDER
ROC CURVE
Nonusers of HRT
Crude relative risk 1.0 2.3 2.8 4.3 6.9 <0.001 0.67
Age-adjusted relative risk 1.0 1.9 2.2 3.2 5.4 <0.001 0.78
Risk-factor–adjusted 
relative risk
1.0 1.8 1.8 2.4 3.0 <0.001 0.84
Users of HRT
Crude relative risk 1.0 1.0 1.5 1.9 2.4 <0.001 0.60
Age-adjusted relative risk 1.0 0.9 1.3 1.6 2.1 <0.001 0.69
Risk-factor–adjusted 
relative risk
1.0 0.9 1.1 1.3 1.3 0.08 0.77
QUINTILE OF LDL CHOLESTEROL
1 2 3 4 5 P VALUE
AREA UNDER
ROC CURVE
Nonusers of HRT
Crude relative risk 1.0 1.0 1.2 1.8 2.6 <0.001 0.61
Age-adjusted relative risk 1.0 0.8 1.0 1.3 1.6 <0.001 0.75
Risk-factor–adjusted 
relative risk
1.0 0.8 0.9 1.1 1.4 0.002 0.84
Users of HRT
Crude relative risk 1.0 1.1 1.5 1.8 1.7 0.001 0.58
Age-adjusted relative risk 1.0 1.1 1.3 1.7 1.5 0.005 0.68
Risk-factor–adjusted 
relative risk
1.0 1.0 1.3 1.5 1.5 0.02 0.77
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risk detection to measurement of either biologic mark-
er alone. Finally, at all levels of estimated 10-year risk
for events according to the Framingham risk score and
at all levels of LDL cholesterol, C-reactive protein re-
mained a strong predictor of future cardiovascular risk.
In addition to their pathophysiological implications
with regard to inflammation and atherothrombo-
sis,21-23 we believe these data have implications for the
detection and prevention of cardiovascular disease.
Seventy-seven percent of first cardiovascular events
among the 27,939 women in this study occurred in
those with LDL cholesterol levels below 160 mg per
deciliter, and 46 percent occurred in those with levels
below 130 mg per deciliter. Thus, large proportions of
first cardiovascular events in women occur at LDL
cholesterol levels below the threshold values for inter-
vention and treatment in the current guidelines of the
National Cholesterol Education Program.1
Our data also help establish the population distribu-
tion of C-reactive protein. That the cutoff points for
the quintiles in the current population are very close
to those previously described in smaller studies from
the United States and Europe is reassuring and con-
sistent with evidence describing the stability and repro-
ducibility of values obtained for C-reactive protein with
new, high-sensitivity assays.24 These data also demon-
strate that a single set of cutoff points for C-reactive
protein in women can be used regardless of their sta-
tus with regard to hormone-replacement therapy — an
issue that has been of concern in previous work.14-16
The current data also have implications for the tar-
geting of preventive therapies. We previously demon-
strated in a randomized trial that statin therapy may
have clinical value for primary prevention among per-
sons with elevated C-reactive protein but low LDL
cholesterol levels.25 According to the survival analy-
Figure 3. Event-free Survival among Women with C-Reactive Protein (CRP) and LDL Cholesterol Levels above or below the Median
for the Study Population.
Data are shown for the entire cohort (27,939 women) and for women who were not taking hormone-replacement therapy at base
line (15,745 women). The median values were as follows: for C-reactive protein, 1.52 mg per liter; for LDL cholesterol, 123.7 mg per
deciliter (3.20 mmol per liter). Note the expanded scale on the ordinate.
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ses in the current study (Fig. 3), women in the high
C-reactive protein–low LDL cholesterol subgroup
were at higher absolute risk than those in the low
C-reactive protein–high LDL cholesterol subgroup,
yet it is only the latter group for whom aggressive pre-
vention is likely to be considered by most physicians.
These observations suggest that continued reliance on
LDL cholesterol to predict the risk of cardiovascular
events will not lead to optimal targeting of statin ther-
apy for primary prevention; this suggestion is consis-
tent with data from the Heart Protection Study, in
which LDL cholesterol levels did not predict the effi-
cacy of statins for secondary prevention.26 Our data
thus strongly support the need for a large-scale trial of
statin therapy among persons with low levels of LDL
cholesterol but high levels of C-reactive protein.27
Unlike other markers of inflammation, C-reactive
protein levels are stable over long periods, have no di-
urnal variation, can be measured inexpensively with
available high-sensitivity assays, and have shown spec-
ificity in terms of predicting the risk of cardiovascular
disease.24,28-30 However, despite the consistency of pro-
spective data in diverse cohorts,4-13,16,25,31 decisions re-
garding the clinical use of C-reactive protein remain
complex. To evaluate fully the clinical usefulness of any
new biologic marker requires more than a direct com-
parison with LDL cholesterol or the Framingham risk
score; other factors, such as lipid subfractions, triglyc-
erides, Lp(a) lipoprotein, homocysteine, insulin resist-
ance, and hypofibrinolysis, either in combination with
or in place of other traditional markers, must also be
taken into account. Furthermore, it is increasingly clear
that no single common pathway is likely to account
for all cardiovascular events and that interactions be-
tween novel biologic markers and more traditional risk
factors, such as high blood pressure, smoking, obesity,
diabetes, low levels of physical activity, and use of hor-
mone-replacement therapy, may be more or less im-
portant for individual patients. Thus, as our findings
indicate, new biologic and statistical approaches will
be needed as information from basic vascular biology
begins the transition into clinical practice.
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